0001594062-18-000204.txt : 20181228 0001594062-18-000204.hdr.sgml : 20181228 20181228172233 ACCESSION NUMBER: 0001594062-18-000204 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181228 DATE AS OF CHANGE: 20181228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rafina Innovations Inc. CENTRAL INDEX KEY: 0001402737 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 300428006 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53089 FILM NUMBER: 181258096 BUSINESS ADDRESS: STREET 1: KINTYRE HOUSE, 209 GOVAN ROAD, CITY: GLASGOW STATE: X0 ZIP: G51 1 HJ BUSINESS PHONE: 44 141 3700321 MAIL ADDRESS: STREET 1: KINTYRE HOUSE, 209 GOVAN ROAD, CITY: GLASGOW STATE: X0 ZIP: G51 1 HJ FORMER COMPANY: FORMER CONFORMED NAME: HCi Viocare DATE OF NAME CHANGE: 20140321 FORMER COMPANY: FORMER CONFORMED NAME: CHINA NORTHERN MEDICAL DEVICE INC DATE OF NAME CHANGE: 20070611 10-Q 1 form10q.htm 10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the quarterly period ended September 30, 2018
 
 
[   ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the transition period from __________ to __________

000-53089
Commission File Number
 
Rafina Innovations Inc.
(Exact name of registrant as specified in its charter)
 
 
Nevada
30-0428006
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
 
 
Kintyre House, 209 Govan Road, Glasgow Scotland
G51 1HJ
(Address of principal executive offices)
(Zip Code)
 
+44 141 370 0321
(Registrant's telephone number, including area code)
 
 HCi Viocare
 (Former name, former address and former fiscal year, if changed since last report)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 
Yes
 [X]
No
 [   ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 
Yes
 [X]
No
 [   ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 
 
Large accelerated filer[  ]
Accelerated filer [  ]
Non-accelerated filer[  ] (Do not check if a smaller reporting company)
Smaller reporting company [X]
 
Emerging growth company [X]

      If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
 
 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 
Yes
 [  ]
No
 [X]

APPLICABLE ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST 5 YEARS:

Indicate by check mark whether the issuer has filed all documents and reports required to be filed by Section 12, 13, or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.


 
Yes
 [   ]
No
 [   ]
 
APPLICABLE ONLY TO CORPORATE REGISTRANTS

Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date.

14,409,593  shares of common stock issued and outstanding as of December 11, 2018




2
RAFINA INNOVATIONS INC.

 
TABLE OF CONTENTS
 
 
Page
 
PART I – Financial Information
 
 
 
 
Item 1
Financial Statements
    5
Item 2
Management's Discussion and Analysis of Financial Condition and Results of Operations
    6
Item 3
Quantitative and Qualitative Disclosures About Market Risk
  13
Item 4
Controls and Procedures
  13
 
 
  
 
PART II – Other Information
  
 
 
  
Item 1
Legal Proceedings
  14
Item 1A
Risk Factors
  14
Item 2
Unregistered Sales of Equity Securities and Use of Proceeds
  14
Item 3
Defaults Upon Senior Securities
  15
Item 4
Mine Safety Disclosures
  15
Item 5
Other Information
  15
Item 6
Exhibits
  16
 
SIGNATURES
  16




3
CAUTIONARY STATEMENT ON FORWARD-LOOKING INFORMATION

This Quarterly Report on Form 10-Q (this "Report") contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act").  These statements relate to future events or our future financial performance.  A number of important factors could cause our actual results to differ materially from those expressed in any forward-looking statements made by us in this Form 10-Q.  In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" or the negative of these terms or other comparable terminology.  These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

We cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that our objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements are found at various places throughout this Report and include information concerning possible or assumed future results of our operations, including statements about potential acquisition or merger targets; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future acquisitions, future cash needs, future operations, business plans and future financial results, and any other statements that are not historical facts.
 
These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by these forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.
 
CERTAIN TERMS USED IN THIS REPORT
 
When this report uses the words "we," "us," "our," and the "Company," they refer to Rafina Innovations Inc.  and its consolidated subsidiaries, and "SEC" refers to the Securities and Exchange Commission.
  

4

 
PART I -- FINANCIAL INFORMATION.


 
ITEM 1.  FINANCIAL STATEMENTS

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.  In the opinion of management, all adjustments considered necessary for a fair presentation have been included.  All such adjustments are of a normal recurring nature.  Operating results for the nine-month period ended September 30, 2018, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2018.  For further information, refer to the audited financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission on May 17, 2018.

 

 
Page
Condensed Consolidated Balance Sheets (Unaudited)
F-1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
F-2
Condensed Consolidated Statements of Cash Flows (Unaudited)
F-3
Notes to Condensed Consolidated Financial Statements (Unaudited)
F-4 to F-25




 






5
Rafina Innovations Inc.
(Formerly HCi Viocare)
CONDENSED CONSOLIDATED BALANCE SHEETS
 
 
  
September 30,
2018
    
December 31,
2017
  
 
  
(unaudited)
        
ASSETS
            
 
            
Current Assets:
            
Cash and cash equivalents
  
$
29,713
      
352,498
  
Accounts receivable
    
50,725
      
27,557
  
Other receivable
    
88,822
      
59,827
  
Inventory
    
4,245
      
4,395
  
Prepaid expenses
    
50,146
      
50,525
  
          Total Current Assets
    
223,651
      
494,802
  
 
                
Property, plant and equipment, net
    
95,635
      
155,029
  
 
                
Total Assets
  
$
319,286
      
649,831
  
 
                
LIABILITIES AND STOCKHOLDERS' DEFICIT
                
 
                
Current Liabilities:
                
Accounts payable, advances and accrued expenses
  
$
519,972
      
582,781
  
Accounts payable and accrued expenses-related party
    
7,131
      
508,853
  
Income tax penalties payable
    
80,000
      
80,000
  
Advances from a related party
    
-
      
341,355
  
Notes payable, third parties
    
80,510
      
47,921
  
          Total Current Liabilities
    
687,613
      
1,560,910
  
 
                
Total Liabilities
    
687,613
      
1,560,910
  
 
                
Commitments and Contingencies
    
-
      
-
  
 
                
Stockholders' Equity (Deficit):
                
Preferred stock, par value $0.0001, 5,000,000 shares authorized; none issued and outstanding as of September 30, 2018 and December 31, 2017
    
-
      
-
  
Common stock, par value $0.0001, 35,000,000 shares authorized; 14,219,681 shares issued and outstanding as of September 30, 2018 and 11,919,285 shares issued and outstanding as of December 31, 2017
    
1,422
      
1,192
  
Additional paid-in capital
    
37,629,553
      
33,841,702
  
Accumulated deficit
    
(37,950,401
)
    
(34,736,633
)
Accumulated other comprehensive income (loss)
    
(48,901
)
    
(17,340
)
Stockholders' equity (deficit)
    
(368,327
)
    
(911,079
)
Total Liabilities and Stockholders' Equity (Deficit)
  
$
319,286
      
649,831
  



See Notes to Unaudited Condensed Consolidated Financial Statements
F-1
Rafina Innovations Inc.
(Formerly HCi Viocare)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
 
     For the Three Months Ended        For the Nine Months Ended  
 
  
September 30,
    
September 30,
    
September 30,
    
September 30,
  
 
  
2018
    
2017
    
2018
    
2017
  
 
                        
Revenues
                        
Sales
  
$
91,173
    
$
50,218
    
$
325,256
    
$
269,918
  
Cost of goods sold    
(20,994
 )    
(8,037
 )    
(110,791
 )    
(84,616
 )
         Gross Profit
    
70,179
      
42,181
      
214,465
      
185,302
  
 
                                
Operating Expenses
                                
Depreciation
    
17,288
      
26,406
      
56,070
      
74,583
  
Office rent
    
18,113
      
26,421
      
71,862
      
73,529
  
Office expenses
    
61,350
      
43,340
      
197,473
      
139,274
  
Consultancy Fees
    
262,043
      
302,825
      
1,071,802
      
842,998
  
Professional fees
    
52,766
      
12,655
      
118,086
      
267,140
  
Research and development
    
18,904
      
49,627
      
202,961
      
222,214
  
Travel and entertainment
    
17,220
      
13,042
      
92,303
      
41,418
  
          Total Operating Expenses
    
447,684
      
474,316
      
1,810,557
      
1,661,156
  
 
                                
Loss from Operations
    
(377,505
)
    
(432,135
)
    
(1,596,092
)
    
(1,475,854
)
 
                                
Other Income (Expenses)
                                
(Loss) on conversion of debt
    
(1,747
)
    
(17,707
)
    
(1,609,436
)
    
(17,707
)
Gain (Loss) on foreign currency transaction
    
(2,278
)
    
(1,141
)
    
(5,755
)
    
343
  
Interest Expenses due to third party
    
(1,256
)
    
-
      
(2,485
)
    
-
  
Interest Expenses due to related party
    
-
      
(3,418
)
    
-
      
(5,520
)
          Total Other Income (Expenses)
    
(5,281
)
    
(22,266
)
    
(1,617,676
)
    
(22,884
)
 
                                
Loss before Provision for Income Tax
    
(382,786
)
    
(454,401
)
    
(3,213,768
)
    
(1,498,738
)
 
                                
Provision for Income Tax
    
-
      
-
      
-
      
-
  
 
                                
Net Loss
  
$
(382,786
)
  
$
(454,401
)
  
$
(3,213,768
)
  
$
(1,498,738
)
 
                                
Basic and fully diluted loss per share
  
$
(0.03
)
  
$
(0.05
)
  
$
(0.24
)
  
$
(0.11
)
 
                                
Weighted average shares outstanding
    
14,312,670
      
9,903,242
      
13,184,341
      
9,753,242
  
 
                                
Comprehensive Income (Loss):
                                
Net loss
  
$
(382,786
)
  
$
(454,401
)
  
$
(3,213,768
)
  
$
(1,498,738
)
Effect of foreign currency translation
    
(6,919
)
    
(26,421
)
    
(31,561
)
    
(89,123
)
Comprehensive Loss
  
$
(389,705
)
  
$
(480,822
)
  
$
(3,245,329
)
  
$
(1,587,861
)

 

 
See Notes to Unaudited Condensed Consolidated Financial Statements
 
F-2
Rafina Innovations Inc.
(Formerly HCi Viocare)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

  
  
For the Nine Months Ended
  
 
  
September 30,
  
 
  
2018
    
2017
  
 
            
Operating Activities
            
Net loss
  
$
(3,213,768
)
  
$
(1,498,738
)
Adjustments to reconcile net loss to net cash used by operating activities:
                
Amortization of stock options
    
369,287
      
367,629
  
Share based compensation
    
468,842
      
407,650
  
Shares issued for services provided
    
-
      
119,950
  
Loss on conversion of debt
    
1,609,436
      
17,707
  
Depreciation
    
56,070
      
74,583
  
Changes in operating assets and liabilities:
                
Decrease (Increase) in accounts receivable
    
(24,527
)
    
(36,995
)
Decrease (Increase) in prepaid expense
    
(31,269
)
    
1,282
  
Decrease (Increase) in other receivable
    
(867
)
    
2,430
  
Decrease (Increase) in inventory
    
-
      
562
  
Increase (Decrease) in accounts payable and accrued expenses
    
(64,884
)
    
128,186
  
Increase (Decrease) in accounts payable and accrued expenses, related party
    
(67,362
)
    
(49,103
)
Net cash used by operating activities
    
(899,042
)
    
(464,857
)
 
                
Investing Activities
                
Net cash (used) by investing activities
    
-
      
-
  
 
                
Financing Activities
                
Advances and loans from related parties
    
202,345
      
149,708
  
(Repayments), advances and loans from related party
    
(314,041
)
    
(250,384
)
Loans from third parties
    
34,673
      
121,535
  
Proceeds from private placement
    
664,911
      
552,784
  
Net cash provided by financing activities
    
587,888
      
573,643
  
 
                
Increase (decrease) in cash
    
(311,154
)
    
108,786
  
Cash at beginning of period
    
352,498
      
2,492
  
Effects of exchange rates on cash
    
(11,631
)
    
(41,317
)
Cash at end of period
  
$
29,713
    
$
69,961
  
 
                
Supplemental Disclosures of Cash Flow Information:
                
Cash paid (received) during year for:
                
Interest
  
$
-
    
$
-
  
Income taxes
  
$
-
    
$
-
  
Supplemental Non-Cash Activities
                
Loan and accrued interest settled with shares
  
$
-
    
$
86,793
  
Reclassification of related party accounts payable and advances to convertible debt, related parties
  
$
721,564
    
$
-
  
Shares issued to settle convertible notes, related parties, accounts payable and advances, related parties
  
$
811,241
    
$
-
  

See Notes to Unaudited Condensed Consolidated Financial Statements
F-3
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 1 - ORGANIZATION AND BUSINESS BACKGROUND
 
Rafina Innovations Inc. (formerly: HCi Viocare) ("VICA" or the "Company") was incorporated on March 26, 2007 under the laws of the State of Nevada. The Company has selected December 31 as its fiscal year end.
 
While the Company has generated revenues from a segment of its planned principal operations, we are not yet able to meet operational overheads and are not yet profitable. We are considered an emerging growth enterprise. The Company was originally formed to sell medical devices with an emphasis on portable medical devices designed for home treatments with the initial focus in the northern regions of China.  The Company's intent was to seek strategic relationships with medical device manufacturers both in China and North America with the aim to be their sales and distribution agent in Northern China and to assist Chinese medical device manufacturers on the development of the North American market.

On September 10, 2013, the controlling shareholder of the Company sold his controlling interest in the shares of the Company and there was a change in the Board of Directors of the Company, effecting a change in control of the Company. The business of the Company remains in the field of medical devices and other opportunities related to their uses. We are currently engaged in the technology development and licensing of bioengineering innovations for the health, sports and wellness sectors, and operate a prosthetic and orthotic (P&O) total rehabilitation clinic in Glasgow, Scotland.

On January 15, 2014, the Company incorporated two wholly-owned subsidiaries in Scotland, U.K., HCi Viocare Technologies Limited and HCi Viocare Clinics UK Limited. The Company intends to operate in Scotland under these two subsidiaries, one of which will undertake the development and marketing of technologies and the other which is a P&O clinic, which will serve as the center of reference and training for the Company's further clinics.

On February 12, 2014, through our wholly owned subsidiary, HCi Viocare Technologies Limited, the Company acquired an interest in a patented technology known as "Socket-Fit". SocketFit is a system that will help overcome technical and resource hurdles endemic to the prosthetic sector. The system has been designed with the aim of offering optimally fitted prosthetic sockets that will reduce the number of prostheses made for patients, resulting in a reduced number of visits by the patient to the prosthetic, and also assisting in the rehabilitation of amputees.  Socket-Fit is a digital system for assessing an amputee's residual limb and for the production of truly functional and comfortable prosthetic sockets. The technology takes account of the external and internal geometry of the amputee's stump, the biomechanical properties of each individual soft tissue layer and the boundary and loading conditions of a complete prosthesis to generate a virtual 3D model of the residual limb making it possible to produce an accurate, functional and comfortable prosthetic socket. By minimizing the time and cost of socket production and reducing the number of faulty sockets there will be a reduction in costs incurred by health services and insurance companies worldwide as well as benefits to the amputee. The Company intends to undertake and fund, through its U.K. subsidiary, a project to improve the nature of the data used in socket modeling software with a view to creating a system that will enable prosthetists to build a socket that evenly distributes weight, provides enhanced comfort, and can be marketed and used across the industry for improved socket creation.

On February 19, 2014, the Company filed a Certificate of Amendment with the Secretary of State of Nevada to change the name of the Company to HCi Viocare effective March 21, 2014.  Effective March 21, 2014, in accordance with approval from FINRA, we changed our name from China Northern Medical Device, Inc. to HCi Viocare. Concurrently we commenced trading on the Over-the-Counter Bulletin Board under the symbol "VICA".
F-4
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018
 
Note 1 - ORGANIZATION AND BUSINESS BACKGROUND (continued)

On April 16, 2014, through our wholly owned subsidiary HCi Viocare Technologies Limited, we acquired all rights and interest in and to the background Intellectual Property Rights ("IPR") for a developing technology known as "Smart Insole".  The Smart Insole system is believed to be a state-of-the-art, pressure and shear (friction)-sensing insole that can wirelessly communicate with connected devices.  The insole has a number of applications, including the mitigation of diabetic foot complications, such as ulceration, infection and amputation, in clinical gait analysis and in sports, as a wearable device to help athletes optimize their performance and prevent injury. The sensing system is very low cost, compared to traditional pressure sensing technologies, in our opinion making such applications affordable to the consumer for the first time.

On June 9, 2014, the Company, through our wholly owned subsidiary, HCi Viocare Clinics, acquired W D Spence Prosthetics Limited (the "Clinic"). The Clinic is located in Glasgow, Scotland, and is a fully operational prosthetics and orthotics clinic. The acquisition of the Clinic is the first step to the Company's and HCi Viocare Clinics' intention to develop the first chain of prosthetics and orthotics (P&O) and diabetic foot rehabilitation clinics in the European market, covering Southern Europe, the Middle East and North Africa.

On March 31, 2015, the Company's wholly owned subsidiary HCi Viocare Clinics and its subsidiary W D Spence Prosthetics Limited completed a merger with the resulting combined entity having the name HCi Viocare Clinics UK Limited.

On July 8, 2015, the Company incorporated HCi Viocare Clinics (Hellas) S A in order to carry out operations for the planning and development of a P&O clinic in Athens, Greece. On August 2, 2017 the Company commenced the dissolution and liquidation of this corporation.  As at the date of this report, the dissolution has not yet been concluded.

On May 24, 2018 the Company incorporated a wholly owned subsidiary for purposes of completing a merger and name change from HCi Viocare to Rafina Innovations, Inc. Concurrently the Company's Board of Directors approved a reverse share split on the basis 20 for 1.  The name change and reverse share split became effective on July 9, 2018.  Unless otherwise noted, impacted share amounts and per share information included in the financial statements and notes thereto have been retroactively adjusted for the reverse share split as if such share split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly differently than previously reported due to rounding of fractional shares as a result of the reverse share split.

Note 2 - GOING CONCERN

The Company incurred net losses of $382,786 and $3,213,768 for the three and nine months ended September 30, 2018, respectively, and net loss of $454,401 and $1,498,738 for the three and nine months ended September 30,2017, respectively and has a retained deficit of $37,950,401. In addition, the Company had a working capital deficiency of $463,962 and a stockholders' deficit of $368,327 at September 30, 2018. These factors raise substantial doubt about the Company's ability to continue as a going concern. 

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders.
 
F-5
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 2 - GOING CONCERN (continued)

The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.
 
The Company has relied heavily for its financing needs up until the close of fiscal 2017 on its Chief Executive Officer and President as more fully disclosed in Note 10.

Note 3 - CONTROL BY PRINCIPAL STOCKHOLDER/OFFICER
 
Up until March 2018 our Chief Executive Officer owned beneficially and, in the aggregate, the majority of the voting power of the Company.  On March 22, 2018 and March 30, 2018 respectively, Sotirios Leontaritis, the President, Chief Executive Officer and a Director of the Company, entered into a Share Purchase Agreement (the "SPA") and an amendment thereto (the "Addendum"), (collectively herein referred to herein as the "Agreement") with Maschari Ltd. ("Maschari"), a Company incorporated in Cyprus, pursuant to which Mr. Leontaritis sold 6,135,529 of his restricted common shares to Maschari.  The shares sold by Mr. Leontaritis represented approximately 42.6% of the Company's total outstanding shares of common stock. Mr. Leontaritis continues to hold 1,965,619 shares of the Company's common stock representing approximately 13.6% of the issued and outstanding shares.  As a result of the aforementioned transaction, Maschari has the ability to control the approval of most corporate actions, including increasing the authorized capital stock and the dissolution, merger or sale of the Company's assets, as may be presented at Shareholder meetings from time to time.
 
Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Principals of Consolidation
 
The consolidated financial statements include the accounts of Rafina Innovations Inc. and its wholly-owned subsidiaries, HCi Viocare Technologies Limited, HCi Viocare Clinics UK Limited and HCi Viocare Clinics (Hellas) S.A. On August 2, 2017 the Company commenced the dissolution and liquidation of HCi Viocare Clinics (Hellas) S.A. All significant intercompany balances and transactions have been eliminated.

Basis of Presentation
 
The interim unaudited financial information referred to above has been prepared and presented in conformity with accounting principles generally accepted in the United States applicable to interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The interim financial information has been prepared on a condensed basis, such that certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission. These interim financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.
 
This report on Form 10-Q should be read in conjunction with the Company's financial statements and notes thereto included in the Company's Form 10-K for the fiscal year ended December 31, 2017 filed on May 17, 2018. Results of the three and nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ended December 31, 2018 and any other future periods.

F-6
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018
 
Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
 
Use of Estimates
 
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results when ultimately realized could differ from these estimates.
 
Cash and Cash Equivalents
 
Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less.

Foreign Currencies

Items included in the consolidated financial statements of each of the Company and its subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the 'functional currency').  The Company's reporting currency is the U.S. dollar.  The functional currency of subsidiaries based in the UK is pound sterling and the functional currency of the Company's subsidiary based in the Greece is the Euro. All transactions initiated in Pounds and Euro are translated into U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830-30, "Translation of Financial Statements," as follows:
 
i)
assets and liabilities are translated at the closing rate at the date of the balance sheet, or
1USD=0.86153EUR, 1USD=0.76728GBP (September 30, 2018), and;
1USD=0.8347EUR, 1USD=0.74108GBP (December 31, 2017);

ii)
income and expenses are translated at average exchange rates for nine months ended September 30, or
1USD=0.8374EUR, 1USD=0.7404GBP (September 30, 2018), and;
1USD=0.9000EUR, 1USD=0.7846GBP (September 30, 2017);

iii)
all resulting exchange differences are recognized as other comprehensive income, a separate component of equity.

Adjustments arising from such translations are included in accumulated other comprehensive income (loss) in stockholders' equity.

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured.
F-7
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018
 
Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenue Recognition (cont'd)

The Company recognizes revenue when the earnings process is complete and persuasive evidence of an arrangement exists. This generally occurs for revenue recorded in our P&O Clinics division when prosthetic products are fitted to customers, both title and the risks and rewards of ownership are transferred or services have been rendered and accepted, the selling price is fixed or determinable, and collectability is reasonably assured.  Revenue is recognized upon issuance of an invoice and completion of each concluded stage of work performed on a prosthetic product.  The Company recognizes revenue from its technology licensing fees and/or product development fees upon conclusion of services provided under contract.
 
There was no impact on the Company's financial statements as a result of adopting Topic 606 for the three and nine months ended September 30, 2018 and 2017.

Inventory
 
Inventories, which consist principally of raw materials and parts, are stated at the lower of cost or market. Cost is determined using the first-in, first-out method and are adjusted to actual cost quarterly based on a physical count. Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. Work-in-process inventory consists of materials, labor and a predetermined fixed rate of overhead which is valued based on established standards for the stage of completion of each custom order. We do not carry finished goods on hand. Material, labor and overhead costs are determined at the individual clinic level. Presently we only maintain very limited parts and raw materials inventory.
 
Warranty
 
We do not record warranty liabilities at the time of sale for the estimated costs that may be incurred under the terms of the applicable limited warranty as all component parts are covered by our respective industry suppliers.

Advertising Costs
 
The Company expenses advertising costs as incurred or the first time the advertising takes place, whichever is earlier, in accordance with ASC 720-35. Advertising costs were immaterial for the three and nine months ended September 30, 2018 and 2017, respectively.

Research and Development Costs
 
The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, "Research and Development". Research and development costs were $18,904 and $202,961for the three and nine months ended September 30, 2018, and $49,627 and $222,214 for the three and nine months ended September 30, 2017. During the period ended September 30, 2018, HCi Viocare Technologies Limited, the Company's subsidiary, received $52,766 (GBP 39,066) from the UK government as research and development tax credit.

Related parties
 
For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.

F-8
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018
 
Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Stock-based compensation

For stock-based compensation, the Company follows the guidance codified in the Compensation – Stock Compensation Topic of FASB ASC ("ASC 718"). The Company determines the value of stock issued at the date of grant. It also determines at the date of grant, the value of stock at fair market value or the value of services rendered (based on contract or otherwise) whichever is more readily determinable.
  
Income Taxes
 
The Company accounts for income taxes in accordance with FASB ASC 740, "Income Taxes", which requires the asset and liability approach for financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company has a retained deficit from operations. Because there is no certainty that we will realize taxable income in the future, the Company did not record any deferred tax benefit as a result of these losses and recorded a valuation allowance offsetting the entire potential tax benefit.

Income tax years for 2014 through 2016 have been remitted timely and remain open to examination by the taxing authorities. The tax return for fiscal 2017 has not yet been filed. The Company has been assessed late filing penalties of $10,000 per year, as well as accrued interest thereon, for each of the late filed returns for the periods from inception to December 31, 2012. Prior to a change in control at the close of fiscal 2013, prior management had not timely filed its annual tax returns.  We have estimated and accrued penalties of $80,000 as taxes payable in our financial statements. The Company has retained a tax professional to assist in reaching a settlement with the IRS.
 
Comprehensive Income

FASB ASC 220, "Comprehensive Income", establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income, as defined, includes all changes in equity during a period, exclusive of shareholder transactions. Accordingly, comprehensive income (loss) may include certain changes in shareholders' equity (deficit) that are excluded from net income (loss).

Segment Reporting
 
FASB ASC 820 "Segments Reporting" establishes standards for reporting information about operating segments on a basis consistent with the Company's internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. Our proposed business segments are expected to span more than one geographical area. Specifically, the Company intends to operate prosthetic and orthotic rehabilitation clinics with various European based locations, as well as a corporate development and technology center which will undertake ongoing research and marketing activities.


F-9
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018
 
Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Basic and Diluted Loss per Share

The Company reports earnings per share in accordance with FASB ASC 260, "Earnings Per Share." FASB ASC 260 requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company had potentially dilutive securities outstanding (convertible debt and liabilities) for the period ended September 30, 2018 and December 31, 2017, respectively, however, since the Company reflected a net loss in the three and nine months ended September 30, 2018 and 2017, the effect of considering any common stock equivalents, if outstanding, would have been anti-dilutive. A separate computation of diluted earnings (loss) per share is not presented.
  
 
  
September 30, 2018
    
December 31, 2017
  
Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options
    
500,000
      
500,000
  
Common stock issuable upon exercise of stock options
    
1,900,000
      
1,400,000
  
Total
    
2,400,000
      
1,900,000
  

Fair Value of Measurements

Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2: Input other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company.
 
Level 3: Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability.

An asset or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities.

F-10
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018
 
Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Recent Issued Accounting Pronouncements
.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842).  The amendments in this Update increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.  ASU 2016-02 will be effective for the Company beginning on October 1, 2019.  Early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases to clarify the implementation guidance and ASU No. 2018-11, Leases (Topic 842) Targeted Improvements. This updated guidance provides an optional transition method, which allows for the initial application of the new accounting standard at the adoption date and the recognition of a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning of the period of adoption. We have begun to identify our significant lease contracts and are in the process of evaluating the effect of the new guidance on our consolidated financial statements and related disclosures.
 
There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.

Note 5 - PREPAID EXPENSES
 
Prepaid expenses consist of the following:
  
 
  
September
30, 2018
    
December
31, 2017
  
Office lease, including security deposits
  
$
38,241
    
$
39,582
  
Travel advances and other expenses
    
11,905
      
10,943
  
      Total prepaid expense
  
$
50,146
    
$
50,525
  

Note 6 – OTHER RECEIVABLES

From time to time the Company makes short term loans to third parties in order to facilitate its business operations. The loans bear interest ranging from 1.5% to 4% per annum and generally have terms of between 60 to 180 days. In general, the Company forgives accrued interest on principal when these short-term loans are repaid on time.

Note 7 - PROPERTY AND EQUIPMENT

Property and improvements consisted of the following as of September 30, 2018 and December 31, 2017:

 
  
September 30,
2018
    
December 31,
2017
  
Cost
            
Leasehold improvements
  
$
197,171
    
$
203,990
  
Furniture and fixture
    
31,695
      
32,781
  
Computers and equipment
    
33,062
      
33,144
  
Vehicle
    
58,036
      
59,902
  
Machine and plant
    
8,892
      
9,206
  
Lab equipment
    
32,958
      
34,123
  
 
    
361,814
      
373,146
  
Less: accumulated depreciation and impairment
    
(266,179
)
    
(218,117
)
Total
  
$
95,635
    
$
155,029
  
F-11
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 7 - PROPERTY AND EQUIPMENT (continued)

Leasehold improvements are amortized over the term of the lease: three to ten years.

Furniture is depreciated over three to five years and computer and equipment is depreciated over three years.

Vehicles are depreciated over five years.
 
Machine equipment and lab equipment are depreciated over 4 years.

Depreciation expense amounted to $17,288 and $56,070 for the three and nine months ended September 30, 2018, respectively.

Depreciation expense amounted to $26,406 and $74,583 for the three and nine months ended September 30, 2017, respectively.

Note 8 - OFFICE LEASE
 
Office in Greece

On February 3, 2014, the Company leased office space in Paleo Faliro, Greece on a three-year lease, commencing on March 1, 2014 and ending on February 28, 2017. The monthly rental fee is $1,900 (EUR € 1,554) including applicable taxes in the first year. Thereafter, for every further lease year and for the whole duration of the lease agreement, as well as in case of compulsory statutory extension or extension by tacit agreement, the monthly rent shall be annually adjusted by a percentage equal to the Consumer Price Index of the adjustment month with respect to the respective month of the year before (simple annual rate of change), as this is calculated by the Hellenic Statistical Authority (ELSTAT), plus two (2) percentage points (+2%).

Under the term of the lease agreement, the Company paid a total of $25,010 (EUR €18,540) including $4,047 (EUR €3,000) for a deposit and $20,963 (EUR €15,540) for ten months' rental fee upon executing the agreement. As of September 30, 2018, $3,482 (EUR €3,000) is shown as deposits in the prepaid account.  The lease has been renewed effective June 13, 2017 for a term of 3 years terminating on February 28, 2020 at a rate of $1,848 (EUR€1,592) plus a fee of 3.6%.

On September 3, 2018, the Company's lease in Paleo Faliro was terminated by the Lessor.  The Company and the Lessor are currently negotiating a settlement of the remaining lease obligation.
 
Clinic in Greece

On December 29, 2014, the Company leased office space at Peania Region of Attica in Greece on a ten-year lease, commencing on January 1, 2015 and ending on October 5, 2024. The monthly rental fee is $6,996 (EUR €6,233) plus applicable taxes and the monthly operating cost estimate is $1,120 (EUR €997).

Under the term of the lease agreement, the Company paid a total of $13,991 (EUR €12,465) as deposits in the prepaid account. 

F-12
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 8 - OFFICE LEASE (continued)

On October 9, 2015, the terms of the lease were amended to include the following provisions:
 
- 
Effective September 1, 2015, the monthly rental fee shall be reduced to $3,500 (EUR €3,116) for a period of 12 months ending August 31, 2016.
 
- 
In the event that the Lessee commences leasehold improvements prior to August 31, 2016, it shall inform the Lessor respectively and pay retroactively the remaining balance of the total amount of monthly rental in full from the period commencing September 1, 2015, as if they have not been reduced;
 
- 
In the event that the Company does not proceed with leasehold improvements in the 12-month period, the lease agreement will terminate and the Lessor with retain the deposit.
 
- 
The Lessor until such time as the leasehold improvements commence, may at any time and without indemnity terminate the lease agreement with a 30-day prior written notice to the Lessee.
 
As of December 31, 2016, the Company and the Lessor concluded the Termination of Lease Agreement dated August 1, 2016, and the Lessor waived all maintenance charges and utility charges for fiscal 2016. The following table is the summary of balance owing to Lessor as at September 30, 2018 and December 31, 2017:

 
September 30,
2018
  
December 31,
 2017
  
 
        
Amount owed for maintenance charges
  
$
15,732
    
$
16,238
  
Amount owed for utility charges
    
16,284
      
16,807
  
 
  
$
32,016
    
$
33,045
  

Lease in UK

On March 2, 2015, the Company entered into a lease agreement for a modern, stand-alone 5,300 square foot facility in Glasgow, Scotland with an entry date of March 1, 2015. The building will host the Company's first Viocare center, a full-service Prosthetic and Orthotic ("P&O") practice with a superior standard of personalized care. The renovations to the clinic were completed in June, and the facility was opened on August 1, 2015 with an official ribbon cutting on 25 September 2015. During the first year from the date of entry, the lease fees are USD$26,066 (GBP £20,000) per annum (exclusive of VAT). On the second anniversary of the date of entry, the lease will increase to USD$52,132 (GBP £40,000) per annum (exclusive of VAT). In the third anniversary of the date of entry, the lease will be USD$52,132 (GBP £40,000) per annum (exclusive of VAT). In the fourth anniversary of the date of entry, the lease will decrease to USD$39,100 (GBP £30,000) per annum (exclusive of VAT). In the fifth anniversary of the date of entry, the lease will be USD$52,132 (GBP £40,000) per annum (exclusive of VAT).

Under the term of the lease agreement, the Company paid a total of $26,066 (GBP £20,000) as security deposits which amount is included on the Company's balance sheet in prepaid expenses.
  
Location
  
September 30, 2018
    
December 31, 2017
  
Greece
  
$
3,482
    
$
3,594
  
UK
    
34,759
      
35,988
  
 
  
$
38,241
    
$
39,582
  
 
F-13
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 8 - OFFICE LEASE (continued)

As of September 30, 2018, the approximate future aggregate minimum lease payments in respect of our current obligations were as follows:
 
Location
 
Greece
 
 
United Kingdom
 
2018
 
 
5,411
 
 
 
10,318
 
2019
 
 
21,645
 
 
 
49,960
 
2020
 
 
3,607
 
 
 
8,688
 
 
 
$
30,663
 
 
$
68,966
 
 
Note 9 -   LOANS

On January 5, 2017, HCi Viocare Clinics Hellas S.A., the Company's subsidiary, entered into a loan agreement with a third party to borrow a total of EUR 40,000 (US$46,429) with an annual interest rate of 5%, payable within one year from the date of the agreement. As at September 30, 2018 and December 31, 2017 a total of $50,452 and $50,276, respectively, including accrued interest to date, remained due and payable in respect of this loan. Interest expenses of $1,791 were accrued in the nine months ended September 30, 2018. The loan was not repaid in January 2018 and is currently in default.

On July 27, 2018, HCi Viocare Clinics UK Limited, the Company's subsidiary, entered into a loan agreement with a third party to borrow a total of EUR 30,000 (US$34,081) with an annual interest rate of 6%, payable within six months from the date of the agreement. As at September 30, 2018 and December 31, 2017 a total of $34,480 and $0, respectively, including accrued interest to date, remained due and payable in respect of this loan. Interest expenses of $413 were accrued in the nine months ended September 30, 2018.

Note 10 -   COMMITMENTS

(1)
Consulting Agreement with Dr. Christos Kapatos
 
On April 16, 2014, the Company entered into a Consulting Agreement with Christos Kapatos whereby he will provide his services as Chief Technical Officer for the Company and the Company's wholly-owned subsidiaries.  The contract has a term of one year, renewable for such further term as may be mutually agreed between the parties. In the case that a research and development project is initiated and completed during the term of the agreement, Kapatos shall receive seventy thousand (70,000) shares of the Company's common stock for each research project completed with a valuation less than twenty million dollars ($20,000,000 USD), one hundred and seventy-five thousand (175,000) shares of the Company's common stock for each research project completed with a valuation equal or greater than twenty million US dollars ($20,000,000 USD). Details of compensation under the terms of the consulting agreement are included in Note 11(ii).

(2)
Consulting Agreement with JAMB
 
Effective July 10, 2017, the Company entered into a business consulting agreement (the "Consulting Agreement") with JAMB Group LLC. ("Consultant") for services to commence July 15, 2017 and to continue for a period of twelve (12) months thereafter. Under the terms of the Agreement, the Consultant shall provide consulting services to the Company for the development and expansion of its business, including the introduction to specific Targets for the purposes of financing transactions or other business relationship. The Consultant is entitled to compensation for the provision of services in the form of 25,000 shares of the common stock which were issued upon execution of the Consulting Agreement, as well as certain other fees and consideration.
  
F-14
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 10 -   COMMITMENTS (continued)

(2)
Consulting Agreement with JAMB (cont'd)

25,000 shares have been valued at $79,950, the fair market value of $3.198 per share, on issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017.  The contract expired without renewal in the current nine months ended September 30, 2018.

(3)
Consulting Agreement with Mr. Stefanos Batzakis
 
On September 1, 2017, the Company entered into a one-year consulting agreement (the "Agreement") with Mr Stefanos Batzakis. As per terms of said Agreement Batzakis will provide services to the Company as IT Solutions Manager, for a term of one (1) year and receive compensation in the form of stock, namely twenty-five thousand (25,000) common shares, which were issued upon signing of this Agreement.

25,000 shares have been valued at $40,000, the fair market value of $1.60 per share on issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017. The contract expired without renewal in the current nine months ended September 30, 2018.

(4)
Consulting Agreement with Dr. Ioannis Doupis
 
On October 9, 2017, the Company appointed Dr. Ioannis Doupis, to the Advisory Board of the Company originally formed on April 15, 2014 and Concurrently entered into an advisory board agreement. Compensation shall be the grant of a total of 25,000 shares of the Company's common stock valued at the fair market price on the date of grant of $1.40 per share. The advisory board appointment is for a term of one year.

25,000 shares have been valued at $35,000, the fair market value of $1.40 per share on issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017.  On October 3, 2018 the Company's Board of Directors determined to terminate the Company's advisory board.

(5)
Consulting Agreement with Ms. Paraskevi Pilarinou
 
On December 12, 2017, the Company entered into a consulting agreement (the "Agreement") with Ms. Paraskevi Pilarinou (the "Consultant").  Under the terms and conditions of the Agreement the Consultant shall be employed in the position of Financial Controller of the Company. The Agreement has a three-year term starting on January 2, 2018 and ending on January 1, 2021 and the Consultant shall be remunerated with a monthly fee of EUR2,000 (IUSD$2,320) and was issued 100,000 shares of the Company's common stock. The 100,000 shares were issued as compensation as of the date of the agreement and were valued at $1 per share or $100,000, the fair market value on the date of issuance in the year ended December 31, 2017.

(6)
Consulting Agreement with Charalampos Sgardelis

On January 2, 2017, the Company entered into a one-year consulting agreement (the "Agreement") with Mr. Charalampos Sgardelis ("Sgardelis"). Under the terms of the Agreement, Sgardelis provides services to the Company as Business Development Manager, for a term of one (1) year and receives compensation of Two Thousand Euros (2,000 €) (USD$2,320) per month.

On February 26, 2018 the Company approved a three (3) year extension to the Agreement (the "Addendum") between the Company and Sgardelis. Under the terms and conditions of the Addendum, Sgardelis is entitled to receive compensation of Three Thousand Euros (3,000 €) (USD$3,480) per month and shall be awarded 250,000 common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $0.98 per share for total consideration of $245,000.  Subsequent to the period ended September 30, 2018, on November 17, 2018, the Company terminated the consulting agreement with Mr. Sgardelis.
F-15
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 10 -   COMMITMENTS (continued)

(7)
Advisory Agreement with Ravi Vaidyanathan

On March 27, 2018, the Company entered into a one-year advisory agreement (the "Agreement") with Mr. Ravi Vaidyanathan (the "Advisor"). Under the terms and conditions of the Agreement, the Advisor is appointed to the Company's Scientific Advisory Board and is entitled to remuneration for the provision of services in the form of 25,000 shares of the common stock to be issued upon signing of the Agreement. Further, the Advisor shall be granted additional 12,500 shares of the common stock to be issued after a time-period of six (6) months from the signing of the Agreement. The Advisor shall serve on the Scientific Advisory Board in the position of Biomechatronics and Human Augmentation Advisor. The Company or the Advisor may terminate the agreement upon 30 days written notice. The issued shares were valued at fair market value on the date of issuance or $1.10 per share for total consideration of $27,500. On October 3, 2018 the Company's Board of Directors determined to terminate the Company's advisory board and no further shares will be issued to Mr. Vaidyanathan under the terms of this Agreement.

(8)
Addendum to Service Agreement with Nikolaos Gemelos

On January 16, 2018, the Company entered into a one-year service agreement (the "Agreement") with Mr. Nikolaos Gemelos ("Gemelos"). Under the terms of the Agreement, Gemelos provides services to the Company as Consultant, for a term of one (1) year and he is entitled to a success fee of 5% of the amount actually invested in the Company by introduced accredited investors, and 5% of the amount invested in the form of restricted shares of the common stock of the Company. On May 3, 2018, the Company entered into an amendment to the aforementioned Agreement. Under the terms and conditions of this Addendum, Gemelos shall be awarded 5,000 restricted common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $1.34 per share for total consideration of $6,700.

(9)
Service Agreement with Georgios Dritsoulas

On June 7, 2018, the Company entered into a six-month service agreement with Mr. Georgios Dritsoulas. As per terms of said Agreement, Mr. Dritsoulas will provide services to the Company as Consultant for the development and expansion of the Company's business for a term of six (6) months. Mr. Dritsoulas received compensation of 2,500 restricted common shares as compensation for the services provided. The issued shares were valued at fair market value on the date of issuance or $2 per share for total consideration of $5,000.

Note 11 -   RELATED PARTY TRANSACTIONS

The following table provides details of the Company's related party transactions during the three and nine months ended September 30, 2018 and 2017

(a)
Services provided from related parties:


 
  
Three Months Ended
September 30,
    
Nine Months Ended
September 30,
  
 
  
2018
    
2017
    
2018
    
2017
  
Consulting fees from CEO and President (i)
  
$
33,739
    
$
30,000
    
$
107,472
    
$
90,000
  
Consulting fees from a Director (ii)
    
13,978
      
11,697
      
44,700
      
33,332
  
Professional fees from Director (iii)
    
3,374
      
3,509
      
10,747
      
9,999
  
Consulting fees for VP (iv)
    
11,808
      
7,018
      
37,615
      
19,999
  
Stock options granted to CEO and President (i)
    
122,544
      
-
      
367,630
      
-
  
Stock options granted to Director (ii)
    
45,300
      
-
      
135,900
      
-
  
Stock options granted to VP (iv)
    
16,800
      
-
      
50,400
      
187,200
  
Stock award granted to Director (iii)
    
-
      
-
      
-
      
172,000
  
 
  
$
247,543
    
$
52,224
    
$
754,464
    
$
512,530
  
F-16
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 11 -   RELATED PARTY TRANSACTIONS (continued)

(i)
On September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016.   Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract.  In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR10,000 (USD$11,650) per month.  Further, Mr. Leontaritis is entitled to acquire at his discretion 150,000 shares of the common stock at a price of $6 per share for a term of five (5) years.  The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 and $245,086 during the three and six months ended September 30, 2018 and 2017. On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated.   Further concurrent with his resignation, and with an effective date of September 30, 2018, Mr. Leontaritis and the Company entered into an agreement whereunder Mr. Leontaritis would surrender for cancelation a total of 189,912 shares of the Company's common stock valued at $0.705 per share in order to settle certain amounts payable to the Company totaling $135,635 including a loss on conversion of $1,747. The shares are held in the possession of the Company's Board of Directors and have not yet been provided to the Company's transfer agent for cancelation as at the date of this report.

(ii)
On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$46,430 (€40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company Euros €40,000 for services rendered in each fiscal year respectively.
 
On December 12, 2017, the Company approved the issuance of 925,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant.  The 925,000 shares have been valued at $925,000, or $1.00 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$58,250) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 1,250,000 shares of the common stock at a price of US$1.00 for a term of six years.
 
On May 23, 2018 the Company approved an amendment to the term of the scientific advisory agreement with Dr. Christos Kapatos, board member CTO and member of the Scientific Advisory Board, originally entered into on April 15, 2014 in order to extend the term to April 15, 2019.
 
The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 and $135,900 during the three and nine months ended September 30, 2018.
Effective October 3, 2018, Dr Christos Kapatos resigned from his position as Director of the Company.  Subsequently on November 21, 2018 Dr, Kapatos terminated his consulting contract.
F-17
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 11 -   RELATED PARTY TRANSACTIONS (continued)

(a)
Services provided from related parties (cont'd)

(iii)
On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. During the nine months ended September 30, 2018 Mr. Kardaras invoiced the Company EUR9,000 (USD$10,747)
 
On March 3, 2017, the Company approved the issuance of 50,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $172,000, the fair market value of $3.44 per share on issue date, which amount has been expensed as stock-based compensation.  On October 3, 2018 Mr. Kardaras resigned as secretary and director of the Company.  He remains the Company's in house legal advisor.

 (iv)
On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President. Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives.  The initial term of the contract is six months and Mr. Katsaros will receive compensation of USD$2,330 (€2,000) per month. On March 1, 2016, the Company approved a one-year extension to the consulting agreement and the Company approved the grant of a stock award of 15,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros.  The award vests in three equal instalments of 5,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 10,000 vested shares was recorded as stock-based compensation. On March 1, 2017, the final installment of 5,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017.
 
On March 17, 2017, the Company approved the issuance of a further 50,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $170,000, the fair market value of $3.40 per share on grant date, which amount has been expensed as stock-based compensation.
 
On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018.  The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,060), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Mr. Katsaros shall also be entitled to acquire at his discretion 500,000 shares of the common stock at a price of US$1.00 for a term of five years commencing January 2, 2018.
 
The Company recognized stock-based compensation expense allocated to consulting fees of $16,800 during the six months ended September 30, 2018.
 
Subsequent to the period ended September 30, 2018, on November 17, 2018, the Company terminated the consulting agreement with Mr. Katsaros.
F-18
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 11 -   RELATED PARTY TRANSACTIONS (continued)

(b)
Accounts payable and accrued liabilities from related parties:

 
  
September 30,
    
December 31,
  
 
  
2018
    
2017
  
CEO and President (i)
  
$
-
    
$
413,010
  
Director (ii)
    
5,390
      
95,843
  
Consulting fees for VP (iv)
    
1,741
      
-
  
 
  
$
7,131
    
$
508,853
  
 
(c)
Advances / other receivable from related parties:

 Advances from related parties:
September 30,
  
December 31,
  
 
2018
  
2017
  
CEO and President (i)
  
$
-
    
$
287,073
  
Director (ii)
    
-
      
54,282
  
 
  
$
-
    
$
341,355
  
 
(d)
Convertible Debt, related parties:

On February 15, 2018, the Company and certain shareholders holding in excess of 5% of the Company's common stock and concurrently holding a position on the Company's Board, or acting in the capacity of any officer of the Company or its subsidiaries, agreed that repayment against pre-existing debt payable by the Company on the agreement date shall be  suspended until such time as  the Company concludes a full profitable year of operations. Further the parties agreed that any such pre-existing debt or portion thereof shall be convertible at any time into restricted shares of the Company's common stock at a price equal or greater to $0.60 per share. On the date of the agreement the fair market value of the Company's common stock as traded on OTCMarkets was $0.806 per share. The Company accounted for this transaction by applying ASC 470-20-35.  As the convertible debt has no stated redemption date, the Company will recognize the discount as interest expense on the earliest conversion date.  
 
The Company has reclassified all debts payable as of February 15, 2018 to our CEO and CTO from advances and accounts payable, related party, to convertible debt, related party. 

On each of May 31, 2018 and on June 26, 2018, the Company entered into Debt Settlement and Subscription Agreements with the President of the Company, Mr. Sotirios Leontaritis to settle total debt in the amount of $679,371 in respect to certain unpaid salary, advances for operational shortfalls and certain unsettled expense reimbursements into 1,132,286 shares of the Company's common stock at a price of US$0.60 per share. The Company valued the aforementioned issuances at the closing price of the Company's stock as traded on the OTCMarkets on the date of issue. The difference in price resulted in the Company recording loss on debt settlement in the amount of $1,321,971 in respect of the transaction.
F-19
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 11 -   RELATED PARTY TRANSACTIONS (continued)

(d)
Convertible Debt, related parties:(cont'd)

On June 26, 2018, the Company entered into a Debt Settlement and Subscription Agreement with a Director of the Company, Dr. Christos Kapatos to settle total debt in the amount of US$131,870 in respect to certain unpaid salary, advances for operational shortfalls and certain unsettled expense reimbursements into 219,784 shares of the Company's common stock at a price of US$0.60 per share. The Company valued those issuances at the closing price of the Company's stock as traded on the OTCMarkets on the date of issue. The difference in price resulted in the Company recording loss on debt settlement in the amount of $285,718 in respect to the transaction.

Note 12 -   CAPITAL STOCK
 
The Articles of Incorporation authorize the Company to issue 5,000,000 shares of preferred stock with a par value of $0.0001, and 35,000,000 shares of common stock with a par value of $0.0001.  No shares of preferred stock have been issued, however, the Company has granted 25,000 fully vested stock options for the purchase of 25,000 shares of Series A Preferred Stock of the Company at a price of $0.04 per share for a period of five (5) years from the date of vesting. (ref: Note 13 below)

On May 24, 2018 the Company's Board of Directors approved a reverse share split on the basis 20 for 1.  The reverse share split became effective on July 9, 2018. Unless otherwise noted, impacted share amounts and per share information included in the financial statements and notes thereto have been retroactively adjusted for the reverse share split as if such share split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly differently than previously reported due to rounding of fractional shares as a result of the reverse share split.

Share issuances during the nine months ended September 30, 2018

During the nine months ended September 30, 2018, 855,717 shares of common stock were issued in respect of various private placements for total cash proceeds of $664,911.

During the nine months ended September 30, 2018, the Company issued 282,500 shares to employees, board members and consultants valued at $284,200, for services rendered.  The Company valued these issuances based on the closing price of the Company's stock as reflected on the OTC Markets on the respective dates of issuance.

During the nine months ended September 30, 2018, the Company issued 1,132,286 shares valued at fair market value on the date(s) of issuance for a total of $2,001,342 to Mr. Leontaritis to settle debt in the amount of $679,371.  The Company valued those issuances at the closing price of the Company's stock as traded on the OTCMarket on the date of issue. The difference in price resulted in the Company recording a loss on debt settlement in the amount of $1,321,971.

During the nine months ended September 30, 2018, the Company issued 219,784 shares valued at fair market value on the date of issuance of $417,588 to Dr. Christos Kapatos to settle debt in the amount of $131,870.  The Company valued those issuances at the closing price of the Company's stock as traded on the OTCMarket on the date of issue. The difference in price resulted in the Company recording loss on debt settlement in the amount of $285,718.

On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated.   Further concurrent with his resignation and with an effective date of September 30, 2018, Mr. Leontaritis and the Company entered into an agreement whereunder Mr. Leontaritis would surrender for cancelation a total of 189,912 shares of the Company's common stock valued at $0.705 per share in order to settle certain amounts payable to the Company totaling $135,635 including a loss on conversion of $1,747. The returned shares are held in the possession of the Company's Board of Directors and have not yet been provided to the Company's transfer agent for cancelation as at the date of this report.

Designation of Series A Preferred Stock

On January 13, 2014, the Company filed a Certificate of Designation with the Secretary of State of the State of Nevada.   The Certificate of Designation sets forth the rights, preferences and privileges of a class of the Company's preferred stock.  Such class shall be designated as the "Series A Preferred Stock" and the number of shares constituting such series shall be 5,000,000 shares.  The holders of Series A Preferred Stock will be entitled to a preference over all of the shares of the Company's common stock.  Holders of Series A Preferred Stock shall have 50 votes per share of Series A Preferred Stock held by them and shall be entitled to notice of any stockholders' meeting and to vote as a single class upon any matter submitted to the stockholders for a vote.  Each share of Series A Preferred Stock is convertible into 20 shares of our common stock at any time at the holder's option.  Shares of Series A Preferred Stock shall not be entitled to any dividends.  The preferred stock shall be entitled to a preference over all of the shares of common stock of the Company with respect to the distribution of assets in the event of the liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs.


F-20
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 13 - STOCK OPTIONS

A total of 25,000 stock options granted during April and June of fiscal 2014 entitling each holder the right to purchase a total of 5,000 shares of Series A Preferred Stock of the Company at a price of $0.04 per share for a period of five (5) years remain unexercised and outstanding as at September 30, 2018.  The Series A Preferred shares are convertible on the basis of 20 shares of common stock for each one share held and have voting rights of 50 votes per share of Series A Preferred stock held at any meetings of the stockholders.

On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019. Further, Mr. Leontaritis is entitled to acquire at his discretion 150,000 shares of the common stock at a price of $6 per share for a term of five (5) years.

On December 12, 2017, Dr. Christos Kapatos, director, was issued a stock option as part of an extension to his employment contract under which, at his discretion, he may acquire 1,250,000 shares of the common stock at a price of US$1.00 for a term of six years.

Mr. Katsaros shall also be entitled to acquire at his discretion 500,000 shares of the common stock at a price of US$1.00 for a term of five years commencing January 2, 2018.

The Company accounts for share-based payments pursuant to ASC 718, "Stock Compensation" and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company's stock price and expected dividends.

Stock compensation expense for stock options is recognized over the vesting period of the award.

The Company recognized stock-based compensation expense allocated to consulting fees of $184,644 and $122,543 during the three months ended September 30, 2018 and 2017, respectively. The Company recognized stock-based compensation expense allocated to consulting fees of $553,930 and $245,086 during the nine months ended September 30, 2018 and 2017, respectively.  Subsequent to September 30, 2018 each of Mr. Leontaritis and Dr. Kapatos resigned all positions with the Board of Directors, including any consulting contracts. In addition, the consulting contract with Mr. Katsaros was terminated. As a result, any unexercised stock options are expected to expire within 90 days of the respective contract terminations.
 
The following table summarizes information concerning stock options outstanding as of September 30, 2018, and December 31, 2017:

Series A Preferred Stock:
 
 
  
September 30, 2018
    
December 31, 2017
  
 
  
Series A
Preferred stock
    
Weighted Average Exercise Price
$
    
Series A
Preferred stock
    
Weighted Average Exercise Price
$
  
Outstanding at beginning of the year
    
25,000
      
0.04
      
25,000
      
0.04
  
   Granted
    
-
      
-
      
-
      
-
  
   Exercised
    
-
      
-
      
-
      
-
  
   Expired or canceled
    
-
      
-
      
-
      
-
  
Outstanding at the period
    
25,000
      
0.04
      
25,000
      
0.04
  
 
F-21
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 13 - STOCK OPTIONS (continued)

The aforementioned options have an average remaining life of 0.57 years. 

Common stock:
 
 
  
September 30, 2018
    
December 31, 2017
  
 
  
Common
stock
    
Weighted Average Exercise Price
$
    
Common
stock
    
Weighted Average Exercise Price
$
  
Outstanding at beginning of the year
    
1,400,000
      
1.52
      
-
      
-
  
   Granted
    
500,000
      
1.00
      
1,400,000
      
1.52
  
   Exercised
    
-
      
-
      
-
      
-
  
   Expired or canceled
    
-
      
-
      
-
      
-
  
Outstanding at the period
    
1,900,000
      
1.4
      
1,400,000
      
1.52
  
 
The aforementioned options have an average remaining life of 5.05 years. 

Valuation Assumptions

The Company accounts for share-based payments pursuant to ASC 718, "Stock Compensation" and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company's stock price and expected dividends.

Stock compensation expense for stock options is recognized over the vesting period of the award.

The following table presents the range of the weighted average fair value of options granted and the related assumptions used in the Black-Scholes model for stock option grants:

Series A Preferred Stock:
  
 
Options Granted
September 30, 2014
 
Fair value of options granted
1.40 ~ 2.00
 
Assumptions used:
 
 
Expected life (years) (a)
1.00
 
Risk free interest rate (b)
0.11%
 
Volatility (c)
117.09 ~ 119.83 %
 
Dividend yield (d)
0.00
 
 
F-22
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 13 - STOCK OPTIONS (continued)

Common stock:
 
 
Options Granted date
 
Fair value of options granted
0.038 ~ 0.925
 
Assumptions used:
 
 
Expected life (years) (a)
5 ~ 6
 
Risk free interest rate (b)
1.93% ~ 2.25%
 
Volatility (c)
175.40% ~ 254.86%
 
Dividend yield (d)
0.00
 

The Company utilizes the Black-Scholes option pricing model to determine the fair value of each option award. Expected volatilities are based on the historical volatility of the Company's common stock over a period consistent with that of the expected term of the options. The expected term of the options are estimated based on factors such as vesting periods, contractual expiration dates and historical exercise behavior. The risk-free rates for periods within the contractual life of the options are based on the yields of U.S. Treasury instruments with terms comparable to the estimated option terms. The dividend yield rate is not considered in the model, as the Company has not established a dividend policy for the stock.

Note 14 - SEGMENT REPORTING

The Company's operations are classified into two reportable segments that provide different products or services. Separate management of each segment is required because each business unit is subject to different marketing, operations, and growth and technology development strategies.
 
The Clinics segment derives its revenue from provision of services at our P&O Clinic located in Glasgow, Scotland. The Technology segment derives its income from the licensing of its proprietary technologies and ultimately recurring royalty income as well as technology access fees. Presently we are only deriving income from our UK-based operations.  We expect this to be the case until such time as we are able to expand our chain of P&O Clinics.
 
There are no inter-segment sales however, the Company's two primary operating segments do share costs on certain operational overhead including facility rent and staff salaries.

Three months ended September 30, 2018:

  
  
Clinics
(UK)
    
Technology
(UK)
    
All Other
(Greece)
    
Total
  
 
                        
Revenue
  
$
87,665
    
$
3,508
    
$
-
    
$
91,173
  
Depreciation & amortization
  
$
1,785
    
$
10,270
    
$
5,233
    
$
17,288
  
Net (Loss) from operations
  
$
4,431
    
$
(14,751
)
  
$
(372,466
)
  
$
(382,786
)
Interest expenses
  
$
(694
)
  
$
-
    
$
(562
)
  
$
(1,256
)
Assets
  
$
85,901
    
$
115,280
    
$
118,105
    
$
319,286
  
Expenditure on long-lived assets
  
$
-
    
$
-
    
$
-
    
$
-
  

F-23
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018

Note 14 - SEGMENT REPORTING (cont'd)

Three months ended September 30, 2017:

 
  
Clinics
(UK)
    
Technology
(UK)
    
All Other
(Greece)
    
Total
  
 
                        
Revenue
  
$
50,184
    
$
34
    
$
-
    
$
50,218
  
Depreciation & amortization
  
$
2,760
    
$
13,536
    
$
10,110
    
$
26,406
  
Net (Loss) from operations
  
$
(26,623
)
  
$
(19,949
)
  
$
(407,829
)
  
$
(454,401
)
Interest expenses
  
$
(2,561
)
  
$
-
    
$
(857
)
  
$
(3,418
)
Assets
  
$
87,382
    
$
212,288
    
$
87,513
    
$
387,183
  
Expenditure on long-lived assets
  
$
-
    
$
-
    
$
-
    
$
-
  
 
Nine months ended September 30, 2018:

  
  
Clinics
(UK)
    
Technology
(UK)
    
All Other
(Greece)
    
Total
  
 
                        
Revenue
  
$
316,858
    
$
8,398
    
$
-
    
$
325,256
  
Depreciation & amortization
  
$
6,499
    
$
32,765
    
$
16,806
    
$
56,070
  
Net (Loss) from operations
  
$
(5,912
)
  
$
(191,904
)
  
$
(3,015,952
)
  
$
(3,213,768
)
Interest expenses
  
$
(694
)
  
$
-
    
$
(1,791
)
  
$
(2,485
)
Assets
  
$
85,901
    
$
115,280
    
$
118,105
    
$
319,286
  
Expenditure on long-lived assets
  
$
-
    
$
-
    
$
-
    
$
-
  

Nine months ended September 30, 2017:
  
  
  
Clinics
(UK)
    
Technology
(UK)
    
All Other
(Greece)
    
Total
  
 
                        
Revenue
  
$
267,288
    
$
2,630
    
$
-
    
$
269,918
  
Depreciation & amortization
  
$
7,685
    
$
37,601
    
$
29,297
    
$
74,583
  
Net (Loss) from operations
  
$
(4,944
)
  
$
(177,807
)
  
$
(1,315,987
)
  
$
(1,498,738
)
Interest expenses
  
$
(3,618
)
  
$
-
    
$
(1,902
)
  
$
(5,520
)
Assets
  
$
87,382
    
$
212,288
    
$
87,513
    
$
387,183
  
Expenditure on long-lived assets
  
$
-
    
$
-
    
$
-
    
$
-
  

Note 15 - SUBSEQUENT EVENTS

Effective October 3, 2018, Dr. Christos Kapatos resigned from his position as Director of the Company.

Effective October 3, 2018, Mr. Sotirios Leontaritis resigned from his position as the President, Director and Chief Financial Officer of the Company.
Effective October 3, 2018, Mr Nikolaos Kardaras resigned from his position as the Secretary and Director of the Company. Mr. Kardaras' resignation was not the result of any disagreement with the Corporation regarding operations, policies, practices or otherwise. Mr. Kardaras will continue to consult for the Company as an independent contractor in his capacity as in-house legal counsel.
Concurrent with the aforementioned resignations, the Board of Directors appointed Mr. Constantinos Zertalis as a member of the Board of Directors and the President of the Company and Miss Paraskevi Pylarinou as a member of the Board of Directors, Secretary and CFO of the Company.

On October 19, 2018 the Company's Board of Directors appointed Mr. Constantinos Zertalis, CEO, President and Director as Chairman of the Board of Directors.
 
F-24
Rafina Innovations Inc.
(Formerly HCi Viocare)
Notes to Unaudited Condensed Consolidated Financial Statements
For the Nine Months Ended September 30, 2018
 
Note 15 - SUBSEQUENT EVENTS (cont'd)

On October 19, 2018 the Company's Board of Directors approved the grant of a total of 1,500,000 stock awards which vested on the date of grant, and a total of 7,500,000 directors' stock options for exercise at  $0.70 per share which options vest as to 1,500,000 shares on grant date, and 1,500,000 shares each year thereafter for a total of four additional years.

On November 17, 2018, the Company's management terminated a consulting contract with Mr. Sergios Katsaros which takes effect as of December 22, 2018.

On November 17, 2018 the Company's management terminated a consulting agreement with Mr. Haralampos Sgardelis.

On November 21, 2018 the Company's Chief Technology Officer, Dr. Christos Kapatos resigned his position as Chief Technology Officer and as a consultant due to the Company's breach of Sections 3.1 and 3.2 of that certain Consulting Agreement originally entered into April 16, 2014 (as amended from time to time, including, without limitation, Addendum 1, Addendum 2 and Addendum 3, collectively, the "Consulting Agreement").  The Company declined to cure the noticed breach(es) in the ten (10) day period as allotted from notice date and subsequently accepted the resignation of Dr. Kapatos effective November 21, 2018.  Further, on December 4, 2018 the Company notified Dr. Kapatos of the termination of that certain Acquisition agreement between Dr. Kapatos and HCI VIOCARE TECHNOLOGIES LIMITED, the Company's wholly owned subsidiary, dated April 16, 2014, as amended May 8, 2015 (collectively the "Acquisition Agreement").
The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there are no additional subsequent events to disclose.
F-25
Item 2. Management's Discussion and Analysis of Financial Conditions and Results of Operations
 
The following discussion and analysis of the results of operations and financial condition of Rafina Innovations Inc.  for the nine-month period ended September 30, 2018 shall be read in conjunction with the financial statements and notes. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results of the timing of events could differ materially from those projected in these forward-looking statements as a result of a number of factors, including those set forth under the Risk Factors, Special Note Regarding Forward-Looking Statements and Business sections in our Form 10-K as filed with the Securities and Exchange Commission on May 17, 2018. We use words such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could," and similar expressions to identify forward-looking statements.
 
BUSINESS OVERVIEW
 
We were incorporated in the State of Nevada on March 26, 2007 as a company intending to sell medical devices in the northern regions of China. Our intent was to seek strategic relationships with medical device manufacturers both in China and North America with the aim to be their sales and distribution agent in northern China. We also intended to assist Chinese medical device manufacturers on the development of the North American market. The Company did not find suitable relationships with which to progress its business until it undertook a change in management in September 2013. With the change in management, the Company determined that it would initially concentrate on the development and marketing of medical and athletic devices in Europe where management had identified several opportunities for entry into the market for prosthetics and orthotics, as well as sensor based technology, and we commenced commercialization of our various products. We currently have various patents, and patents in progress, for the development of certain healthcare innovations including various athletic applications relative to our FlexisenseTM sensor technology.  In addition, during fiscal 2015, we opened our first Prosthetics and Orthotics total rehabilitation clinic in Glasgow, Scotland.  During fiscal 2016, our flagship P&O clinic in Scotland completed its first full year of operations after relocation to a larger state of the art facility which allowed for a substantive increase in our period over period revenues.  Presently our revenue stream is derived primarily from the Company's flagship P&O clinic with some initial commercial income from prospective licensing partners for applications of our developed technology.

As we continue to implement our growth strategy, our complementary business model of 1) creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and 2) developing a wide portfolio of proprietary hardware solutions with first in line the FlexisenseTM sensor system, aiming to empower the user by providing on demand information in the fields of Digital Health, Prosthetics, Orthotics, Diabetes, Assistive Devices, Sports and Wellbeing, and licensing to established industry participants. Rafina Innovations Inc.  is listed on the OTC Markets in the USA (OTCMarkets: VICA), has its executive office in Athens, Greece and its R&D center in Glasgow, UK.

We have two wholly-owned Scottish subsidiaries: HCi Viocare Technologies Inc. and HCi Viocare Clinics UK Limited, and one wholly owned Greek subsidiary, HCi Viocare Clinics (Hellas) S A. Our Greek subsidiary is currently being liquidated and dissolved. On July 19, 2018 we incorporated a Cyprus subsidiary, Rafina Innovations (Cyprus) Ltd. in order to better facilitate our international banking requirements.

The Company's technologies and R&D portfolio presently consists of:
 
•  
Filing of 3 patents in the UK: pressure sensor system; pressure & shear; pressure & positioning (Dec 2014) (all of which patents were abandoned upon the filing of a new International (PCT) patent application in December 2015 which covers over 140 countries around the world, and includes further advances made to the sensor systems, and a wider range of applications in products that touch people's everyday lives;
Filing of 4 national patents for the Flexisense technology, following the progression of the PCT patent:
Chinese Patent Application
United States Patent Application
Canadian Patent Application
European Patent Application
 
•  
2 further patents drafted and pending filing during fiscal 2018, with a further 4 patent applications currently in draft form;

•  
In excess of 12 prototypes: including 4 different types of  pressure & shear insoles and diabetic walkers; smart cushions, force platessmart mattresses, and tires, with several of these prototypes in the commercialization stage;
 
•  
1 proof of concept device: robotic surgical assistive device;

•  
High level diagrams or complex documentation and software for other innovations in the portfolio.
 
• 
Various customized prototypes in testing and development with commercial partners.
 
6
Key business developments and material events in the most nine months ended September 30, 2018 and to date
  
On January 31, 2018 the Company announced that it will commence development of its own proprietary Blockchain based system for handling sensitive client records in its flagship Prosthetics and Orthotics clinic in Scotland.  Furthermore, the team plans to develop a proprietary Blockchain based system for handling and storing the data produced from the medical applications of its FlexisenseTM technology.

On February 15, 2018, the Company entered into a Term Sheet with Mr. Georgios Thrapsaniotis and Mrs. Stella Thrapsanioti, his spouse ("Stella"), pursuant to which Mr. and Mrs. Thrapsaniotis will purchase certain securities of the Company at a fixed price of US$0.60 per share.  Upon execution of the Term Sheet, one or multiple Private Placement Subscription Agreements are agreed to be entered into during  the immediately following 10 days for total proceeds of USD $360,000 in respect of the issuance of a total of 600,000 shares of the restricted common stock of the Company.  As at the date of the Term Sheet, Mr. and Mrs. Thrapsaniotis collectively owned 902,495 restricted shares of the Company's common stock.

The Term Sheet also provides that Mr. Thrapsaniotis, or his designee, shall be entitled to hold the position of Treasurer of the Company, provided that Mr. and Mrs. Thrapsaniotis hold in excess of 5% of the Company's issued and outstanding common stock collectively, until the conclusion of a full profitable year irrespective of the number of shareholdings held individually or collectively by them at the relevant time. Furthermore, it is agreed by and between the shareholders of the Company who hold as of the date of the Term Sheet in excess of 5% of the Company's common stock, and concurrently hold a position on the Company's Board, or act in the capacity of any officer of the Company or its subsidiaries, that he/she shall not be entitled to receive any repayment against pre-existing debt owed by the Company, as of February 15, 2018, as it is recorded in the Company's financial records, except as otherwise agreed in writing.

Effective February 15, 2018, Mr. Sotirios Leontaritis resigned from his position as the Treasurer of the Company. Concurrently, the Board of Directors appointed Mr. Georgios Thrapsaniotis ("Thrapsaniotis") as a member of the Board of Directors of the Company. Mr. Thrapsaniotis was also appointed Treasurer in accordance with the provisions of a Term Sheet more fully described above.

On February 16, 2018, Thrapsaniotis subscribed for a total of 600,000 shares of the Company's restricted common stock at US$0.60 per share for total cash proceeds of $360,000.  Concurrently, Thrapsaniotis and Stella became affiliates of the Company, holding jointly a total of 1,502,495 shares of the Company's common stock or 11.99% percent of the total issued and outstanding share capital at the time of issuance.

On March 27, 2018, the Company entered into a one-year advisory agreement with Mr. Ravi Vaidyanathan (the "Advisor"). Under the terms and conditions of the Agreement, the Advisor is appointed to the Company's Scientific Advisory Board and shall serve in the position of Biomechatronics and Human Augmentation Advisor.

On March 22, 2018 and March 30, 2018 respectively, Sotirios Leontaritis, the President, Chief Executive Officer and a Director of the Company, entered into a Share Purchase Agreement (the "SPA") and an amendment thereto (the "Addendum"), (collectively herein referred to herein as the "Agreement") with Maschari Ltd. ("Maschari"), a Company incorporated in Cyprus, pursuant to which Mr. Leontaritis sold 6,135,528 of his restricted common shares to Maschari. Mr. Leontaritis received in exchange a Promissory Note dated March 30, 2018, to reflect the terms of the Agreement, in the principal amount of US$7,362,633 or US$1.20 per share, which note shall come due on March 29, 2021. The parties agreed that in the event Maschari defaults on the obligation to pay the Purchase Price according to the terms of the Agreement and the Promissory Note, Maschari will surrender the shares and shall return ownership of said shares to Mr. Leontaritis.  Further, under the terms of the Agreement, the common shares are to be registered in the name of Maschari, however, until such time as the Promissory Note is paid in full, or the parties agree by written addendum thereto to the release of shares on a pro-rata basis in such amounts as may equal installment payments received, the shares shall remain encumbered. Further, in the event of any reverse split, forward split, cancellation or class conversion, as may occur in the normal course, which impacts the Company's common shares, it is agreed by the parties that such replacement shares, regardless of class and number, will continue to remain in escrow and may not be sold until paid in full and/or the parties have agreed to their release on a pro-rata basis for consideration received.

The shares sold by Mr. Leontaritis represented approximately 49.1% of the Company's total outstanding shares common stock. Mr. Leontaritis continues to hold 1,965,619 shares of the Company's common stock representing approximately 13.6% of the issued and outstanding shares.  As a result of the aforementioned transaction, Maschari has the ability to control the approval of most corporate actions, including increasing the authorized capital stock and the dissolution, merger or sale of the Company's assets, as may be presented at Shareholder meetings from time to time.

7
On January 16, 2018, the Company entered into a one-year service agreement with Mr. Nikolaos Gemelos ("Gemelos"). Under the terms of the Agreement, Gemelos provides services to the Company as Consultant, for a term of one (1) year and he is entitled to a success fee of 5% of the amount actually invested in the Company by introduced accredited investors, and 5% of the amount invested in the form of restricted shares of the common stock of the Company. On May 3, 2018, the Company entered into an amendment to the aforementioned Agreement. Under the terms and conditions of this Addendum, Gemelos shall be awarded 5,000 restricted common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $1.34 per share for total consideration of $6,700.

On May 23, 2018 the Company approved an amendment to the term of the scientific advisory agreement with Dr. Christos Kapatos, board member CTO and member of the Scientific Advisory Board, originally entered into on April 15, 2014 in order to extend the term to April 15, 2019.

On May 24, 2018 the Company incorporated a wholly owned subsidiary for purposes of completing a merger and name change from HCi Viocare to Rafina Innovations, Inc. Concurrently the Company's Board of Directors approved a reverse share split on the basis 20 for 1.  The name change and reverse share split became effective on July 9, 2018.  Unless otherwise noted, impacted share amounts and per share information included in the financial statements and notes thereto have been retroactively adjusted for the reverse share split as if such share split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly differently than previously reported due to rounding of fractional shares as a result of the reverse share split.

On June 7, 2018, the Company entered into a six-month service agreement with Mr. Georgios Dritsoulas. As per terms of said Agreement, Mr. Dritsoulas will provide services to the Company as Consultant for the development and expansion of the Company's business for a term of six (6) months. Mr. Dritsoulas received compensation of 2,500 restricted common shares as compensation for the services provided. The issued shares were valued at fair market value on the date of issuance or $2 per share for total consideration of $5,000.

On each of May 31, 2018 and on June 26, 2018, the Company entered into Debt Settlement and Subscription Agreements with the President of the Company, Mr. Sotirios Leontaritis to settle total debt in the amount of $679,371 in respect to certain unpaid salary, advances for operational shortfalls and certain unsettled expense reimbursements.  into 1,132,286 shares of the Company's common stock at a price of US$0.60 per share. The Company valued the aforementioned issuances at the closing price of the Company's stock as traded on the OTCMarket on the date of issue. The difference in price resulted in the Company recording interest expenses in the amount of $1,321,971 in respect of the transactions.

On June 26, 2018, the Company entered into a Debt Settlement and Subscription Agreement with a Director of the Company, Dr. Christos Kapatos to settle total debt in the amount of US$131,870 in respect to certain unpaid salary, advances for operational shortfalls and certain unsettled expense reimbursements into 219,784 shares of the Company's common stock at a price of US$0.60 per share. The Company valued those issuances at the closing price of the Company's stock as traded on the OTCMarket on the date of issue. The difference in price resulted in the Company recording interest expenses in the amount of $285,718 in respect to the transaction.

Effective October 3, 2018, Dr. Christos Kapatos resigned from his position as Director of the Company.

On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated.   Further concurrent with his resignation and with an effective date of September 30, 2018, Mr. Leontaritis and the Company entered into an agreement whereunder Mr. Leontaritis would surrender for cancelation a total of 189,912 shares of the Company's common stock valued at $0.705 per share in order to settle certain amounts payable to the Company totaling $135,635 including a loss on conversion of $1,747. The shares are held in the possession of the Company's Board of Directors and have not yet been provided to the Company's transfer agent for cancelation as at the date of this report.
8

Effective October 3, 2018, Mr Nikolaos Kardaras resigned from his position as the Secretary and Director of the Company. Mr. Kardaras' resignation was not the result of any disagreement with the Corporation regarding operations, policies, practices or otherwise. Mr. Kardaras will continue to consult for the Company as an independent contractor in his capacity as in-house legal counsel.

Concurrent with the aforementioned resignations, the Board of Directors appointed Mr. Constantinos Zertalis as a member of the Board of Directors and the President of the Company and Miss Paraskevi Pylarinou as a member of the Board of Directors, Secretary and CFO of the Company.

On October 19, 2018 the Company's Board of Directors appointed Mr. Constantinos Zertalis, CEO, President and Director as Chairman of the Board of Directors.

On October 19, 2018 the Company's Board of Directors approved the grant of a total of 1,500,000 stock awards which vested on the date of grant, and a total of 7,500,000 directors' stock options for exercise at  $0.70 per share which options vest as to 1,500,000 shares on grant date, and 1,500,000 shares each year thereafter for a total of four additional years.

On November 17, 2018, the Company's management terminated a consulting contract with Mr. Sergios Katsaros which takes effect as of December 22, 2018.

On November 17, 2018 the Company's management terminated a consulting agreement with Mr. Haralampos Sgardelis

On November 21, 2018 the Company's Chief Technology Officer, Dr. Christos Kapatos resigned his position as Chief Technology Officer and as a consultant due to the Company's breach of Sections 3.1 and 3.2 of that certain Consulting Agreement originally entered into April 16, 2014 (as amended from time to time, including, without limitation, Addendum 1, Addendum 2 and Addendum 3, collectively, the "Consulting Agreement").  The Company declined to cure the noticed breach(es) in the ten (10) day period as allotted from notice date and subsequently accepted the resignation of Dr. Kapatos effective November 21, 2018.  Further, on December 4, 2018 the Company notified Dr. Kapatos of the termination of that certain Acquisition agreement between Dr. Kapatos and HCI VIOCARE TECHNOLOGIES LIMITED, the Company's wholly owned subsidiary, dated April 16, 2014, as amended May 8, 2015 (collectively the "Acquisition Agreement").

Additional information on the Company's activities, technologies and management team can be found at the Company's website: http://www.rafinainnovations.com

Other than as set out herein, we have not been involved in any bankruptcy, receivership or similar proceedings, nor have we been a party to any material reclassification, merger, consolidation or purchase or sale of a significant amount of assets not in the ordinary course of our business.
9

 
RESULTS OF OPERATIONS
 
Comparison of the Three Months Ended September 30, 2018 and 2017

Revenue, Cost of Revenue, and Gross Profit - We have incurred losses since inception. We generated $91,173 in revenues from operations and $20,994 in costs of goods sold for the three months ended September 30, 2018, compared to $50,218 in revenue and $8,037 in costs of goods sold for the three-month period ended September 30, 2017.   The current quarter increase in revenue is due to growth in the services provided period over period at the P&O clinic.  In addition, during the current three-month period we experienced an increase in consultation and repair services for which there are no associated costs of goods as these services are provided by salaried employees.
 
During fiscal 2018 the Company was able to continue to provide high margin orthotics services to a larger number of customers. This is despite the fluctuation in the exchange rate of the GBP to USD period over period, which greatly impacts our US dollar reporting results as the majority of our income is earned in GBP. The slight increase to costs of goods sold period over period is due to more costly supplies required for the current period prosthetic devices and associated products. 

Operating Expenses – Operating expenses totaled $447,684 in the three months ended September 30, 2018 and were increased as compared to operating expenses of $474,316 in the prior three-month comparative period.   Professional fees increased dramatically period over period from $12,655 in fiscal 2017 to $52,766 in the current three-month period ended September 30, 2018 as a result of certain additional legal services required. Consulting fees decreased substantially from $302,825 (2017) to $262,043 in 2018.  In the case of the consulting fees the change in reported expenses relates to the valuation of stock-based compensation in the prior three-month period with no similar charges in the three months ended September 30, 2018.   Office rent decreased in the comparative periods as we relocated from our Athens office, however research and development, office and travel expenses decreased in the three months ended September 30, 2018 as compared to results from the same three month period in 2017 due the Company received R&D tax credit in the amount of $52,766.
 
Loss from Operations – During the three-month periods ended September 30, 2018 and 2017 we recorded losses from operations of $377,505 and $432,135 respectively.

Other expenses - During the three months ended September 30, 2018, the Company recorded a loss on foreign currency translation of $2,278 as compared to only $1,141 in the prior comparative three-month period.  Further we recorded interest expenses to third parties of $1,256 with no comparative costs in the prior three-month period, and interest expenses due to related parties of $0 compared to $3,418 in the prior three months ended September 30, 2017. During the three months ended September 30, 2018 and 2017, the Company reported a loss on debt settlement of $1,747 and $17,707, respectively.

Net Loss - During the comparative three-month periods ended September 30, 2018  we recorded a net loss of $382,786 and $454,401 respectively at the three months ended September 30, 2018 and 2017.

Comparison of the Nine Months Ended September 30, 2018 and 2017

Revenue, Cost of Revenue, and Gross Profit - We have incurred losses since inception. We generated $325,256 in revenues from operations and $110,791 in costs of goods sold for the nine months ended September 30, 2018, compared to $269,918 in revenue and $84,616 in costs of goods sold for the nine-month period ended September 30, 2017.   The current period increase in revenue is due to growth in the services provided period over period at the P&O clinic.  In addition, during the current nine-month period we experienced an increase in consultation and repair services for which there are no associated costs of goods as these services are provided by salaried employees.
10
During fiscal 2018 the Company was able to continue to provide high margin orthotics services to a larger number of customers. This is despite the fluctuation in the exchange rate of the GBP to USD period over period, which greatly impacts our US dollar reporting results as the majority of our income is earned in GBP. The slight increase to costs of goods sold period over period is due to more costly supplies required for the current period prosthetic devices and associated products. 

Operating Expenses – Operating expenses totaled $1,810,557 in the nine months ended September 30, 2018 and were increased as compared to operating expenses of $1,661,156 in the prior nine months comparative period.   Professional fees decreased dramatically period over period from $267,140 in fiscal 2017 to $118,086 in the current nine months period ended September 30, 2018 as a result of certain professional fees being settled by the issuance of stock based compensation in fiscal 2017, with no similar expense in fiscal 2018. Consulting fees increased substantially from $842,998 (2017) to $1,071,802 (2018).  In the case of the consulting fees the change in reported expenses relates to the valuation of stock-based compensation in the current nine-month period as well as an overall increase to consulting services provided to the Company in the current period.  During fiscal 2017 the Company recorded stock-based compensation of $407,650 as compared to $468,842 in the nine months ended September 30, 2018.   While expenses paid for office rent remained relatively consistent, research and development and travel expenses increased substantially in the nine months ended September 30, 2018 as compared to results from the same nine months period in 2017.
 
Loss from Operations – During the nine-month periods ended September 30, 2018 and 2017 we recorded losses from operations of $1,596,092 and $1,475,854 respectively.

Other expenses - During the nine months ended September 30, 2018, the Company recorded loss on debt settlement of $1,607,689 in respect to certain advances, fees and expenses settled by the issuance of shares at a discount to market. Further the Company recorded a loss on foreign currency translation of $5,755 in the current period as compared to a gain of $343 in the prior comparative nine months. Interest expenses to third parties totaled $2,485 and $Nil over the comparative nine months periods ended September 30, 2018 and 2017. During the nine months ended September 30, 2018 and 2017, the Company reported a loss on debt settlement of $1,609,436 and $17,707, respectively.

Net Loss - During the comparative nine-month periods ended September 30, 2018 we recorded a net loss of $3,213,768 and $1,498,738 respectively at the nine months ended September 30, 2018 and 2017.

CAPITAL RESOURCES AND LIQUIDITY
 
At September 30, 2018, we had $29,713 cash on deposit, $50,725 in accounts receivables, $88,822 in other receivables, $4,245 in inventory, and prepaid expenses of $50,146 for total current assets of $223,651.  Further we had current liabilities of $527,103 in accounts payable and accrued expenses (including amounts due to related parties), $80,000 in income taxes payable and $80,510 in short term notes from third parties.   We had a working capital deficit of $463,962 as at September 30, 2018. While the Company's prosthetics and orthotics clinic in Glasgow has increased its patient through-put year over year, sales were not sufficient to cover our consolidated operational expenses.  We commenced generating revenue from commercial evaluation of our available technologies in fiscal 2016, however we did not record revenue in this segment in the nine months ended September 30, 2018, as we continue to work towards a larger commercial licensing contract.  Presently we rely on our advances from our President and director, third party loans, as well as private placements from qualified investors, and our Board members, to fund our general operating expenses.   We secured loans and advances from related parties during the nine months ended September 30, 2018 of $202,345 and made repayments towards related party advances of $314,041 in the current nine months period. The Company has closed private placements in the amount of $664,911 in the nine months ended September 30, 2018 and has received loans from third parties of $34,673.  These amounts contribute to our ongoing operating expenses and obligations until such time as the Company can conclude a larger equity-based financing, anticipated during the fiscal year 2019.
11

The Company expects it will need to raise a total of $5,000,000 to $15,000,000 to fund its proposed operations for the next twelve to thirty-nine months, including the planned expansion of its P&O Clinics to add up to 5 additional site locations. It intends to fund operations by a combination of related party loans, debt financing and equity placements, as well as through joint venture partnerships negotiated in our recently completed quarter. The Company is seeking equity private placements from qualified investors with which to fund operations until such time as it can secure alternate financing arrangements.  The Company is also seeking joint venture partners for its various Insole technology applications as a further means to fund ongoing commercialization efforts.

There can be no assurance that continued funding will be available on satisfactory terms.
 
GOING CONCERN

The Company incurred net losses of $382,786 and $3,213,768 for the three and nine months ended September 30, 2018, respectively, and net loss of $454,401 and $1,498,738 for the three and nine months ended September 30,2017, respectively and has a retained deficit of $37,950,401. In addition, the Company had a working capital deficiency of $463,962 and a stockholders' deficit of $368,327 at September 30, 2018. These factors raise substantial doubt about the Company's ability to continue as a going concern. 
 
There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders. 
   
NEED FOR ADDITIONAL FINANCING
 
Costs associated with being a public company are much higher than those of a private company. Rafina Innovations Inc.  has chosen public registration before the business has developed a predictable cash flow. There are present registration expenses and future legal and accounting expenses, future reporting requirements to the SEC, future exchange listing requirements, and future investor relations costs that must be borne by a public company but not by a private company. These costs can be a burdensome expense which could adversely affect our financial survival. The ongoing regulatory costs, reporting requirements, and management details, which must be met when registering and maintaining a public company, may make the economic viability of Rafina Innovations Inc.  very doubtful.  In addition, the Company requires additional financing in order to continue to execute its business plan which includes the commercialization of one or more technologies, the ongoing operation of a P&O clinic in Glasgow, the opening of several additional P&O clinics in identified European markets, as well as other strategically placed P&O clinics, as well as ongoing research and development to bring new technologies to market.
 
In the past we have relied on advances from our President and private placements from accredited investors to cover our operating costs. There can be no assurance that any other capital will be available if and when required from qualified investors or related parties.   Our need for capital may change dramatically if we acquire an interest in a business opportunity during that period which requires us to provide financing. Recently we have entered into a joint venture agreement with a third party for a series of P&O clinics in the Kingdom of Saudi Arabia.  While the burden of the financing rests with our joint venture partner, our revenue stream from these clinics will not commence until such time as they are in operation, at which time we will commence earning management fees. Further there can be no assurance that we will identify and conclude contracts for our various technologies which will result in profitable operation. We cannot assure that we will be successful in consummating any acquisition or contracts on favorable terms or that we will be able to profitably manage any business venture we acquire. Should we require additional capital, we may seek additional advances from officers, sell common stock or find other forms of debt financing.
 
CRITICAL ACCOUNTING POLICIES
 
Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States ("GAAP"). GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, and revenue and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.
 
12
Our significant accounting policies are summarized in Note 4 of our financial statements for the nine-month period ended September 30, 2018.  While all these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause a material effect on our consolidated results of operations, financial position or liquidity for the periods presented in this report.

RECENT ACCOUNTING PRONOUNCEMENTS
 
There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.  During the period the Company adopted ASC 606 – Revenue from Contracts with Customers. There was no impact on the Company's financial statements as a result of adopting Topic 606 for the nine months ended September 30, 2018 and 2017, or the twelve months ended December 31, 2017.

OFF BALANCE SHEET ARRANGEMENTS
 
We do not have any off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as "special purpose entities" (SPEs).
 
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
 
Not applicable.
 
Item 4. Controls and Procedures.
 
Evaluation of Disclosure Controls and Procedures

Our management, under supervision and with the participation of the Company's Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined under Exchange Act Rule 13a-15(e). Based upon this evaluation, the Principal Executive Officer and Principal Financial Officer concluded that, as of September 30, 2018, because of the material weakness in our internal control over financial reporting ("ICFR") described below, our disclosure controls and procedures were not effective.
 
Disclosure controls and procedures are controls and other procedures that are designed to ensure that required information to be disclosed in our reports filed or submitted under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that required information to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the period covered by this report, there were no changes (including corrective actions with regard to significant deficiencies or material weaknesses) in our internal controls over financial reporting that occurred that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
13

PART II - OTHER INFORMATION
 
Item 1. Legal Proceedings. 
 
Viocare, Inc. a New Jersey corporation (the «Plaintiff») filed a complaint on October 24, 2016 in the United States District Court, District of Nevada objecting to the use of the name «viocare» by Rafina Innovations Inc. , of Nevada (the «Defendant»). The Company and Viocare Inc. have agreed to terms of settlement effective October 19, 2017.  Under the terms of the settlement, among other concessions the Company has agreed to the following:

 - To remove "Viocare" from its registered name in the State of Nevada, its website and all usage in the United States of America and Canada, including any registered trademarks;
 
 - To remove "Viocare" from the subsidiary UK registered company "HCI VIOCARE TECHNOLOGIES LIMITED", its website, if any, and all usage in the United States of America and Canada, including any registered trademarks;

 - It is allowed to the Company to use the trademark "VIOCARE" only on its activities in health care services field excluding the territory of U.S.A. and Canada.

 - No objection to the Plaintiff's use of its mark in Europe provided Plaintiff does not use for P&O clinics, or goods and services related diabetic foot care; and,

- The Company undertook to terminate the website at http://www.hciviocare.com and assign Company's URL(s) to Plaintiff.

The Company has completed a name change in the State of Nevada effective July 9, 2018, in order to comply with this settlement and will alter the name of its UK subsidiary company HCI VIOCARE TECHNOLOGIES LIMITED to RAFINA TECHNOLOGIES LIMITED at the earliest practicable date.
 
We know of no other material, active or pending legal proceedings against our Company, nor of any proceedings that a governmental authority is contemplating against us.
 
Item 1A. Risk Factors.
 
Smaller reporting companies are not required to provide the information required by this item.
 
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated.   Further concurrent with his resignation and with an effective date of September 30, 2018, Mr. Leontaritis and the Company entered into an agreement whereunder Mr. Leontaritis would surrender for cancelation a total of 189,912 shares of the Company's common stock valued at $0.705 per share in order to settle certain amounts payable to the Company totaling $135,635 including a loss on conversion of $1,747. The shares are held in the possession of the Company's Board of Directors and have not yet been provided to the Company's transfer agent for cancelation as at the date of this report.

There were no unregistered securities to report which were sold or issued by the Company without the registration of these securities under the Securities Act of 1933 in reliance on exemptions from such registration requirements, within the period covered by this report, which have not been previously included in a Quarterly Report on Form 10-Q or a Current Report on Form 8-K.

14
Item 3. Defaults Upon Senior Securities.
 
None.
 
Item 4. Mine Safety Disclosures.
 
Not applicable.
 
Item 5. Other Information.

(a)
The Company has received two oppositions for use of the filed trade mark «Flexisense» by the Company in certain usage classes.  The first  being a USPTO Office Action and another from the company Grupo Flexi de Leon, S.A. de C.V. 

The FLEXISENSE word mark (Serial Number 86969718) and the class IC 025 in connection with footwear and shoes has been abandoned due to opposition of Grupo Flexi de Leon S.A. de C.V.

With regard to the FLEXISENSE design mark (Serial Number 86969716), we are required to submit specimens to show use in each class in the application: IC 009, IC 010 and IC 012. As our specimens are not yet available we have filed an extension of time for another six months from May 31, 2018, and we are expecting the consent of USPTO.

(b)
On May 24, 2018 the Company incorporated a wholly owned subsidiary for purposes of completing a merger and name change from HCi Viocare to Rafina Innovations, Inc. Concurrently the Company's Board of Directors approved a reverse share split on the basis 20 for 1.  The name change and reverse share split became effective on July 9, 2018.

The Company's trading symbol remained unchanged and is OTC Markets:VICA.  The Company's CUSIP is 75063R106.

(c) Changes in Management

Effective October 3, 2018, Dr. Christos Kapatos resigned from his position as Director of the Company.

Effective October 3, 2018, Mr. Sotirios Leontaritis resigned from his position as the President, Director and Chief Financial Officer of the Company.
Effective October 3, 2018, Mr Nikolaos Kardaras resigned from his position as the Secretary and Director of the Company. Mr. Kardaras' resignation was not the result of any disagreement with the Corporation regarding operations, policies, practices or otherwise. Mr. Kardaras will continue to consult for the Company as an independent contractor in his capacity as in-house legal counsel.
Concurrent with the aforementioned resignations, the Board of Directors appointed Mr. Constantinos Zertalis as a member of the Board of Directors and the President of the Company and Miss Paraskevi Pylarinou as a member of the Board of Directors, Secretary and CFO of the Company.

On October 19, 2018 the Company's Board of Directors appointed Mr. Constantinos Zertalis, CEO, President and Director as Chairman of the Board of Directors.

On November 21, 2018 the Company's Chief Technology Officer, Dr. Christos Kapatos resigned his position as Chief Technology Officer and as a consultant due to the Company's breach of Sections 3.1 and 3.2 of that certain Consulting Agreement originally entered into April 16, 2014 (as amended from time to time, including, without limitation, Addendum 1, Addendum 2 and Addendum 3, collectively, the "Consulting Agreement").  The Company declined to cure the noticed breach(es) in the ten (10) day period as allotted from notice date and subsequently accepted the resignation of Dr. Kapatos effective November 21, 2018.  Further, on December 4, 2018 the Company notified Dr. Kapatos of the termination of that certain Acquisition agreement between Dr. Kapatos and HCI VIOCARE TECHNOLOGIES LIMITED, the Company's wholly owned subsidiary, dated April 16, 2014, as amended May 8, 2015 (collectively the "Acquisition Agreement").
15
Item 6. Exhibits, Financial Statement Schedules

 
Exhibits:
Description
 
Filed herewith
31.2 Certification of Principal Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith
Filed herewith
32.2 Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Filed herewith
Filed herewith
Filed herewith
Filed herewith
Filed herewith
Filed herewith
Filed herewith


SIGNATURES

 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
 
Rafina Innovations Inc.
 
 
 
 
Date:
December 28, 2018
By:
/s/ Constantinos Zertalis
 
 
Name:
Constantinos Zertalis
 
 
Title:
Chief Executive Officer and President (Principal Executive Officer) Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
       
Date:
December 28, 2018
By:
/s/ Paraskevi Pylarinou
 
 
Name:
Paraskevi Pylarinou
 
 
Title:
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)


16
 EX-31.1 2 ex311.htm CERTIFICATION
EXHIBIT 31.1
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Constantinos Zertalis, certify that:

 1.  
I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 of Rafina Innovations, Inc. (the "registrant");

 2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

 3.  
Based on my knowledge, the financial statements, and other financial information included in this  report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;

 4.  
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 a)  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

 b)  
Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 c)  
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this Report,  our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

 d)  
Disclosed in this Report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the  registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
 5.  
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 a)  
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 b)  
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

  
 
 
 
Date: December 28, 2018
By:
/s/ Constantinos Zertalis
 
 
Name:
 Constantinos Zertalis
 
 
Title:
 Chief Executive Officer and Principal Executive Officer
 



EX-31.2 3 ex312.htm CERTIFICATION
EXHIBIT 31.2
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Paraskevi Pylarinou, certify that:

 1.  
I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 of Rafina Innovations, Inc. (the "registrant");

 2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

 3.  
Based on my knowledge, the financial statements, and other financial information included in this  report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;

 4.  
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 a)  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

 b)  
Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 c)  
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this Report,  our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

 d)  
Disclosed in this Report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the  registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 5.  
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 a)  
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 b)  
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

  
 
 
 
Date: December 28, 2018
By:
/s/Paraskevi Pylarinou
 
 
Name:
 Paraskevi Pylarinou
 
 
Title:
 Chief Financial Officer (Principal Financial and Accounting Officer)
 

EX-32.1 4 ex321.htm CERTIFICATION
 
EXHIBIT 32.1
CERTIFICATION OF
CHIEF EXECUTIVE OFFICER AND PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Constantinos Zertalis, Chief Executive Officer and Principal Executive Officer of Rafina Innovations, Inc.  (the "Company"), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 1.  
The Report on Form 10-Q of the Company for the quarter ended September 30, 2018, which this certification accompanies (the "Periodic Report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 2.  
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 Date:  December 28, 2018
By:
/s/ Constantinos Zertalis
 
 
Name:
Constantinos Zertalis
 
 
Title:
Chief Executive Officer and Principal Executive Officer
 

This certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.


 EX-32.2 5 ex322.htm CERTIFICATION
EXHIBIT 32.2
CERTIFICATION OF
PRESIDENT AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Paraskevi Pylarinoubov, Chief Financial Officer and Principal Financial Officer of Rafina Innovations, Inc.  (the "Company"), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 1.  
The Report on Form 10-Q of the Company for the quarter ended September 30, 2018, which this certification accompanies (the "Periodic Report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 2.  
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 Date:  December 28, 2018
By:
/s/Paraskevi Pylarinou
 
 
Name:
Paraskevi Pylarinou
 
 
Title:
Chief Financial Officer and Principal Financial Officer
 

This certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.



 EX-101.INS 6 vica-20180930.xml XBRL INSTANCE DOCUMENT 0001402737 us-gaap:SeriesAPreferredStockMember 2014-01-01 2014-01-13 0001402737 us-gaap:PresidentMember 2014-01-01 2014-01-15 0001402737 country:GR 2014-02-03 0001402737 country:GR 2014-01-26 2014-02-03 0001402737 vica:LeaseAgreementMember 2014-01-26 2014-02-03 0001402737 vica:ChristosKapatosMember 2014-04-05 2014-04-16 0001402737 vica:ConsultingAgreementMember vica:ChiefTechnicalOfficerMember 2014-04-05 2014-04-16 0001402737 us-gaap:SeriesAPreferredStockMember us-gaap:StockOptionMember 2014-04-17 2014-04-30 0001402737 us-gaap:SeriesAPreferredStockMember us-gaap:StockOptionMember 2014-06-12 2014-06-30 0001402737 us-gaap:SeriesAPreferredStockMember 2014-09-01 2014-09-30 0001402737 us-gaap:SeriesAPreferredStockMember srt:MaximumMember 2014-09-01 2014-09-30 0001402737 us-gaap:SeriesAPreferredStockMember srt:MinimumMember 2014-09-01 2014-09-30 0001402737 us-gaap:CommonStockMember 2014-09-01 2014-09-30 0001402737 us-gaap:CommonStockMember srt:MaximumMember 2014-09-01 2014-09-30 0001402737 us-gaap:CommonStockMember srt:MinimumMember 2014-09-01 2014-09-30 0001402737 vica:ClinicInGreeceMember 2014-12-29 0001402737 vica:ClinicInGreeceMember 2014-12-20 2014-12-29 0001402737 country:GB 2015-03-02 0001402737 country:GB vica:ValueAddedTaxMember 2015-03-02 0001402737 vica:SecretaryMember 2015-05-06 2015-05-28 0001402737 2015-08-20 2015-09-01 0001402737 vica:ClinicInGreeceMember 2015-08-20 2015-09-01 0001402737 us-gaap:VicePresidentMember vica:FinalInstalmentsMember 2016-02-25 2016-03-01 0001402737 2016-01-01 2016-12-31 0001402737 vica:SecretaryMember 2016-01-01 2016-12-31 0001402737 2016-12-31 0001402737 us-gaap:SeriesAPreferredStockMember 2016-12-31 0001402737 us-gaap:CommonStockMember 2016-12-31 0001402737 vica:ConsultingAgreementMember vica:CharalamposSgardelisMember 2016-12-28 2017-01-03 0001402737 us-gaap:SubsidiaryOfCommonParentMember 2016-12-26 2017-01-05 0001402737 us-gaap:VicePresidentMember 2017-02-24 2017-03-01 0001402737 vica:InstallmentsMember us-gaap:VicePresidentMember 2017-02-24 2017-03-01 0001402737 2017-03-03 0001402737 2017-03-02 2017-03-03 0001402737 vica:ChristosKapatosMember 2017-03-02 2017-03-03 0001402737 vica:SecretaryMember 2017-03-02 2017-03-03 0001402737 vica:KatsarosMember 2017-03-17 0001402737 us-gaap:VicePresidentMember 2017-03-02 2017-03-17 0001402737 2017-03-31 0001402737 vica:ConsultingAgreementMember vica:JambGroupLlcMember 2017-06-22 2017-07-10 0001402737 vica:ConsultingAgreementMember vica:MrStefanosBatzakisMember 2017-08-26 2017-09-01 0001402737 2017-07-01 2017-09-30 0001402737 us-gaap:PresidentMember 2017-07-01 2017-09-30 0001402737 us-gaap:VicePresidentMember 2017-07-01 2017-09-30 0001402737 us-gaap:DirectorMember 2017-07-01 2017-09-30 0001402737 vica:CeoAndPresidentMember 2017-07-01 2017-09-30 0001402737 us-gaap:HealthcareSectorMember country:GB 2017-07-01 2017-09-30 0001402737 us-gaap:TechnologySectorMember country:GB 2017-07-01 2017-09-30 0001402737 vica:AllOtherMember country:GR 2017-07-01 2017-09-30 0001402737 us-gaap:PresidentMember 2017-04-01 2017-09-30 0001402737 2017-01-01 2017-09-30 0001402737 us-gaap:VicePresidentMember 2017-01-01 2017-09-30 0001402737 us-gaap:DirectorMember 2017-01-01 2017-09-30 0001402737 vica:CeoAndPresidentMember 2017-01-01 2017-09-30 0001402737 us-gaap:HealthcareSectorMember country:GB 2017-01-01 2017-09-30 0001402737 us-gaap:TechnologySectorMember country:GB 2017-01-01 2017-09-30 0001402737 vica:AllOtherMember country:GR 2017-01-01 2017-09-30 0001402737 2017-09-30 0001402737 us-gaap:HealthcareSectorMember country:GB 2017-09-30 0001402737 us-gaap:TechnologySectorMember country:GB 2017-09-30 0001402737 vica:AllOtherMember country:GR 2017-09-30 0001402737 vica:ConsultingAgreementMember vica:IoannisDoupisMember 2017-10-01 2017-10-09 0001402737 vica:ChristosKapatosMember 2017-12-12 0001402737 vica:KatsarosMember 2017-12-12 0001402737 us-gaap:CommonStockMember vica:ChristosKapatosMember 2017-12-12 0001402737 2017-12-01 2017-12-12 0001402737 vica:ChristosKapatosMember 2017-12-01 2017-12-12 0001402737 vica:KatsarosMember 2017-12-01 2017-12-12 0001402737 us-gaap:CommonStockMember vica:ChristosKapatosMember 2017-12-01 2017-12-12 0001402737 vica:ConsultingAgreementMember vica:ParaskeviPilarinouMember 2017-12-01 2017-12-12 0001402737 2017-01-01 2017-12-31 0001402737 us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-12-31 0001402737 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001402737 vica:SecretaryMember 2017-01-01 2017-12-31 0001402737 2017-12-31 0001402737 us-gaap:SeriesAPreferredStockMember 2017-12-31 0001402737 country:GR 2017-12-31 0001402737 us-gaap:CommonStockMember 2017-12-31 0001402737 country:GB 2017-12-31 0001402737 us-gaap:SubsidiaryOfCommonParentMember 2017-12-31 0001402737 us-gaap:VicePresidentMember 2017-12-31 0001402737 us-gaap:DirectorMember 2017-12-31 0001402737 vica:CeoAndPresidentMember 2017-12-31 0001402737 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001402737 us-gaap:OfficeEquipmentMember 2017-12-31 0001402737 us-gaap:ComputerEquipmentMember 2017-12-31 0001402737 us-gaap:VehiclesMember 2017-12-31 0001402737 vica:PlantAndMachineMember 2017-12-31 0001402737 vica:LabEquipmentMember 2017-12-31 0001402737 vica:SubsidiaryOfCommonParentOneMember 2017-12-31 0001402737 vica:ServicesAgreementMember vica:NikolaosGemelosMember 2018-01-01 2018-01-16 0001402737 2018-02-01 2018-02-15 0001402737 vica:ConsultingAgreementMember vica:CharalamposSgardelisMember 2018-02-01 2018-02-26 0001402737 vica:ConsultingAgreementMember vica:RaviVaidyanathanMember 2018-03-01 2018-03-27 0001402737 vica:ServicesAgreementMember vica:NikolaosGemelosMember 2018-04-15 2018-05-03 0001402737 2018-05-01 2018-05-24 0001402737 2018-05-31 0001402737 2018-05-15 2018-05-31 0001402737 us-gaap:PresidentMember 2018-05-15 2018-05-31 0001402737 vica:ServicesAgreementMember vica:GeorgiosDritsoulasMember 2018-05-15 2018-06-07 0001402737 2018-06-26 0001402737 2018-06-01 2018-06-26 0001402737 vica:SubsidiaryOfCommonParentOneMember 2018-07-01 2018-07-27 0001402737 2018-07-01 2018-09-30 0001402737 us-gaap:PresidentMember 2018-07-01 2018-09-30 0001402737 vica:ChristosKapatosMember 2018-07-01 2018-09-30 0001402737 us-gaap:VicePresidentMember 2018-07-01 2018-09-30 0001402737 us-gaap:DirectorMember 2018-07-01 2018-09-30 0001402737 vica:CeoAndPresidentMember 2018-07-01 2018-09-30 0001402737 us-gaap:HealthcareSectorMember country:GB 2018-07-01 2018-09-30 0001402737 us-gaap:TechnologySectorMember country:GB 2018-07-01 2018-09-30 0001402737 vica:AllOtherMember country:GR 2018-07-01 2018-09-30 0001402737 us-gaap:PresidentMember 2018-04-01 2018-09-30 0001402737 2018-01-01 2018-09-30 0001402737 us-gaap:SeriesAPreferredStockMember 2018-01-01 2018-09-30 0001402737 us-gaap:PresidentMember 2018-01-01 2018-09-30 0001402737 country:GR 2018-01-01 2018-09-30 0001402737 vica:ChristosKapatosMember 2018-01-01 2018-09-30 0001402737 us-gaap:SeriesAPreferredStockMember us-gaap:StockOptionMember 2018-01-01 2018-09-30 0001402737 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001402737 vica:SecretaryMember 2018-01-01 2018-09-30 0001402737 us-gaap:SubsidiaryOfCommonParentMember 2018-01-01 2018-09-30 0001402737 us-gaap:VicePresidentMember 2018-01-01 2018-09-30 0001402737 us-gaap:DirectorMember 2018-01-01 2018-09-30 0001402737 vica:CeoAndPresidentMember 2018-01-01 2018-09-30 0001402737 us-gaap:HealthcareSectorMember country:GB 2018-01-01 2018-09-30 0001402737 us-gaap:TechnologySectorMember country:GB 2018-01-01 2018-09-30 0001402737 vica:AllOtherMember country:GR 2018-01-01 2018-09-30 0001402737 us-gaap:ComputerEquipmentMember 2018-01-01 2018-09-30 0001402737 us-gaap:VehiclesMember 2018-01-01 2018-09-30 0001402737 vica:PlantAndMachineMember 2018-01-01 2018-09-30 0001402737 vica:LabEquipmentMember 2018-01-01 2018-09-30 0001402737 vica:LeontaritisMember 2018-01-01 2018-09-30 0001402737 us-gaap:PrivatePlacementMember 2018-01-01 2018-09-30 0001402737 vica:EmployeesBoardMembersAndConsultantsMember 2018-01-01 2018-09-30 0001402737 us-gaap:LeaseholdImprovementsMember srt:MaximumMember 2018-01-01 2018-09-30 0001402737 us-gaap:LeaseholdImprovementsMember srt:MinimumMember 2018-01-01 2018-09-30 0001402737 us-gaap:OfficeEquipmentMember srt:MinimumMember 2018-01-01 2018-09-30 0001402737 us-gaap:OfficeEquipmentMember srt:MaximumMember 2018-01-01 2018-09-30 0001402737 vica:SecretaryMember vica:InstallmentsMember 2018-01-01 2018-09-30 0001402737 us-gaap:CommonStockMember vica:KatsarosMember 2018-01-01 2018-09-30 0001402737 vica:HciViocareTechnologiesLimitedMember 2018-01-01 2018-09-30 0001402737 vica:SubsidiaryOfCommonParentOneMember 2018-01-01 2018-09-30 0001402737 2018-09-30 0001402737 us-gaap:SeriesAPreferredStockMember 2018-09-30 0001402737 us-gaap:PresidentMember 2018-09-30 0001402737 country:GR 2018-09-30 0001402737 us-gaap:SeriesAPreferredStockMember us-gaap:StockOptionMember 2018-09-30 0001402737 us-gaap:CommonStockMember 2018-09-30 0001402737 country:GB 2018-09-30 0001402737 us-gaap:SubsidiaryOfCommonParentMember 2018-09-30 0001402737 us-gaap:VicePresidentMember 2018-09-30 0001402737 us-gaap:DirectorMember 2018-09-30 0001402737 vica:CeoAndPresidentMember 2018-09-30 0001402737 us-gaap:HealthcareSectorMember country:GB 2018-09-30 0001402737 us-gaap:TechnologySectorMember country:GB 2018-09-30 0001402737 vica:AllOtherMember country:GR 2018-09-30 0001402737 us-gaap:LeaseholdImprovementsMember 2018-09-30 0001402737 us-gaap:OfficeEquipmentMember 2018-09-30 0001402737 us-gaap:ComputerEquipmentMember 2018-09-30 0001402737 us-gaap:VehiclesMember 2018-09-30 0001402737 vica:PlantAndMachineMember 2018-09-30 0001402737 vica:LabEquipmentMember 2018-09-30 0001402737 us-gaap:CommonStockMember vica:KatsarosMember 2018-09-30 0001402737 vica:SubsidiaryOfCommonParentOneMember 2018-09-30 0001402737 us-gaap:SubsequentEventMember us-gaap:BoardOfDirectorsChairmanMember 2018-10-19 0001402737 us-gaap:SubsequentEventMember us-gaap:BoardOfDirectorsChairmanMember 2018-10-01 2018-10-19 0001402737 2018-12-11 0001402737 2017-06-30 xbrli:shares iso4217:USD iso4217:USDxbrli:shares iso4217:EUR iso4217:GBP xbrli:pure utr:sqft vica:Segment Rafina Innovations Inc. 0001402737 VICA false --12-31 10-Q 2018-09-30 2018 Q3 Non-accelerated Filer 14409593 2492 6431 69961 352498 29713 6431 27557 50725 59827 88822 4395 4245 50525 50146 494802 223651 155029 95635 387183 87382 212288 87513 649831 319286 85901 115280 118105 582781 519972 508853 7131 80000 80000 341355 47921 80510 1560910 687613 1560910 687613 1192 1422 33841702 37629553 -34736633 -37950401 -17340 -48901 -911079 -368327 649831 319286 0.0001 0.0001 0.04 5000000 5000000 0.0001 0.0001 0.705 35000000 35000000 11919285 14219681 11919285 14219681 50218 269918 91173 325256 8037 84616 20994 110791 42181 185302 70179 214465 26406 74583 17288 56070 1900 1554 20963 15540 6996 6233 3500 3116 26421 73529 18113 71862 43340 139274 61350 197473 302825 842998 262043 1071802 12655 3509 267140 9999 52766 3374 118086 10747 49627 222214 18904 202961 52766 39066 13042 41418 17220 92303 474316 1661156 447684 1810557 -432135 -26623 -19949 -407829 -1475854 -4944 -177807 -1315987 -377505 4431 -14751 -372466 -1596092 -5912 -191904 -3015952 -1141 343 -2278 -5755 1256 2485 3418 5520 -22266 -22884 -5281 -1617676 -454401 -1498738 -382786 -3213768 -454401 -1498738 -382786 -3213768 -0.05 -0.11 -0.03 -0.24 9903242 9753242 14312670 13184341 -454401 -1498738 -382786 -3213768 -26421 -89123 -6919 -31561 -480822 -1587861 -389705 -3245329 367629 369287 407650 468842 -17707 -17707 -1747 -1609436 1321971 285718 36995 24527 -1282 31269 -2430 867 -562 128186 -64884 -49103 -67362 -464857 -899042 149708 202345 250384 314041 121535 34673 46429 40000 552784 34081 30000 664911 573643 587888 108786 -311154 -41317 -11631 721564 811241 <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 1 - ORGANIZATION AND BUSINESS BACKGROUND</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">Rafina Innovations Inc. (formerly: HCi Viocare)&#160;</font>("VICA" or the "Company") was incorporated on March 26, 2007 under the laws of the State of Nevada. The Company has selected December 31 as its fiscal year end.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">While the Company has generated revenues from a segment of its planned principal operations, we are not yet able to meet operational overheads and are not yet profitable. We are considered an emerging growth enterprise. The Company was originally formed to sell medical devices with an emphasis on portable medical devices designed for home treatments with the initial focus in the northern regions of China.&#160;&#160;The Company's intent was to seek strategic relationships with medical device manufacturers both in China and North America with the aim to be their sales and distribution agent in Northern China and to assist Chinese medical device manufacturers on the development of the North American market.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On September 10, 2013, the controlling shareholder of the Company sold his controlling interest in the shares of the Company and there was a change in the Board of Directors of the Company, effecting a change in control of the Company. The business of the Company remains in the field of medical devices and other opportunities related to their uses. We are currently engaged in the technology development and licensing of bioengineering innovations for the health, sports and wellness sectors, and operate a prosthetic and orthotic (P&amp;O) total rehabilitation clinic in Glasgow, Scotland.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On January 15, 2014, the Company incorporated two wholly-owned subsidiaries in Scotland, U.K., HCi Viocare Technologies Limited and HCi Viocare Clinics UK Limited. The Company intends to operate in Scotland under these two subsidiaries, one of which will undertake the development and marketing of technologies and the other which is a P&amp;O clinic, which will serve as the center of reference and training for the Company's further clinics.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On February 12, 2014, through our wholly owned subsidiary, HCi Viocare Technologies Limited, the Company acquired an interest in a patented technology known as "Socket-Fit". SocketFit is a system that will help overcome technical and resource hurdles endemic to the prosthetic sector. The system has been designed with the aim of offering optimally fitted prosthetic sockets that will reduce the number of prostheses made for patients, resulting in a reduced number of visits by the patient to the prosthetic, and also assisting in the rehabilitation of amputees.&#160;&#160;Socket-Fit is a digital system for assessing an amputee's residual limb and for the production of truly functional and comfortable prosthetic sockets. The technology takes account of the external and internal geometry of the amputee's stump, the biomechanical properties of each individual soft tissue layer and the boundary and loading conditions of a complete prosthesis to generate a virtual 3D model of the residual limb making it possible to produce an accurate, functional and comfortable prosthetic socket. By minimizing the time and cost of socket production and reducing the number of faulty sockets there will be a reduction in costs incurred by health services and insurance companies worldwide as well as benefits to the amputee. The Company intends to undertake and fund, through its U.K. subsidiary, a project to improve the nature of the data used in socket modeling software with a view to creating a system that will enable prosthetists to build a socket that evenly distributes weight, provides enhanced comfort, and can be marketed and used across the industry for improved socket creation.</div> <div>&#160;</div> </div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On February 19, 2014, the Company filed a Certificate of Amendment with the Secretary of State of Nevada to change the name of the Company to HCi Viocare effective March 21, 2014.&#160;&#160;Effective March 21, 2014, in accordance with approval from FINRA, we changed our name from China Northern Medical Device, Inc. to HCi Viocare. Concurrently we commenced trading on the Over-the-Counter Bulletin Board under the symbol "VICA".</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On April 16, 2014, through our wholly owned subsidiary HCi Viocare Technologies Limited, we acquired all rights and interest in and to the background Intellectual Property Rights ("IPR") for a developing technology known as "Smart Insole".&#160;&#160;The Smart Insole system is believed to be a state-of-the-art, pressure and shear (friction)-sensing insole that can wirelessly communicate with connected devices.&#160;&#160;The insole has a number of applications, including the mitigation of diabetic foot complications, such as ulceration, infection and amputation, in clinical gait analysis and in sports, as a wearable device to help athletes optimize their performance and prevent injury. The sensing system is very low cost, compared to traditional pressure sensing technologies, in our opinion making such applications affordable to the consumer for the first time.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On June 9, 2014, the Company, through our wholly owned subsidiary, HCi Viocare Clinics, acquired W D Spence Prosthetics Limited (the "Clinic"). The Clinic is located in Glasgow, Scotland, and is a fully operational prosthetics and orthotics clinic. The acquisition of the Clinic is the first step to the Company's and HCi Viocare Clinics' intention to develop the first chain of prosthetics and orthotics (P&amp;O) and diabetic foot rehabilitation&#160;clinics in the European market, covering Southern Europe, the Middle East and North Africa.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On March 31, 2015, the Company's wholly owned subsidiary HCi Viocare Clinics and its subsidiary W D Spence Prosthetics Limited completed a merger with the resulting combined entity having the name HCi Viocare Clinics UK Limited.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On July 8, 2015, the Company incorporated HCi Viocare Clinics (Hellas) S A in order to carry out operations for the planning and development of a P&amp;O clinic in Athens, Greece. On August 2, 2017 the Company commenced the dissolution and liquidation of this corporation.&#160; As at the date of this report, the dissolution has not yet been concluded.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On May 24, 2018 the Company incorporated a wholly owned subsidiary for purposes of completing a merger and name change from HCi Viocare to Rafina Innovations, Inc. Concurrently the Company's Board of Directors approved a reverse share split on the basis 20 for 1.&#160; The name change and reverse share split became effective on July 9, 2018.&#160; Unless otherwise noted, impacted share amounts and per share information included in the financial statements and notes thereto have been retroactively adjusted for the reverse share split as if such share split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly differently than previously reported due to rounding of fractional shares as a result of the reverse share split.</div> </div> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 2 - GOING CONCERN</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">The Company incurred net&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">losses of $</font>382,786&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">and $</font>3,213,768&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">for the three and nine months ended September 30, 2018, respectively, and net loss of $</font>454,401&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">and $</font>1,498,738<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">&#160;for</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">&#160;the three and nine months ended September 30,2017,&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">respectively and has&#160;a retained deficit&#160;of&#160;$</font>37,950,401<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">. In addition, the Company had a working capital deficiency of $463,962 and a stockholders' deficit of $368,327 at September</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">&#160;30, 2018. These factors raise substantial doubt about the Company's ability to continue as a going concern.</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></div> <div>&#160;</div> </div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Company has relied heavily for its financing needs up until the close of fiscal 2017 on its Chief Executive Officer and President as more fully disclosed in Note 10.</div> </div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Note 3 - CONTROL BY PRINCIPAL STOCKHOLDER/OFFICER</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">Up until March 2018 our Chief Executive Officer owned beneficially and, in the aggregate, the majority of the voting power of the Company.&#160;&#160;</font>On March 22, 2018 and March 30, 2018 respectively, Sotirios Leontaritis, the President, Chief Executive Officer and a Director of the Company, entered into a Share Purchase Agreement (the "SPA") and an amendment thereto (the "Addendum"), (collectively herein referred to herein as the "Agreement") with Maschari Ltd. ("Maschari"), a Company incorporated in Cyprus, pursuant to which Mr. Leontaritis sold 6,135,529 of his restricted common shares to Maschari.&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">&#160;</font>The shares sold by Mr. Leontaritis represented approximately 42.6% of the Company's total outstanding shares of common stock.<a name="_hlk523841662"></a>&#160;Mr. Leontaritis continues to hold 1,965,619 shares of the Company's common stock representing approximately 13.6% of the issued and outstanding shares.&#160; As a result of the aforementioned transaction, Maschari&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">has the ability to control the approval of most corporate actions, including increasing the authorized capital stock and the dissolution, merger or sale of the Company's assets, as may be presented at Shareholder meetings from time to time.</font></div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Principals of Consolidation</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The consolidated financial statements include the accounts of Rafina Innovations Inc. and its wholly-owned subsidiaries, HCi Viocare Technologies Limited, HCi Viocare Clinics UK Limited and HCi Viocare Clinics (Hellas) S.A. On August 2, 2017 the Company commenced the dissolution and liquidation of&#160;HCi Viocare Clinics (Hellas) S.A. All significant intercompany balances and transactions have been eliminated.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Basis of Presentation</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The interim unaudited financial information referred to above has been prepared and presented in conformity with accounting principles generally accepted in the United States applicable to interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The interim financial information has been prepared on a condensed basis, such that certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission. These interim financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">This report on Form 10-Q should be read in conjunction with the Company's financial statements and notes thereto included in the Company's Form 10-K for the fiscal year ended December 31, 2017 filed on May 17, 2018. Results of the three and nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ended December 31, 2018 and any other future periods.</div> <div>&#160;</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Use of Estimates</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results when ultimately realized could differ from these estimates.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Cash and Cash Equivalents</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Foreign Currencies</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Items included in the consolidated financial statements of each of the Company and its subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the 'functional currency').&#160; The Company's reporting currency is the U.S. dollar.&#160;&#160;The functional currency of subsidiaries based in the UK is pound sterling and the functional currency of the&#160;Company's subsidiary&#160;based in the Greece is the Euro. All transactions initiated in Pounds and Euro are translated into U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830-30, "Translation of Financial Statements," as follows:</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 62px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">i)</div> </td> <td style="width: 1505px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">assets and liabilities are translated at the closing rate at the date of the balance sheet, or</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">1USD=0.86153EUR, 1USD=0.76728GBP (September 30, 2018), and;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">1USD=0.8347EUR, 1USD=0.74108GBP (December 31, 2017);</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 62px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">ii)</div> </td> <td style="width: 1505px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">income and expenses are translated at average exchange rates for nine months ended September 30, or</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">1USD=0.8374EUR, 1USD=0.7404GBP (September 30, 2018), and;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">1USD=0.9000EUR, 1USD=0.7846GBP (September 30, 2017);</font></div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 62px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">iii)</div> </td> <td style="width: 1505px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">all resulting exchange differences are recognized as other comprehensive income, a separate component of equity.</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Adjustments arising from such translations are included in accumulated other comprehensive income (loss) in stockholders' equity.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Revenue Recognition</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Effective January 1, 2018, the Company adopted ASC 606 &#8212; Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 &#8212; Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Company recognizes revenue when the earnings process is complete and persuasive evidence of an arrangement exists. This generally occurs for revenue recorded in our P&amp;O Clinics division when prosthetic products are fitted to customers, both title and the risks and rewards of ownership are transferred or services have been rendered and accepted, the selling price is fixed or determinable, and collectability is reasonably assured.&#160;&#160;Revenue is recognized&#160;upon issuance of an invoice and&#160;completion of each concluded stage of work performed on a prosthetic product. &#160;The Company recognizes revenue from its technology licensing fees and/or product development fees upon conclusion of services provided under contract.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">There was no impact on the Company's financial statements as a result of adopting Topic 606 for the three and nine months ended September 30, 2018 and 2017.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Inventory</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Inventories,&#160;which consist principally of raw materials and parts,&#160;are stated at the lower of cost or market. Cost is determined using the first-in, first-out method and are adjusted to actual cost quarterly based on a physical count. Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses.&#160;Work-in-process inventory consists of materials, labor and a predetermined fixed rate of overhead which is valued based on established standards for the stage of completion of each custom order. We do not carry finished goods on hand. Material, labor and overhead costs are determined at the individual clinic level. Presently&#160;we only maintain very limited parts and raw materials inventory.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Warranty</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">We do not record warranty liabilities at the time of sale for the estimated costs that may be incurred under the terms of the applicable limited warranty as all component parts are covered by our respective industry suppliers.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Advertising Costs</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Company expenses advertising costs as incurred or the first time the advertising takes place, whichever is earlier, in accordance with ASC 720-35. Advertising costs were immaterial for the three and nine months ended September 30, 2018 and 2017, respectively.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Research and Development Costs</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, "Research and Development".&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">Research and development costs were&#160;$</font>18,904&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">and&#160;$</font>202,961<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">for the&#160;three&#160;and nine months ended September 30, 2018, and&#160;$49,627 and&#160;$222,214 for the&#160;three&#160;and nine months ended September 30, 2017. During the period ended September 30, 2018,&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">HCi Viocare Technologies Limited</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">, the Company's subsidiary, received $52,766 (GBP 39,066) from the UK government as research and development tax credit.</font></div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Related parties</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.</div> <div>&#160;</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Stock-based compensation</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">For stock-based compensation, the Company follows the guidance codified in the Compensation &#8211; Stock Compensation Topic of FASB ASC ("ASC 718"). The Company determines the value of stock issued at the date of grant. It also determines at the date of grant, the value of stock at fair market value or the value of services rendered (based on contract or otherwise) whichever is more readily determinable.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">&#160;</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Income Taxes</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Company accounts for income taxes in accordance with FASB ASC 740, "Income Taxes", which requires the asset and liability approach for financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160;&#160;A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Company has a retained deficit from operations. Because there is no certainty that we will realize taxable income in the future, the Company did not record any deferred tax benefit as a result of these losses and recorded a valuation allowance offsetting the entire potential tax benefit.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Income tax years for 2014 through 2016 have been remitted timely and remain&#160;open to examination by the taxing authorities. The tax return for fiscal 2017 has not yet been filed. The Company has been assessed late filing penalties of $10,000 per year, as well as accrued interest thereon, for each of the late filed returns for the periods from inception to December 31, 2012. Prior to a change in control at the close of fiscal 2013, prior management had not timely filed its annual tax returns.&#160; We have estimated and accrued penalties of $80,000 as taxes payable in our financial statements. The Company has retained a tax professional to assist in reaching a settlement with the IRS.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Comprehensive Income</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">FASB ASC 220, "Comprehensive Income", establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income, as defined, includes all changes in equity during a period, exclusive of&#160;shareholder transactions. Accordingly, comprehensive income (loss) may include certain changes in shareholders' equity (deficit) that are excluded from net income (loss).</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Segment Reporting</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">FASB ASC 820 "Segments Reporting" establishes standards for reporting information about operating segments on a basis consistent with the Company's internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. Our proposed business segments are expected to span more than one geographical area. Specifically, the Company intends to operate prosthetic and orthotic rehabilitation clinics with various European based locations, as well as a corporate development and technology center which will undertake ongoing research and marketing activities.</div> <div>&#160;</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Basic and Diluted Loss per Share</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Company reports earnings per share in accordance with FASB ASC 260, "Earnings Per Share." FASB ASC 260 requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company had potentially dilutive securities outstanding (convertible debt and liabilities) for the period ended&#160;September 30, 2018 and December 31, 2017, respectively, however, since the Company reflected a net loss in the three and nine months ended September 30, 2018 and 2017, the effect of considering any common stock equivalents, if outstanding, would have been anti-dilutive. A separate computation of diluted earnings (loss) per share is not presented.<font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">December 31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">500,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">500,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Common stock issuable upon exercise of stock options</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,900,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,400,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Total</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2,400,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,900,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> <div style="text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Fair Value of Measurements</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Level 1:</font>&#160;Unadjusted quoted prices in active markets for identical assets or liabilities.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Level 2:</font>&#160;Input other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Level 3:</font>&#160;Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">An asset or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities.</div> <div>&#160;</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Recent Issued Accounting Pronouncements</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">In February 2016, the FASB issued ASU 2016-02,&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Leases (Topic 842)</font>.&#160;&#160;The amendments in this Update increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.&#160;&#160;ASU 2016-02 will be effective for the Company beginning on October&#160;1, 2019.&#160;&#160;Early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-10,&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Codification Improvements to Topic 842, Leases</font>&#160;to clarify the implementation guidance and ASU No. 2018-11,&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Leases (Topic 842) Targeted Improvements</font>. This updated guidance provides an optional transition method, which allows for the initial application of the new accounting standard at the adoption date and the recognition of a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning of the period of adoption. We have begun to identify our significant lease contracts and are in the process of&#160;evaluating the effect of the new guidance on our consolidated financial statements and related disclosures.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.</font></div> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 5 - PREPAID EXPENSES</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk514080161"></a>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Prepaid expenses consist of the following:<font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">September</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">December</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk515353814"></a>Office lease, including security deposits</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">38,241</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">39,582</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Travel advances and other expenses</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">11,905</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">10,943</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Total prepaid expense</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">50,146</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">50,525</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Note 6 &#8211; OTHER RECEIVABLES</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">From time to time the Company makes short term loans to third parties in order to facilitate its business operations. The loans bear interest ranging from 1.5% to 4% per annum and generally have terms of between 60 to 180 days. In general, the Company forgives accrued interest on principal when these short-term loans are repaid on time.</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 7 - PROPERTY AND EQUIPMENT</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link100"></a><a name="ole_link101"></a>Property and improvements consisted of the following as of September 30, 2018 and December 31, 2017:</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">September 30,</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">December 31,</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Cost</div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk515353894"></a>Leasehold improvements</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">197,171</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">203,990</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Furniture and fixture</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">31,695</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">32,781</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Computers and equipment</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">33,062</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">33,144</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Vehicle</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">58,036</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">59,902</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Machine and plant</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">8,892</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">9,206</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Lab equipment</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">32,958</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">34,123</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">361,814</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">373,146</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Less: accumulated depreciation and impairment</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(266,179</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(218,117</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Total</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">95,635</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">155,029</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Leasehold improvements are amortized over the term of the lease:&#160;three to ten years.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Furniture is&#160;depreciated over three to five years and computer and equipment is depreciated&#160;over three years.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Vehicles are depreciated&#160;over five years.</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Machine equipment and lab equipment are depreciated&#160;over 4 years.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><a name="ole_link106"></a><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Depreciation expense amounted to $</font>17,288<font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;and $</font>56,070<font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;for the three and nine months ended September 30, 2018, respectively.</font></div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Depreciation expense amounted to $</font>26,406<font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;and $</font>74,583<font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;for the three and nine months ended September 30, 2017, respectively.</font></div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 8 - OFFICE LEASE</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Office in Greece</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On February 3, 2014, the Company leased office space in Paleo Faliro, Greece on a three-year lease, commencing on March 1, 2014 and ending on February 28, 2017. The monthly rental fee is $1,900 (EUR &#8364; 1,554) including applicable taxes in the first year. Thereafter, for every further lease year and for the whole duration of the lease agreement, as well as in case of compulsory statutory extension or extension by tacit agreement, the monthly rent shall be annually adjusted by a percentage equal to the Consumer Price Index of the adjustment month with respect to the respective month of the year before (simple annual rate of change), as this is calculated by the Hellenic Statistical Authority (ELSTAT), plus two (2) percentage points (+2%).</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Under the term of the lease agreement, the Company paid a total of $25,010 (EUR &#8364;18,540) including $4,047 (EUR &#8364;3,000) for a deposit and $20,963 (EUR &#8364;15,540) for ten months' rental fee upon executing the agreement. As of September 30, 2018, $3,482 (EUR &#8364;3,000) is shown as deposits in the prepaid account.&#160; The lease has been renewed effective June 13, 2017 for a term of 3 years terminating on February 28, 2020 at a rate of $1,848 (EUR&#8364;1,592) plus a fee of 3.6%<a name="ole_link110"></a><a name="ole_link114"></a><a name="ole_link115"></a>.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On September 3, 2018, the Company's lease in Paleo Faliro was terminated by the Lessor.&#160; The Company and the Lessor are currently negotiating a settlement of the remaining lease obligation.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Clinic in Greece</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On December 29, 2014, the Company leased office space at Peania Region of Attica in Greece on a ten-year lease, commencing on January 1, 2015 and ending on October 5, 2024. The monthly rental fee is $6,996 (EUR &#8364;6,233) plus applicable taxes and the monthly operating cost estimate is $1,120 (EUR &#8364;997).</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Under the term of the lease agreement, the Company paid a total of $13,991 (EUR &#8364;12,465) as deposits in the prepaid account.&#160;</div> <div>&#160;</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On October 9, 2015, the terms of the lease were amended to include the following provisions:</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 47px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">-&#160;</div> </td> <td style="width: 1520px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Effective September 1, 2015, the monthly rental fee shall be reduced to $3,500 (EUR &#8364;3,116) for a period of 12 months ending August 31, 2016.</div> </td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 47px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">-&#160;</div> </td> <td style="width: 1520px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">In the event that the Lessee commences leasehold improvements prior to August 31, 2016, it shall inform the Lessor respectively and pay retroactively the remaining balance of the total amount of monthly rental in full from the period commencing September 1, 2015, as if they have not been reduced;</div> </td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 47px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">-&#160;</div> </td> <td style="width: 1520px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">In the event that the Company does not proceed with leasehold improvements in the 12-month period, the lease agreement will terminate and the Lessor with retain the deposit.</div> </td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 47px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">-&#160;</div> </td> <td style="width: 1520px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Lessor until such time as the leasehold improvements commence, may at any time and without indemnity terminate the lease agreement with a 30-day prior written notice to the Lessee.</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">As of December 31, 2016, the Company and the Lessor concluded the Termination of Lease Agreement dated August 1, 2016, and the Lessor waived all maintenance charges and utility charges for fiscal 2016. The following table is the summary of balance owing to Lessor as at September 30, 2018 and December 31, 2017:</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="font-weight: bold; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">September 30,</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">2018</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; font-weight: bold; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="font-weight: bold; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">December 31,</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;2017</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 4px; text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom;" colspan="3">&#160;</td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="3">&#160;</td> <td nowrap="nowrap" valign="bottom" style="width: 4px; text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk515360782"></a>Amount owed for maintenance charges</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 156px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">15,732</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">16,238</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 4px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Amount owed for utility charges</div> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 156px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">16,284</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">16,807</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 4px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 156px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">32,016</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">33,045</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 4px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"><a name="ole_link118"></a><a name="ole_link123"></a><a name="ole_link124"></a>Lease in UK</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On March 2, 2015, the Company entered into a lease agreement for a modern, stand-alone 5,300 square foot facility in Glasgow, Scotland with an entry date of March 1, 2015. The building will host the Company's first Viocare center, a full-service Prosthetic and Orthotic ("P&amp;O") practice with a superior standard of personalized care. The renovations to the clinic were completed in June, and the facility was opened on August 1, 2015 with an official ribbon cutting on 25 September 2015. During the first year from the date of entry, the lease fees are USD$26,066 (GBP &#163;20,000) per annum (exclusive of VAT). On the second anniversary of the date of entry, the lease will increase to USD$52,132 (GBP &#163;40,000) per annum (exclusive of VAT). In the third anniversary of the date of entry, the lease will be USD$52,132 (GBP &#163;40,000) per annum (exclusive of VAT). In the fourth anniversary of the date of entry, the lease will decrease to USD$39,100 (GBP &#163;30,000) per annum (exclusive of VAT). In the fifth anniversary of the date of entry, the lease will be USD$52,132 (GBP &#163;40,000) per annum (exclusive of VAT).</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Under the term of the lease agreement, the Company paid a total of $26,066 (GBP &#163;20,000) as security deposits which amount is included on the Company's balance sheet in prepaid expenses.<font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Location</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">December 31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk515362433"></a>Greece</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">3,482</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">3,594</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">UK</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">34,759</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">35,988</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">38,241</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">39,582</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">As of September 30, 2018, the approximate future aggregate minimum lease payments&#160;in respect of our current obligations were as follows:</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 1192px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Location</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 158px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Greece</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 156px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">United Kingdom</div> </td> <td style="width: 14px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1192px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2018</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 141px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">5,411</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 140px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">10,318</div> </td> <td style="width: 14px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1192px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2019</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 141px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">21,645</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 140px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">49,960</div> </td> <td style="width: 14px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1192px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2020</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 17px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 141px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">3,607</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 16px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 140px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">8,688</div> </td> <td style="width: 14px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1192px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 17px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td style="width: 141px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">30,663</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 16px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td style="width: 140px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">68,966</div> </td> <td style="width: 14px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> </table> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Note 9 -&#160;&#160;&#160;LOANS</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><a name="ole_link65"></a><a name="_hlk514080313"></a>On January 5, 2017, HCi Viocare Clinics Hellas S.A., the Company's subsidiary, entered into a loan agreement with a third party to borrow a total of EUR 40,000 (US$46,429) with an annual interest rate of 5%, payable within one year from the date of the agreement.&#160;As at September 30, 2018 and December 31, 2017 a total of $50,452 and $50,276, respectively, including accrued interest to date, remained due and payable in respect of this loan. Interest expenses of $1,791 were accrued in the nine months ended September 30, 2018. The loan was not repaid in January 2018 and is currently in default.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On July 27, 2018, HCi Viocare Clinics UK Limited, the Company's subsidiary, entered into a loan agreement with a third party to borrow a total of EUR 30,000 (US$34,081) with an annual interest rate of 6%, payable within six months from the date of the agreement.&#160;As at September 30, 2018 and December 31, 2017 a total of $34,480 and $0, respectively, including accrued interest to date, remained due and payable in respect of this loan. Interest expenses of $413 were accrued in the nine months ended September 30, 2018.</div> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 10 -&#160;&#160;&#160;COMMITMENTS</div> <div style="text-align: left;"><a name="ole_link75"></a><a name="ole_link23"></a>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 63px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link11"></a>(1)</div> </td> <td style="width: 1504px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Consulting Agreement with Dr. Christos Kapatos</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On April 16, 2014, the Company entered into a Consulting Agreement with Christos Kapatos whereby he will provide his services as Chief Technical Officer for the Company and the Company's wholly-owned subsidiaries.&#160;&#160;The contract has a term of one year, renewable for such further term as may be mutually agreed between the parties. In the case that&#160;a research and development project is initiated and completed during the term of the agreement, Kapatos shall receive seventy thousand (70,000) shares of the Company's common stock for each research project completed with a valuation less than twenty million dollars ($20,000,000 USD), one hundred and seventy-five thousand (175,000) shares of the Company's common stock for each research project completed with a valuation equal or greater than twenty million US dollars ($20,000,000 USD). Details of compensation under the terms of the consulting agreement are included in Note 11(ii).</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 69px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link24"></a><a name="ole_link62"></a><a name="ole_link61"></a><a name="ole_link21"></a><a name="ole_link22"></a>(2)</div> </td> <td style="width: 1498px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Consulting Agreement with JAMB</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk513631753"></a>Effective July 10, 2017, the Company entered into a business consulting agreement&#160;(the "Consulting Agreement") with JAMB Group LLC. ("Consultant") for services to commence July 15, 2017 and to continue for a period of twelve (12) months thereafter. Under the terms of the Agreement, the Consultant shall provide consulting services to the Company for the development and expansion of its business, including the introduction to specific Targets for the purposes of&#160;financing transactions or other business relationship. The Consultant is entitled to compensation for the provision of services in the form of 25,000&#160;shares of the common stock which were issued upon execution of the Consulting Agreement, as well as certain other fees and consideration.<font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font>&#160;</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">25,000 shares have been valued at $79,950, the fair market value of $3.198 per share,&#160;on issue&#160;date, which amount has been expensed as consulting expenses in the year ended December 31, 2017.&#160; The contract expired without renewal in the current nine months ended September 30, 2018.</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 66px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link26"></a>(3)</div> </td> <td style="width: 1501px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Consulting Agreement with Mr. Stefanos Batzakis</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk513631664"></a><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">On September 1, 2017, the Company entered into a one-year consulting agreement (the "Agreement") with Mr Stefanos Batzakis. As per terms of said Agreement Batzakis will provide services to the Company as IT Solutions Manager, for a term of one (1) year and receive compensation in the form of stock, namely twenty-five thousand (25,000) common shares, which were issued upon signing of this Agreement.</font></div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">25,000 shares have been valued at $40,000, the fair market value of $1.60 per share on&#160;issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017. The contract expired without renewal in the current nine months ended September 30, 2018.</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 64px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">(4)</div> </td> <td style="width: 1503px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Consulting Agreement with Dr. Ioannis Doupis</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk513631678"></a><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">On October 9, 2017, the Company appointed Dr. Ioannis Doupis, to the Advisory Board of the Company originally formed on April 15, 2014 and Concurrently entered into an advisory board agreement. Compensation shall be the grant of a total of 25,000 shares of the Company's common stock valued at the fair market price on the date of grant of $1.40 per share. The advisory board appointment is for a term of one year.</font></div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">25,000 shares have been valued at $35,000, the fair market value of $1.40 per share on&#160;issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017.&#160; On October 3, 2018 the Company's Board of Directors determined to terminate the Company's advisory board.</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 64px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">(5)</div> </td> <td style="width: 1503px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Consulting Agreement with Ms. Paraskevi Pilarinou</div> </td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On December 12, 2017, the Company entered into a consulting agreement (the "Agreement") with Ms. Paraskevi Pilarinou (the "Consultant").&#160; Under the terms and conditions of the Agreement the Consultant shall be employed in the position of Financial Controller of the Company. The Agreement has a three-year term starting on January 2, 2018 and ending on January 1, 2021 and the Consultant shall be remunerated with a monthly fee of EUR2,000 (IUSD$2,320) and was issued 100,000 shares of the Company's&#160;common stock. The 100,000 shares were issued as compensation as of the date of the agreement and were valued at $1 per share or $100,000, the fair market value on the date of issuance in the year ended December 31, 2017.</div> &#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 63px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">(6)</div> </td> <td style="width: 1504px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Consulting Agreement with Charalampos Sgardelis</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On January 2, 2017, the Company entered into a one-year consulting agreement (the "Agreement") with Mr. Charalampos Sgardelis ("Sgardelis"). Under the terms of the Agreement, Sgardelis provides services to the Company as Business Development Manager, for a term of one (1) year and receives compensation of Two Thousand Euros (2,000 &#8364;) (USD$2,320) per month.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On February 26, 2018 the Company approved a three (3) year extension to the Agreement (the "Addendum") between the Company and Sgardelis.&#160;Under the terms and conditions of the Addendum, Sgardelis is entitled to receive compensation of Three Thousand Euros (3,000 &#8364;) (USD$3,480) per month and shall be awarded 250,000 common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $0.98 per share for total consideration of $245,000.&#160; Subsequent to the period ended September 30, 2018, on November 17, 2018, the Company terminated the consulting agreement with Mr. Sgardelis.</div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 63px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">(7)</div> </td> <td style="width: 1504px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Advisory Agreement with Ravi Vaidyanathan</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On March 27, 2018, the Company entered into a one-year advisory agreement (the "Agreement") with Mr. Ravi Vaidyanathan (the "Advisor"). Under the terms and conditions of the Agreement, the Advisor is appointed to the Company's Scientific Advisory Board&#160;and is entitled to remuneration for the provision of services in the form of 25,000 shares of the common stock to be issued upon signing of the Agreement. Further, the Advisor shall be granted additional 12,500 shares of the common stock to be issued after a time-period of six (6) months from the signing of the Agreement.&#160;The Advisor shall serve on the Scientific Advisory Board in the position of Biomechatronics and Human Augmentation Advisor. The Company or the Advisor may terminate the agreement upon 30 days written notice.&#160;The issued shares were valued at fair market value on the date of issuance or $1.10 per share for total consideration of $27,500. On October 3, 2018 the Company's Board of Directors determined to terminate the Company's advisory board and no further shares will be issued to Mr. Vaidyanathan under the terms of this Agreement.</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 63px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk523133810"></a>(8)</div> </td> <td style="width: 1504px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Addendum to Service Agreement with Nikolaos Gemelos</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On January 16, 2018, the Company entered into a one-year service agreement (the "Agreement") with Mr. Nikolaos Gemelos ("Gemelos"). Under the terms of the Agreement, Gemelos provides services to the Company as Consultant, for a term of one (1) year and he is entitled to a success fee of 5% of the amount actually invested in the Company by introduced accredited investors, and 5% of the amount invested in the form of restricted shares of the common stock of the Company. On May 3, 2018, the Company entered into an amendment to the aforementioned Agreement. Under the terms and conditions of this Addendum, Gemelos shall be awarded 5,000 restricted common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $1.34 per share for total consideration of $6,700.</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 63px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">(9)</div> </td> <td style="width: 1504px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Service Agreement with&#160;Georgios Dritsoulas</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On June 7, 2018, the Company entered into a six-month service agreement with Mr. Georgios Dritsoulas. As per terms of said Agreement, Mr. Dritsoulas will provide services to the Company as Consultant for the development and expansion of the Company's business for a term of six (6) months. Mr. Dritsoulas received compensation of 2,500 restricted common shares as compensation for the services provided. The issued shares were valued at fair market value on the date of issuance or $2 per share for total consideration of $5,000.</div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"><font size="2" style="font-family: times new roman,times;">Note 11 -&#160;&#160;&#160;RELATED PARTY TRANSACTIONS</font></div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">The following table provides details of the Company's related party transactions during the three and nine months ended September 30, 2018 and 2017</font></div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 63px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"><font size="2" style="font-family: times new roman,times;">(a)</font></div> </td> <td style="width: 1504px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"><font size="2" style="font-family: times new roman,times;">Services provided from related parties:</font></div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br />&#160;</font></div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Three Months Ended</font></div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">September 30,</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Nine Months Ended</font></div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">September 30,</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">2018</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">2017</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">2018</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">2017</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><a name="_hlk490813038"></a>Consulting fees from CEO and President&#160;(i)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">33,739</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">30,000</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">107,472</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">90,000</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Consulting fees from a Director&#160;(ii)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">13,978</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">11,697</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">44,700</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">33,332</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Professional fees from Director&#160;(iii)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">3,374</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">3,509</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">10,747</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">9,999</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><a name="ole_link3"></a><a name="ole_link4"></a>Consulting fees for VP (iv)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">11,808</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">7,018</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">37,615</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">19,999</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Stock options granted to CEO and President (i)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">122,544</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">367,630</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Stock options granted to Director (ii)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">45,300</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">135,900</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Stock options granted to VP (iv)</font></div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">16,800</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">50,400</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">187,200</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Stock award granted to Director (iii)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">172,000</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">247,543</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">52,224</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">754,464</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">512,530</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table class="dspflisttable" style="width: 1567px; font-family: 'times new roman', times, serif; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">(i)</font></div> </td> <td style="width: auto; vertical-align: top;"> <div style="text-align: left; text-indent: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">&#160;<br /></font></div> <div style="text-align: left; text-indent: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">On&#160;September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016.&#160;&#160;&#160;Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract.&#160;&#160;In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR10,000 (USD$11,650) per month.&#160;&#160;</font><a name="_hlk522275744"></a><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">Further, Mr. Leontaritis is entitled to acquire at his discretion 150,000 shares of the common stock at a price of $6 per share for a term of five (5) years.&#160;&#160;The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 and $245,086 during the three and six months ended September 30, 2018 and 2017. On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated.&#160;&#160; Further concurrent with his resignation, and with an effective date of September 30, 2018, Mr. Leontaritis and the Company&#160;entered into an agreement whereunder Mr. Leontaritis would surrender for cancelation a total of 189,912 shares of the Company's common stock valued at $0.705 per share in order to settle certain amounts payable to the Company totaling $135,635 including a loss on conversion of $1,747. The shares are held in the possession of the Company's Board of Directors and have not yet been provided to the Company's transfer agent for cancelation as at the date of this report.</font></font></div> </td> </tr> </table> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 61px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"><font size="2" style="font-family: times new roman,times;">(ii)</font></div> </td> <td style="width: 1506px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;"><font size="2" style="font-family: times new roman,times;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$46,430&#160;(&#8364;40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement</font>, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company&#160;<a name="ole_link78"></a>Euros &#8364;40,000 for services rendered in each fiscal year respectively.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On December 12, 2017, the Company approved the issuance of 925,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant.&#160; The 925,000 shares have been valued at $925,000, or $1.00 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with&#160;Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$58,250) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 1,250,000 shares of the common stock at a price of US$1.00 for a term of six years.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;"><font size="2" style="font-family: times new roman,times;">On May 23, 2018 the Company approved an amendment to the term of the scientific advisory agreement with Dr. Christos Kapatos, board member CTO and member of the Scientific Advisory Board, originally entered into on April 15, 2014 in order to extend the term to April 15, 2019.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><a name="ole_link66"></a><a name="ole_link67"></a><a name="ole_link71"></a><a name="ole_link104"></a><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 and $135,900 during the three and nine months ended September 30, 2018.</font></font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">Effective October 3, 2018, Dr Christos Kapatos resigned from his position as Director of the Company.&#160; Subsequently on November 21, 2018 Dr, Kapatos terminated his consulting contract.</font></div> </div> </td> </tr> </table> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 63px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">(iii)</font></div> </td> <td style="width: 1504px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of&#160;fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. During the nine months ended September 30, 2018 Mr. Kardaras invoiced the Company EUR9,000 (USD$10,747)</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On March 3, 2017, the Company approved&#160;the issuance of 50,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $172,000, the fair market value of $3.44 per share&#160;on&#160;issue date, which amount has been expensed as stock-based compensation.&#160; On October 3, 2018 Mr. Kardaras resigned as secretary and director of the Company.&#160; He remains the Company's in house legal advisor.</font></div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 63px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">&#160;<a name="_hlk513721843"></a>(iv)</font></div> </td> <td style="width: 1504px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President.&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives.&#160;&#160;</font>The initial term of the contract is six months and Mr. Katsaros will receive compensation of&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">USD$2,330 (&#8364;2,000)</font>&#160;per month.&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">On March 1, 2016, the Company approved a one-year extension to the consulting agreement</font>&#160;and the Company approved the grant of a stock award of 15,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros.&#160;&#160;The award vests in three equal instalments of 5,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 10,000 vested shares was recorded as stock-based compensation. On March 1, 2017, the final installment of 5,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On March 17, 2017, the Company approved the issuance of a further 50,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $170,000, the fair market value of $3.40 per share on grant date, which amount has been expensed as stock-based compensation.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018.&#160; The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,060), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company.&#160;<a name="ole_link184"></a><a name="ole_link185"></a><a name="ole_link186"></a><a name="ole_link187"></a>Mr. Katsaros shall also be entitled to acquire at his discretion 500,000 shares of the common stock at a price of US$1.00 for a term of five years commencing January 2, 2018.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">The Company recognized stock-based compensation expense allocated to consulting fees of $16,800 during the six months ended September 30, 2018.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Subsequent to the period ended September 30, 2018, on November 17, 2018, the Company terminated the consulting agreement with Mr. Katsaros.</font></div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; background-color: white;"> <td style="width: 32px; font-size: 10pt;"><font size="2" style="font-family: 'times new roman', times, serif; font-size: 10pt;"><i>(b)</i></font></td> <td style="width: 1535px; font-size: 10pt;"><font size="2" style="font-family: 'times new roman', times, serif; font-size: 10pt;"><i>Accounts payable and accrued&#160;liabilities from related parties:</i></font></td> </tr> </table> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">September 30,</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">December 31,</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><a name="ole_link98"></a><a name="ole_link80"></a>&#160;</font></div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">2018</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">2017</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><a name="_hlk515365525"></a>CEO and President&#160;(i)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">413,010</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Director&#160;(ii)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">5,390</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">95,843</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Consulting fees for VP (iv)</font></div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">1,741</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><a name="ole_link168"></a><a name="ole_link167"></a>&#160;</font></div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">7,131</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">508,853</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 48px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"><font size="2" style="font-family: times new roman,times;">(c)</font></div> </td> <td style="width: 1519px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"><font size="2" style="font-family: times new roman,times;">Advances / other receivable from related parties:</font></div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">&#160;Advances from related parties:</font></div> </td> <td valign="bottom" style="vertical-align: bottom;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">September 30,</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">December 31,</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">2018</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">2017</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><a name="_hlk515365547"></a><a name="_hlk530753968"></a>CEO and President&#160;(i)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">287,073</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Director&#160;(ii)</font></div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">54,282</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">341,355</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 48px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"><font size="2" style="font-family: times new roman,times;"><a name="ole_link34"></a>(d)</font></div> </td> <td style="width: 1519px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"><font size="2" style="font-family: times new roman,times;">Convertible Debt,&#160;related parties:</font></div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On February 15, 2018, the Company and certain shareholders holding in excess of 5% of the Company's common stock and concurrently holding a position on the Company's Board, or acting in the capacity of any officer of the Company or its subsidiaries, agreed that repayment against pre-existing debt payable by the Company on the agreement date shall be&#160; suspended until such time as&#160; the Company concludes a full profitable year of operations. Further the parties agreed that any such pre-existing debt or portion thereof shall be convertible at any time into restricted shares of the Company's common stock at a price equal or greater to $0.60 per share. On the date of the agreement the fair market value of the Company's common stock as traded on OTCMarkets was $0.806 per share. The Company accounted for this transaction by applying ASC 470-20-35.&#160; As the convertible debt has no stated redemption date, the Company will recognize the discount as interest expense on the earliest conversion date. &#160;</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">The Company has reclassified all debts payable as of February 15, 2018 to our CEO and CTO from advances and accounts payable, related party, to convertible debt, related party.&#160;</font></div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">On each of May 31, 2018 and on June 26, 2018, the Company entered into Debt Settlement and Subscription Agreements with the President of the Company, Mr. Sotirios Leontaritis to settle total debt in the amount of $679,371 in respect to certain unpaid salary, advances for operational shortfalls and certain unsettled expense reimbursements&#160;into 1,132,286 shares of the Company's common stock at a price of US$0.60 per share.&#160;</font>The Company valued the aforementioned issuances at the closing price of the Company's stock as traded on the OTCMarkets on the date of issue. The difference in price resulted in the Company recording loss on debt settlement in the amount of $1,321,971 in respect of the transaction.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">On June 26, 2018, the Company entered into a Debt Settlement and Subscription Agreement with a Director of the Company, Dr. Christos Kapatos to settle total debt in the amount of US$131,870 in respect to certain unpaid salary, advances for operational shortfalls and certain unsettled expense reimbursements into 219,784 shares of the Company's common stock at a price of US$0.60 per share.&#160;</font>The Company valued those issuances at the closing price of the Company's stock as traded on the OTCMarkets on the date of issue. The difference in price resulted in the Company recording loss on debt settlement in the amount of $285,718 in respect to the transaction.</font></div> </div> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 12 -&#160;&#160;&#160;CAPITAL STOCK</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Articles of Incorporation authorize the Company to issue 5,000,000 shares of preferred stock with a par value of $0.0001, and 35,000,000 shares of common stock with a par value of $0.0001.&#160;&#160;No shares of preferred stock have been issued, however, the Company has granted 25,000 fully vested stock options for the purchase of&#160;25,000 shares of Series A Preferred Stock of the Company at a price of $0.04 per share for a period of five (5) years from the date of vesting. (ref: Note 13 below)</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On May 24, 2018 the Company's Board of Directors approved a reverse share split on the basis 20 for 1.&#160; The reverse share split became effective on July 9, 2018.&#160;Unless otherwise noted, impacted share amounts and per share information included in the financial statements and notes thereto have been retroactively adjusted for the reverse share split as if such share split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly differently than previously reported due to rounding of fractional shares as a result of the reverse share split.</div> <div style="text-align: left;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Share issuances during the nine months ended September 30, 2018</div> </div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link122"></a><a name="ole_link125"></a><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">During the nine months ended September 30, 2018</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">, 855,717 shares of common stock were issued in respect of various private placements for total cash proceeds&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">of $664,911.</font></div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link174"></a><a name="ole_link175"></a><a name="ole_link176"></a>During the nine months ended September 30, 2018, the Company issued 282,500 shares to employees, board members and consultants valued at $284,200, for services rendered.&#160; The Company valued these issuances based on the closing price of the Company's stock as reflected on the OTC Markets on the respective dates of issuance.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link160"></a><a name="ole_link161"></a><a name="ole_link164"></a>During the nine months ended September 30, 2018, the Company issued 1,132,286 shares valued at fair market value on the date(s) of issuance for a total of $2,001,342 to Mr. Leontaritis to settle debt in the amount of $679,371. &#160;The Company valued those issuances at the closing price of the Company's stock as traded on the OTCMarket on the date of issue. The difference in price resulted in the Company recording a loss on debt settlement in the amount of $1,321,971.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">During the nine months ended September 30, 2018, the Company issued 219,784 shares valued at fair market value on the date of issuance of $417,588 to Dr. Christos Kapatos to settle debt in the amount of $131,870. &#160;The Company valued those issuances at the closing price of the Company's stock as traded on the OTCMarket on the date of issue. The difference in price resulted in the Company recording loss on debt settlement in the amount of $285,718.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated.&#160;&#160; Further concurrent with his resignation and with an effective date of September 30, 2018, Mr. Leontaritis and the Company</font>&#160;entered into an agreement whereunder Mr. Leontaritis would surrender for cancelation a total of 189,912 shares of the Company's common stock valued at $0.705 per share in order to settle certain amounts payable to the Company totaling $135,635 including a loss on conversion of $1,747. The returned shares are held in the possession of the Company's Board of Directors and have not yet been provided to the Company's transfer agent for cancelation as at the date of this report.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><u>Designation of Series A Preferred Stock</u></div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On January 13, 2014, the Company filed a Certificate of Designation with the Secretary of State of the State of Nevada.&#160;&#160;&#160;The Certificate of Designation sets forth the rights, preferences and privileges of a class of the Company's preferred stock.&#160;&#160;Such class shall be designated as the "Series A Preferred Stock" and the number of shares constituting such series shall be 5,000,000 shares.&#160;&#160;The holders of Series A Preferred Stock will be entitled to a preference over all of the shares of the Company's common stock.&#160;&#160;Holders of Series A Preferred Stock shall have 50 votes per share of Series A Preferred Stock held by them and shall be entitled to notice of any stockholders' meeting and to vote as a single class upon any matter submitted to the stockholders for a vote.&#160;&#160;Each share of Series A Preferred Stock is convertible into 20 shares of our common stock at any time at the holder's option.&#160;&#160;Shares of Series A Preferred Stock shall not be entitled to any dividends.&#160;&#160;The preferred stock shall be entitled to a preference over all of the shares of common stock of the Company with respect to the distribution of assets in the event of the liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs.</div> </div> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 13 - STOCK OPTIONS</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">A total of 25,000 stock options granted during April and June of fiscal 2014 entitling each holder the right to purchase a total of 5,000 shares of Series A Preferred Stock of the Company at a price of $0.04 per share for a period of five (5) years remain unexercised and outstanding as at September 30, 2018. &#160;The Series A Preferred shares are convertible on the basis of 20 shares of common stock for each one share held and have voting rights of 50 votes per share of Series A Preferred stock held at any meetings of the stockholders.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <div style="text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><a name="ole_link105"></a><a name="ole_link119"></a><a name="ole_link120"></a><a name="ole_link128"></a></div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">On January 1, 2017, the Company approved a three-year extension to the consulting agreement.&#160;<a name="ole_link159"></a>Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019. Further, Mr. Leontaritis is entitled to acquire at his discretion 150,000 shares of the common stock at a price of $6 per share for a term of five (5) years.</div> <div>&#160;</div> </div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On December 12, 2017,&#160;<a name="ole_link165"></a><a name="ole_link166"></a>Dr. Christos Kapatos, director, was issued a stock option as part of an extension to his employment contract under which, at his discretion, he may acquire 1,250,000 shares of the common stock at a price of US$1.00 for a term of six years.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Mr. Katsaros shall also be entitled to acquire at his discretion 500,000 shares of the common stock at a price of US$1.00 for a term of five years commencing January 2, 2018.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">The Company accounts for share-based payments pursuant to ASC 718, "Stock Compensation" and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company's stock price and expected dividends.</font></div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">Stock compensation expense for stock options is recognized over the vesting period of the award.</font></div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link51"></a><a name="ole_link52"></a><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">The Company recognized stock-based&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">compensation expense allocated to consulting fees of $184,644 and $122,543 during the three months ended September 30, 2018 and 2017, respectively. The Company recognized stock-based compensation expense allocated to consulting fees of $553,930 and $245,086 during&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">the nine months ended September 30, 2018 and 2017, respectively.&#160; Subsequent to September 30, 2018 each of Mr. Leontaritis and Dr. Kapatos resigned all positions with the Board of Directors, including any consulting contracts. In addition, the consulting contract with Mr. Katsaros was terminated. As a result, any unexercised stock options are expected to expire within 90 days of the respective contract terminations.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The following table summarizes information concerning stock options outstanding as of September 30, 2018, and December 31, 2017:</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><u>Series A Preferred Stock:</u></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">December 31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Series A</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Preferred stock</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Exercise Price</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Series A</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Preferred stock</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Exercise Price</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Outstanding at beginning of the year</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">25,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.04</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">25,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.04</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;Granted</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;Exercised</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;Expired or canceled</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Outstanding at the period</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">25,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.04</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">25,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.04</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The aforementioned options have an average remaining life of 0.57 years.&#160;<a name="ole_link33"></a></div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><u>Common stock:</u></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">December 31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Common</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">stock</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Exercise Price</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Common</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">stock</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Exercise Price</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk515373054"></a>Outstanding at beginning of the year</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,400,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.52</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;Granted</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">500,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.00</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,400,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.52</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;Exercised</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;Expired or canceled</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Outstanding at the period</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,900,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.4</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,400,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.52</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The aforementioned options have an average remaining life of 5.05 years.&#160;</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><a name="ole_link130"></a><a name="ole_link131"></a><a name="ole_link132"></a>Valuation Assumptions</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">The Company accounts for share-based payments pursuant to ASC 718, "Stock Compensation" and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company's stock price and expected dividends.</font></div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">Stock compensation expense for stock options is recognized over the vesting period of the award.</font></div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The following table presents the range of the weighted average fair value of options granted and the related assumptions used in the Black-Scholes model for stock option grants:</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Series A Preferred Stock:<font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 1295px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 268px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Options Granted</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2014</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1295px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Fair value of options granted</div> </td> <td style="width: 268px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">1.40 &#126; 2.00</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1295px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Assumptions used:</div> </td> <td style="width: 268px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1295px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expected life (years)&#160;(a)</div> </td> <td style="width: 268px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">1.00</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1295px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Risk free interest rate&#160;(b)</div> </td> <td style="width: 268px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.11%</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1295px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Volatility&#160;(c)</div> </td> <td style="width: 268px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">117.09 &#126; 119.83 %</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1295px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Dividend yield&#160;(d)</div> </td> <td style="width: 268px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.00</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Common stock:</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 1292px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 271px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Options Granted date</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1292px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Fair value of options granted</div> </td> <td style="width: 271px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.038 &#126; 0.925</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1292px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Assumptions used:</div> </td> <td style="width: 271px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1292px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expected life (years)&#160;(a)</div> </td> <td style="width: 271px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">5 &#126; 6</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1292px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Risk free interest rate&#160;(b)</div> </td> <td style="width: 271px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">1.93% &#126; 2.25%</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1292px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Volatility&#160;(c)</div> </td> <td style="width: 271px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">175.40% &#126; 254.86%</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1292px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Dividend yield&#160;(d)</div> </td> <td style="width: 271px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.00</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Company utilizes the Black-Scholes option pricing model to determine the fair value of each option award. Expected volatilities are based on the historical volatility of the Company's common stock over a period consistent with that of the expected term of the options. The expected term of the options are estimated based on factors such as vesting periods, contractual expiration dates and historical exercise behavior. The risk-free rates for periods within the contractual life of the options are based on the yields of U.S. Treasury instruments with terms comparable to the estimated option terms.&#160;The dividend yield rate is not considered in the model, as the Company has not established a dividend policy for the stock.</div> </div> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 14 - SEGMENT REPORTING</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Company's operations are classified into two reportable segments that provide different products or services. Separate management of each segment is required because each business unit is subject to different marketing, operations, and growth and technology development strategies.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Clinics segment derives its revenue from provision of services at our P&amp;O Clinic located in Glasgow, Scotland. The Technology segment derives its income from the licensing of its proprietary technologies and ultimately recurring royalty income as well as technology access fees. Presently we are only deriving income from our UK-based operations.&#160; We expect this to be the case until such time as we are able to expand our chain of P&amp;O Clinics.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">There are no inter-segment sales however, the Company's two primary operating segments do share costs on certain operational overhead including facility rent and staff salaries.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link139"></a><a name="ole_link140"></a>Three months ended September 30, 2018:</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Clinics</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Technology</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">All Other</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(Greece)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Total</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Revenue</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">87,665</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">3,508</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">91,173</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Depreciation &amp; amortization</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,785</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">10,270</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">5,233</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">17,288</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Net (Loss) from operations</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">4,431</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(14,751</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(372,466</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(382,786</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Interest expenses</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(694</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(562</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,256</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Assets</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">85,901</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">115,280</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">118,105</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">319,286</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expenditure on long-lived assets</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Three months ended September 30, 2017:</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Clinics</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Technology</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">All Other</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(Greece)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Total</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Revenue</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">50,184</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">34</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">50,218</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Depreciation &amp; amortization</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2,760</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">13,536</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">10,110</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">26,406</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Net (Loss) from operations</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(26,623</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(19,949</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(407,829</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(454,401</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Interest expenses</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(2,561</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(857</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(3,418</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Assets</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">87,382</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">212,288</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">87,513</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">387,183</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expenditure on long-lived assets</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Nine months ended September 30, 2018:</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link82"></a><a name="ole_link76"></a>&#160;&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Clinics</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Technology</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">All Other</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(Greece)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Total</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Revenue</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">316,858</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">8,398</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">325,256</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Depreciation &amp; amortization</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">6,499</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">32,765</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">16,806</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">56,070</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Net (Loss) from operations</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(5,912</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(191,904</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(3,015,952</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(3,213,768</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Interest expenses</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(694</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,791</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(2,485</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk522282188"></a>Assets</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">85,901</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">115,280</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">118,105</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">319,286</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expenditure on long-lived assets</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Nine months ended September 30, 2017:</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Clinics</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Technology</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">All Other</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(Greece)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Total</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Revenue</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">267,288</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2,630</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">269,918</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Depreciation &amp; amortization</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">7,685</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">37,601</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">29,297</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">74,583</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Net (Loss) from operations</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(4,944</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(177,807</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,315,987</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,498,738</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Interest expenses</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(3,618</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,902</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(5,520</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Assets</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">87,382</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">212,288</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">87,513</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">387,183</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expenditure on long-lived assets</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> </table> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 15 - SUBSEQUENT EVENTS</div> <div>&#160;</div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Effective October 3, 2018, Dr. Christos Kapatos resigned from his position as Director of the Company.</div> <div>&#160;</div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; margin-bottom: 8pt;">Effective October 3, 2018, Mr. Sotirios Leontaritis resigned from his position as the President, Director and Chief Financial Officer of the Company.</div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; margin-bottom: 8pt;">Effective October 3, 2018, Mr Nikolaos Kardaras resigned from his position as the Secretary and Director of the Company. Mr. Kardaras' resignation was not the result of any disagreement with the Corporation regarding operations, policies, practices or otherwise. Mr. Kardaras will continue to consult for the Company as an independent contractor in his capacity as in-house legal counsel.</div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Concurrent with the aforementioned resignations, the Board of Directors appointed Mr. Constantinos Zertalis as a member of the Board of Directors and the President of the Company and Miss Paraskevi Pylarinou as a member of the Board of Directors, Secretary and CFO of the Company.</div> <div>&#160;</div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On October 19, 2018 the Company's Board of Directors appointed Mr. Constantinos Zertalis, CEO, President and Director as Chairman of the Board of Directors.</div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On October 19, 2018 the Company's Board of Directors approved the grant of a total of 1,500,000 stock awards which vested on the date of grant, and a total of 7,500,000 directors' stock options for exercise at&#160; $0.70 per share which options vest as to 1,500,000 shares on grant date, and 1,500,000 shares each year thereafter for a total of four additional years.</div> <div>&#160;</div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On November 17, 2018, the Company's management terminated a consulting contract with Mr. Sergios Katsaros which takes effect as of December 22, 2018.</div> <div>&#160;</div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On November 17, 2018 the Company's management terminated a consulting agreement with Mr. Haralampos Sgardelis.</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; margin-bottom: 12pt;">On November 21, 2018 the Company's Chief Technology Officer, Dr. Christos Kapatos resigned his position as Chief Technology Officer and as a consultant due to the Company's breach of Sections 3.1 and 3.2 of that certain Consulting Agreement originally entered into April 16, 2014 (as amended from time to time, including, without limitation, Addendum 1, Addendum 2 and Addendum 3, collectively, the "Consulting Agreement").&#160; The Company declined to cure the noticed breach(es) in the ten (10) day period as allotted from notice date and subsequently accepted the resignation of Dr. Kapatos effective November 21, 2018.&#160; Further, on December 4, 2018 the Company notified Dr. Kapatos of the termination of that certain Acquisition agreement between Dr. Kapatos and HCI VIOCARE TECHNOLOGIES LIMITED, the Company's wholly owned subsidiary, dated April 16, 2014, as amended May 8, 2015 (collectively the "Acquisition Agreement").</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; margin-bottom: 12pt;">The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there are no additional subsequent events to disclose.</div> </div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Principals of Consolidation</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The consolidated financial statements include the accounts of Rafina Innovations Inc. and its wholly-owned subsidiaries, HCi Viocare Technologies Limited, HCi Viocare Clinics UK Limited and HCi Viocare Clinics (Hellas) S.A. On August 2, 2017 the Company commenced the dissolution and liquidation of&#160;HCi Viocare Clinics (Hellas) S.A. All significant intercompany balances and transactions have been eliminated.</div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Basis of Presentation</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The interim unaudited financial information referred to above has been prepared and presented in conformity with accounting principles generally accepted in the United States applicable to interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The interim financial information has been prepared on a condensed basis, such that certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission. These interim financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">This report on Form 10-Q should be read in conjunction with the Company's financial statements and notes thereto included in the Company's Form 10-K for the fiscal year ended December 31, 2017 filed on May 17, 2018. Results of the three and nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ended December 31, 2018 and any other future periods.</div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Use of Estimates</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results when ultimately realized could differ from these estimates.</div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Cash and Cash Equivalents</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less.</div> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Foreign Currencies</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Items included in the consolidated financial statements of each of the Company and its subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the 'functional currency').&#160; The Company's reporting currency is the U.S. dollar.&#160;&#160;The functional currency of subsidiaries based in the UK is pound sterling and the functional currency of the&#160;Company's subsidiary&#160;based in the Greece is the Euro. All transactions initiated in Pounds and Euro are translated into U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830-30, "Translation of Financial Statements," as follows:</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 62px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">i)</div> </td> <td style="width: 1505px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">assets and liabilities are translated at the closing rate at the date of the balance sheet, or</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">1USD=0.86153EUR, 1USD=0.76728GBP (September 30, 2018), and;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">1USD=0.8347EUR, 1USD=0.74108GBP (December 31, 2017);</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 62px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">ii)</div> </td> <td style="width: 1505px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">income and expenses are translated at average exchange rates for nine months ended September 30, or</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">1USD=0.8374EUR, 1USD=0.7404GBP (September 30, 2018), and;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">1USD=0.9000EUR, 1USD=0.7846GBP (September 30, 2017);</font></div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 62px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">iii)</div> </td> <td style="width: 1505px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">all resulting exchange differences are recognized as other comprehensive income, a separate component of equity.</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Adjustments arising from such translations are included in accumulated other comprehensive income (loss) in stockholders' equity.</div> </div> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Revenue Recognition</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Effective January 1, 2018, the Company adopted ASC 606 &#8212; Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 &#8212; Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Company recognizes revenue when the earnings process is complete and persuasive evidence of an arrangement exists. This generally occurs for revenue recorded in our P&amp;O Clinics division when prosthetic products are fitted to customers, both title and the risks and rewards of ownership are transferred or services have been rendered and accepted, the selling price is fixed or determinable, and collectability is reasonably assured.&#160;&#160;Revenue is recognized&#160;upon issuance of an invoice and&#160;completion of each concluded stage of work performed on a prosthetic product. &#160;The Company recognizes revenue from its technology licensing fees and/or product development fees upon conclusion of services provided under contract.</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">There was no impact on the Company's financial statements as a result of adopting Topic 606 for the three and nine months ended September 30, 2018 and 2017.</div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Inventory</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Inventories,&#160;which consist principally of raw materials and parts,&#160;are stated at the lower of cost or market. Cost is determined using the first-in, first-out method and are adjusted to actual cost quarterly based on a physical count. Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses.&#160;Work-in-process inventory consists of materials, labor and a predetermined fixed rate of overhead which is valued based on established standards for the stage of completion of each custom order. We do not carry finished goods on hand. Material, labor and overhead costs are determined at the individual clinic level. Presently&#160;we only maintain very limited parts and raw materials inventory.</div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Warranty</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We do not record warranty liabilities at the time of sale for the estimated costs that may be incurred under the terms of the applicable limited warranty as all component parts are covered by our respective industry suppliers.</div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Advertising Costs</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company expenses advertising costs as incurred or the first time the advertising takes place, whichever is earlier, in accordance with ASC 720-35. Advertising costs were immaterial for the three and nine months ended September 30, 2018 and 2017, respectively.</div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Research and Development Costs</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, "Research and Development".&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">Research and development costs were&#160;$</font>18,904&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">and&#160;$</font>202,961<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">for the&#160;three&#160;and nine months ended September 30, 2018, and&#160;$49,627 and&#160;$222,214 for the&#160;three&#160;and nine months ended September 30, 2017. During the period ended September 30, 2018,&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">HCi Viocare Technologies Limited</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">, the Company's subsidiary, received $52,766 (GBP 39,066) from the UK government as research and development tax credit.</font></div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Related parties</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.</div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Stock-based compensation</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For stock-based compensation, the Company follows the guidance codified in the Compensation &#8211; Stock Compensation Topic of FASB ASC ("ASC 718"). The Company determines the value of stock issued at the date of grant. It also determines at the date of grant, the value of stock at fair market value or the value of services rendered (based on contract or otherwise) whichever is more readily determinable.</div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Income Taxes</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company accounts for income taxes in accordance with FASB ASC 740, "Income Taxes", which requires the asset and liability approach for financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160;&#160;A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has a retained deficit from operations. Because there is no certainty that we will realize taxable income in the future, the Company did not record any deferred tax benefit as a result of these losses and recorded a valuation allowance offsetting the entire potential tax benefit.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Income tax years for 2014 through 2016 have been remitted timely and remain&#160;open to examination by the taxing authorities. The tax return for fiscal 2017 has not yet been filed. The Company has been assessed late filing penalties of $10,000 per year, as well as accrued interest thereon, for each of the late filed returns for the periods from inception to December 31, 2012. Prior to a change in control at the close of fiscal 2013, prior management had not timely filed its annual tax returns.&#160; We have estimated and accrued penalties of $80,000 as taxes payable in our financial statements. The Company has retained a tax professional to assist in reaching a settlement with the IRS.</div> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Basic and Diluted Loss per Share</div> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">The Company reports earnings per share in accordance with FASB ASC 260, "Earnings Per Share." FASB ASC 260 requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company had potentially dilutive securities outstanding (convertible debt and liabilities) for the period ended&#160;September 30, 2018 and December 31, 2017, respectively, however, since the Company reflected a net loss in the three and nine months ended September 30, 2018 and 2017, the effect of considering any common stock equivalents, if outstanding, would have been anti-dilutive. A separate computation of diluted earnings (loss) per share is not presented.<font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">December 31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">500,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">500,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Common stock issuable upon exercise of stock options</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,900,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,400,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Total</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2,400,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,900,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Comprehensive Income</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">FASB ASC 220, "Comprehensive Income", establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income, as defined, includes all changes in equity during a period, exclusive of&#160;shareholder transactions. Accordingly, comprehensive income (loss) may include certain changes in shareholders' equity (deficit) that are excluded from net income (loss).</div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Segment Reporting</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">FASB ASC 820 "Segments Reporting" establishes standards for reporting information about operating segments on a basis consistent with the Company's internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. Our proposed business segments are expected to span more than one geographical area. Specifically, the Company intends to operate prosthetic and orthotic rehabilitation clinics with various European based locations, as well as a corporate development and technology center which will undertake ongoing research and marketing activities.</div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Fair Value of Measurements</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Level 1:</font>&#160;Unadjusted quoted prices in active markets for identical assets or liabilities.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Level 2:</font>&#160;Input other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company.</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Level 3:</font>&#160;Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">An asset or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities.</div> </div> <div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Recent Issued Accounting Pronouncements</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">.</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In February 2016, the FASB issued ASU 2016-02,&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Leases (Topic 842)</font>.&#160;&#160;The amendments in this Update increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.&#160;&#160;ASU 2016-02 will be effective for the Company beginning on October&#160;1, 2019.&#160;&#160;Early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-10,&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Codification Improvements to Topic 842, Leases</font>&#160;to clarify the implementation guidance and ASU No. 2018-11,&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Leases (Topic 842) Targeted Improvements</font>. This updated guidance provides an optional transition method, which allows for the initial application of the new accounting standard at the adoption date and the recognition of a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning of the period of adoption. We have begun to identify our significant lease contracts and are in the process of&#160;evaluating the effect of the new guidance on our consolidated financial statements and related disclosures.</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.</font></div> </div> <div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">December 31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">500,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">500,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Common stock issuable upon exercise of stock options</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,900,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,400,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Total</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2,400,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,900,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> </div> <div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">September</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">December</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk515353814"></a>Office lease, including security deposits</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">38,241</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">39,582</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Travel advances and other expenses</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">11,905</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">10,943</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Total prepaid expense</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">50,146</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">50,525</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> </div> <div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">September 30,</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">December 31,</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Cost</div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk515353894"></a>Leasehold improvements</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">197,171</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">203,990</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Furniture and fixture</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">31,695</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">32,781</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Computers and equipment</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">33,062</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">33,144</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Vehicle</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">58,036</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">59,902</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Machine and plant</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">8,892</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">9,206</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Lab equipment</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">32,958</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">34,123</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">361,814</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">373,146</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Less: accumulated depreciation and impairment</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(266,179</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(218,117</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Total</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">95,635</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">155,029</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> </div> <div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="font-weight: bold; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">September 30,</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">2018</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; font-weight: bold; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="font-weight: bold; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">December 31,</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;2017</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 4px; text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom;" colspan="3">&#160;</td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="3">&#160;</td> <td nowrap="nowrap" valign="bottom" style="width: 4px; text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk515360782"></a>Amount owed for maintenance charges</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 156px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">15,732</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">16,238</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 4px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Amount owed for utility charges</div> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 156px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">16,284</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">16,807</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 4px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 156px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">32,016</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">33,045</div> </td> </tr> </table> </div> <div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Location</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">December 31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk515362433"></a>Greece</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">3,482</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">3,594</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">UK</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">34,759</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">35,988</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">38,241</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">39,582</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> </div> <div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 1192px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Location</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 158px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Greece</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 156px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">United Kingdom</div> </td> <td style="width: 14px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1192px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2018</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 141px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">5,411</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 140px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">10,318</div> </td> <td style="width: 14px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1192px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2019</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 141px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">21,645</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 140px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">49,960</div> </td> <td style="width: 14px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1192px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2020</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 17px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 141px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">3,607</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 16px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 140px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">8,688</div> </td> <td style="width: 14px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1192px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 17px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 17px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td style="width: 141px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">30,663</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 16px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td style="width: 140px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">68,966</div> </td> <td style="width: 14px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> </table> </div> <div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 63px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"><font size="2" style="font-family: times new roman,times;">(a)</font></div> </td> <td style="width: 1504px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"><font size="2" style="font-family: times new roman,times;">Services provided from related parties:</font></div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br />&#160;</font></div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Three Months Ended</font></div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">September 30,</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Nine Months Ended</font></div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">September 30,</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">2018</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">2017</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">2018</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">2017</font></div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><a name="_hlk490813038"></a>Consulting fees from CEO and President&#160;(i)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">33,739</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">30,000</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">107,472</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">90,000</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Consulting fees from a Director&#160;(ii)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">13,978</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">11,697</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">44,700</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">33,332</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Professional fees from Director&#160;(iii)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">3,374</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">3,509</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">10,747</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">9,999</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><a name="ole_link3"></a><a name="ole_link4"></a>Consulting fees for VP (iv)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">11,808</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">7,018</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">37,615</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">19,999</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Stock options granted to CEO and President (i)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">122,544</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">367,630</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Stock options granted to Director (ii)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">45,300</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">135,900</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Stock options granted to VP (iv)</font></div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">16,800</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">50,400</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">187,200</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Stock award granted to Director (iii)</font></div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">-</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">172,000</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">247,543</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">52,224</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">754,464</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">$</font></div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">512,530</font></div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"> <table class="dspflisttable" style="width: 1567px; font-family: 'times new roman', times, serif; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">(i)</font></div> </td> <td style="width: auto; vertical-align: top;"> <div style="text-align: left; text-indent: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">&#160;<br /></font></div> <div style="text-align: left; text-indent: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">On&#160;September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016.&#160;&#160;&#160;Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract.&#160;&#160;In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR10,000 (USD$11,650) per month.&#160;&#160;</font><a name="_hlk522275744"></a><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">Further, Mr. Leontaritis is entitled to acquire at his discretion 150,000 shares of the common stock at a price of $6 per share for a term of five (5) years.&#160;&#160;The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 and $245,086 during the three and six months ended September 30, 2018 and 2017. On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated.&#160;&#160; Further concurrent with his resignation, and with an effective date of September 30, 2018, Mr. Leontaritis and the Company&#160;entered into an agreement whereunder Mr. Leontaritis would surrender for cancelation a total of 189,912 shares of the Company's common stock valued at $0.705 per share in order to settle certain amounts payable to the Company totaling $135,635 including a loss on conversion of $1,747. The shares are held in the possession of the Company's Board of Directors and have not yet been provided to the Company's transfer agent for cancelation as at the date of this report.</font></font></div> </td> </tr> </table> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 61px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"><font size="2" style="font-family: times new roman,times;">(ii)</font></div> </td> <td style="width: 1506px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;"><font size="2" style="font-family: times new roman,times;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$46,430&#160;(&#8364;40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement</font>, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company&#160;<a name="ole_link78"></a>Euros &#8364;40,000 for services rendered in each fiscal year respectively.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On December 12, 2017, the Company approved the issuance of 925,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant.&#160; The 925,000 shares have been valued at $925,000, or $1.00 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with&#160;Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$58,250) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 1,250,000 shares of the common stock at a price of US$1.00 for a term of six years.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;"><font size="2" style="font-family: times new roman,times;">On May 23, 2018 the Company approved an amendment to the term of the scientific advisory agreement with Dr. Christos Kapatos, board member CTO and member of the Scientific Advisory Board, originally entered into on April 15, 2014 in order to extend the term to April 15, 2019.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;"><font size="2" style="font-family: times new roman,times;">The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 and $135,900 during the three and nine months ended September 30, 2018.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;"><font size="2" style="font-family: times new roman,times;">Effective October 3, 2018, Dr Christos Kapatos resigned from his position as Director of the Company.&#160; Subsequently on November 21, 2018 Dr, Kapatos terminated his consulting contract.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">&#160;</div> </td> </tr> </table> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 63px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">(iii)</font></div> </td> <td style="width: 1504px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of&#160;fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. During the nine months ended September 30, 2018 Mr. Kardaras invoiced the Company EUR9,000 (USD$10,747)</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On March 3, 2017, the Company approved&#160;the issuance of 50,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $172,000, the fair market value of $3.44 per share&#160;on&#160;issue date, which amount has been expensed as stock-based compensation.&#160; On October 3, 2018 Mr. Kardaras resigned as secretary and director of the Company.&#160; He remains the Company's in house legal advisor.</font></div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: medium; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 63px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">&#160;<a name="_hlk513721843"></a>(iv)</font></div> </td> <td style="width: 1504px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President.&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives.&#160;&#160;</font>The initial term of the contract is six months and Mr. Katsaros will receive compensation of&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">USD$2,330 (&#8364;2,000)</font>&#160;per month.&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">On March 1, 2016, the Company approved a one-year extension to the consulting agreement</font>&#160;and the Company approved the grant of a stock award of 15,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros.&#160;&#160;The award vests in three equal instalments of 5,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 10,000 vested shares was recorded as stock-based compensation. On March 1, 2017, the final installment of 5,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On March 17, 2017, the Company approved the issuance of a further 50,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $170,000, the fair market value of $3.40 per share on grant date, which amount has been expensed as stock-based compensation.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018.&#160; The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,060), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company.&#160;<a name="ole_link184"></a><a name="ole_link185"></a><a name="ole_link186"></a><a name="ole_link187"></a>Mr. Katsaros shall also be entitled to acquire at his discretion 500,000 shares of the common stock at a price of US$1.00 for a term of five years commencing January 2, 2018.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">The Company recognized stock-based compensation expense allocated to consulting fees of $16,800 during the six months ended September 30, 2018.</font></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><font size="2" style="font-family: times new roman,times;">Subsequent to the period ended September 30, 2018, on November 17, 2018, the Company terminated the consulting agreement with Mr. Katsaros.</font></div> </td> </tr> </table> </div> <div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">September 30,</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">December 31,</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link98"></a><a name="ole_link80"></a>&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk515365525"></a>CEO and President&#160;(i)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">413,010</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Director&#160;(ii)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">5,390</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">95,843</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Consulting fees for VP (iv)</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,741</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link168"></a><a name="ole_link167"></a>&#160;</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">7,131</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">508,853</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> </table> </div> <div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;Advances from related parties:</div> </td> <td valign="bottom" style="vertical-align: bottom;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">September 30,</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">December 31,</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk515365547"></a><a name="_hlk530753968"></a>CEO and President&#160;(i)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">287,073</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Director&#160;(ii)</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">54,282</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">341,355</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><u>Series A Preferred Stock:</u></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <table style="width: 1551px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">December 31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Series A</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Preferred stock</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Exercise Price</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Series A</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Preferred stock</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Exercise Price</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 807px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Outstanding at beginning of the year</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">25,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.04</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">25,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.04</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 807px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;Granted</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 807px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;Exercised</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 807px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;Expired or canceled</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 807px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Outstanding at the period</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">25,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.04</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">25,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.04</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><u>Common stock:</u></div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <table style="width: 1551px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">December 31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Common</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">stock</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Exercise Price</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Common</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">stock</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Exercise Price</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 807px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk515373054"></a>Outstanding at beginning of the year</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,400,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.52</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 807px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;Granted</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">500,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.00</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,400,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.52</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 807px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;Exercised</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 807px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;&#160;Expired or canceled</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div>-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 807px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Outstanding at the period</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,900,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.4</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,400,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 139px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.52</div> </td> </tr> </table> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Series A Preferred Stock:<font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font>&#160;</div> </div> <table style="width: 1551px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 1282px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 265px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Options Granted</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2014</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1282px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Fair value of options granted</div> </td> <td style="width: 265px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">1.40 &#126; 2.00</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1282px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Assumptions used:</div> </td> <td style="width: 265px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1282px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expected life (years)&#160;(a)</div> </td> <td style="width: 265px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">1.00</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1282px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Risk free interest rate&#160;(b)</div> </td> <td style="width: 265px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.11%</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1282px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Volatility&#160;(c)</div> </td> <td style="width: 265px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">117.09 &#126; 119.83 %</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1282px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Dividend yield&#160;(d)</div> </td> <td style="width: 265px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.00</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Common stock:</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </div> <table style="width: 1551px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 1278px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 269px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Options Granted date</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1278px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Fair value of options granted</div> </td> <td style="width: 269px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.038 &#126; 0.925</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1278px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Assumptions used:</div> </td> <td style="width: 269px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1278px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expected life (years)&#160;(a)</div> </td> <td style="width: 269px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">5 &#126; 6</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1278px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Risk free interest rate&#160;(b)</div> </td> <td style="width: 269px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">1.93% &#126; 2.25%</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1278px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Volatility&#160;(c)</div> </td> <td style="width: 269px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">175.40% &#126; 254.86%</div> </td> <td style="width: 4px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> </tr> <tr> <td style="width: 1278px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Dividend yield&#160;(d)</div> </td> <td style="width: 269px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.00</div> </td> </tr> </table> </div> <div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Three months ended September 30, 2018:</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Clinics</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Technology</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">All Other</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(Greece)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Total</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Revenue</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">87,665</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">3,508</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">91,173</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Depreciation &amp; amortization</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,785</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">10,270</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">5,233</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">17,288</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Net (Loss) from operations</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">4,431</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(14,751</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(372,466</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(382,786</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Interest expenses</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(694</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(562</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,256</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Assets</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">85,901</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">115,280</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">118,105</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">319,286</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expenditure on long-lived assets</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> </table> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Three months ended September 30, 2017:</div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Clinics</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Technology</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">All Other</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(Greece)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Total</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Revenue</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">50,184</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">34</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">50,218</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Depreciation &amp; amortization</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2,760</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">13,536</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">10,110</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">26,406</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Net (Loss) from operations</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(26,623</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(19,949</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(407,829</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(454,401</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Interest expenses</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(2,561</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(857</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(3,418</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Assets</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">87,382</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">212,288</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">87,513</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">387,183</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expenditure on long-lived assets</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Nine months ended September 30, 2018:</div> <div>&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link82"></a><a name="ole_link76"></a>&#160;&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Clinics</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Technology</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">All Other</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(Greece)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Total</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Revenue</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">316,858</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">8,398</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">325,256</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Depreciation &amp; amortization</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">6,499</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">32,765</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">16,806</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">56,070</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Net (Loss) from operations</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(5,912</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(191,904</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(3,015,952</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(3,213,768</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Interest expenses</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(694</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,791</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(2,485</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="_hlk522282188"></a>Assets</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">85,901</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">115,280</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">118,105</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">319,286</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expenditure on long-lived assets</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div>&#160;</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Nine months ended September 30, 2017:</div> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;</div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;</div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Clinics</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Technology</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(UK)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">All Other</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">(Greece)</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Total</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div> </td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;">&#160;</td> <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Revenue</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">267,288</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2,630</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">269,918</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Depreciation &amp; amortization</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">7,685</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">37,601</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">29,297</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">74,583</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Net (Loss) from operations</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(4,944</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(177,807</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,315,987</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,498,738</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Interest expenses</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(3,618</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,902</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(5,520</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Assets</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">87,382</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">212,288</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">87,513</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">387,183</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;">&#160;</td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expenditure on long-lived assets</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;">&#160;</td> </tr> </table> </div> A reverse share split on the basis 20 for 1. 463962 5000 2500 6135529 0.426 5000000 100000 925000 10000000 1965619 0.136 500000 500000 1400000 1900000 1900000 2400000 i) assets and liabilities are translated at the closing rate at the date of the balance sheet, or 1USD=0.86153EUR, 1USD=0.76728GBP (September 30, 2018), and; 1USD=0.8347EUR, 1USD=0.74108GBP (December 31, 2017); ii) income and expenses are translated at average exchange rates for nine months ended September 30, or 1USD=0.8374EUR, 1USD=0.7404GBP (September 30, 2018), and; 1USD=0.9000EUR, 1USD=0.7846GBP (September 30, 2017); iii) all resulting exchange differences are recognized as other comprehensive income, a separate component of equity. Adjustments arising from such translations are included in accumulated other comprehensive income (loss) in stockholders' equity. Income tax years for 2014 through 2016 have been remitted timely and remain open to examination by the taxing authorities. The tax return for fiscal 2017 has not yet been filed. The Company has been assessed late filing penalties of $10,000 per year, as well as accrued interest thereon, for each of the late filed returns for the periods from inception to December 31, 2012. 25000 39582 38241 10943 11905 The loans bear interest ranging from 1.5% to 4% per annum. Between 60 to 180 days. 373146 203990 32781 33144 59902 9206 34123 361814 197171 31695 33062 58036 8892 32958 218117 266179 P3Y P5Y P4Y P4Y P10Y P3Y P3Y P5Y 16238 15732 16807 16284 33045 32016 39582 3594 35988 38241 3482 34759 26066 20000 5411 10318 52132 40000 21645 49960 52132 40000 3607 8688 30663 68966 The Company leased office space in Paleo Faliro, Greece on a three-year lease, commencing on March 1, 2014 and ending on February 28, 2017. The Company leased office space at Peania Region of Attica in Greece on a ten-year lease, commencing on January 1, 2015 and ending on October 5, 2024. 25010 18540 4047 3000 13991 12465 P10M 3482 3000 1120 997 5300 39100 30000 52132 40000 0.02 The lease has been renewed effective June 13, 2017 for a term of 3 years terminating on February 28, 2020 at a rate of $1,848 (EUR 1,592) plus a fee of 3.6%. 20000 26066 0.05 0.06 One year from the date of the agreement. Six months from the date of the agreement. 50276 0 50452 34480 1791 413 2320 2000 3480 3000 The Company entered into a Consulting Agreement with Christos Kapatos whereby he will provide his services as Chief Technical Officer for the Company and the Company's wholly-owned subsidiaries. The contract has a term of one year, renewable for such further term as may be mutually agreed between the parties. In the case that a research and development project is initiated and completed during the term of the agreement, Kapatos shall receive seventy thousand (70,000) shares of the Company's common stock for each research project completed with a valuation less than twenty million dollars ($20,000,000 USD), one hundred and seventy-five thousand (175,000) shares of the Company's common stock for each research project completed with a valuation equal or greater than twenty million US dollars ($20,000,000 USD). Details of compensation under the terms of the consulting agreement are included in Note 11(ii). The Company entered into a one-year consulting agreement (the "Agreement") with Mr. Charalampos Sgardelis ("Sgardelis"). Under the terms of the Agreement, Sgardelis provides services to the Company as Business Development Manager, for a term of one (1) year and receives compensation of Two Thousand Euros (2,000 ) (USD$2,320) per month. The Company entered into a business consulting agreement (the "Consulting Agreement") with JAMB Group LLC. ("Consultant") for services to commence July 15, 2017 and to continue for a period of twelve (12) months thereafter. The Company entered into a one-year consulting agreement (the "Agreement") with Mr Stefanos Batzakis. As per terms of said Agreement Batzakis will provide services to the Company as IT Solutions Manager, for a term of one (1) year and receive compensation in the form of stock, namely twenty-five thousand (25,000) common shares, which were issued upon signing of this Agreement. The Company appointed Dr. Ioannis Doupis, to the Advisory Board of the Company originally formed on April 15, 2014 and Concurrently entered into an advisory board agreement. Compensation shall be the grant of a total of 25,000 shares of the Company's common stock valued at the fair market price on the date of grant of $1.40 per share. The advisory board appointment is for a term of one year. The Company entered into a consulting agreement (the "Agreement") with Ms. Paraskevi Pilarinou (the "Consultant"). Under the terms and conditions of the Agreement the Consultant shall be employed in the position of Financial Controller of the Company. The Agreement has a three-year term starting on January 2, 2018 and ending on January 1, 2021 and the Consultant shall be remunerated with a monthly fee of EUR2,000 (IUSD$2,320) and was issued 100,000 shares of the Company's common stock. The 100,000 shares were issued as compensation as of the date of the agreement and were valued at $1 per share or $100,000, the fair market value on the date of issuance in the year ended December 31, 2017. The Company entered into a one-year service agreement (the "Agreement") with Mr. Nikolaos Gemelos ("Gemelos"). Under the terms of the Agreement, Gemelos provides services to the Company as Consultant, for a term of one (1) year and he is entitled to a success fee of 5% of the amount actually invested in the Company by introduced accredited investors, and 5% of the amount invested in the form of restricted shares of the common stock of the Company. The Company approved a three (3) year extension to the Agreement (the "Addendum") between the Company and Sgardelis. Under the terms and conditions of the Addendum, Sgardelis is entitled to receive compensation of Three Thousand Euros (3,000 ) (USD$3,480) per month and shall be awarded 250,000 common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $0.98 per share for total consideration of $245,000. The Company entered into a one-year advisory agreement (the "Agreement") with Mr. Ravi Vaidyanathan (the "Advisor"). Under the terms and conditions of the Agreement, the Advisor is appointed to the Company's Scientific Advisory Board and is entitled to remuneration for the provision of services in the form of 25,000 shares of the common stock to be issued upon signing of the Agreement. Further, the Advisor shall be granted additional 12,500 shares of the common stock to be issued after a time-period of six (6) months from the signing of the Agreement. The Company entered into a six-month service agreement with Mr. Georgios Dritsoulas. As per terms of said Agreement, Mr. Dritsoulas will provide services to the Company as Consultant for the development and expansion of the Company's business for a term of six (6) months. 700000 50000 50000 50000 25000 25000 25000 100000 25000 282500 15000 100000 25000 25000 25000 1400000 5000 500000 17200 172000 170000 79950 40000 35000 100000 3.198 1.60 1.40 1 0.98 1.10 1.34 2 2320 2000 100000 250000 245000 27500 6700 5000 7018 11697 30000 19999 33332 90000 11808 13978 33739 37615 44700 107472 187200 16800 45300 122544 50400 135900 367630 172000 52224 512530 247543 754464 508853 95843 413010 7131 1741 5390 341355 54282 287073 P5Y 500000 1250000 150000 500000 3.40 1.00 0.60 0.60 6 Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract. In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR10,000 (USD$11,650) per month. Company's common stock at a price equal or greater to $0.60 per share. On the date of the agreement the fair market value of the Company's common stock as traded on OTCMarkets was $0.806 per share. 2330 2000 40000 13300 12000 40000 13500 12000 10747 9000 245086 245086 122543 45300 122543 135900 16800 49430 40000 58250 50000 172000 925000 1.00 1.00 5000 1500000 3.44 25000 1500000 169000 3500 4060 1250000 1.00 721564 679371 131870 1132286 1132286 219784 25000 P5Y 284200 The holders of Series A Preferred Stock will be entitled to a preference over all of the shares of the Company's common stock. Holders of Series A Preferred Stock shall have 50 votes per share of Series A Preferred Stock held by them and shall be entitled to notice of any stockholders' meeting and to vote as a single class upon any matter submitted to the stockholders for a vote. Each share of Series A Preferred Stock is convertible into 20 shares of our common stock at any time at the holder's option. Shares of Series A Preferred Stock shall not be entitled to any dividends. The Series A Preferred shares are convertible on the basis of 20 shares of common stock for each one share held and have voting rights of 50 votes per share of Series A Preferred stock held at any meetings of the stockholders. 679371 131870 664911 1132286 219784 855717 2001342 417588 3418 2561 857 5520 3618 1902 1256 694 562 2485 694 1791 25000 25000 1400000 25000 1900000 7500000 0.04 0.04 1.52 0.04 1.4 1.52 1.00 2.00 1.40 0.925 0.038 P1Y P6Y P5Y 0.0011 0.0225 0.0193 1.1983 1.1709 2.5486 1.7540 0.0000 0.0000 25000 25000 P6Y 1.00 0.04 1.00 0.70 122543 245086 184644 553930 P5Y P0Y6M25D P5Y P5Y P5Y0M18D P5Y 1.00 6 On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019. 50218 50184 34 269918 267288 2630 91173 87665 3508 325256 316858 8398 26406 2760 13536 10110 74583 7685 37601 29297 17288 1785 10270 5233 56070 6499 32765 16806 2 0.705 true true true 119950 86793 189912 135635 1747 1,500,000 shares each year thereafter for a total of four additional years. 189912 1747 135635 1321971 285718 The award vests in three equal instalments of 5,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. During the nine months ended September 30, 2018 Mr. Kardaras invoiced the Company EUR9,000 (USD$10,747) On March 3, 2017, the Company approved the issuance of 50,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $172,000, the fair market value of $3.44 per share on issue date, which amount has been expensed as stock-based compensation. On October 3, 2018 Mr. Kardaras resigned as secretary and director of the Company. He remains the Company's in house legal advisor. On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President. Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives. The initial term of the contract is six months and Mr. Katsaros will receive compensation of USD$2,330 ( 2,000) per month. On March 1, 2016, the Company approved a one-year extension to the consulting agreement and the Company approved the grant of a stock award of 15,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros. The award vests in three equal instalments of 5,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 10,000 vested shares was recorded as stock-based compensation. On March 1, 2017, the final installment of 5,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017. On March 17, 2017, the Company approved the issuance of a further 50,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $170,000, the fair market value of $3.40 per share on grant date, which amount has been expensed as stock-based compensation. On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018. The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,060), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Mr. Katsaros shall also be entitled to acquire at his discretion 500,000 shares of the common stock at a price of US$1.00 for a term of five years commencing January 2, 2018. The Company recognized stock-based compensation expense allocated to consulting fees of $16,800 during the six months ended September 30, 2018. Subsequent to the period ended September 30, 2018, on November 17, 2018, the Company terminated the consulting agreement with Mr. Katsaros. On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$46,430 ( 40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company Euros 40,000 for services rendered in each fiscal year respectively. On December 12, 2017, the Company approved the issuance of 925,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant. The 925,000 shares have been valued at $925,000, or $1.00 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$58,250) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 1,250,000 shares of the common stock at a price of US$1.00 for a term of six years. On May 23, 2018 the Company approved an amendment to the term of the scientific advisory agreement with Dr. Christos Kapatos, board member CTO and member of the Scientific Advisory Board, originally entered into on April 15, 2014 in order to extend the term to April 15, 2019. The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 and $135,900 during the three and nine months ended September 30, 2018. Effective October 3, 2018, Dr Christos Kapatos resigned from his position as Director of the Company. Subsequently on November 21, 2018 Dr, Kapatos terminated his consulting contract. On September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016. Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract. In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR10,000 (USD$11,650) per month. Further, Mr. Leontaritis is entitled to acquire at his discretion 150,000 shares of the common stock at a price of $6 per share for a term of five (5) years. The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 and $245,086 during the three and six months ended September 30, 2018 and 2017. On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated. Further concurrent with his resignation, and with an effective date of September 30, 2018, Mr. Leontaritis and the Company entered into an agreement whereunder Mr. Leontaritis would surrender for cancelation a total of 189,912 shares of the Company's common stock valued at $0.705 per share in order to settle certain amounts payable to the Company totaling $135,635 including a loss on conversion of $1,747. The shares are held in the possession of the Company's Board of Directors and have not yet been provided to the Company's transfer agent for cancelation as at the date of this report. EX-101.SCH 7 vica-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Organization and Business Background link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Control by Principal Stockholder/Officer link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Prepaid Expenses link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Other Receivables link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Office Lease link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Loans link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Commitments link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Capital Stock link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Stock Options link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Segment Reporting link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Prepaid Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Office Lease (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Stock Options (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Segment Reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Organization and Business Background (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Control by Principal Stockholder/Officer (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Prepaid Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Other Receivables (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Property and Equipment (Details Textual) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Office Lease (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Office Lease (Details 1) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Office Lease (Details 2) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Office Lease (Details Textual) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Loans (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Commitments (Details) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Related Party Transactions (Details 1) link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Related Party Transactions (Details 2) link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Capital Stock (Details) link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Stock Options (Details) link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Stock Options (Details 1) link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - Stock Options (Details Textual) link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - Segment Reporting (Details) link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - Segment Reporting (Details Textual) link:presentationLink link:definitionLink link:calculationLink 054 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 vica-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 vica-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 vica-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 vica-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Dec. 11, 2018
Document and Entity Information [Abstract]    
Entity Registrant Name Rafina Innovations Inc.  
Entity Central Index Key 0001402737  
Trading Symbol VICA  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Common Stock, Shares Outstanding   14,409,593
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Current Assets:    
Cash and cash equivalents $ 29,713 $ 352,498
Accounts receivable 50,725 27,557
Other receivable 88,822 59,827
Inventory 4,245 4,395
Prepaid expenses 50,146 50,525
Total Current Assets 223,651 494,802
Property, plant and equipment, net 95,635 155,029
Total Assets 319,286 649,831
Current Liabilities:    
Accounts payable, advances and accrued expenses 519,972 582,781
Accounts payable and accrued expenses-related party 7,131 508,853
Income tax penalties payable 80,000 80,000
Advances from a related party 341,355
Notes payable, third parties 80,510 47,921
Total Current Liabilities 687,613 1,560,910
Total Liabilities 687,613 1,560,910
Commitments and Contingencies
Stockholders' Equity (Deficit):    
Preferred stock, par value $0.0001, 5,000,000 shares authorized; none issued and outstanding as of September 30, 2018 and December 31, 2017
Common stock, par value $0.0001, 35,000,000 shares authorized; 14,219,681 shares issued and outstanding as of September 30, 2018 and 11,919,285 shares issued and outstanding as of December 31, 2017 1,422 1,192
Additional paid-in capital 37,629,553 33,841,702
Accumulated deficit (37,950,401) (34,736,633)
Accumulated other comprehensive income (loss) (48,901) (17,340)
Stockholders' equity (deficit) (368,327) (911,079)
Total Liabilities and Stockholders' Equity (Deficit) $ 319,286 $ 649,831
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 35,000,000 35,000,000
Common stock, shares issued 14,219,681 11,919,285
Common stock, shares outstanding 14,219,681 11,919,285
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenues        
Sales $ 91,173 $ 50,218 $ 325,256 $ 269,918
Cost of goods sold (20,994) (8,037) (110,791) (84,616)
Gross Profit 70,179 42,181 214,465 185,302
Operating Expenses        
Depreciation 17,288 26,406 56,070 74,583
Office rent 18,113 26,421 71,862 73,529
Office expenses 61,350 43,340 197,473 139,274
Consultancy Fees 262,043 302,825 1,071,802 842,998
Professional fees 52,766 12,655 118,086 267,140
Research and development 18,904 49,627 202,961 222,214
Travel and entertainment 17,220 13,042 92,303 41,418
Total Operating Expenses 447,684 474,316 1,810,557 1,661,156
Loss from Operations (377,505) (432,135) (1,596,092) (1,475,854)
Other Income (Expenses)        
(Loss) on conversion of debt (1,747) (17,707) (1,609,436) (17,707)
Gain (Loss) on foreign currency transaction (2,278) (1,141) (5,755) 343
Interest Expenses due to third party (1,256) (2,485)
Interest Expenses due to related party (3,418) (5,520)
Total Other Income (Expenses) (5,281) (22,266) (1,617,676) (22,884)
Loss before Provision for Income Tax (382,786) (454,401) (3,213,768) (1,498,738)
Provision for Income Tax
Net Loss $ (382,786) $ (454,401) $ (3,213,768) $ (1,498,738)
Basic and fully diluted loss per share $ (0.03) $ (0.05) $ (0.24) $ (0.11)
Weighted average shares outstanding 14,312,670 9,903,242 13,184,341 9,753,242
Comprehensive Income (Loss):        
Net loss $ (382,786) $ (454,401) $ (3,213,768) $ (1,498,738)
Effect of foreign currency translation (6,919) (26,421) (31,561) (89,123)
Comprehensive Loss $ (389,705) $ (480,822) $ (3,245,329) $ (1,587,861)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Operating Activities    
Net loss $ (3,213,768) $ (1,498,738)
Adjustments to reconcile net loss to net cash used by operating activities:    
Amortization of stock options 369,287 367,629
Share based compensation 468,842 407,650
Shares issued for services provided 119,950
Loss on conversion of debt 1,609,436 17,707
Depreciation 56,070 74,583
Changes in operating assets and liabilities:    
Decrease (Increase) in accounts receivable (24,527) (36,995)
Decrease (Increase) in prepaid expense (31,269) 1,282
Decrease (Increase) in other receivable (867) 2,430
Decrease (Increase) in inventory 562
Increase (Decrease) in accounts payable and accrued expenses (64,884) 128,186
Increase (Decrease) in accounts payable and accrued expenses, related party (67,362) (49,103)
Net cash used by operating activities (899,042) (464,857)
Investing Activities    
Net cash (used) by investing activities
Financing Activities    
Advances and loans from related parties 202,345 149,708
(Repayments), advances and loans from related party (314,041) (250,384)
Loans from third parties 34,673 121,535
Proceeds from private placement 664,911 552,784
Net cash provided by financing activities 587,888 573,643
Increase (decrease) in cash (311,154) 108,786
Cash at beginning of period 352,498 2,492
Effects of exchange rates on cash (11,631) (41,317)
Cash at end of period 29,713 69,961
Cash paid (received) during year for:    
Interest
Income taxes
Supplemental Non-Cash Activities    
Loan and accrued interest settled with shares 86,793
Reclassification of related party accounts payable and advances to convertible debt, related parties 721,564
Shares issued to settle convertible notes, related parties, accounts payable and advances, related parties $ 811,241
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Business Background
 9 Months Ended
Sep. 30, 2018
Organization and Business Background [Abstract]  
ORGANIZATION AND BUSINESS BACKGROUND
Note 1 - ORGANIZATION AND BUSINESS BACKGROUND
 
Rafina Innovations Inc. (formerly: HCi Viocare) ("VICA" or the "Company") was incorporated on March 26, 2007 under the laws of the State of Nevada. The Company has selected December 31 as its fiscal year end.
 
While the Company has generated revenues from a segment of its planned principal operations, we are not yet able to meet operational overheads and are not yet profitable. We are considered an emerging growth enterprise. The Company was originally formed to sell medical devices with an emphasis on portable medical devices designed for home treatments with the initial focus in the northern regions of China.  The Company's intent was to seek strategic relationships with medical device manufacturers both in China and North America with the aim to be their sales and distribution agent in Northern China and to assist Chinese medical device manufacturers on the development of the North American market.
 
On September 10, 2013, the controlling shareholder of the Company sold his controlling interest in the shares of the Company and there was a change in the Board of Directors of the Company, effecting a change in control of the Company. The business of the Company remains in the field of medical devices and other opportunities related to their uses. We are currently engaged in the technology development and licensing of bioengineering innovations for the health, sports and wellness sectors, and operate a prosthetic and orthotic (P&O) total rehabilitation clinic in Glasgow, Scotland.
 
On January 15, 2014, the Company incorporated two wholly-owned subsidiaries in Scotland, U.K., HCi Viocare Technologies Limited and HCi Viocare Clinics UK Limited. The Company intends to operate in Scotland under these two subsidiaries, one of which will undertake the development and marketing of technologies and the other which is a P&O clinic, which will serve as the center of reference and training for the Company's further clinics.
 
On February 12, 2014, through our wholly owned subsidiary, HCi Viocare Technologies Limited, the Company acquired an interest in a patented technology known as "Socket-Fit". SocketFit is a system that will help overcome technical and resource hurdles endemic to the prosthetic sector. The system has been designed with the aim of offering optimally fitted prosthetic sockets that will reduce the number of prostheses made for patients, resulting in a reduced number of visits by the patient to the prosthetic, and also assisting in the rehabilitation of amputees.  Socket-Fit is a digital system for assessing an amputee's residual limb and for the production of truly functional and comfortable prosthetic sockets. The technology takes account of the external and internal geometry of the amputee's stump, the biomechanical properties of each individual soft tissue layer and the boundary and loading conditions of a complete prosthesis to generate a virtual 3D model of the residual limb making it possible to produce an accurate, functional and comfortable prosthetic socket. By minimizing the time and cost of socket production and reducing the number of faulty sockets there will be a reduction in costs incurred by health services and insurance companies worldwide as well as benefits to the amputee. The Company intends to undertake and fund, through its U.K. subsidiary, a project to improve the nature of the data used in socket modeling software with a view to creating a system that will enable prosthetists to build a socket that evenly distributes weight, provides enhanced comfort, and can be marketed and used across the industry for improved socket creation.
 
On February 19, 2014, the Company filed a Certificate of Amendment with the Secretary of State of Nevada to change the name of the Company to HCi Viocare effective March 21, 2014.  Effective March 21, 2014, in accordance with approval from FINRA, we changed our name from China Northern Medical Device, Inc. to HCi Viocare. Concurrently we commenced trading on the Over-the-Counter Bulletin Board under the symbol "VICA".
 
On April 16, 2014, through our wholly owned subsidiary HCi Viocare Technologies Limited, we acquired all rights and interest in and to the background Intellectual Property Rights ("IPR") for a developing technology known as "Smart Insole".  The Smart Insole system is believed to be a state-of-the-art, pressure and shear (friction)-sensing insole that can wirelessly communicate with connected devices.  The insole has a number of applications, including the mitigation of diabetic foot complications, such as ulceration, infection and amputation, in clinical gait analysis and in sports, as a wearable device to help athletes optimize their performance and prevent injury. The sensing system is very low cost, compared to traditional pressure sensing technologies, in our opinion making such applications affordable to the consumer for the first time.
 
On June 9, 2014, the Company, through our wholly owned subsidiary, HCi Viocare Clinics, acquired W D Spence Prosthetics Limited (the "Clinic"). The Clinic is located in Glasgow, Scotland, and is a fully operational prosthetics and orthotics clinic. The acquisition of the Clinic is the first step to the Company's and HCi Viocare Clinics' intention to develop the first chain of prosthetics and orthotics (P&O) and diabetic foot rehabilitation clinics in the European market, covering Southern Europe, the Middle East and North Africa.
 
On March 31, 2015, the Company's wholly owned subsidiary HCi Viocare Clinics and its subsidiary W D Spence Prosthetics Limited completed a merger with the resulting combined entity having the name HCi Viocare Clinics UK Limited.
 
On July 8, 2015, the Company incorporated HCi Viocare Clinics (Hellas) S A in order to carry out operations for the planning and development of a P&O clinic in Athens, Greece. On August 2, 2017 the Company commenced the dissolution and liquidation of this corporation.  As at the date of this report, the dissolution has not yet been concluded.
 
On May 24, 2018 the Company incorporated a wholly owned subsidiary for purposes of completing a merger and name change from HCi Viocare to Rafina Innovations, Inc. Concurrently the Company's Board of Directors approved a reverse share split on the basis 20 for 1.  The name change and reverse share split became effective on July 9, 2018.  Unless otherwise noted, impacted share amounts and per share information included in the financial statements and notes thereto have been retroactively adjusted for the reverse share split as if such share split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly differently than previously reported due to rounding of fractional shares as a result of the reverse share split.
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Going Concern
 9 Months Ended
Sep. 30, 2018
Going Concern [Abstract]  
GOING CONCERN
Note 2 - GOING CONCERN
 
The Company incurred net losses of $382,786 and $3,213,768 for the three and nine months ended September 30, 2018, respectively, and net loss of $454,401 and $1,498,738 for the three and nine months ended September 30,2017, respectively and has a retained deficit of $37,950,401. In addition, the Company had a working capital deficiency of $463,962 and a stockholders' deficit of $368,327 at September 30, 2018. These factors raise substantial doubt about the Company's ability to continue as a going concern. 
 
There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders.
 
The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.
 
The Company has relied heavily for its financing needs up until the close of fiscal 2017 on its Chief Executive Officer and President as more fully disclosed in Note 10.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Control by Principal Stockholder/Officer
 9 Months Ended
Sep. 30, 2018
Control by Principal Stockholder/Officer [Abstract]  
CONTROL BY PRINCIPAL STOCKHOLDER/OFFICER
Note 3 - CONTROL BY PRINCIPAL STOCKHOLDER/OFFICER
 
Up until March 2018 our Chief Executive Officer owned beneficially and, in the aggregate, the majority of the voting power of the Company.  On March 22, 2018 and March 30, 2018 respectively, Sotirios Leontaritis, the President, Chief Executive Officer and a Director of the Company, entered into a Share Purchase Agreement (the "SPA") and an amendment thereto (the "Addendum"), (collectively herein referred to herein as the "Agreement") with Maschari Ltd. ("Maschari"), a Company incorporated in Cyprus, pursuant to which Mr. Leontaritis sold 6,135,529 of his restricted common shares to Maschari.  The shares sold by Mr. Leontaritis represented approximately 42.6% of the Company's total outstanding shares of common stock. Mr. Leontaritis continues to hold 1,965,619 shares of the Company's common stock representing approximately 13.6% of the issued and outstanding shares.  As a result of the aforementioned transaction, Maschari has the ability to control the approval of most corporate actions, including increasing the authorized capital stock and the dissolution, merger or sale of the Company's assets, as may be presented at Shareholder meetings from time to time.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Principals of Consolidation
 
The consolidated financial statements include the accounts of Rafina Innovations Inc. and its wholly-owned subsidiaries, HCi Viocare Technologies Limited, HCi Viocare Clinics UK Limited and HCi Viocare Clinics (Hellas) S.A. On August 2, 2017 the Company commenced the dissolution and liquidation of HCi Viocare Clinics (Hellas) S.A. All significant intercompany balances and transactions have been eliminated.
 
Basis of Presentation
 
The interim unaudited financial information referred to above has been prepared and presented in conformity with accounting principles generally accepted in the United States applicable to interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The interim financial information has been prepared on a condensed basis, such that certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission. These interim financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.
 
This report on Form 10-Q should be read in conjunction with the Company's financial statements and notes thereto included in the Company's Form 10-K for the fiscal year ended December 31, 2017 filed on May 17, 2018. Results of the three and nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ended December 31, 2018 and any other future periods.
 
Use of Estimates
 
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results when ultimately realized could differ from these estimates.
 
Cash and Cash Equivalents
 
Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less.
 
Foreign Currencies
 
Items included in the consolidated financial statements of each of the Company and its subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the 'functional currency').  The Company's reporting currency is the U.S. dollar.  The functional currency of subsidiaries based in the UK is pound sterling and the functional currency of the Company's subsidiary based in the Greece is the Euro. All transactions initiated in Pounds and Euro are translated into U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830-30, "Translation of Financial Statements," as follows:
 
i)
assets and liabilities are translated at the closing rate at the date of the balance sheet, or
1USD=0.86153EUR, 1USD=0.76728GBP (September 30, 2018), and;
1USD=0.8347EUR, 1USD=0.74108GBP (December 31, 2017);
 
ii)
income and expenses are translated at average exchange rates for nine months ended September 30, or
1USD=0.8374EUR, 1USD=0.7404GBP (September 30, 2018), and;
1USD=0.9000EUR, 1USD=0.7846GBP (September 30, 2017);
 
iii)
all resulting exchange differences are recognized as other comprehensive income, a separate component of equity.
 
Adjustments arising from such translations are included in accumulated other comprehensive income (loss) in stockholders' equity.
 
Revenue Recognition
 
Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured.
 
The Company recognizes revenue when the earnings process is complete and persuasive evidence of an arrangement exists. This generally occurs for revenue recorded in our P&O Clinics division when prosthetic products are fitted to customers, both title and the risks and rewards of ownership are transferred or services have been rendered and accepted, the selling price is fixed or determinable, and collectability is reasonably assured.  Revenue is recognized upon issuance of an invoice and completion of each concluded stage of work performed on a prosthetic product.  The Company recognizes revenue from its technology licensing fees and/or product development fees upon conclusion of services provided under contract.
 
There was no impact on the Company's financial statements as a result of adopting Topic 606 for the three and nine months ended September 30, 2018 and 2017.
 
Inventory
 
Inventories, which consist principally of raw materials and parts, are stated at the lower of cost or market. Cost is determined using the first-in, first-out method and are adjusted to actual cost quarterly based on a physical count. Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. Work-in-process inventory consists of materials, labor and a predetermined fixed rate of overhead which is valued based on established standards for the stage of completion of each custom order. We do not carry finished goods on hand. Material, labor and overhead costs are determined at the individual clinic level. Presently we only maintain very limited parts and raw materials inventory.
 
Warranty
 
We do not record warranty liabilities at the time of sale for the estimated costs that may be incurred under the terms of the applicable limited warranty as all component parts are covered by our respective industry suppliers.
 
Advertising Costs
 
The Company expenses advertising costs as incurred or the first time the advertising takes place, whichever is earlier, in accordance with ASC 720-35. Advertising costs were immaterial for the three and nine months ended September 30, 2018 and 2017, respectively.
 
Research and Development Costs
 
The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, "Research and Development". Research and development costs were $18,904 and $202,961for the three and nine months ended September 30, 2018, and $49,627 and $222,214 for the three and nine months ended September 30, 2017. During the period ended September 30, 2018, HCi Viocare Technologies Limited, the Company's subsidiary, received $52,766 (GBP 39,066) from the UK government as research and development tax credit.
 
Related parties
 
For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.
 
Stock-based compensation
 
For stock-based compensation, the Company follows the guidance codified in the Compensation – Stock Compensation Topic of FASB ASC ("ASC 718"). The Company determines the value of stock issued at the date of grant. It also determines at the date of grant, the value of stock at fair market value or the value of services rendered (based on contract or otherwise) whichever is more readily determinable.
  
Income Taxes
 
The Company accounts for income taxes in accordance with FASB ASC 740, "Income Taxes", which requires the asset and liability approach for financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.
 
The Company has a retained deficit from operations. Because there is no certainty that we will realize taxable income in the future, the Company did not record any deferred tax benefit as a result of these losses and recorded a valuation allowance offsetting the entire potential tax benefit.
 
Income tax years for 2014 through 2016 have been remitted timely and remain open to examination by the taxing authorities. The tax return for fiscal 2017 has not yet been filed. The Company has been assessed late filing penalties of $10,000 per year, as well as accrued interest thereon, for each of the late filed returns for the periods from inception to December 31, 2012. Prior to a change in control at the close of fiscal 2013, prior management had not timely filed its annual tax returns.  We have estimated and accrued penalties of $80,000 as taxes payable in our financial statements. The Company has retained a tax professional to assist in reaching a settlement with the IRS.
 
Comprehensive Income
 
FASB ASC 220, "Comprehensive Income", establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income, as defined, includes all changes in equity during a period, exclusive of shareholder transactions. Accordingly, comprehensive income (loss) may include certain changes in shareholders' equity (deficit) that are excluded from net income (loss).
 
Segment Reporting
 
FASB ASC 820 "Segments Reporting" establishes standards for reporting information about operating segments on a basis consistent with the Company's internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. Our proposed business segments are expected to span more than one geographical area. Specifically, the Company intends to operate prosthetic and orthotic rehabilitation clinics with various European based locations, as well as a corporate development and technology center which will undertake ongoing research and marketing activities.
 
Basic and Diluted Loss per Share
 
The Company reports earnings per share in accordance with FASB ASC 260, "Earnings Per Share." FASB ASC 260 requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company had potentially dilutive securities outstanding (convertible debt and liabilities) for the period ended September 30, 2018 and December 31, 2017, respectively, however, since the Company reflected a net loss in the three and nine months ended September 30, 2018 and 2017, the effect of considering any common stock equivalents, if outstanding, would have been anti-dilutive. A separate computation of diluted earnings (loss) per share is not presented.
 
 
  
September 30, 2018
    
December 31, 2017
  
Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options
    
500,000
      
500,000
  
Common stock issuable upon exercise of stock options
    
1,900,000
      
1,400,000
  
Total
    
2,400,000
      
1,900,000
  
 
Fair Value of Measurements
 
Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
 
Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
 
Level 2: Input other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company.
 
Level 3: Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability.
 
An asset or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities.
 
Recent Issued Accounting Pronouncements
.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842).  The amendments in this Update increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.  ASU 2016-02 will be effective for the Company beginning on October 1, 2019.  Early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases to clarify the implementation guidance and ASU No. 2018-11, Leases (Topic 842) Targeted Improvements. This updated guidance provides an optional transition method, which allows for the initial application of the new accounting standard at the adoption date and the recognition of a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning of the period of adoption. We have begun to identify our significant lease contracts and are in the process of evaluating the effect of the new guidance on our consolidated financial statements and related disclosures.
 
There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Prepaid Expenses
 9 Months Ended
Sep. 30, 2018
Prepaid Expenses [Abstract]  
PREPAID EXPENSES
Note 5 - PREPAID EXPENSES
 
Prepaid expenses consist of the following:
 
 
  
September
30, 2018
    
December
31, 2017
  
Office lease, including security deposits
  
$
38,241
    
$
39,582
  
Travel advances and other expenses
    
11,905
      
10,943
  
      Total prepaid expense
  
$
50,146
    
$
50,525
  
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Receivables
 9 Months Ended
Sep. 30, 2018
Other Receivables [Abstract]  
OTHER RECEIVABLES
Note 6 – OTHER RECEIVABLES
 
From time to time the Company makes short term loans to third parties in order to facilitate its business operations. The loans bear interest ranging from 1.5% to 4% per annum and generally have terms of between 60 to 180 days. In general, the Company forgives accrued interest on principal when these short-term loans are repaid on time.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment
 9 Months Ended
Sep. 30, 2018
Property and Equipment [Abstract]  
PROPERTY AND EQUIPMENT
Note 7 - PROPERTY AND EQUIPMENT
 
Property and improvements consisted of the following as of September 30, 2018 and December 31, 2017:
 
 
  
September 30,
2018
    
December 31,
2017
  
Cost
            
Leasehold improvements
  
$
197,171
    
$
203,990
  
Furniture and fixture
    
31,695
      
32,781
  
Computers and equipment
    
33,062
      
33,144
  
Vehicle
    
58,036
      
59,902
  
Machine and plant
    
8,892
      
9,206
  
Lab equipment
    
32,958
      
34,123
  
 
    
361,814
      
373,146
  
Less: accumulated depreciation and impairment
    
(266,179
)
    
(218,117
)
Total
  
$
95,635
    
$
155,029
  
 
Leasehold improvements are amortized over the term of the lease: three to ten years.
 
Furniture is depreciated over three to five years and computer and equipment is depreciated over three years.
 
Vehicles are depreciated over five years.
 
Machine equipment and lab equipment are depreciated over 4 years.
 
Depreciation expense amounted to $17,288 and $56,070 for the three and nine months ended September 30, 2018, respectively.
 
Depreciation expense amounted to $26,406 and $74,583 for the three and nine months ended September 30, 2017, respectively.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Office Lease
 9 Months Ended
Sep. 30, 2018
Office Lease [Abstract]  
OFFICE LEASE
Note 8 - OFFICE LEASE
 
Office in Greece
 
On February 3, 2014, the Company leased office space in Paleo Faliro, Greece on a three-year lease, commencing on March 1, 2014 and ending on February 28, 2017. The monthly rental fee is $1,900 (EUR € 1,554) including applicable taxes in the first year. Thereafter, for every further lease year and for the whole duration of the lease agreement, as well as in case of compulsory statutory extension or extension by tacit agreement, the monthly rent shall be annually adjusted by a percentage equal to the Consumer Price Index of the adjustment month with respect to the respective month of the year before (simple annual rate of change), as this is calculated by the Hellenic Statistical Authority (ELSTAT), plus two (2) percentage points (+2%).
 
Under the term of the lease agreement, the Company paid a total of $25,010 (EUR €18,540) including $4,047 (EUR €3,000) for a deposit and $20,963 (EUR €15,540) for ten months' rental fee upon executing the agreement. As of September 30, 2018, $3,482 (EUR €3,000) is shown as deposits in the prepaid account.  The lease has been renewed effective June 13, 2017 for a term of 3 years terminating on February 28, 2020 at a rate of $1,848 (EUR€1,592) plus a fee of 3.6%.
 
On September 3, 2018, the Company's lease in Paleo Faliro was terminated by the Lessor.  The Company and the Lessor are currently negotiating a settlement of the remaining lease obligation.
 
Clinic in Greece
 
On December 29, 2014, the Company leased office space at Peania Region of Attica in Greece on a ten-year lease, commencing on January 1, 2015 and ending on October 5, 2024. The monthly rental fee is $6,996 (EUR €6,233) plus applicable taxes and the monthly operating cost estimate is $1,120 (EUR €997).
 
Under the term of the lease agreement, the Company paid a total of $13,991 (EUR €12,465) as deposits in the prepaid account. 
 
On October 9, 2015, the terms of the lease were amended to include the following provisions:
 
- 
Effective September 1, 2015, the monthly rental fee shall be reduced to $3,500 (EUR €3,116) for a period of 12 months ending August 31, 2016.
 
- 
In the event that the Lessee commences leasehold improvements prior to August 31, 2016, it shall inform the Lessor respectively and pay retroactively the remaining balance of the total amount of monthly rental in full from the period commencing September 1, 2015, as if they have not been reduced;
 
- 
In the event that the Company does not proceed with leasehold improvements in the 12-month period, the lease agreement will terminate and the Lessor with retain the deposit.
 
- 
The Lessor until such time as the leasehold improvements commence, may at any time and without indemnity terminate the lease agreement with a 30-day prior written notice to the Lessee.
 
As of December 31, 2016, the Company and the Lessor concluded the Termination of Lease Agreement dated August 1, 2016, and the Lessor waived all maintenance charges and utility charges for fiscal 2016. The following table is the summary of balance owing to Lessor as at September 30, 2018 and December 31, 2017:
 
 
September 30,
2018
  
December 31,
 2017
  
 
        
Amount owed for maintenance charges
  
$
15,732
    
$
16,238
  
Amount owed for utility charges
    
16,284
      
16,807
  
 
  
$
32,016
    
$
33,045
  
 
Lease in UK
 
On March 2, 2015, the Company entered into a lease agreement for a modern, stand-alone 5,300 square foot facility in Glasgow, Scotland with an entry date of March 1, 2015. The building will host the Company's first Viocare center, a full-service Prosthetic and Orthotic ("P&O") practice with a superior standard of personalized care. The renovations to the clinic were completed in June, and the facility was opened on August 1, 2015 with an official ribbon cutting on 25 September 2015. During the first year from the date of entry, the lease fees are USD$26,066 (GBP £20,000) per annum (exclusive of VAT). On the second anniversary of the date of entry, the lease will increase to USD$52,132 (GBP £40,000) per annum (exclusive of VAT). In the third anniversary of the date of entry, the lease will be USD$52,132 (GBP £40,000) per annum (exclusive of VAT). In the fourth anniversary of the date of entry, the lease will decrease to USD$39,100 (GBP £30,000) per annum (exclusive of VAT). In the fifth anniversary of the date of entry, the lease will be USD$52,132 (GBP £40,000) per annum (exclusive of VAT).
 
Under the term of the lease agreement, the Company paid a total of $26,066 (GBP £20,000) as security deposits which amount is included on the Company's balance sheet in prepaid expenses.
 
Location
  
September 30, 2018
    
December 31, 2017
  
Greece
  
$
3,482
    
$
3,594
  
UK
    
34,759
      
35,988
  
 
  
$
38,241
    
$
39,582
  
 
As of September 30, 2018, the approximate future aggregate minimum lease payments in respect of our current obligations were as follows:
 
Location
 
Greece
 
 
United Kingdom
 
2018
 
 
5,411
 
 
 
10,318
 
2019
 
 
21,645
 
 
 
49,960
 
2020
 
 
3,607
 
 
 
8,688
 
 
 
$
30,663
 
 
$
68,966
 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loans
 9 Months Ended
Sep. 30, 2018
Loans [Abstract]  
LOANS
Note 9 -   LOANS
 
On January 5, 2017, HCi Viocare Clinics Hellas S.A., the Company's subsidiary, entered into a loan agreement with a third party to borrow a total of EUR 40,000 (US$46,429) with an annual interest rate of 5%, payable within one year from the date of the agreement. As at September 30, 2018 and December 31, 2017 a total of $50,452 and $50,276, respectively, including accrued interest to date, remained due and payable in respect of this loan. Interest expenses of $1,791 were accrued in the nine months ended September 30, 2018. The loan was not repaid in January 2018 and is currently in default.
 
On July 27, 2018, HCi Viocare Clinics UK Limited, the Company's subsidiary, entered into a loan agreement with a third party to borrow a total of EUR 30,000 (US$34,081) with an annual interest rate of 6%, payable within six months from the date of the agreement. As at September 30, 2018 and December 31, 2017 a total of $34,480 and $0, respectively, including accrued interest to date, remained due and payable in respect of this loan. Interest expenses of $413 were accrued in the nine months ended September 30, 2018.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments
 9 Months Ended
Sep. 30, 2018
Commitments [Abstract]  
COMMITMENTS
Note 10 -   COMMITMENTS
 
(1)
Consulting Agreement with Dr. Christos Kapatos
 
On April 16, 2014, the Company entered into a Consulting Agreement with Christos Kapatos whereby he will provide his services as Chief Technical Officer for the Company and the Company's wholly-owned subsidiaries.  The contract has a term of one year, renewable for such further term as may be mutually agreed between the parties. In the case that a research and development project is initiated and completed during the term of the agreement, Kapatos shall receive seventy thousand (70,000) shares of the Company's common stock for each research project completed with a valuation less than twenty million dollars ($20,000,000 USD), one hundred and seventy-five thousand (175,000) shares of the Company's common stock for each research project completed with a valuation equal or greater than twenty million US dollars ($20,000,000 USD). Details of compensation under the terms of the consulting agreement are included in Note 11(ii).
 
(2)
Consulting Agreement with JAMB
 
Effective July 10, 2017, the Company entered into a business consulting agreement (the "Consulting Agreement") with JAMB Group LLC. ("Consultant") for services to commence July 15, 2017 and to continue for a period of twelve (12) months thereafter. Under the terms of the Agreement, the Consultant shall provide consulting services to the Company for the development and expansion of its business, including the introduction to specific Targets for the purposes of financing transactions or other business relationship. The Consultant is entitled to compensation for the provision of services in the form of 25,000 shares of the common stock which were issued upon execution of the Consulting Agreement, as well as certain other fees and consideration.
 
25,000 shares have been valued at $79,950, the fair market value of $3.198 per share, on issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017.  The contract expired without renewal in the current nine months ended September 30, 2018.
 
(3)
Consulting Agreement with Mr. Stefanos Batzakis
 
On September 1, 2017, the Company entered into a one-year consulting agreement (the "Agreement") with Mr Stefanos Batzakis. As per terms of said Agreement Batzakis will provide services to the Company as IT Solutions Manager, for a term of one (1) year and receive compensation in the form of stock, namely twenty-five thousand (25,000) common shares, which were issued upon signing of this Agreement.
 
25,000 shares have been valued at $40,000, the fair market value of $1.60 per share on issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017. The contract expired without renewal in the current nine months ended September 30, 2018.
 
(4)
Consulting Agreement with Dr. Ioannis Doupis
 
On October 9, 2017, the Company appointed Dr. Ioannis Doupis, to the Advisory Board of the Company originally formed on April 15, 2014 and Concurrently entered into an advisory board agreement. Compensation shall be the grant of a total of 25,000 shares of the Company's common stock valued at the fair market price on the date of grant of $1.40 per share. The advisory board appointment is for a term of one year.
 
25,000 shares have been valued at $35,000, the fair market value of $1.40 per share on issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017.  On October 3, 2018 the Company's Board of Directors determined to terminate the Company's advisory board.
 
(5)
Consulting Agreement with Ms. Paraskevi Pilarinou
 
On December 12, 2017, the Company entered into a consulting agreement (the "Agreement") with Ms. Paraskevi Pilarinou (the "Consultant").  Under the terms and conditions of the Agreement the Consultant shall be employed in the position of Financial Controller of the Company. The Agreement has a three-year term starting on January 2, 2018 and ending on January 1, 2021 and the Consultant shall be remunerated with a monthly fee of EUR2,000 (IUSD$2,320) and was issued 100,000 shares of the Company's common stock. The 100,000 shares were issued as compensation as of the date of the agreement and were valued at $1 per share or $100,000, the fair market value on the date of issuance in the year ended December 31, 2017.
 
(6)
Consulting Agreement with Charalampos Sgardelis
 
On January 2, 2017, the Company entered into a one-year consulting agreement (the "Agreement") with Mr. Charalampos Sgardelis ("Sgardelis"). Under the terms of the Agreement, Sgardelis provides services to the Company as Business Development Manager, for a term of one (1) year and receives compensation of Two Thousand Euros (2,000 €) (USD$2,320) per month.
 
On February 26, 2018 the Company approved a three (3) year extension to the Agreement (the "Addendum") between the Company and Sgardelis. Under the terms and conditions of the Addendum, Sgardelis is entitled to receive compensation of Three Thousand Euros (3,000 €) (USD$3,480) per month and shall be awarded 250,000 common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $0.98 per share for total consideration of $245,000.  Subsequent to the period ended September 30, 2018, on November 17, 2018, the Company terminated the consulting agreement with Mr. Sgardelis.
 
(7)
Advisory Agreement with Ravi Vaidyanathan
 
On March 27, 2018, the Company entered into a one-year advisory agreement (the "Agreement") with Mr. Ravi Vaidyanathan (the "Advisor"). Under the terms and conditions of the Agreement, the Advisor is appointed to the Company's Scientific Advisory Board and is entitled to remuneration for the provision of services in the form of 25,000 shares of the common stock to be issued upon signing of the Agreement. Further, the Advisor shall be granted additional 12,500 shares of the common stock to be issued after a time-period of six (6) months from the signing of the Agreement. The Advisor shall serve on the Scientific Advisory Board in the position of Biomechatronics and Human Augmentation Advisor. The Company or the Advisor may terminate the agreement upon 30 days written notice. The issued shares were valued at fair market value on the date of issuance or $1.10 per share for total consideration of $27,500. On October 3, 2018 the Company's Board of Directors determined to terminate the Company's advisory board and no further shares will be issued to Mr. Vaidyanathan under the terms of this Agreement.
 
(8)
Addendum to Service Agreement with Nikolaos Gemelos
 
On January 16, 2018, the Company entered into a one-year service agreement (the "Agreement") with Mr. Nikolaos Gemelos ("Gemelos"). Under the terms of the Agreement, Gemelos provides services to the Company as Consultant, for a term of one (1) year and he is entitled to a success fee of 5% of the amount actually invested in the Company by introduced accredited investors, and 5% of the amount invested in the form of restricted shares of the common stock of the Company. On May 3, 2018, the Company entered into an amendment to the aforementioned Agreement. Under the terms and conditions of this Addendum, Gemelos shall be awarded 5,000 restricted common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $1.34 per share for total consideration of $6,700.
 
(9)
Service Agreement with Georgios Dritsoulas
 
On June 7, 2018, the Company entered into a six-month service agreement with Mr. Georgios Dritsoulas. As per terms of said Agreement, Mr. Dritsoulas will provide services to the Company as Consultant for the development and expansion of the Company's business for a term of six (6) months. Mr. Dritsoulas received compensation of 2,500 restricted common shares as compensation for the services provided. The issued shares were valued at fair market value on the date of issuance or $2 per share for total consideration of $5,000.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions
 9 Months Ended
Sep. 30, 2018
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS
Note 11 -   RELATED PARTY TRANSACTIONS
 
The following table provides details of the Company's related party transactions during the three and nine months ended September 30, 2018 and 2017
 
(a)
Services provided from related parties:
 

 
  
Three Months Ended
September 30,
    
Nine Months Ended
September 30,
  
 
  
2018
    
2017
    
2018
    
2017
  
Consulting fees from CEO and President (i)
  
$
33,739
    
$
30,000
    
$
107,472
    
$
90,000
  
Consulting fees from a Director (ii)
    
13,978
      
11,697
      
44,700
      
33,332
  
Professional fees from Director (iii)
    
3,374
      
3,509
      
10,747
      
9,999
  
Consulting fees for VP (iv)
    
11,808
      
7,018
      
37,615
      
19,999
  
Stock options granted to CEO and President (i)
    
122,544
      
-
      
367,630
      
-
  
Stock options granted to Director (ii)
    
45,300
      
-
      
135,900
      
-
  
Stock options granted to VP (iv)
    
16,800
      
-
      
50,400
      
187,200
  
Stock award granted to Director (iii)
    
-
      
-
      
-
      
172,000
  
 
  
$
247,543
    
$
52,224
    
$
754,464
    
$
512,530
  
 
(i)
 
On September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016.   Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract.  In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR10,000 (USD$11,650) per month.  Further, Mr. Leontaritis is entitled to acquire at his discretion 150,000 shares of the common stock at a price of $6 per share for a term of five (5) years.  The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 and $245,086 during the three and six months ended September 30, 2018 and 2017. On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated.   Further concurrent with his resignation, and with an effective date of September 30, 2018, Mr. Leontaritis and the Company entered into an agreement whereunder Mr. Leontaritis would surrender for cancelation a total of 189,912 shares of the Company's common stock valued at $0.705 per share in order to settle certain amounts payable to the Company totaling $135,635 including a loss on conversion of $1,747. The shares are held in the possession of the Company's Board of Directors and have not yet been provided to the Company's transfer agent for cancelation as at the date of this report.
 
(ii)
On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$46,430 (€40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company Euros €40,000 for services rendered in each fiscal year respectively.
 
On December 12, 2017, the Company approved the issuance of 925,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant.  The 925,000 shares have been valued at $925,000, or $1.00 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$58,250) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 1,250,000 shares of the common stock at a price of US$1.00 for a term of six years.
 
On May 23, 2018 the Company approved an amendment to the term of the scientific advisory agreement with Dr. Christos Kapatos, board member CTO and member of the Scientific Advisory Board, originally entered into on April 15, 2014 in order to extend the term to April 15, 2019.
 
The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 and $135,900 during the three and nine months ended September 30, 2018.
Effective October 3, 2018, Dr Christos Kapatos resigned from his position as Director of the Company.  Subsequently on November 21, 2018 Dr, Kapatos terminated his consulting contract.
 
(iii)
 
On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. During the nine months ended September 30, 2018 Mr. Kardaras invoiced the Company EUR9,000 (USD$10,747)
 
On March 3, 2017, the Company approved the issuance of 50,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $172,000, the fair market value of $3.44 per share on issue date, which amount has been expensed as stock-based compensation.  On October 3, 2018 Mr. Kardaras resigned as secretary and director of the Company.  He remains the Company's in house legal advisor.
 
 (iv)
On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President. Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives.  The initial term of the contract is six months and Mr. Katsaros will receive compensation of USD$2,330 (€2,000) per month. On March 1, 2016, the Company approved a one-year extension to the consulting agreement and the Company approved the grant of a stock award of 15,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros.  The award vests in three equal instalments of 5,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 10,000 vested shares was recorded as stock-based compensation. On March 1, 2017, the final installment of 5,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017.
 
On March 17, 2017, the Company approved the issuance of a further 50,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $170,000, the fair market value of $3.40 per share on grant date, which amount has been expensed as stock-based compensation.
 
On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018.  The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,060), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Mr. Katsaros shall also be entitled to acquire at his discretion 500,000 shares of the common stock at a price of US$1.00 for a term of five years commencing January 2, 2018.
 
The Company recognized stock-based compensation expense allocated to consulting fees of $16,800 during the six months ended September 30, 2018.
 
Subsequent to the period ended September 30, 2018, on November 17, 2018, the Company terminated the consulting agreement with Mr. Katsaros.
 
(b) Accounts payable and accrued liabilities from related parties:
 
  
September 30,
    
December 31,
  
 
  
2018
    
2017
  
CEO and President (i)
  
$
-
    
$
413,010
  
Director (ii)
    
5,390
      
95,843
  
Consulting fees for VP (iv)
    
1,741
      
-
  
 
  
$
7,131
    
$
508,853
  
 
(c)
Advances / other receivable from related parties:
 
 Advances from related parties:
September 30,
  
December 31,
  
 
2018
  
2017
  
CEO and President (i)
  
$
-
    
$
287,073
  
Director (ii)
    
-
      
54,282
  
 
  
$
-
    
$
341,355
  
 
(d)
Convertible Debt, related parties:
 
On February 15, 2018, the Company and certain shareholders holding in excess of 5% of the Company's common stock and concurrently holding a position on the Company's Board, or acting in the capacity of any officer of the Company or its subsidiaries, agreed that repayment against pre-existing debt payable by the Company on the agreement date shall be  suspended until such time as  the Company concludes a full profitable year of operations. Further the parties agreed that any such pre-existing debt or portion thereof shall be convertible at any time into restricted shares of the Company's common stock at a price equal or greater to $0.60 per share. On the date of the agreement the fair market value of the Company's common stock as traded on OTCMarkets was $0.806 per share. The Company accounted for this transaction by applying ASC 470-20-35.  As the convertible debt has no stated redemption date, the Company will recognize the discount as interest expense on the earliest conversion date.  
 
The Company has reclassified all debts payable as of February 15, 2018 to our CEO and CTO from advances and accounts payable, related party, to convertible debt, related party. 
 
On each of May 31, 2018 and on June 26, 2018, the Company entered into Debt Settlement and Subscription Agreements with the President of the Company, Mr. Sotirios Leontaritis to settle total debt in the amount of $679,371 in respect to certain unpaid salary, advances for operational shortfalls and certain unsettled expense reimbursements into 1,132,286 shares of the Company's common stock at a price of US$0.60 per share. The Company valued the aforementioned issuances at the closing price of the Company's stock as traded on the OTCMarkets on the date of issue. The difference in price resulted in the Company recording loss on debt settlement in the amount of $1,321,971 in respect of the transaction.
 
On June 26, 2018, the Company entered into a Debt Settlement and Subscription Agreement with a Director of the Company, Dr. Christos Kapatos to settle total debt in the amount of US$131,870 in respect to certain unpaid salary, advances for operational shortfalls and certain unsettled expense reimbursements into 219,784 shares of the Company's common stock at a price of US$0.60 per share. The Company valued those issuances at the closing price of the Company's stock as traded on the OTCMarkets on the date of issue. The difference in price resulted in the Company recording loss on debt settlement in the amount of $285,718 in respect to the transaction.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Capital Stock
 9 Months Ended
Sep. 30, 2018
Capital Stock [Abstract]  
CAPITAL STOCK
Note 12 -   CAPITAL STOCK
 
The Articles of Incorporation authorize the Company to issue 5,000,000 shares of preferred stock with a par value of $0.0001, and 35,000,000 shares of common stock with a par value of $0.0001.  No shares of preferred stock have been issued, however, the Company has granted 25,000 fully vested stock options for the purchase of 25,000 shares of Series A Preferred Stock of the Company at a price of $0.04 per share for a period of five (5) years from the date of vesting. (ref: Note 13 below)
 
On May 24, 2018 the Company's Board of Directors approved a reverse share split on the basis 20 for 1.  The reverse share split became effective on July 9, 2018. Unless otherwise noted, impacted share amounts and per share information included in the financial statements and notes thereto have been retroactively adjusted for the reverse share split as if such share split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly differently than previously reported due to rounding of fractional shares as a result of the reverse share split.
 
Share issuances during the nine months ended September 30, 2018
 
During the nine months ended September 30, 2018, 855,717 shares of common stock were issued in respect of various private placements for total cash proceeds of $664,911.
 
During the nine months ended September 30, 2018, the Company issued 282,500 shares to employees, board members and consultants valued at $284,200, for services rendered.  The Company valued these issuances based on the closing price of the Company's stock as reflected on the OTC Markets on the respective dates of issuance.
 
During the nine months ended September 30, 2018, the Company issued 1,132,286 shares valued at fair market value on the date(s) of issuance for a total of $2,001,342 to Mr. Leontaritis to settle debt in the amount of $679,371.  The Company valued those issuances at the closing price of the Company's stock as traded on the OTCMarket on the date of issue. The difference in price resulted in the Company recording a loss on debt settlement in the amount of $1,321,971.
 
During the nine months ended September 30, 2018, the Company issued 219,784 shares valued at fair market value on the date of issuance of $417,588 to Dr. Christos Kapatos to settle debt in the amount of $131,870.  The Company valued those issuances at the closing price of the Company's stock as traded on the OTCMarket on the date of issue. The difference in price resulted in the Company recording loss on debt settlement in the amount of $285,718.
 
On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated.   Further concurrent with his resignation and with an effective date of September 30, 2018, Mr. Leontaritis and the Company entered into an agreement whereunder Mr. Leontaritis would surrender for cancelation a total of 189,912 shares of the Company's common stock valued at $0.705 per share in order to settle certain amounts payable to the Company totaling $135,635 including a loss on conversion of $1,747. The returned shares are held in the possession of the Company's Board of Directors and have not yet been provided to the Company's transfer agent for cancelation as at the date of this report.
 
Designation of Series A Preferred Stock
 
On January 13, 2014, the Company filed a Certificate of Designation with the Secretary of State of the State of Nevada.   The Certificate of Designation sets forth the rights, preferences and privileges of a class of the Company's preferred stock.  Such class shall be designated as the "Series A Preferred Stock" and the number of shares constituting such series shall be 5,000,000 shares.  The holders of Series A Preferred Stock will be entitled to a preference over all of the shares of the Company's common stock.  Holders of Series A Preferred Stock shall have 50 votes per share of Series A Preferred Stock held by them and shall be entitled to notice of any stockholders' meeting and to vote as a single class upon any matter submitted to the stockholders for a vote.  Each share of Series A Preferred Stock is convertible into 20 shares of our common stock at any time at the holder's option.  Shares of Series A Preferred Stock shall not be entitled to any dividends.  The preferred stock shall be entitled to a preference over all of the shares of common stock of the Company with respect to the distribution of assets in the event of the liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Options
 9 Months Ended
Sep. 30, 2018
Stock Options [Abstract]  
STOCK OPTIONS
Note 13 - STOCK OPTIONS
 
A total of 25,000 stock options granted during April and June of fiscal 2014 entitling each holder the right to purchase a total of 5,000 shares of Series A Preferred Stock of the Company at a price of $0.04 per share for a period of five (5) years remain unexercised and outstanding as at September 30, 2018.  The Series A Preferred shares are convertible on the basis of 20 shares of common stock for each one share held and have voting rights of 50 votes per share of Series A Preferred stock held at any meetings of the stockholders.
 
On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019. Further, Mr. Leontaritis is entitled to acquire at his discretion 150,000 shares of the common stock at a price of $6 per share for a term of five (5) years.
 
On December 12, 2017, Dr. Christos Kapatos, director, was issued a stock option as part of an extension to his employment contract under which, at his discretion, he may acquire 1,250,000 shares of the common stock at a price of US$1.00 for a term of six years.
 
Mr. Katsaros shall also be entitled to acquire at his discretion 500,000 shares of the common stock at a price of US$1.00 for a term of five years commencing January 2, 2018.
 
The Company accounts for share-based payments pursuant to ASC 718, "Stock Compensation" and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company's stock price and expected dividends.
 
Stock compensation expense for stock options is recognized over the vesting period of the award.
 
The Company recognized stock-based compensation expense allocated to consulting fees of $184,644 and $122,543 during the three months ended September 30, 2018 and 2017, respectively. The Company recognized stock-based compensation expense allocated to consulting fees of $553,930 and $245,086 during the nine months ended September 30, 2018 and 2017, respectively.  Subsequent to September 30, 2018 each of Mr. Leontaritis and Dr. Kapatos resigned all positions with the Board of Directors, including any consulting contracts. In addition, the consulting contract with Mr. Katsaros was terminated. As a result, any unexercised stock options are expected to expire within 90 days of the respective contract terminations.
 
The following table summarizes information concerning stock options outstanding as of September 30, 2018, and December 31, 2017:
 
Series A Preferred Stock:
 
 
  
September 30, 2018
    
December 31, 2017
  
 
  
Series A
Preferred stock
    
Weighted Average Exercise Price
$
    
Series A
Preferred stock
    
Weighted Average Exercise Price
$
  
Outstanding at beginning of the year
    
25,000
      
0.04
      
25,000
      
0.04
  
   Granted
    
-
      
-
      
-
      
-
  
   Exercised
    
-
      
-
      
-
      
-
  
   Expired or canceled
    
-
      
-
      
-
      
-
  
Outstanding at the period
    
25,000
      
0.04
      
25,000
      
0.04
  
 
The aforementioned options have an average remaining life of 0.57 years. 
 
Common stock:
 
 
  
September 30, 2018
    
December 31, 2017
  
 
  
Common
stock
    
Weighted Average Exercise Price
$
    
Common
stock
    
Weighted Average Exercise Price
$
  
Outstanding at beginning of the year
    
1,400,000
      
1.52
      
-
      
-
  
   Granted
    
500,000
      
1.00
      
1,400,000
      
1.52
  
   Exercised
    
-
      
-
      
-
      
-
  
   Expired or canceled
    
-
      
-
      
-
      
-
  
Outstanding at the period
    
1,900,000
      
1.4
      
1,400,000
      
1.52
  
 
The aforementioned options have an average remaining life of 5.05 years. 
 
Valuation Assumptions
 
The Company accounts for share-based payments pursuant to ASC 718, "Stock Compensation" and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company's stock price and expected dividends.
 
Stock compensation expense for stock options is recognized over the vesting period of the award.
 
The following table presents the range of the weighted average fair value of options granted and the related assumptions used in the Black-Scholes model for stock option grants:
 
Series A Preferred Stock:
 
 
Options Granted
September 30, 2014
 
Fair value of options granted
1.40 ~ 2.00
 
Assumptions used:
 
 
Expected life (years) (a)
1.00
 
Risk free interest rate (b)
0.11%
 
Volatility (c)
117.09 ~ 119.83 %
 
Dividend yield (d)
0.00
 
 
Common stock:
 
 
Options Granted date
 
Fair value of options granted
0.038 ~ 0.925
 
Assumptions used:
 
 
Expected life (years) (a)
5 ~ 6
 
Risk free interest rate (b)
1.93% ~ 2.25%
 
Volatility (c)
175.40% ~ 254.86%
 
Dividend yield (d)
0.00
 
 
The Company utilizes the Black-Scholes option pricing model to determine the fair value of each option award. Expected volatilities are based on the historical volatility of the Company's common stock over a period consistent with that of the expected term of the options. The expected term of the options are estimated based on factors such as vesting periods, contractual expiration dates and historical exercise behavior. The risk-free rates for periods within the contractual life of the options are based on the yields of U.S. Treasury instruments with terms comparable to the estimated option terms. The dividend yield rate is not considered in the model, as the Company has not established a dividend policy for the stock.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Reporting
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
SEGMENT REPORTING
Note 14 - SEGMENT REPORTING
 
The Company's operations are classified into two reportable segments that provide different products or services. Separate management of each segment is required because each business unit is subject to different marketing, operations, and growth and technology development strategies.
 
The Clinics segment derives its revenue from provision of services at our P&O Clinic located in Glasgow, Scotland. The Technology segment derives its income from the licensing of its proprietary technologies and ultimately recurring royalty income as well as technology access fees. Presently we are only deriving income from our UK-based operations.  We expect this to be the case until such time as we are able to expand our chain of P&O Clinics.
 
There are no inter-segment sales however, the Company's two primary operating segments do share costs on certain operational overhead including facility rent and staff salaries.
 
Three months ended September 30, 2018:
 
  
  
Clinics
(UK)
    
Technology
(UK)
    
All Other
(Greece)
    
Total
  
 
                        
Revenue
  
$
87,665
    
$
3,508
    
$
-
    
$
91,173
  
Depreciation & amortization
  
$
1,785
    
$
10,270
    
$
5,233
    
$
17,288
  
Net (Loss) from operations
  
$
4,431
    
$
(14,751
)
  
$
(372,466
)
  
$
(382,786
)
Interest expenses
  
$
(694
)
  
$
-
    
$
(562
)
  
$
(1,256
)
Assets
  
$
85,901
    
$
115,280
    
$
118,105
    
$
319,286
  
Expenditure on long-lived assets
  
$
-
    
$
-
    
$
-
    
$
-
  
 
Three months ended September 30, 2017:
 
 
  
Clinics
(UK)
    
Technology
(UK)
    
All Other
(Greece)
    
Total
  
 
                        
Revenue
  
$
50,184
    
$
34
    
$
-
    
$
50,218
  
Depreciation & amortization
  
$
2,760
    
$
13,536
    
$
10,110
    
$
26,406
  
Net (Loss) from operations
  
$
(26,623
)
  
$
(19,949
)
  
$
(407,829
)
  
$
(454,401
)
Interest expenses
  
$
(2,561
)
  
$
-
    
$
(857
)
  
$
(3,418
)
Assets
  
$
87,382
    
$
212,288
    
$
87,513
    
$
387,183
  
Expenditure on long-lived assets
  
$
-
    
$
-
    
$
-
    
$
-
  
 
Nine months ended September 30, 2018:
 
  
  
Clinics
(UK)
    
Technology
(UK)
    
All Other
(Greece)
    
Total
  
 
                        
Revenue
  
$
316,858
    
$
8,398
    
$
-
    
$
325,256
  
Depreciation & amortization
  
$
6,499
    
$
32,765
    
$
16,806
    
$
56,070
  
Net (Loss) from operations
  
$
(5,912
)
  
$
(191,904
)
  
$
(3,015,952
)
  
$
(3,213,768
)
Interest expenses
  
$
(694
)
  
$
-
    
$
(1,791
)
  
$
(2,485
)
Assets
  
$
85,901
    
$
115,280
    
$
118,105
    
$
319,286
  
Expenditure on long-lived assets
  
$
-
    
$
-
    
$
-
    
$
-
  
 
Nine months ended September 30, 2017:
  
  
  
Clinics
(UK)
    
Technology
(UK)
    
All Other
(Greece)
    
Total
  
 
                        
Revenue
  
$
267,288
    
$
2,630
    
$
-
    
$
269,918
  
Depreciation & amortization
  
$
7,685
    
$
37,601
    
$
29,297
    
$
74,583
  
Net (Loss) from operations
  
$
(4,944
)
  
$
(177,807
)
  
$
(1,315,987
)
  
$
(1,498,738
)
Interest expenses
  
$
(3,618
)
  
$
-
    
$
(1,902
)
  
$
(5,520
)
Assets
  
$
87,382
    
$
212,288
    
$
87,513
    
$
387,183
  
Expenditure on long-lived assets
  
$
-
    
$
-
    
$
-
    
$
-
  
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
 9 Months Ended
Sep. 30, 2018
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS
Note 15 - SUBSEQUENT EVENTS
 
Effective October 3, 2018, Dr. Christos Kapatos resigned from his position as Director of the Company.
 
Effective October 3, 2018, Mr. Sotirios Leontaritis resigned from his position as the President, Director and Chief Financial Officer of the Company.
Effective October 3, 2018, Mr Nikolaos Kardaras resigned from his position as the Secretary and Director of the Company. Mr. Kardaras' resignation was not the result of any disagreement with the Corporation regarding operations, policies, practices or otherwise. Mr. Kardaras will continue to consult for the Company as an independent contractor in his capacity as in-house legal counsel.
Concurrent with the aforementioned resignations, the Board of Directors appointed Mr. Constantinos Zertalis as a member of the Board of Directors and the President of the Company and Miss Paraskevi Pylarinou as a member of the Board of Directors, Secretary and CFO of the Company.
 
On October 19, 2018 the Company's Board of Directors appointed Mr. Constantinos Zertalis, CEO, President and Director as Chairman of the Board of Directors.
 
On October 19, 2018 the Company's Board of Directors approved the grant of a total of 1,500,000 stock awards which vested on the date of grant, and a total of 7,500,000 directors' stock options for exercise at  $0.70 per share which options vest as to 1,500,000 shares on grant date, and 1,500,000 shares each year thereafter for a total of four additional years.
 
On November 17, 2018, the Company's management terminated a consulting contract with Mr. Sergios Katsaros which takes effect as of December 22, 2018.
 
On November 17, 2018 the Company's management terminated a consulting agreement with Mr. Haralampos Sgardelis.
 
On November 21, 2018 the Company's Chief Technology Officer, Dr. Christos Kapatos resigned his position as Chief Technology Officer and as a consultant due to the Company's breach of Sections 3.1 and 3.2 of that certain Consulting Agreement originally entered into April 16, 2014 (as amended from time to time, including, without limitation, Addendum 1, Addendum 2 and Addendum 3, collectively, the "Consulting Agreement").  The Company declined to cure the noticed breach(es) in the ten (10) day period as allotted from notice date and subsequently accepted the resignation of Dr. Kapatos effective November 21, 2018.  Further, on December 4, 2018 the Company notified Dr. Kapatos of the termination of that certain Acquisition agreement between Dr. Kapatos and HCI VIOCARE TECHNOLOGIES LIMITED, the Company's wholly owned subsidiary, dated April 16, 2014, as amended May 8, 2015 (collectively the "Acquisition Agreement").
The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there are no additional subsequent events to disclose.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]  
Principals of Consolidation
Principals of Consolidation
 
The consolidated financial statements include the accounts of Rafina Innovations Inc. and its wholly-owned subsidiaries, HCi Viocare Technologies Limited, HCi Viocare Clinics UK Limited and HCi Viocare Clinics (Hellas) S.A. On August 2, 2017 the Company commenced the dissolution and liquidation of HCi Viocare Clinics (Hellas) S.A. All significant intercompany balances and transactions have been eliminated.
Basis of Presentation
Basis of Presentation
 
The interim unaudited financial information referred to above has been prepared and presented in conformity with accounting principles generally accepted in the United States applicable to interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The interim financial information has been prepared on a condensed basis, such that certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission. These interim financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.
 
This report on Form 10-Q should be read in conjunction with the Company's financial statements and notes thereto included in the Company's Form 10-K for the fiscal year ended December 31, 2017 filed on May 17, 2018. Results of the three and nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ended December 31, 2018 and any other future periods.
Use of Estimates
Use of Estimates
 
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results when ultimately realized could differ from these estimates.
Cash and Cash Equivalents
Cash and Cash Equivalents
 
Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less.
Foreign Currencies
Foreign Currencies
 
Items included in the consolidated financial statements of each of the Company and its subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the 'functional currency').  The Company's reporting currency is the U.S. dollar.  The functional currency of subsidiaries based in the UK is pound sterling and the functional currency of the Company's subsidiary based in the Greece is the Euro. All transactions initiated in Pounds and Euro are translated into U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830-30, "Translation of Financial Statements," as follows:
 
i)
assets and liabilities are translated at the closing rate at the date of the balance sheet, or
1USD=0.86153EUR, 1USD=0.76728GBP (September 30, 2018), and;
1USD=0.8347EUR, 1USD=0.74108GBP (December 31, 2017);
 
ii)
income and expenses are translated at average exchange rates for nine months ended September 30, or
1USD=0.8374EUR, 1USD=0.7404GBP (September 30, 2018), and;
1USD=0.9000EUR, 1USD=0.7846GBP (September 30, 2017);
 
iii)
all resulting exchange differences are recognized as other comprehensive income, a separate component of equity.
 
Adjustments arising from such translations are included in accumulated other comprehensive income (loss) in stockholders' equity.
Revenue Recognition
Revenue Recognition
 
Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured.
 
The Company recognizes revenue when the earnings process is complete and persuasive evidence of an arrangement exists. This generally occurs for revenue recorded in our P&O Clinics division when prosthetic products are fitted to customers, both title and the risks and rewards of ownership are transferred or services have been rendered and accepted, the selling price is fixed or determinable, and collectability is reasonably assured.  Revenue is recognized upon issuance of an invoice and completion of each concluded stage of work performed on a prosthetic product.  The Company recognizes revenue from its technology licensing fees and/or product development fees upon conclusion of services provided under contract.
 
There was no impact on the Company's financial statements as a result of adopting Topic 606 for the three and nine months ended September 30, 2018 and 2017.
Inventory
Inventory
 
Inventories, which consist principally of raw materials and parts, are stated at the lower of cost or market. Cost is determined using the first-in, first-out method and are adjusted to actual cost quarterly based on a physical count. Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. Work-in-process inventory consists of materials, labor and a predetermined fixed rate of overhead which is valued based on established standards for the stage of completion of each custom order. We do not carry finished goods on hand. Material, labor and overhead costs are determined at the individual clinic level. Presently we only maintain very limited parts and raw materials inventory.
Warranty
Warranty
 
We do not record warranty liabilities at the time of sale for the estimated costs that may be incurred under the terms of the applicable limited warranty as all component parts are covered by our respective industry suppliers.
Advertising Costs
Advertising Costs
 
The Company expenses advertising costs as incurred or the first time the advertising takes place, whichever is earlier, in accordance with ASC 720-35. Advertising costs were immaterial for the three and nine months ended September 30, 2018 and 2017, respectively.
Research and Development Costs
Research and Development Costs
 
The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, "Research and Development". Research and development costs were $18,904 and $202,961for the three and nine months ended September 30, 2018, and $49,627 and $222,214 for the three and nine months ended September 30, 2017. During the period ended September 30, 2018, HCi Viocare Technologies Limited, the Company's subsidiary, received $52,766 (GBP 39,066) from the UK government as research and development tax credit.
Related parties
Related parties
 
For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.
Stock-based compensation
Stock-based compensation
 
For stock-based compensation, the Company follows the guidance codified in the Compensation – Stock Compensation Topic of FASB ASC ("ASC 718"). The Company determines the value of stock issued at the date of grant. It also determines at the date of grant, the value of stock at fair market value or the value of services rendered (based on contract or otherwise) whichever is more readily determinable.
Income Taxes
Income Taxes
 
The Company accounts for income taxes in accordance with FASB ASC 740, "Income Taxes", which requires the asset and liability approach for financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.
 
The Company has a retained deficit from operations. Because there is no certainty that we will realize taxable income in the future, the Company did not record any deferred tax benefit as a result of these losses and recorded a valuation allowance offsetting the entire potential tax benefit.
 
Income tax years for 2014 through 2016 have been remitted timely and remain open to examination by the taxing authorities. The tax return for fiscal 2017 has not yet been filed. The Company has been assessed late filing penalties of $10,000 per year, as well as accrued interest thereon, for each of the late filed returns for the periods from inception to December 31, 2012. Prior to a change in control at the close of fiscal 2013, prior management had not timely filed its annual tax returns.  We have estimated and accrued penalties of $80,000 as taxes payable in our financial statements. The Company has retained a tax professional to assist in reaching a settlement with the IRS.
Comprehensive Income
Comprehensive Income
 
FASB ASC 220, "Comprehensive Income", establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income, as defined, includes all changes in equity during a period, exclusive of shareholder transactions. Accordingly, comprehensive income (loss) may include certain changes in shareholders' equity (deficit) that are excluded from net income (loss).
Segment Reporting
Segment Reporting
 
FASB ASC 820 "Segments Reporting" establishes standards for reporting information about operating segments on a basis consistent with the Company's internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. Our proposed business segments are expected to span more than one geographical area. Specifically, the Company intends to operate prosthetic and orthotic rehabilitation clinics with various European based locations, as well as a corporate development and technology center which will undertake ongoing research and marketing activities.
Basic and Diluted Loss per Share
Basic and Diluted Loss per Share
 
The Company reports earnings per share in accordance with FASB ASC 260, "Earnings Per Share." FASB ASC 260 requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company had potentially dilutive securities outstanding (convertible debt and liabilities) for the period ended September 30, 2018 and December 31, 2017, respectively, however, since the Company reflected a net loss in the three and nine months ended September 30, 2018 and 2017, the effect of considering any common stock equivalents, if outstanding, would have been anti-dilutive. A separate computation of diluted earnings (loss) per share is not presented.
 
 
  
September 30, 2018
    
December 31, 2017
  
Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options
    
500,000
      
500,000
  
Common stock issuable upon exercise of stock options
    
1,900,000
      
1,400,000
  
Total
    
2,400,000
      
1,900,000
  
Fair Value of Measurements
Fair Value of Measurements
 
Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
 
Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
 
Level 2: Input other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company.
 
Level 3: Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability.
 
An asset or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities.
Recent Issued Accounting Pronouncements
Recent Issued Accounting Pronouncements
.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842).  The amendments in this Update increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.  ASU 2016-02 will be effective for the Company beginning on October 1, 2019.  Early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases to clarify the implementation guidance and ASU No. 2018-11, Leases (Topic 842) Targeted Improvements. This updated guidance provides an optional transition method, which allows for the initial application of the new accounting standard at the adoption date and the recognition of a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning of the period of adoption. We have begun to identify our significant lease contracts and are in the process of evaluating the effect of the new guidance on our consolidated financial statements and related disclosures.
 
There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]  
Schedule of computation of diluted earnings (loss) per share
 
  
September 30, 2018
    
December 31, 2017
  
Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options
    
500,000
      
500,000
  
Common stock issuable upon exercise of stock options
    
1,900,000
      
1,400,000
  
Total
    
2,400,000
      
1,900,000
  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Prepaid Expenses (Tables)
 9 Months Ended
Sep. 30, 2018
Prepaid Expenses [Abstract]  
Schedule of prepaid expenses
 
  
September
30, 2018
    
December
31, 2017
  
Office lease, including security deposits
  
$
38,241
    
$
39,582
  
Travel advances and other expenses
    
11,905
      
10,943
  
      Total prepaid expense
  
$
50,146
    
$
50,525
  
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment (Tables)
 9 Months Ended
Sep. 30, 2018
Property and Equipment [Abstract]  
Schedule of property and improvements
 
  
September 30,
2018
    
December 31,
2017
  
Cost
            
Leasehold improvements
  
$
197,171
    
$
203,990
  
Furniture and fixture
    
31,695
      
32,781
  
Computers and equipment
    
33,062
      
33,144
  
Vehicle
    
58,036
      
59,902
  
Machine and plant
    
8,892
      
9,206
  
Lab equipment
    
32,958
      
34,123
  
 
    
361,814
      
373,146
  
Less: accumulated depreciation and impairment
    
(266,179
)
    
(218,117
)
Total
  
$
95,635
    
$
155,029
  
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Office Lease (Tables)
 9 Months Ended
Sep. 30, 2018
Office Lease [Abstract]  
Schedule of balance owing to lessor
 
September 30,
2018
  
December 31,
 2017
  
 
        
Amount owed for maintenance charges
  
$
15,732
    
$
16,238
  
Amount owed for utility charges
    
16,284
      
16,807
  
 
  
$
32,016
    
$
33,045
Schedule of security deposits paid under the term of the lease agreement
Location
  
September 30, 2018
    
December 31, 2017
  
Greece
  
$
3,482
    
$
3,594
  
UK
    
34,759
      
35,988
  
 
  
$
38,241
    
$
39,582
  
Schedule of approximate future aggregate minimum lease payments
Location
 
Greece
 
 
United Kingdom
 
2018
 
 
5,411
 
 
 
10,318
 
2019
 
 
21,645
 
 
 
49,960
 
2020
 
 
3,607
 
 
 
8,688
 
 
 
$
30,663
 
 
$
68,966
 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions (Tables)
 9 Months Ended
Sep. 30, 2018
Related Party Transactions [Abstract]  
Schedule of services provided from related parties
(a)
Services provided from related parties:
 

 
  
Three Months Ended
September 30,
    
Nine Months Ended
September 30,
  
 
  
2018
    
2017
    
2018
    
2017
  
Consulting fees from CEO and President (i)
  
$
33,739
    
$
30,000
    
$
107,472
    
$
90,000
  
Consulting fees from a Director (ii)
    
13,978
      
11,697
      
44,700
      
33,332
  
Professional fees from Director (iii)
    
3,374
      
3,509
      
10,747
      
9,999
  
Consulting fees for VP (iv)
    
11,808
      
7,018
      
37,615
      
19,999
  
Stock options granted to CEO and President (i)
    
122,544
      
-
      
367,630
      
-
  
Stock options granted to Director (ii)
    
45,300
      
-
      
135,900
      
-
  
Stock options granted to VP (iv)
    
16,800
      
-
      
50,400
      
187,200
  
Stock award granted to Director (iii)
    
-
      
-
      
-
      
172,000
  
 
  
$
247,543
    
$
52,224
    
$
754,464
    
$
512,530
  
 
(i)
 
On September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016.   Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract.  In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR10,000 (USD$11,650) per month.  Further, Mr. Leontaritis is entitled to acquire at his discretion 150,000 shares of the common stock at a price of $6 per share for a term of five (5) years.  The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 and $245,086 during the three and six months ended September 30, 2018 and 2017. On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated.   Further concurrent with his resignation, and with an effective date of September 30, 2018, Mr. Leontaritis and the Company entered into an agreement whereunder Mr. Leontaritis would surrender for cancelation a total of 189,912 shares of the Company's common stock valued at $0.705 per share in order to settle certain amounts payable to the Company totaling $135,635 including a loss on conversion of $1,747. The shares are held in the possession of the Company's Board of Directors and have not yet been provided to the Company's transfer agent for cancelation as at the date of this report.
 
(ii)
On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$46,430 (€40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company Euros €40,000 for services rendered in each fiscal year respectively.
 
On December 12, 2017, the Company approved the issuance of 925,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant.  The 925,000 shares have been valued at $925,000, or $1.00 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$58,250) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 1,250,000 shares of the common stock at a price of US$1.00 for a term of six years.
 
On May 23, 2018 the Company approved an amendment to the term of the scientific advisory agreement with Dr. Christos Kapatos, board member CTO and member of the Scientific Advisory Board, originally entered into on April 15, 2014 in order to extend the term to April 15, 2019.
 
The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 and $135,900 during the three and nine months ended September 30, 2018.
Effective October 3, 2018, Dr Christos Kapatos resigned from his position as Director of the Company.  Subsequently on November 21, 2018 Dr, Kapatos terminated his consulting contract.
 
(iii)
On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. During the nine months ended September 30, 2018 Mr. Kardaras invoiced the Company EUR9,000 (USD$10,747)
 
On March 3, 2017, the Company approved the issuance of 50,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $172,000, the fair market value of $3.44 per share on issue date, which amount has been expensed as stock-based compensation.  On October 3, 2018 Mr. Kardaras resigned as secretary and director of the Company.  He remains the Company's in house legal advisor.
 
 (iv)
On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President. Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives.  The initial term of the contract is six months and Mr. Katsaros will receive compensation of USD$2,330 (€2,000) per month. On March 1, 2016, the Company approved a one-year extension to the consulting agreement and the Company approved the grant of a stock award of 15,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros.  The award vests in three equal instalments of 5,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 10,000 vested shares was recorded as stock-based compensation. On March 1, 2017, the final installment of 5,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017.
 
On March 17, 2017, the Company approved the issuance of a further 50,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $170,000, the fair market value of $3.40 per share on grant date, which amount has been expensed as stock-based compensation.
 
On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018.  The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,060), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Mr. Katsaros shall also be entitled to acquire at his discretion 500,000 shares of the common stock at a price of US$1.00 for a term of five years commencing January 2, 2018.
 
The Company recognized stock-based compensation expense allocated to consulting fees of $16,800 during the six months ended September 30, 2018.
 
Subsequent to the period ended September 30, 2018, on November 17, 2018, the Company terminated the consulting agreement with Mr. Katsaros.
Schedule of accounts payable and accrued liabilities from related parties
 
  
September 30,
    
December 31,
  
 
  
2018
    
2017
  
CEO and President (i)
  
$
-
    
$
413,010
  
Director (ii)
    
5,390
      
95,843
  
Consulting fees for VP (iv)
    
1,741
      
-
  
 
  
$
7,131
    
$
508,853
  
Schedule of advances from related parties
 Advances from related parties:
September 30,
  
December 31,
  
 
2018
  
2017
  
CEO and President (i)
  
$
-
    
$
287,073
  
Director (ii)
    
-
      
54,282
  
 
  
$
-
    
$
341,355
  
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Options (Tables)
 9 Months Ended
Sep. 30, 2018
Stock Options [Abstract]  
Schedule of stock options outstanding
Series A Preferred Stock:
 
 
  
September 30, 2018
    
December 31, 2017
  
 
  
Series A
Preferred stock
    
Weighted Average Exercise Price
$
    
Series A
Preferred stock
    
Weighted Average Exercise Price
$
  
Outstanding at beginning of the year
    
25,000
      
0.04
      
25,000
      
0.04
  
   Granted
    
-
      
-
      
-
      
-
  
   Exercised
    
-
      
-
      
-
      
-
  
   Expired or canceled
    
-
      
-
      
-
      
-
  
Outstanding at the period
    
25,000
      
0.04
      
25,000
      
0.04
  
 
Common stock:
 
 
  
September 30, 2018
    
December 31, 2017
  
 
  
Common
stock
    
Weighted Average Exercise Price
$
    
Common
stock
    
Weighted Average Exercise Price
$
  
Outstanding at beginning of the year
    
1,400,000
      
1.52
      
-
      
-
  
   Granted
    
500,000
      
1.00
      
1,400,000
      
1.52
  
   Exercised
    
-
      
-
      
-
      
-
  
   Expired or canceled
    
-
      
-
      
-
      
-
  
Outstanding at the period
    
1,900,000
      
1.4
      
1,400,000
      
1.52
Schedule of weighted average fair value of options granted in the Black-Scholes model for stock option grants
Series A Preferred Stock:
 
 
Options Granted
September 30, 2014
 
Fair value of options granted
1.40 ~ 2.00
 
Assumptions used:
 
 
Expected life (years) (a)
1.00
 
Risk free interest rate (b)
0.11%
 
Volatility (c)
117.09 ~ 119.83 %
 
Dividend yield (d)
0.00
 
 
Common stock:
 
 
Options Granted date
 
Fair value of options granted
0.038 ~ 0.925
 
Assumptions used:
 
 
Expected life (years) (a)
5 ~ 6
 
Risk free interest rate (b)
1.93% ~ 2.25%
 
Volatility (c)
175.40% ~ 254.86%
 
Dividend yield (d)
0.00
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Schedule of segment reporting information
Three months ended September 30, 2018:
 
  
  
Clinics
(UK)
    
Technology
(UK)
    
All Other
(Greece)
    
Total
  
 
                        
Revenue
  
$
87,665
    
$
3,508
    
$
-
    
$
91,173
  
Depreciation & amortization
  
$
1,785
    
$
10,270
    
$
5,233
    
$
17,288
  
Net (Loss) from operations
  
$
4,431
    
$
(14,751
)
  
$
(372,466
)
  
$
(382,786
)
Interest expenses
  
$
(694
)
  
$
-
    
$
(562
)
  
$
(1,256
)
Assets
  
$
85,901
    
$
115,280
    
$
118,105
    
$
319,286
  
Expenditure on long-lived assets
  
$
-
    
$
-
    
$
-
    
$
-
  
 
Three months ended September 30, 2017:
 
 
  
Clinics
(UK)
    
Technology
(UK)
    
All Other
(Greece)
    
Total
  
 
                        
Revenue
  
$
50,184
    
$
34
    
$
-
    
$
50,218
  
Depreciation & amortization
  
$
2,760
    
$
13,536
    
$
10,110
    
$
26,406
  
Net (Loss) from operations
  
$
(26,623
)
  
$
(19,949
)
  
$
(407,829
)
  
$
(454,401
)
Interest expenses
  
$
(2,561
)
  
$
-
    
$
(857
)
  
$
(3,418
)
Assets
  
$
87,382
    
$
212,288
    
$
87,513
    
$
387,183
  
Expenditure on long-lived assets
  
$
-
    
$
-
    
$
-
    
$
-
  
 
Nine months ended September 30, 2018:
 
  
  
Clinics
(UK)
    
Technology
(UK)
    
All Other
(Greece)
    
Total
  
 
                        
Revenue
  
$
316,858
    
$
8,398
    
$
-
    
$
325,256
  
Depreciation & amortization
  
$
6,499
    
$
32,765
    
$
16,806
    
$
56,070
  
Net (Loss) from operations
  
$
(5,912
)
  
$
(191,904
)
  
$
(3,015,952
)
  
$
(3,213,768
)
Interest expenses
  
$
(694
)
  
$
-
    
$
(1,791
)
  
$
(2,485
)
Assets
  
$
85,901
    
$
115,280
    
$
118,105
    
$
319,286
  
Expenditure on long-lived assets
  
$
-
    
$
-
    
$
-
    
$
-
  
 
Nine months ended September 30, 2017:
  
  
  
Clinics
(UK)
    
Technology
(UK)
    
All Other
(Greece)
    
Total
  
 
                        
Revenue
  
$
267,288
    
$
2,630
    
$
-
    
$
269,918
  
Depreciation & amortization
  
$
7,685
    
$
37,601
    
$
29,297
    
$
74,583
  
Net (Loss) from operations
  
$
(4,944
)
  
$
(177,807
)
  
$
(1,315,987
)
  
$
(1,498,738
)
Interest expenses
  
$
(3,618
)
  
$
-
    
$
(1,902
)
  
$
(5,520
)
Assets
  
$
87,382
    
$
212,288
    
$
87,513
    
$
387,183
  
Expenditure on long-lived assets
  
$
-
    
$
-
    
$
-
    
$
-
  
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Business Background (Details)
 1 Months Ended
May 24, 2018
Organization and Business Background (Textual)  
Reverse stock split, description A reverse share split on the basis 20 for 1.
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Going Concern (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Going Concern (Textual)          
Net losses $ (382,786) $ (454,401) $ (3,213,768) $ (1,498,738)  
Retained deficit (37,950,401)   (37,950,401)   $ (34,736,633)
Working capital deficiency     463,962    
Stockholders' deficit $ (368,327)   $ (368,327)   $ (911,079)
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Control by Principal Stockholder/Officer (Details) - Mr. Leontaritis [Member]
 9 Months Ended
Sep. 30, 2018
shares
Control by Principal Stockholder/Officer (Textual)  
Shares of restricted common stock 6,135,529
Sale of outstanding shares of common stock percentage 42.60%
Common stock shares issued 1,965,619
Percentage of issued and outstanding shares 13.60%
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Details) - shares
 9 Months Ended 12 Months Ended
Sep. 30, 2018
Dec. 31, 2017
Summary of Significant Accounting Policies [Abstract]    
Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options 500,000 500,000
Common stock issuable upon exercise of stock options 1,900,000 1,400,000
Total 2,400,000 1,900,000
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Details Textual)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
shares
Sep. 30, 2018
GBP (£)
shares
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Summary of Significant Accounting Policies (Textual)            
Research and development costs $ 18,904 $ 49,627 $ 202,961   $ 222,214  
Foreign currencies translation of financial statements, description     i) assets and liabilities are translated at the closing rate at the date of the balance sheet, or 1USD=0.86153EUR, 1USD=0.76728GBP (September 30, 2018), and; 1USD=0.8347EUR, 1USD=0.74108GBP (December 31, 2017); ii) income and expenses are translated at average exchange rates for nine months ended September 30, or 1USD=0.8374EUR, 1USD=0.7404GBP (September 30, 2018), and; 1USD=0.9000EUR, 1USD=0.7846GBP (September 30, 2017); iii) all resulting exchange differences are recognized as other comprehensive income, a separate component of equity. Adjustments arising from such translations are included in accumulated other comprehensive income (loss) in stockholders' equity. i) assets and liabilities are translated at the closing rate at the date of the balance sheet, or 1USD=0.86153EUR, 1USD=0.76728GBP (September 30, 2018), and; 1USD=0.8347EUR, 1USD=0.74108GBP (December 31, 2017); ii) income and expenses are translated at average exchange rates for nine months ended September 30, or 1USD=0.8374EUR, 1USD=0.7404GBP (September 30, 2018), and; 1USD=0.9000EUR, 1USD=0.7846GBP (September 30, 2017); iii) all resulting exchange differences are recognized as other comprehensive income, a separate component of equity. Adjustments arising from such translations are included in accumulated other comprehensive income (loss) in stockholders' equity.    
Income tax examination, description     Income tax years for 2014 through 2016 have been remitted timely and remain open to examination by the taxing authorities. The tax return for fiscal 2017 has not yet been filed. The Company has been assessed late filing penalties of $10,000 per year, as well as accrued interest thereon, for each of the late filed returns for the periods from inception to December 31, 2012. Income tax years for 2014 through 2016 have been remitted timely and remain open to examination by the taxing authorities. The tax return for fiscal 2017 has not yet been filed. The Company has been assessed late filing penalties of $10,000 per year, as well as accrued interest thereon, for each of the late filed returns for the periods from inception to December 31, 2012.    
Accrued as taxes payable $ 80,000   $ 80,000     $ 80,000
Hci Viocare Technologies Limited [Member]            
Summary of Significant Accounting Policies (Textual)            
Research and development costs     $ 52,766 £ 39,066    
Series A Preferred Stock Options [Member]            
Summary of Significant Accounting Policies (Textual)            
Common stock issuable upon conversion of options | shares     25,000 25,000    
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Prepaid Expenses (Details) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Prepaid Expenses [Abstract]    
Office lease, including security deposits $ 38,241 $ 39,582
Travel advances and other expenses 11,905 10,943
Total prepaid expense $ 50,146 $ 50,525
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Receivables (Details)
 9 Months Ended
Sep. 30, 2018
Other Receivables (Textual)  
Loans bear interest, description The loans bear interest ranging from 1.5% to 4% per annum.
Loans bear interest term, description Between 60 to 180 days.
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment (Details) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Property, Plant and Equipment [Line Items]    
Property and equipment, Gross $ 361,814 $ 373,146
Less: accumulated depreciation and impairment (266,179) (218,117)
Total 95,635 155,029
Leasehold improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, Gross 197,171 203,990
Furniture and fixture [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, Gross 31,695 32,781
Computers and equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, Gross 33,062 33,144
Vehicle [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, Gross 58,036 59,902
Machine and plant [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, Gross 8,892 9,206
Lab equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, Gross $ 32,958 $ 34,123
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment (Details Textual) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Property and Equipment (Textual)        
Depreciation expense $ 17,288 $ 26,406 $ 56,070 $ 74,583
Leasehold improvements [Member] | Minimum [Member]        
Property and Equipment (Textual)        
Property and equipment useful lifes     3 years  
Leasehold improvements [Member] | Maximum [Member]        
Property and Equipment (Textual)        
Property and equipment useful lifes     10 years  
Furniture [Member] | Minimum [Member]        
Property and Equipment (Textual)        
Property and equipment useful lifes     3 years  
Furniture [Member] | Maximum [Member]        
Property and Equipment (Textual)        
Property and equipment useful lifes     5 years  
Computer and equipment [Member]        
Property and Equipment (Textual)        
Property and equipment useful lifes     3 years  
Vehicles [Member]        
Property and Equipment (Textual)        
Property and equipment useful lifes     5 years  
Machine equipment [Member]        
Property and Equipment (Textual)        
Property and equipment useful lifes     4 years  
Lab equipment [Member]        
Property and Equipment (Textual)        
Property and equipment useful lifes     4 years  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Office Lease (Details) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Office Lease [Abstract]    
Amount owed for maintenance charges $ 15,732 $ 16,238
Amount owed for utility charges 16,284 16,807
Total $ 32,016 $ 33,045
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Office Lease (Details 1) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Operating Leased Assets [Line Items]    
Prepaid expenses $ 38,241 $ 39,582
Greece [Member]    
Operating Leased Assets [Line Items]    
Prepaid expenses 3,482 3,594
UK [Member]    
Operating Leased Assets [Line Items]    
Prepaid expenses $ 34,759 $ 35,988
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Office Lease (Details 2)
Sep. 30, 2018
USD ($)
Greece [Member]  
Operating Leased Assets [Line Items]  
2018 $ 5,411
2019 21,645
2020 3,607
Total 30,663
United Kingdom [Member]  
Operating Leased Assets [Line Items]  
2018 10,318
2019 49,960
2020 8,688
Total $ 68,966
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Office Lease (Details Textual)
 3 Months Ended 9 Months Ended
Sep. 01, 2015
USD ($)
Sep. 01, 2015
EUR (€)
Dec. 29, 2014
USD ($)
Dec. 29, 2014
EUR (€)
Feb. 03, 2014
USD ($)
Feb. 03, 2014
EUR (€)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2018
EUR (€)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
GBP (£)
Mar. 02, 2015
USD ($)
ft²
Mar. 02, 2015
GBP (£)
ft²
Dec. 29, 2014
EUR (€)
Feb. 03, 2014
EUR (€)
Office Lease (Textual)                                
Rental fee             $ 18,113 $ 26,421 $ 71,862   $ 73,529          
Security deposits             26,066   26,066     £ 20,000        
Lease agreement [Member]                                
Office Lease (Textual)                                
Rental fee         $ 20,963 € 15,540                    
Office in Greece [Member]                                
Office Lease (Textual)                                
Lease agreement term, description         The Company leased office space in Paleo Faliro, Greece on a three-year lease, commencing on March 1, 2014 and ending on February 28, 2017. The Company leased office space in Paleo Faliro, Greece on a three-year lease, commencing on March 1, 2014 and ending on February 28, 2017.                    
Rental fee         $ 1,900 € 1,554                    
Lease agreement payment         25,010 € 18,540                    
Lease deposit         $ 4,047                     € 3,000
Rental fee term         10 months 10 months                    
Prepaid deposit                 3,482 € 3,000            
Lease fees, during first year             5,411   5,411              
Lease fees, during second anniversary             21,645   21,645              
Lease fees, during third anniversary             3,607   $ 3,607              
Simple annual rate percentage points         2.00% 2.00%                    
Lease expired and renewed                 The lease has been renewed effective June 13, 2017 for a term of 3 years terminating on February 28, 2020 at a rate of $1,848 (EUR 1,592) plus a fee of 3.6%. The lease has been renewed effective June 13, 2017 for a term of 3 years terminating on February 28, 2020 at a rate of $1,848 (EUR 1,592) plus a fee of 3.6%.            
Lease in UK [Member]                                
Office Lease (Textual)                                
Area of Land | ft²                         5,300 5,300    
Lease fees, during first year             10,318   $ 10,318              
Lease fees, during second anniversary             49,960   49,960              
Lease fees, during third anniversary             $ 8,688   $ 8,688              
Lease in UK [Member] | VAT [Member]                                
Office Lease (Textual)                                
Lease fees, during first year                         $ 26,066 £ 20,000    
Lease fees, during second anniversary                         52,132 40,000    
Lease fees, during third anniversary                         52,132 40,000    
Lease fees, during fourth anniversary                         39,100 30,000    
Lease fees, during fifth anniversary                         $ 52,132 £ 40,000    
Clinic in Greece [Member]                                
Office Lease (Textual)                                
Lease agreement term, description     The Company leased office space at Peania Region of Attica in Greece on a ten-year lease, commencing on January 1, 2015 and ending on October 5, 2024. The Company leased office space at Peania Region of Attica in Greece on a ten-year lease, commencing on January 1, 2015 and ending on October 5, 2024.                        
Rental fee $ 3,500 € 3,116 $ 6,996 € 6,233                        
Lease deposit     13,991                       € 12,465  
Operating cost     $ 1,120 € 997                        
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Loans (Details)
 1 Months Ended 9 Months Ended
Jan. 05, 2017
USD ($)
Jan. 05, 2017
EUR (€)
Jul. 27, 2018
USD ($)
Jul. 27, 2018
EUR (€)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Loans (Textual)              
Loans from third party borrow         $ 664,911 $ 552,784  
HCi Viocare Clinics Hellas S.A. [Member]              
Loans (Textual)              
Loans from third party borrow $ 46,429 € 40,000          
Loan payable, interest rate 5.00% 5.00%          
Loans payable, description One year from the date of the agreement. One year from the date of the agreement.          
Loan payable         50,452   $ 50,276
Accrued interest expenses         1,791    
HCi Viocare Clinics UK Limited [Member]              
Loans (Textual)              
Loans from third party borrow     $ 34,081 € 30,000      
Loan payable, interest rate     6.00% 6.00%      
Loans payable, description     Six months from the date of the agreement. Six months from the date of the agreement.      
Loan payable         34,480   $ 0
Accrued interest expenses         $ 413    
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments (Details)
 1 Months Ended
Dec. 12, 2017
USD ($)
$ / shares
shares
Dec. 12, 2017
EUR (€)
shares
Oct. 09, 2017
USD ($)
$ / shares
shares
Sep. 01, 2017
USD ($)
$ / shares
shares
Mar. 03, 2017
USD ($)
Jan. 03, 2017
USD ($)
Jan. 03, 2017
EUR (€)
Apr. 16, 2014
Jun. 07, 2018
USD ($)
$ / shares
shares
May 03, 2018
USD ($)
$ / shares
shares
Mar. 27, 2018
USD ($)
$ / shares
shares
Feb. 26, 2018
USD ($)
$ / shares
shares
Feb. 26, 2018
EUR (€)
shares
Jan. 16, 2018
Jul. 10, 2017
USD ($)
$ / shares
shares
Mar. 17, 2017
USD ($)
shares
Commitments (Textual)                                
Fair market value on grant date | $         $ 17,200                      
Sergios Katsaros [Member]                                
Commitments (Textual)                                
Issuance of common shares for the services                               50,000
Fair market value on grant date | $                               $ 170,000
Consulting Agreement [Member] | Kapatos [Member]                                
Commitments (Textual)                                
Agreement, description               The Company entered into a Consulting Agreement with Christos Kapatos whereby he will provide his services as Chief Technical Officer for the Company and the Company's wholly-owned subsidiaries. The contract has a term of one year, renewable for such further term as may be mutually agreed between the parties. In the case that a research and development project is initiated and completed during the term of the agreement, Kapatos shall receive seventy thousand (70,000) shares of the Company's common stock for each research project completed with a valuation less than twenty million dollars ($20,000,000 USD), one hundred and seventy-five thousand (175,000) shares of the Company's common stock for each research project completed with a valuation equal or greater than twenty million US dollars ($20,000,000 USD). Details of compensation under the terms of the consulting agreement are included in Note 11(ii).                
Consulting Agreement [Member] | JAMB Group LLC [Member]                                
Commitments (Textual)                                
Agreement, description                             The Company entered into a business consulting agreement (the "Consulting Agreement") with JAMB Group LLC. ("Consultant") for services to commence July 15, 2017 and to continue for a period of twelve (12) months thereafter.  
Issuance of common shares for the services                             25,000  
Granted shares                             25,000  
Fair market value on grant date | $                             $ 79,950  
Fair market price on the date of grant | $ / shares                             $ 3.198  
Consulting Agreement [Member] | Mr. Stefanos Batzakis [Member]                                
Commitments (Textual)                                
Agreement, description       The Company entered into a one-year consulting agreement (the "Agreement") with Mr Stefanos Batzakis. As per terms of said Agreement Batzakis will provide services to the Company as IT Solutions Manager, for a term of one (1) year and receive compensation in the form of stock, namely twenty-five thousand (25,000) common shares, which were issued upon signing of this Agreement.                        
Issuance of common shares for the services       25,000                        
Granted shares       25,000                        
Fair market value on grant date | $       $ 40,000                        
Fair market price on the date of grant | $ / shares       $ 1.60                        
Consulting Agreement [Member] | Dr. Ioannis Doupis [Member]                                
Commitments (Textual)                                
Agreement, description     The Company appointed Dr. Ioannis Doupis, to the Advisory Board of the Company originally formed on April 15, 2014 and Concurrently entered into an advisory board agreement. Compensation shall be the grant of a total of 25,000 shares of the Company's common stock valued at the fair market price on the date of grant of $1.40 per share. The advisory board appointment is for a term of one year.                          
Issuance of common shares for the services     25,000                          
Granted shares     25,000                          
Fair market value on grant date | $     $ 35,000                          
Fair market price on the date of grant | $ / shares     $ 1.40                          
Consulting Agreement [Member] | Ms. Paraskevi Pilarinou [Member]                                
Commitments (Textual)                                
Agreement, description The Company entered into a consulting agreement (the "Agreement") with Ms. Paraskevi Pilarinou (the "Consultant"). Under the terms and conditions of the Agreement the Consultant shall be employed in the position of Financial Controller of the Company. The Agreement has a three-year term starting on January 2, 2018 and ending on January 1, 2021 and the Consultant shall be remunerated with a monthly fee of EUR2,000 (IUSD$2,320) and was issued 100,000 shares of the Company's common stock. The 100,000 shares were issued as compensation as of the date of the agreement and were valued at $1 per share or $100,000, the fair market value on the date of issuance in the year ended December 31, 2017. The Company entered into a consulting agreement (the "Agreement") with Ms. Paraskevi Pilarinou (the "Consultant"). Under the terms and conditions of the Agreement the Consultant shall be employed in the position of Financial Controller of the Company. The Agreement has a three-year term starting on January 2, 2018 and ending on January 1, 2021 and the Consultant shall be remunerated with a monthly fee of EUR2,000 (IUSD$2,320) and was issued 100,000 shares of the Company's common stock. The 100,000 shares were issued as compensation as of the date of the agreement and were valued at $1 per share or $100,000, the fair market value on the date of issuance in the year ended December 31, 2017.                            
Issuance of common shares for the services 100,000 100,000                            
Fair market value on grant date | $ $ 100,000                              
Fair market price on the date of grant | $ / shares $ 1                              
Consultant remuneration monthly fee $ 2,320 € 2,000                            
Shares issued compensation 100,000 100,000                            
Consulting Agreement [Member] | Charalampos Sgardelis [Member]                                
Commitments (Textual)                                
Compensation receivables           $ 2,320 € 2,000         $ 3,480 € 3,000      
Agreement, description           The Company entered into a one-year consulting agreement (the "Agreement") with Mr. Charalampos Sgardelis ("Sgardelis"). Under the terms of the Agreement, Sgardelis provides services to the Company as Business Development Manager, for a term of one (1) year and receives compensation of Two Thousand Euros (2,000 ) (USD$2,320) per month. The Company entered into a one-year consulting agreement (the "Agreement") with Mr. Charalampos Sgardelis ("Sgardelis"). Under the terms of the Agreement, Sgardelis provides services to the Company as Business Development Manager, for a term of one (1) year and receives compensation of Two Thousand Euros (2,000 ) (USD$2,320) per month.         The Company approved a three (3) year extension to the Agreement (the "Addendum") between the Company and Sgardelis. Under the terms and conditions of the Addendum, Sgardelis is entitled to receive compensation of Three Thousand Euros (3,000 ) (USD$3,480) per month and shall be awarded 250,000 common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $0.98 per share for total consideration of $245,000. The Company approved a three (3) year extension to the Agreement (the "Addendum") between the Company and Sgardelis. Under the terms and conditions of the Addendum, Sgardelis is entitled to receive compensation of Three Thousand Euros (3,000 ) (USD$3,480) per month and shall be awarded 250,000 common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $0.98 per share for total consideration of $245,000.      
Fair market price on the date of grant | $ / shares                       $ 0.98        
Shares issued compensation                       250,000 250,000      
Total consideration | $                       $ 245,000        
Consulting Agreement [Member] | Ravi Vaidyanathan [Member]                                
Commitments (Textual)                                
Agreement, description                     The Company entered into a one-year advisory agreement (the "Agreement") with Mr. Ravi Vaidyanathan (the "Advisor"). Under the terms and conditions of the Agreement, the Advisor is appointed to the Company's Scientific Advisory Board and is entitled to remuneration for the provision of services in the form of 25,000 shares of the common stock to be issued upon signing of the Agreement. Further, the Advisor shall be granted additional 12,500 shares of the common stock to be issued after a time-period of six (6) months from the signing of the Agreement.          
Issuance of common shares for the services                     25,000          
Fair market price on the date of grant | $ / shares                     $ 1.10          
Total consideration | $                     $ 27,500          
Services Agreement [Member] | Nikolaos Gemelos [Member]                                
Commitments (Textual)                                
Agreement, description                           The Company entered into a one-year service agreement (the "Agreement") with Mr. Nikolaos Gemelos ("Gemelos"). Under the terms of the Agreement, Gemelos provides services to the Company as Consultant, for a term of one (1) year and he is entitled to a success fee of 5% of the amount actually invested in the Company by introduced accredited investors, and 5% of the amount invested in the form of restricted shares of the common stock of the Company.    
Fair market price on the date of grant | $ / shares                   $ 1.34            
Total consideration | $                   $ 6,700            
Shares of restricted common stock                   5,000            
Services Agreement [Member] | Georgios Dritsoulas [Member]                                
Commitments (Textual)                                
Agreement, description                 The Company entered into a six-month service agreement with Mr. Georgios Dritsoulas. As per terms of said Agreement, Mr. Dritsoulas will provide services to the Company as Consultant for the development and expansion of the Company's business for a term of six (6) months.              
Fair market price on the date of grant | $ / shares                 $ 2              
Total consideration | $                 $ 5,000              
Shares of restricted common stock                 2,500              
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Schedule of services provided from related parties        
Professional fees $ 52,766 $ 12,655 $ 118,086 $ 267,140
Stock-based compensation     468,842 407,650
Services provided from related parties, Total 247,543 52,224 754,464 512,530
CEO and President [Member]        
Schedule of services provided from related parties        
Consulting fees [1] 33,739 30,000 107,472 90,000
Stock options granted [1] 122,544 367,630
Director [Member]        
Schedule of services provided from related parties        
Consulting fees [2] 13,978 11,697 44,700 33,332
Professional fees [3] 3,374 3,509 10,747 9,999
Stock options granted [2] 45,300 135,900
Stock award granted [3] 172,000
VP [Member]        
Schedule of services provided from related parties        
Consulting fees [4] 11,808 7,018 37,615 19,999
Stock options granted [4] $ 16,800 $ 50,400 $ 187,200
[1] On September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016. Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract. In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR10,000 (USD$11,650) per month. Further, Mr. Leontaritis is entitled to acquire at his discretion 150,000 shares of the common stock at a price of $6 per share for a term of five (5) years. The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 and $245,086 during the three and six months ended September 30, 2018 and 2017. On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated. Further concurrent with his resignation, and with an effective date of September 30, 2018, Mr. Leontaritis and the Company entered into an agreement whereunder Mr. Leontaritis would surrender for cancelation a total of 189,912 shares of the Company's common stock valued at $0.705 per share in order to settle certain amounts payable to the Company totaling $135,635 including a loss on conversion of $1,747. The shares are held in the possession of the Company's Board of Directors and have not yet been provided to the Company's transfer agent for cancelation as at the date of this report.
[2] On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$46,430 ( 40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company Euros 40,000 for services rendered in each fiscal year respectively. On December 12, 2017, the Company approved the issuance of 925,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant. The 925,000 shares have been valued at $925,000, or $1.00 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$58,250) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 1,250,000 shares of the common stock at a price of US$1.00 for a term of six years. On May 23, 2018 the Company approved an amendment to the term of the scientific advisory agreement with Dr. Christos Kapatos, board member CTO and member of the Scientific Advisory Board, originally entered into on April 15, 2014 in order to extend the term to April 15, 2019. The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 and $135,900 during the three and nine months ended September 30, 2018. Effective October 3, 2018, Dr Christos Kapatos resigned from his position as Director of the Company. Subsequently on November 21, 2018 Dr, Kapatos terminated his consulting contract.
[3] On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. During the nine months ended September 30, 2018 Mr. Kardaras invoiced the Company EUR9,000 (USD$10,747) On March 3, 2017, the Company approved the issuance of 50,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $172,000, the fair market value of $3.44 per share on issue date, which amount has been expensed as stock-based compensation. On October 3, 2018 Mr. Kardaras resigned as secretary and director of the Company. He remains the Company's in house legal advisor.
[4] On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President. Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives. The initial term of the contract is six months and Mr. Katsaros will receive compensation of USD$2,330 ( 2,000) per month. On March 1, 2016, the Company approved a one-year extension to the consulting agreement and the Company approved the grant of a stock award of 15,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros. The award vests in three equal instalments of 5,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 10,000 vested shares was recorded as stock-based compensation. On March 1, 2017, the final installment of 5,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017. On March 17, 2017, the Company approved the issuance of a further 50,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $170,000, the fair market value of $3.40 per share on grant date, which amount has been expensed as stock-based compensation. On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018. The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,060), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Mr. Katsaros shall also be entitled to acquire at his discretion 500,000 shares of the common stock at a price of US$1.00 for a term of five years commencing January 2, 2018. The Company recognized stock-based compensation expense allocated to consulting fees of $16,800 during the six months ended September 30, 2018. Subsequent to the period ended September 30, 2018, on November 17, 2018, the Company terminated the consulting agreement with Mr. Katsaros.
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions (Details 1) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Related Party Transaction [Line Items]    
Accounts payable and accrued liabilities from related parties $ 7,131 $ 508,853
CEO and President [Member]    
Related Party Transaction [Line Items]    
Accounts payable and accrued liabilities from related parties 413,010
Director [Member]    
Related Party Transaction [Line Items]    
Accounts payable and accrued liabilities from related parties 5,390 95,843
VP [Member]    
Related Party Transaction [Line Items]    
Accounts payable and accrued liabilities from related parties $ 1,741
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions (Details 2) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Schedule of advances from related parties    
Advances from related parties $ 341,355
CEO and President [Member]    
Schedule of advances from related parties    
Advances from related parties 287,073
Director [Member]    
Schedule of advances from related parties    
Advances from related parties $ 54,282
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions (Details Textual)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Dec. 12, 2017
USD ($)
$ / shares
shares
Dec. 12, 2017
EUR (€)
shares
Mar. 03, 2017
USD ($)
$ / shares
shares
Mar. 01, 2017
shares
Mar. 01, 2016
shares
Sep. 01, 2015
USD ($)
Sep. 01, 2015
EUR (€)
Apr. 16, 2014
USD ($)
Apr. 16, 2014
EUR (€)
Jan. 15, 2014
Jun. 26, 2018
USD ($)
$ / shares
shares
May 31, 2018
USD ($)
$ / shares
shares
Feb. 15, 2018
Mar. 17, 2017
USD ($)
$ / shares
shares
May 28, 2015
shares
Sep. 30, 2018
USD ($)
$ / shares
shares
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
$ / shares
shares
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
$ / shares
shares
Sep. 30, 2018
EUR (€)
shares
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
shares
Dec. 31, 2017
EUR (€)
shares
Dec. 31, 2016
USD ($)
Dec. 31, 2016
EUR (€)
Related Party Transactions (Textual)                                                    
Common stock price per share | $ / shares                     $ 0.60 $ 0.60                            
Related party payments, description                         Company's common stock at a price equal or greater to $0.60 per share. On the date of the agreement the fair market value of the Company's common stock as traded on OTCMarkets was $0.806 per share.                          
Issuance of common shares as compensation           $ 2,330 € 2,000                                      
Fair market value on grant date | $     $ 17,200                                              
Invoiced for services rendered | €                                               € 40,000   € 40,000
Issuance of common stock, Value | $     $ 172,000                                          
Percentage annual compensation 100.00% 100.00%                                                
Granted shares | shares     5,000                                              
Fair market value price | $ / shares     $ 3.44                                              
Vested values | $                                                 169,000  
Monthly stipend $ 4,060 € 3,500                                                
Convertible debt, related parties | $                               $ 721,564   $ 721,564   $ 721,564          
Convertible restricted common stock | shares                                                
Loss on debt settlement | $                               $ (1,747) $ (17,707)     $ (1,609,436)   $ (17,707)        
Total debt | $                     $ 131,870 $ 679,371                            
Unsettled expense reimbursements into shares | shares                     219,784 1,132,286                            
Vesting term, description           The award vests in three equal instalments of 5,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. The award vests in three equal instalments of 5,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant.                                      
Mr. Leontaritis [Member]                                                    
Related Party Transactions (Textual)                                                    
Term of acquire discretion common stock                                       5 years 5 years          
Acquire discretion common stock shares | shares                                       150,000 150,000          
Common stock price per share | $ / shares                               $ 6   $ 6   $ 6            
Related party payments, description                   Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract. In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR10,000 (USD$11,650) per month.                                
Consulting fees | $                               $ 122,543 $ 245,086 $ 122,543 $ 245,086              
Loss on debt settlement | $                                       $ 1,321,971            
Unsettled expense reimbursements into shares | shares                       1,132,286                            
Cancelation of shares | shares                               189,912   189,912   189,912            
Common stock, per share | $ / shares                               $ 0.705   $ 0.705   $ 0.705            
Amounts payable to company | $                               $ 135,635   $ 135,635   $ 135,635            
Loss on conversion | $                                       $ 1,747            
Expected life term                                       5 years 5 years          
Christos Kapatos [Member]                                                    
Related Party Transactions (Textual)                                                    
Common stock price per share | $ / shares $ 1.00                                                  
Issuance of common shares for the services | shares     50,000                                              
Fair market value on grant date | $     $ 172,000                                              
Consulting fees | $                               $ 45,300       $ 135,900            
Compensation expenses $ 58,250 € 50,000           $ 49,430 € 40,000                                  
Issuance of common stock | shares 925,000 925,000                                                
Issuance of common stock, Value | $ $ 925,000                                                  
Percentage annual compensation 100.00% 100.00%                                                
Director acquire discretion common stock | shares 1,250,000 1,250,000                                                
Director acquire discretion common stock per share | $ / shares $ 1.00                                                  
Loss on debt settlement | $                                       285,718            
Vice President [Member]                                                    
Related Party Transactions (Textual)                                                    
Issuance of common shares for the services | shares                           50,000                        
Fair market value on grant date | $                           $ 170,000                        
Issuance of common stock | shares       100,000                                            
Vice President [Member] | Final installments [Member]                                                    
Related Party Transactions (Textual)                                                    
Granted shares | shares         15,000                                          
Vice President [Member] | Installments [Member]                                                    
Related Party Transactions (Textual)                                                    
Granted shares | shares       100,000                                            
Nikolaos Kardaras [Member]                                                    
Related Party Transactions (Textual)                                                    
Issuance of common shares for the services | shares     50,000                       700,000                      
Invoiced for services rendered                                       10,747 € 9,000   $ 13,500 € 12,000 $ 13,300 € 12,000
Nikolaos Kardaras [Member] | Installments [Member]                                                    
Related Party Transactions (Textual)                                                    
Consulting fees | $                                       $ 16,800            
Katsaros [Member]                                                    
Related Party Transactions (Textual)                                                    
Acquire discretion common stock shares | shares 500,000 500,000                                                
Common stock price per share | $ / shares                           $ 3.40                        
Issuance of common stock | shares 10,000,000 10,000,000                                                
Share price | $ / shares $ 1.00                                                  
Expected life term 5 years 5 years                                                
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Capital Stock (Details) - USD ($)
 1 Months Ended 9 Months Ended
Dec. 12, 2017
Mar. 03, 2017
Jan. 13, 2014
May 24, 2018
Sep. 30, 2018
Dec. 31, 2017
Capital Stock (Textual)            
Preferred Stock, shares authorized         5,000,000 5,000,000
Preferred stock, par value         $ 0.0001 $ 0.0001
Common Stock, shares authorized         35,000,000 35,000,000
Common stock, par value         $ 0.0001 $ 0.0001
Reverse stock split, description       A reverse share split on the basis 20 for 1.    
Mr. Leontaritis [Member]            
Capital Stock (Textual)            
Surrender for cancelation a total of shares         189,912  
Common stock, par value         $ 0.705  
Order to settle certain amounts payable         $ 135,635  
Loss on conversion of debt         1,747  
Total cash proceeds of common stock         $ 679,371  
Number of shares issued         1,132,286  
Fair market value issuance total         $ 2,001,342  
Loss on debt settlement amount         1,321,971  
Christos Kapatos [Member]            
Capital Stock (Textual)            
Shares issuance for services provided, shares   50,000        
Common stock shares issued 925,000          
Total cash proceeds of common stock         $ 131,870  
Number of shares issued         219,784  
Fair market value issuance total         $ 417,588  
Loss on debt settlement amount         285,718  
Employees, board members and consultants [Member]            
Capital Stock (Textual)            
Shares issuance for services provided         $ 284,200  
Shares issuance for services provided, shares         282,500  
Private placements [Member]            
Capital Stock (Textual)            
Total cash proceeds of common stock         $ 664,911  
Number of shares issued         855,717  
Series A Preferred Stock [Member]            
Capital Stock (Textual)            
Preferred stock, par value         $ 0.04  
Stock options granted shares         25,000  
Vested stock options, shares         25,000  
Vested stock options, period         5 years  
Common stock shares issued     5,000,000      
Description of preferred stock voting rights     The holders of Series A Preferred Stock will be entitled to a preference over all of the shares of the Company's common stock. Holders of Series A Preferred Stock shall have 50 votes per share of Series A Preferred Stock held by them and shall be entitled to notice of any stockholders' meeting and to vote as a single class upon any matter submitted to the stockholders for a vote. Each share of Series A Preferred Stock is convertible into 20 shares of our common stock at any time at the holder's option. Shares of Series A Preferred Stock shall not be entitled to any dividends.      
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Options (Details) - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2018
Dec. 31, 2017
Series A Preferred Stock [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding at beginning of the year 25,000 25,000
Granted  
Exercised
Expired or canceled
Outstanding at the period 25,000 25,000
Weighted Average Exercise Price, Outstanding at beginning of the year $ 0.04 $ 0.04
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired or canceled
Weighted Average Exercise Price, Outstanding at the period $ 0.04 $ 0.04
Common Stock [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding at beginning of the year 1,400,000
Granted 500,000 1,400,000
Exercised
Expired or canceled
Outstanding at the period 1,900,000 1,400,000
Weighted Average Exercise Price, Outstanding at beginning of the year $ 1.52
Weighted Average Exercise Price, Granted 1.00 1.52
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired or canceled
Weighted Average Exercise Price, Outstanding at the period $ 1.4 $ 1.52
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Options (Details 1)
 1 Months Ended
Sep. 30, 2014
$ / shares
Series A Preferred Stock [Member]  
Assumptions used:  
Expected life (years) (a) 1 year
Risk free interest rate (b) 0.11%
Dividend yield (d) 0.00%
Series A Preferred Stock [Member] | Minimum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Fair value of options granted $ 1.40
Assumptions used:  
Volatility (c) 117.09%
Series A Preferred Stock [Member] | Maximum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Fair value of options granted $ 2.00
Assumptions used:  
Volatility (c) 119.83%
Common stock [Member]  
Assumptions used:  
Dividend yield (d) 0.00%
Common stock [Member] | Minimum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Fair value of options granted $ 0.038
Assumptions used:  
Expected life (years) (a) 5 years
Risk free interest rate (b) 1.93%
Volatility (c) 175.40%
Common stock [Member] | Maximum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Fair value of options granted $ 0.925
Assumptions used:  
Expected life (years) (a) 6 years
Risk free interest rate (b) 2.25%
Volatility (c) 254.86%
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Options (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 12, 2017
Apr. 30, 2014
Jan. 13, 2014
Jun. 30, 2014
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Stock Options (Textual)                  
Stock-based compensation expense allocated to consulting fees         $ 184,644 $ 122,543 $ 553,930 $ 245,086  
Mr.Leontaritis [Member]                  
Stock Options (Textual)                  
Expected life term             5 years    
Acquire discretion common stock shares             150,000    
Acquisition of stock price per share         $ 6   $ 6    
Agreement term             On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019.    
Katsaros [Member]                  
Stock Options (Textual)                  
Share price $ 1.00                
Expected life term 5 years                
Acquire discretion common stock shares 500,000                
Common Stock [Member]                  
Stock Options (Textual)                  
Granted shares             500,000   1,400,000
Expected life term             5 years 18 days    
Common Stock [Member] | Dr. Christos Kapatos [Member]                  
Stock Options (Textual)                  
Common stock average remaining life 6 years                
Acquire discretion common stock shares 1,250,000                
Acquisition of stock price per share $ 1.00                
Common Stock [Member] | Katsaros [Member]                  
Stock Options (Textual)                  
Share price         1.00   $ 1.00    
Expected life term             5 years    
Acquire discretion common stock shares             500,000    
Series A Preferred Stock [Member]                  
Stock Options (Textual)                  
Granted shares                
Description of preferred stock voting rights     The holders of Series A Preferred Stock will be entitled to a preference over all of the shares of the Company's common stock. Holders of Series A Preferred Stock shall have 50 votes per share of Series A Preferred Stock held by them and shall be entitled to notice of any stockholders' meeting and to vote as a single class upon any matter submitted to the stockholders for a vote. Each share of Series A Preferred Stock is convertible into 20 shares of our common stock at any time at the holder's option. Shares of Series A Preferred Stock shall not be entitled to any dividends.            
Expected life term             6 months 25 days    
Series A Preferred Stock [Member] | Stock Options [Member]                  
Stock Options (Textual)                  
Stock options granted   25,000   25,000          
Granted shares             5,000    
Description of preferred stock voting rights             The Series A Preferred shares are convertible on the basis of 20 shares of common stock for each one share held and have voting rights of 50 votes per share of Series A Preferred stock held at any meetings of the stockholders.    
Share price         $ 0.04   $ 0.04    
Expected life term             5 years    
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Reporting (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Segment Reporting Information [Line Items]          
Revenue $ 91,173 $ 50,218 $ 325,256 $ 269,918  
Depreciation & amortization 17,288 26,406 56,070 74,583  
Net (Loss) from operations (377,505) (432,135) (1,596,092) (1,475,854)  
Interest expenses (1,256) (3,418) (2,485) (5,520)  
Assets 319,286 387,183 319,286 387,183 $ 649,831
Expenditure on long-lived assets  
Clinics [Member] | UK [Member]          
Segment Reporting Information [Line Items]          
Revenue 87,665 50,184 316,858 267,288  
Depreciation & amortization 1,785 2,760 6,499 7,685  
Net (Loss) from operations 4,431 (26,623) (5,912) (4,944)  
Interest expenses (694) (2,561) (694) (3,618)  
Assets 85,901 87,382 85,901 87,382  
Expenditure on long-lived assets  
Technology [Member] | UK [Member]          
Segment Reporting Information [Line Items]          
Revenue 3,508 34 8,398 2,630  
Depreciation & amortization 10,270 13,536 32,765 37,601  
Net (Loss) from operations (14,751) (19,949) (191,904) (177,807)  
Interest expenses  
Assets 115,280 212,288 115,280 212,288  
Expenditure on long-lived assets  
All Other [Member] | Greece [Member]          
Segment Reporting Information [Line Items]          
Revenue  
Depreciation & amortization 5,233 10,110 16,806 29,297  
Net (Loss) from operations (372,466) (407,829) (3,015,952) (1,315,987)  
Interest expenses (562) (857) (1,791) (1,902)  
Assets 118,105 87,513 118,105 87,513  
Expenditure on long-lived assets  
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Reporting (Details Textual)
 9 Months Ended
Sep. 30, 2018
Segment
Segment Reporting (Textual)  
Number of reportable segments 2
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events (Details) - $ / shares
 1 Months Ended
Oct. 19, 2018
Mar. 03, 2017
Subsequent Events (Textual)    
Total of grant stock awards   5,000
Subsequent Event [Member] | Board of Directors [Member]    
Subsequent Events (Textual)    
Total of grant stock awards 1,500,000  
Stock options for exercise 7,500,000  
Price per share $ 0.70  
Vested stock options, shares 1,500,000  
Stock option, description 1,500,000 shares each year thereafter for a total of four additional years.  
EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ᣌ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end XML 67 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 169 258 1 true 47 0 false 8 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.Rafinainnovations.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.Rafinainnovations.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.Rafinainnovations.com/role/CondensedConsolidatedBalanceSheetsparenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.Rafinainnovations.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossunaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.Rafinainnovations.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - Organization and Business Background Sheet http://www.Rafinainnovations.com/role/Organizationandbusinessbackground Organization and Business Background Notes 6 false false R7.htm 007 - Disclosure - Going Concern Sheet http://www.Rafinainnovations.com/role/GoingConcern Going Concern Notes 7 false false R8.htm 008 - Disclosure - Control by Principal Stockholder/Officer Sheet http://www.Rafinainnovations.com/role/Controlbyprincipalstockholderofficer Control by Principal Stockholder/Officer Notes 8 false false R9.htm 009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.Rafinainnovations.com/role/Summaryofsignificantaccountingpolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 010 - Disclosure - Prepaid Expenses Sheet http://www.Rafinainnovations.com/role/PrepaidExpenses Prepaid Expenses Notes 10 false false R11.htm 011 - Disclosure - Other Receivables Sheet http://www.Rafinainnovations.com/role/OtherReceivables Other Receivables Notes 11 false false R12.htm 012 - Disclosure - Property and Equipment Sheet http://www.Rafinainnovations.com/role/PropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 013 - Disclosure - Office Lease Sheet http://www.Rafinainnovations.com/role/OfficeLease Office Lease Notes 13 false false R14.htm 014 - Disclosure - Loans Sheet http://www.Rafinainnovations.com/role/Loans Loans Notes 14 false false R15.htm 015 - Disclosure - Commitments Sheet http://www.Rafinainnovations.com/role/Commitments Commitments Notes 15 false false R16.htm 016 - Disclosure - Related Party Transactions Sheet http://www.Rafinainnovations.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 017 - Disclosure - Capital Stock Sheet http://www.Rafinainnovations.com/role/CapitalStock Capital Stock Notes 17 false false R18.htm 018 - Disclosure - Stock Options Sheet http://www.Rafinainnovations.com/role/StockOptions Stock Options Notes 18 false false R19.htm 019 - Disclosure - Segment Reporting Sheet http://www.Rafinainnovations.com/role/Segmentreporting Segment Reporting Notes 19 false false R20.htm 020 - Disclosure - Subsequent Events Sheet http://www.Rafinainnovations.com/role/Subsequentevents Subsequent Events Notes 20 false false R21.htm 021 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.Rafinainnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.Rafinainnovations.com/role/Summaryofsignificantaccountingpolicies 21 false false R22.htm 022 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.Rafinainnovations.com/role/Summaryofsignificantaccountingpoliciestables Summary of Significant Accounting Policies (Tables) Tables http://www.Rafinainnovations.com/role/Summaryofsignificantaccountingpolicies 22 false false R23.htm 023 - Disclosure - Prepaid Expenses (Tables) Sheet http://www.Rafinainnovations.com/role/PrepaidExpensesTables Prepaid Expenses (Tables) Tables http://www.Rafinainnovations.com/role/PrepaidExpenses 23 false false R24.htm 024 - Disclosure - Property and Equipment (Tables) Sheet http://www.Rafinainnovations.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.Rafinainnovations.com/role/PropertyAndEquipment 24 false false R25.htm 025 - Disclosure - Office Lease (Tables) Sheet http://www.Rafinainnovations.com/role/Officeleasetables Office Lease (Tables) Tables http://www.Rafinainnovations.com/role/OfficeLease 25 false false R26.htm 026 - Disclosure - Related Party Transactions (Tables) Sheet http://www.Rafinainnovations.com/role/Relatedpartytransactionstables Related Party Transactions (Tables) Tables http://www.Rafinainnovations.com/role/RelatedPartyTransactions 26 false false R27.htm 027 - Disclosure - Stock Options (Tables) Sheet http://www.Rafinainnovations.com/role/StockOptionsTables Stock Options (Tables) Tables http://www.Rafinainnovations.com/role/StockOptions 27 false false R28.htm 028 - Disclosure - Segment Reporting (Tables) Sheet http://www.Rafinainnovations.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.Rafinainnovations.com/role/Segmentreporting 28 false false R29.htm 029 - Disclosure - Organization and Business Background (Details) Sheet http://www.Rafinainnovations.com/role/OrganizationAndBusinessBackgroundDetails Organization and Business Background (Details) Details http://www.Rafinainnovations.com/role/Organizationandbusinessbackground 29 false false R30.htm 030 - Disclosure - Going Concern (Details) Sheet http://www.Rafinainnovations.com/role/Goingconcerndetails Going Concern (Details) Details http://www.Rafinainnovations.com/role/GoingConcern 30 false false R31.htm 031 - Disclosure - Control by Principal Stockholder/Officer (Details) Sheet http://www.Rafinainnovations.com/role/Controlbyprincipalstockholderofficerdetails Control by Principal Stockholder/Officer (Details) Details http://www.Rafinainnovations.com/role/Controlbyprincipalstockholderofficer 31 false false R32.htm 032 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.Rafinainnovations.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.Rafinainnovations.com/role/Summaryofsignificantaccountingpoliciestables 32 false false R33.htm 033 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.Rafinainnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://www.Rafinainnovations.com/role/Summaryofsignificantaccountingpoliciestables 33 false false R34.htm 034 - Disclosure - Prepaid Expenses (Details) Sheet http://www.Rafinainnovations.com/role/PrepaidExpensesDetails Prepaid Expenses (Details) Details http://www.Rafinainnovations.com/role/PrepaidExpensesTables 34 false false R35.htm 035 - Disclosure - Other Receivables (Details) Sheet http://www.Rafinainnovations.com/role/OtherReceivablesDetails Other Receivables (Details) Details http://www.Rafinainnovations.com/role/OtherReceivables 35 false false R36.htm 036 - Disclosure - Property and Equipment (Details) Sheet http://www.Rafinainnovations.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.Rafinainnovations.com/role/PropertyAndEquipmentTables 36 false false R37.htm 037 - Disclosure - Property and Equipment (Details Textual) Sheet http://www.Rafinainnovations.com/role/PropertyAndEquipmentDetailsTextual Property and Equipment (Details Textual) Details http://www.Rafinainnovations.com/role/PropertyAndEquipmentTables 37 false false R38.htm 038 - Disclosure - Office Lease (Details) Sheet http://www.Rafinainnovations.com/role/Officeleasedetails Office Lease (Details) Details http://www.Rafinainnovations.com/role/Officeleasetables 38 false false R39.htm 039 - Disclosure - Office Lease (Details 1) Sheet http://www.Rafinainnovations.com/role/OfficeLeaseDetails1 Office Lease (Details 1) Details http://www.Rafinainnovations.com/role/Officeleasetables 39 false false R40.htm 040 - Disclosure - Office Lease (Details 2) Sheet http://www.Rafinainnovations.com/role/OfficeLeaseDetails2 Office Lease (Details 2) Details http://www.Rafinainnovations.com/role/Officeleasetables 40 false false R41.htm 041 - Disclosure - Office Lease (Details Textual) Sheet http://www.Rafinainnovations.com/role/OfficeLeaseDetailsTextual Office Lease (Details Textual) Details http://www.Rafinainnovations.com/role/Officeleasetables 41 false false R42.htm 042 - Disclosure - Loans (Details) Sheet http://www.Rafinainnovations.com/role/LoansDetails Loans (Details) Details http://www.Rafinainnovations.com/role/Loans 42 false false R43.htm 043 - Disclosure - Commitments (Details) Sheet http://www.Rafinainnovations.com/role/CommitmentsDetails Commitments (Details) Details http://www.Rafinainnovations.com/role/Commitments 43 false false R44.htm 044 - Disclosure - Related Party Transactions (Details) Sheet http://www.Rafinainnovations.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.Rafinainnovations.com/role/Relatedpartytransactionstables 44 false false R45.htm 045 - Disclosure - Related Party Transactions (Details 1) Sheet http://www.Rafinainnovations.com/role/Relatedpartytransactionsdetails1 Related Party Transactions (Details 1) Details http://www.Rafinainnovations.com/role/Relatedpartytransactionstables 45 false false R46.htm 046 - Disclosure - Related Party Transactions (Details 2) Sheet http://www.Rafinainnovations.com/role/RelatedPartyTransactionsDetails2 Related Party Transactions (Details 2) Details http://www.Rafinainnovations.com/role/Relatedpartytransactionstables 46 false false R47.htm 047 - Disclosure - Related Party Transactions (Details Textual) Sheet http://www.Rafinainnovations.com/role/RelatedPartyTransactionsDetailsTextual Related Party Transactions (Details Textual) Details http://www.Rafinainnovations.com/role/Relatedpartytransactionstables 47 false false R48.htm 048 - Disclosure - Capital Stock (Details) Sheet http://www.Rafinainnovations.com/role/CapitalStockDetails Capital Stock (Details) Details http://www.Rafinainnovations.com/role/CapitalStock 48 false false R49.htm 049 - Disclosure - Stock Options (Details) Sheet http://www.Rafinainnovations.com/role/StockOptionsDetails Stock Options (Details) Details http://www.Rafinainnovations.com/role/StockOptionsTables 49 false false R50.htm 050 - Disclosure - Stock Options (Details 1) Sheet http://www.Rafinainnovations.com/role/StockOptionsDetails1 Stock Options (Details 1) Details http://www.Rafinainnovations.com/role/StockOptionsTables 50 false false R51.htm 051 - Disclosure - Stock Options (Details Textual) Sheet http://www.Rafinainnovations.com/role/StockOptionsDetailsTextual Stock Options (Details Textual) Details http://www.Rafinainnovations.com/role/StockOptionsTables 51 false false R52.htm 052 - Disclosure - Segment Reporting (Details) Sheet http://www.Rafinainnovations.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.Rafinainnovations.com/role/SegmentReportingTables 52 false false R53.htm 053 - Disclosure - Segment Reporting (Details Textual) Sheet http://www.Rafinainnovations.com/role/SegmentReportingDetailsTextual Segment Reporting (Details Textual) Details http://www.Rafinainnovations.com/role/SegmentReportingTables 53 false false R54.htm 054 - Disclosure - Subsequent Events (Details) Sheet http://www.Rafinainnovations.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.Rafinainnovations.com/role/Subsequentevents 54 false false All Reports Book All Reports vica-20180930.xml vica-20180930.xsd vica-20180930_cal.xml vica-20180930_def.xml vica-20180930_lab.xml vica-20180930_pre.xml http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 72 0001594062-18-000204-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001594062-18-000204-xbrl.zip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

    -=$R)/%@H&@[JP"U MA45L'%#:42OQ;+X(H/@)LZWRPN9THV\L6T 6H(*!WU1%THWNH"C@R^!CKXH8>]BXM ?6=[E*J5X I$NJB TX6 M,)M+-D6$8Q53TX3W+*7E< G51HR^/A-Z]@0X2UGIQJZW=B;FN(25*M'HY1R4 M]D!7+_77!'"[:]MX^WJMY6Q@Y;5]YN$I"T:7O@=J';?>3K^ 30D<, Z0/C%# M4/C*VC(@2[58S>K ;6U)F^Y4?S#(E PK=$DBRG+[N[0\:J\XR J5,@"2R;E% MH:EP#"@6];WG?_3.UBJ*8VE>,+,CK-5C]32W,Q- 5"O;&=T6ZV]?6A5C<+6[PRUP3C_](' M?3CDEPXS*0.]#(U,[[06$-%BN+:RDDUWHMU5R_5OMI"5""GMN?1.M.WI9E;0 M[.3LD3JPFROWRYOWQ;YP8U>SO<%[-N%NU([IW9337]\"4C(Z?VT M$_K=D 5WNV 2/F'K%JBX[VT7N';))E('##^UCW^OW^IBO" M5TY<"__!-+1[YJ"2<\E]&W/1LM;QV7?3B2PJ@6J.F'O'KV#KSX9#;I:AT33[ MF3C,@@#?#2XVCU32=;7JY!:0(;ZY&*I/7;CY$Y7AX=!;NN+@6 >Z+:YJXXM: MO:O6\'OJJN+,TDMF6\ &RD_'7'?Z[:1A\@ AV%DRZLK3%[)Z"A*ZXJ;#@L > MP@<1*)315^9=T=8]&DS!C0>0W7,_M.%[%-LE.'.JMX8-3V\/;.QN6X9K;6D5 M"98H;BE BY=;-]XU#T.'*V]^]D(>9%]=/.<.-WNGR]CT[E/7#?0);7DAF0AK M_XZY,@@01@\\Q[;BKN48*8-].06U236/.4F9P^"='9B.%T38:N1[^-;QS&_% M(.FW_W3"GRW[_C_OPI]_D']K03AU^*\'IN=X_AOM?S;I/S]K.,-1B";5T//' M;S37<[G\UG8QSN>-UIQ\_UES (/3392? ,3;;S;@#]$5A+[WC1_!I.%(0DC? M XUZHO1$O$H;:-C&]V=_EZ#%OQ_D;2"]PP!.]PULRC#<9 N:DW &U[>>8XEY M\81HNG:D75Q]./E\_G^=W)Q??-9./K_3WGZY/O]\=GVMO3TY_?/#U<67S^\0 MQM<+**YH@ FZ_V3CR<__4^\V?RY_:I@#?X@GV1#]BRF39KMB0^ O>B M?@G\;1YKAWA[T MX)7VP *@-Z# "1(AMS3/U3YAQR+-Z#8TH]GL MXY=$ M/W\?V0XG%*K8NJ,VMX@NG]]S-X)QAS"HQF"L._+D ZH1=1.'N2X\-O%AV^P) M8-%+2MLTM >N 1D @PH!N:%&(7>AIXTY?$B>PW= $(XXLP*-N5;FE8GO#6U* M?3G6_BY& Z&$,9\^S,I<#827?P=<6 .J?0A'L'\@& ":@&=I "G+\VUXE#G. M5"-ZM1 8( P'(+*POB]( * MHLEI%SXC:-H)H!?>2I?![#%.=TLT8_M:P#"2#%^PL!DR)BIAI#Z[0]A@P,_Q M"M.1X774?8.0O@.U9#EHGD"5E38LBP]]!D077O._\3#W].[XD%VX&NA%H> [ M>A,YF=YJT!I0Q?(]QT$2IGSV$<@\>$HN,29?T.4L;60'F>=M:4G'U"3RX6=? M)93#%G B%:8)9T'\SEN/^1:^$C?%G'V_H7'R,^"$ZLL2D)FGQ:&[C0+$L#LP'[ 36!F#\"VPQ/PC(^@+EXYSTTM&O3"X'GY@NIW9,YF 41\Z>:WB$B;S&#!THSD/+TR'M ]AG$=R6XU;#F>*D-[PSWBYEVE33 Z%P*KP-8 MD;X!:C]H)P\V"!%Z/F3? M^!R_PM$$=Y*4%JK@RP,J*5X,:.-)50A$DD)#G0^VXIZC#D-\A 0?CNWS(<=4 M4RX&]N'$X:PQ!:<"9!@1:Y9#!Q6EJ/?\UA4BWQS83[$_,$UF,D\/'IOAP?'FO@ ?XOM M"Z8!L'R8AH5BPT;)JWB1$)P7J0'88DNJ6CDP+"!20 261 M*0C:I;HI.)9\ SOKC9G%B;0 338J/ U<2>2$@H$"%L0(EO+ZO1V@ZG@[%0L3 M+\ZO4_!1Y@2QNB"'Q*=F^"0,"C0:A1RD09[BE.Z2V!D+]$!DMQ)["#_#U!@2 M!$ !!@D(X%/*I%. @C,830=L@SL8Z#N@%\'*D&V; MQ)-PHQX\W[$>P-A!7H-ZAD;GG.I&!O&)D7N_4+2E8HG(-W*ME(/B,"A<,YR3 M5)9_XM4DO&V/X<.]Y #DC(IWSF(A0P6,U"R)/-I:4F6!GAX8X00M*=A^8/PP M'%XJ2E5RCCUR-[M[@5CC;62#ELCB*>AY-$KAO"4F!^**?$8-?!UOM)&!CA"= M"6D(?H*&PBV7TECJ#+0(9OI81%&8:J(O#)UUB0 KGE^LP'.?(BYW)SL'>>K8 M$$Q_Q.PI\@6ZBJ#-!8/*M4AO283(-=X&ATPPG!E?"VVK, L$D8SYK-X/3ZCB M6!H40%72MZ,+Z')Y]]F"AQLD7H!9^A:=&D%H$]PLM++16_'^_//5"7DA!'P6 M:0P$(/TN3-+$0OTDK9!W9(4TA&!LY#BJ TN1*_5C!='P+AI1PBKTHYQ.0Z,G$MQU-[ZZAVZV@ MVJ'C*='H4(U!WA"D,C36[MS8EE04#OH+42Q="G$YE2[$D,<'IQ?7AV\ M$CI#K.23?,A5#X'/A# @F._\8*%/1WTJ9HLV,GK'YO?"W"6I$N#!._*&1%;, M)V8'2@OR9%Q),$('YN'0MTGTO#H*I&EKBY&)P"\@(H9.%,BW\@51Y]. M$$AV5SA*I3&^$&HYZHB<"JEDA"/HR%O- ,^H#!\A),/NX(V&U)E@,V])2 \] M+Q0J1/IB$,%9AZ$CQY1^0AR,6(&4S"3WDE^D%8.Z$;/1XF+.%+40L>727F]H M!.P#X(E$C?0W 7Y)-6?A")680.C(0*O2RP $@/Y"%MM4$W**(@7],_*ERR/& M=;I]PHF-;8 M<(B<4&I,TK,41&/8E%AC'=I^$-*Q7,IDGL^=W \O[%)N]]S\C\CE6IZN\02C M77IO&BDG_[OV3KN>D&OC,E'Q4_?/H;A,HM<.7DE]6'K0 CB))KF=\IQI0C4D MTW 8$63*Y<1$F4IUX 62Y8B)",C 3NS!S-SIZ0/F,(D/:.J)6>"X^DGZ^'%, M>$<*&V4T4&ML5['(AF%GUYENUE+.J4>Z12*#>ZS".5@XF1'=G8O_ G7 M7B34)_&(V/5/MF4!)SIC0:A>)J!H8A7U,PGMLB6TRTYC9H=6445B=R/1$J@* MRF./4&YL/J,RCO=9Z :,5>_4G0)/W=HX/Y)$B!=U]XEABCKM(Z[/:J+]#_2; M]'.0GG46YZWM\'=0TUCP2KO63DA.^J11@S7"?+14(N62,?7@TXVE\/-8LY=* M>2Y7'/DDQ'IE#>V#S[D)1@#JK=$=V(B:\$GV,H K)@&:R78 >E*4J"V.#8S" M8BFCH$L=L5 R*Y/MT$Z EL+8UN;)TSZ?D#D[.SIJ8O&]*3D#00- [:NR>_^) M336C31CL+]YZMO#PD=\Q@@<#X=22QTBX%^0Y0I33Z9 F*AE^*C4!OR('R"?PUM@MOZ3[9:!+TNKK=-_%!EJ *]]/\ M0+?*RFY"-L6S"(89Z-0/XB!CAH^\Q AA 953M MDJ?NU+R%8GC&4.BZ&42:TI/FN8HLM%CB#15?3"B>G?1KQ%:5.)THOT4$7&11BFO?88^ MBWV6\JZ6[!'!XE./Z!PFYL]O[@>E&&G!D8!)1.8'#Y:"QP(D?ATG6,<)5C). MT-".M \7YY\_:*<7GT_/KCY74/R5&[>7O1J0[-/EX8( O7*!AU^[L"*1:68$MSH1^ )LNU,0PS$C?&EA)H MU!*!1GVZDIUP*7J%K0M[KR'>Y['>[K0;[:9>':SKC?:@W^BU^N4"DB( L+[# MTY'"L=;.HU72J,3Q5HF/( <[)04,M1]4RLCA/+1-6^%)WC#]>^8D]AJ#3I/H MM-2U'(-= +JK<-YFS=41(U/%\\E!"Q*7(@S$FK#P.YVT=K?5&'0-X;\&D$%Y M$O%^P4_Q\NFY5K??:!D]-/^27:T$#<8\A9Q>H*1BF";:/CY#XP)MLQ 4#E2? M+2^ZQ9!?-,-GO%WD;Z);050<;3?B0@^^\V1L 6J7QUM<;]Z]ESI3E:]U;RC4 M0%YCNQ0;(^,&Z'XGB(:"XD*ZZD=O@?2>6I&?N(L ,!'N+@2*S]DP)*>3"&!( MP[_)7%:\*/0\B\=. A[NF>W0W0,]G\2LB)"F(+G,L; 0S!J85I;&NY=S2N M"'^;>.3Q3%\6[E4'")0\-%9R<1(?L=1!1I.+"WR%QI(@%),%(VV(-S)YJ_(D M#) #8%\[ #;$*8R M UL3IL3U,TO8@<+.1V.7HJ9D:.VQ]EZ$[XWIY7 Y55 (,6Y"0@VT@0VTKY/- M:^3L)SJMPM 7=CMH_OXXI0&80:^3!!_#SRB6 C0PEY ^%ZZA"PGX-]E M6)?*"5_4#;BX.A 1/U.BX3S_@^41BJ4/AG:3)>U"9L.BX2,YY^,C@!2823:E M3CS+\ MV@%0.P#VY>"J&5,^!FM8&-EW;SLRWEI9PW DGK/M]#+.]KI.^;8$L$2GX/R^5H=+I#ZJ92R"_%:;\HB*,P*B MPY9VA+ZXFZN+C]K;?VB75^>?3\\O3SYJUS<7IW_^?O'QW=G5ZXOW[\]/SZ[6 M.\K[MN5%2(6*[_A3N7*]E=7;RE+=#%]BX2@C??%:&,.%%LE"<2$LXN%-8791 M,(^\UV-W=SZ_HV0!"CYD__1\4HC%/=N]1Z;'Q'N82[?,C7G,> F2@!'#D/?7 M*)AE#(GTDUC:!UKAP?Q9QR< MY5_[8S+R=.)'@*-)Y&/I5LI'$/EOG_QC%8TB/;;;T%N=1L<8('I$H 2F!Y@R MPF8,FI6\=85Q8@B._W-'CNX%A'63YO'2HFZG7*G+6(.OMOH-("=:1O' MW;_-$,=/@1\ZUCM/IMO=LU$F;PFF5A MGX4MMN\(QZ@8:GICT.TTNOH@/SWYIR #0KHX,DLSJP/3*UT=I2J)](WYA#82NM@568SD&9IQDF*F-7T=)SA@UC0F+B4G1I-% M2-68:UL4\XO=?BP*1\ "_XWG07JY!-+C7"\EFJ@1!]!X(L=_?MO(A2!"JF5\ MA$*6H>!!,ID="SZ0FT]XZ##S"GT5223R0M_KC'FRE@&2Z2>8>J5D824 Y])S MT%,:;,EDJ5T7M>MB_=B%-EA*UU\^?3JY^H=V\5Z[/O_P^1S,HI//-]K)Z>G% ME\\W&-=P>?'Q_/3\[/J%N$H782QA Z)PBAKH5 7P=NR>,A-\H+\_SZ\<.Y1# MZ846/N!A3D"DB(>,(YL7EFU8)>U^>9CRPB(.:;3O\4F1$;CI)CT^ZPE675 N M."B7S(S]W,RA^GQQV86D++@2!,D=6*7+JA>.O8B$WXKJ1T--C1I\(5PG.4BT MS?88KS% K\J>)C5&5K6(V"UF32=U&2;8:-"7Y)WJ2:*.#HZ NIY(84WTD[BH M%E:#$)>89.&:)D8$)(&X7UR"B,(W@S@G3-ZVQ(#G@TO7D&EY*I"FD218>/4] M/ 9H./HO>NS$#VT3QNP3=^!WD:@NI5T?_;>XGUT^TSP:<'JJ(H!]%RT1%"V3 M_D2:H@S5G847,G\>;G#&R$^/>/IJM!0'XLB M&SGS^5%<.%)QH_HNNC;H-E*>OHC;W;,@)!=6\+)8 M(9?2-HD;62"AYC2@')&;+YME,%.@B*U$//$8Z8(M!$$TGDCEA@*B1$228#PR M82<)@I'A,8&T%M)H%UGF4BH>PGU*4(F[^/QW9C/X\L5F(W'"Y<$CJ[#2,UPT MJP[4@#[Q#J&'^!V8*J)\1J<@;'.];YGZ+ M2]"B8+#C&F1"C9#: PAXS%2,B[XYV@@V @A5&.LP#C8ZE25UZ0H(M8K(5:YX M1!U,[GY!1$R1IL&M ;7 MPQJ+W+VW?<\=RYK%@ECP29EI+ZN#!N)J]">E]%P\]$^O9C-Y4U4\9[AXM'@IW36 M%/(TUSK]-3.72(B/EX,5((23+./^$KJ8M((O/8H<)Z,6'JT2.'.X]%U+"\C4SY6X2MUPHAO*;C M5SL*:D?!:F2K?[E^]VOSN-_5.ZVS+U<-37[1Z_:,_H>WE]KAO _M%6FQY2MM M,:RM=B\#:EMO"E#G7(BO-DZ@JZ59+EV9/%&<57A$UALQZ>.9%& DR(J1HI*!CE)EK5D?2F2=<=^]1,EK =P$22%,$0P M5>KW%"2O.N"QF^>DL@I%UOKBCH8Z/XKBT]CM!I:6=M-C<0:8 M+"*1P('M?$0Y?6UB.QXJ8I%%=QA3"EZ,*5?WLW9HS#RJ5O#W;AW9A"!0;J%H)'BS]4JS.-8Y06N*@IW2JPR\ M.#*!"1^V7^$5)144SW\&ETFW5OD3S\^+2#KLO$IQGZ">;NZ7CA7 5H1V,+2Q MQNE[&2DEV@V(""L9 ]5(QHPK!5.\8E**-=ZH)'_K5@E&B!1ZZ>02G'*RLN35 M22>F\+A$YM+2LGMM^C:5OY%7>:'8=EA $#'B21R;^Q &AI2]Z/LHV>GFCJK) M!&+WYS9]&'=;2H-1?;22XW#=A'KP[A>;&%'[!GPV+C" '+L@*)U1Q3(GK28B\4?L2S94Q&S-F-9VQ#- ME4,[='@:Y&4'W^+@[P>ZO\8>C0\ (W9L3AU_,J$ DS#C9G%J26TW[H-M);%R M0I9C5VL9+2?NYP4G(MZ6,B+9$BW+@!9PG9SPA*L\KI[^'$U(.F'J=K(_MGOO MV:*-3OI@7+==W,V3K$M*UV,HR)WHM.KYWV*>'F<0S&_#L98-GY#T]L-"K88Z MZ:6]FU(5!C@P[=!KK#(O!L_T"Z#?:8T"V$#"GVR4[$07R\Y8V.\% U?A0/4 M%*F76:!C?UGZ3=+SV_5DO?_Y"GSY>0;9E'FR-O!$W'@3.&AH<#RM$#$]B%[. MNM3;N MH]R0?V'!8+#\1I[4:[ ]26RBHJ4F MMIBG]% !/WG:F,@!0ZP6@:4"- "A(\ MUC[S4(:[TV7(/7.B)&(QCG*W9A4FF1GG6\ ??4PHCGR1S!'77VU0@+":;TD' M$/^(AXJO<17=Z>^@P\!2CQ+%-B;0>!L"D84G\0Z3L%LOKOXS 3TL1:!0Z'P9 MPH0%/T>86I:TCZ=U6BEB8*D G1V,A$XEHR9C1IYH67FZ&&FR(OWO6/L[C\N1 MBC9+($'$H'>>AVJL" $_UC[)1:AK2* 4+9%Q:Y4522I2NE++#DP.:EW'<0JR MHP2C/F"%6MC^,;-=RA<531=E*CE1K%"R,]2<8+U2JM@.6-+?R5P*2V6/N^:% M*?T*JP\T)(&$O*P=*E6#.CU6P(G/2LHT!!FK&8M)X6B?IH7%TE[5081#+ZJ?7#W:.['H]I#$ ,J' M%Y5/HWI"TF@?!2.202IMX^>:N IZ4M[!'N\!]K?#YM4D!["3%,H"SGPDC=R6 MV>BC[1G-HU;G6#N9@^ !;0A[G!0EWU#QS[8BV1-*O0*Q0X7]?&>&+2XY(#G6_/[E^*TB7!3!G M'?79N%J^<#R,*9PS77+ZC4&SO:NJ=1EW7A8PHVDT!MV2^[1(-I7"1/Q*L5U6 M;IV475E[T.AB6Y;,EX9A- R]K14T:>]8>Y=F]LHNA@L!+(5N":>/57;:X;F9 M[=:KMI0&+8_;V)7SQX[1Z'6[VB&&WK4&C6:W^RJ]V/[R)Q@P(/U$$B!;PH1" M]ETS@=W$;1DWB-7;B3 3\1ZH6RY(%'VNTBN^&E=;QHID]_R$?(DBJ8"[6*)7 MWA;3Q;A,6 3;V^7TK+@N5HIW-C2+"O8ZU(0#[5KQJ3%;U5.\C8UQOF-P!792 MRE09&X(I3WMI3(_^LT8HR?XL+G\P=SI6J2G)6NOI_8-75(SLAV3RQ*DGYA9L$N8=.D&.M7,0OD[@J4/D/=C(&QC[DC$[=CO'O_HSC\;7L\GM M^6'B(TTBRF+&A"VS7V5M:>JW@E6\L(R5>IF^:V=B@>K6:C<8RQ2?\F]Z*%3U MAGU_63J-:CXG%5RI^9! 2(@(66X8M]$P5O%W(+U':7TETFDPVSJ3;#T5U M75[7(4YHHU 8Y,8DG1"GEP5#4002R2L=\O( E_!0")AP*84)JW?L;U@P"X!Q MZ=9 =-E$:(FJ\9[,)[^]]/#GC9\T210%(*GR5L6:;\\ZVSCS6WG*3 M10$7)2D1:ZX75V\-IP);#UQ@0"Y] 7Y9*'-QPBF<<^%[1&L'1DTHI4F:J*VW:>L%1Y\)%%&DV]C6YZ M+[JC5CK=3."@+$N+@\NNS/ =;%FZ"MAC5[A:&96L1HS=BFAZF(CXH6@G078; M<0UJ%T><3[F,.J=*H\?:+,6)B'3<-U3)\-#BDZ*PG*!XY5;@,4/WXD:@EQK \F2!,59(1*+285CX\7Z01W>B$N M8^9EC*"+L96( 4#(;,D# V^F;=%"5F5WL:&L%""9:?;7:F"X <5))/4+L8TT ML1FQ,P(XFYBK&TE2E+"J%:?^SL7VIG>3,B:4,)'%75_@#GT5I!U,V%0>1[I< MS'.&S&]4PA@8@01ZP)!376*$D?K/8E )M0D"A!.Y2%%"RTQ*WIY?7>]:<=ZU M[GJ:2;H2A[F"7";1& T#-<8\J$%S3,-,@IDPDU0-E&4T)PZ;QB$G\QF72//) M57@0DW.2KQ97VS_63O,3-@,262ZW&JD.0=?K=$!).9)MJ&4=32;/? /S13&< MEVH3IP@/E(8V:GVS8ZI'AI%"=^C:6Y9"ARZPI&"BK'"NP*/,D*37:8=2\KZ2 MA4M)79.QT<2<7!YFIZF8B%KH=N%WQ JN8KJH E!5.%]]HZD=2.P$*7H.5CI; MF8+YMQA+EWJ#@WA,BI.CFOMQW%F&)Z<7*21"7:JE><= 6Q?CBDX!:'PI4G=^ MXCONW?EL,J)@/(8Y!8TD?"Z%!0\VM>9+,R86E>\_UBXBBL6?4)/;G+%F;)D MEB&T>%+?T5$_!]2Q=@TOD/_:(=>\(NAP^5BM$(:2)2#5C -RM?N@ ^$'.+C" M\!$8,&76".$47:I>%%#!PPG''NWD<*($0N&<5[47I:67>NU$9F::IV!2RS]I MWY%V31%'& ,"ZQ2-M3-76,(I1HP.3=3:W5Z[VW?#8K&EC#@\[VPGPI/Z$:06 MJ?+4,ZY:TBLG<0U9;: DJ0'@)+F7NMF,+BI-9_%+E_%JCP\RSZ0^MXG2<(<" MCQ.T61)M^1#D-I;(%BW';T2$M> E41"WHAE/(B$IL'; _/A@[1,4R2]2KU$ M".0H(EB1KOID)T)%#V+WS'9B_YS:FE,J/[&A*8B'6T=QV2LW(LM+Z5LI>THJ M+2"MV>")XX30\C"F !S80"2,#+G;[#K3YT'W E-0Z&+"W8,EA,$^]NAV0'9< M%.)';:^50H[%8^(2O-FNI.0KH7KLJ:FNKLR6Y8L3OT3V?30=Z1VE-Z9\9>&< M%-]'! 7:ZJR59Z5347=Y\12A0_BOEK\-ISU![Z:,:Y%4$MZ MK!?$# ES-PA-%.GREE,'2$-L!(3T;RB_U-3PYA#!5'Z#") M#!"&S33;S52IE-Z@4($47XVYK08Q8!^E>W&2+3D3I:Q@C@'D'4-T(B2-IHZW M$ ^$0][ZVNOD"BBY#ZIH<:H?ZNI4#A5SNB?Y^.O!K1>"PGT0[X!\\4A\#6O+ M*_$D?BQ'@W@T>35;HZJH91C6^1Z#V!\_7H@_CU8A,UY0BIE$VM*V1:E MS,GP?2 4M6[;2@PT%F'Z0%\R:Y[ ,$W.2RV0=ZIJ*52C 65Q7,T 8P2EKF%T MZ++@FE.CB1-,PI/W;R)&Z$)T57HB;XXQUMT 7T\YA)EYYQ&\ TC:QBPH\D 6 M1$4%T$RG21='!1W=ZFU!;DG+LN:M! ;:^@LEPK*V8%.1LHYTJT0AUB5R)HEU M3^(WO>)D29&(*E/ %*\$;G-UZPNM\M>W!1ZD-P9EBL*JT'*G2@=K78Z]9P=K M;4'\3 Y6NTSQ7@XM%RWSVU6W+6^\D#G;$.*;K+S:0KR]\"Q:7D058RME>NY@ M@5O@-L:6N,V*8GQ7U)PKQG<*S#,^6B7(\2H>K6UIR"L*\NU0\VI]/%3H1)!6 ME0JGUK%1/ZP4'+5:L%&]K]79UTK'O+W'M.2_XA3D3R+3CV)6*QCMIK37ED5! ML=%'6D ]KC2>-!QWJ8X===*.H^Y%(K9(NI9%,9(N3+)#1AKM)%(.1966(96* ME-FF6'D;^RI@GJ.LAJXQ)?_TD*$;T0[%D*^2_,&XE"G5(,5"H!R,E$R5CHN!?*XH>(FI?TIWCSB!5(Y!M2UP*HH^#F5D7;*[(DU1.TFB MK^( 8]N=1/!&) /%Y"L9I/E<) ?!F_]6ZW@R$;AT1$4QM9$-F^*;HZDL\YG"S MN(JRS"90F8D<&M@4@U7)C#[1/=")FP/H3X$0 M:!1$'Z>HIP(L%;2V@KVX"CJH'.)EZGHR%?LB"QH$F8)9J-ID1U;T!U =Q'8D MK:'F]QI&P00C<M(@<)U+"Y_(>EVT2/8],4!474'G!"3EI+YB-=*$:@,9!0GOFK+K;;<-JR7 MB$X<[5RD5"BFT:7ON?"WN=B,VRK/*E_ZGKO:>W[K4U=*K"T:-$94U (BS1CV8GE=K1#4:>LWS9>9:1H;K&8&VKF!]J-2!\E M+@\L],N$:HW%N3S" 2!QUUS*CMF47/%6+\:>T /:H8L)3#%%6Z06!P:1V6/ M]$6F6(Z0'C*O70M&7)9;DKE;.,PW/LT1RS@699^DO<^"_-HXZ?Z(E-';.)$% M#8G8'HY%PRV_LUV2 S#3!WC)KD@@J1/::FB"W!8H M:IC5Y@"KE-U';6RI,4Z2^9)R?+B[V07K53@WV@V6X4850EU_]C0);T-$!\5* M5R1;G@7D/IG(C#,Z/N0 D5F'<7TQ)DH4QH0G^7W<(R'.=J+L.5BG4E4L3GZ/ M72X)J=&Y37KLI0U)92DJ43T"B/U(YF^QI'ERK(AAV1N<(CZ'V HG+G62Y%NQ MI)^#BJH-"K:0=LN-3;?$L27:QJAE M*;@L:!37+DH2TV*\)9OCB?HNF+"& 1ZT<_G]O\AH%74VTLS1?/VK-OB**& M M>[7A_\7% G+(7>P,U628(%'*'L:"<_JDJ*#/ 757:I@H#ME,302B1)9TPU%* MNF5+/Z0UOAH*E4P\>9*Q7@,+1MH0C_ CA;#C#[^\CH*C.\8F;ZY3FD]5JDN@ M2A-$X0WLYUO',[_]]A\__'(/#[VY]#GZ@<]DIXSD 3HI\.&*#W\].!5_?QU\ M.OO:U+_^P=ROR%1OFLVOXK\W%U];S:_7?)+]_N WQ92H[83:3GB2G?#9 \G3 MT8ZTRZNSRY/S=]K9?U^>?;X^N]X)YV*:"WKMKP=?1\ZWCMYN]D'KTY-?7[,= M,U=YGM/6-W$3NKCY==P/_$VQ;'@_\Y;KM.6EL39UVO+3XY2JFHP:!\X4L!%) MDO*J7*[ N>NTZ)H24VJ(DZ!W08AUVG4E0N/G=;-.J]/JZ^T9W>QB.,08&7(' MQ/4K104_*KV#%W=DB=5YUUL*8/UQ0\3N03IWJ]\PVGHYL>]U-G=U]GUCTJY^ MDGAKT.CTC7)BS^L<\8WSQ7R&M_X4HVG*B +9%DSZ!XJ0]OFWD MNV#"2Z<<65H50J[3P>MT\"V?JF9CT&Z5(\;K7/!MNT'7_HORR+&&J7I7L U5 MH,XKWRO[HZ1T]1^JAKA.LZ&WN[M1,NID]?U(5J_B>7VA.?!P7#M&T39!51/@ MTQ"?I0$[&-$3QP!]])@;8-A$<.,SBY^XU@4:_5>4"8J#!^^2V+,2(W[FD5N= M&*"Y0,[< " *2MDT JCB83X4;M/-]*R^N/G][$J[.CL].__KY.W'Y9$WU=G3 M4N.Z*KZK3PU)JLYNKG9"7\!6OL7=W\0SOY M_$X[^Z\OYY>?SC[?Y F0341,P<$?GL._.K;[36\V9\-RD'X1,9?TLF:.P5+QWXR892UFI>$G1<823Z8C22G M]'YLJYNQ$HJX1=^#"_/]NRNK?MBX/N@U]%X=-[[KR^7]H^WJQXT;S59C,'BI MS<6J'"/^/O)=&QV?Y*L:VM_Q[Y*EV*XBP*L4K5UZ#"C8@-U!29'5NXI;WH-X MZ2K%-I=/@T:CUR]:XREK!YZS$807KE'(?9$SQ./+RMJZJ8!_ S_49DC=C'@1$>KM=N4$0VTN_,5'MNG4!D(5!,&6E;-.O]%LE90541L( MM8&02X.#QJ!9O7H#M8'PB9DC[$:%YL$$8QIKTZ "$F'+6EF_T1^48QG4AD%M M&.22X*!A-(O62?;%+MB[^C,?V6VQOJ.J%,6H2\WL>GW;<48/.D5%2M:E9K8O M"/?L5+W,4C.M=D,WZE(S>V+6;9PT4-MS>V3/M;IZHZ\7[6:OSA;4%MT>6'2M M7FL+U7=JFVY;-AT/@C>8?RU:?F$C*S[QN6G+QGDB:Y+9_G.T^7YXQNKIRS3Z M#HUNMZ'W!OMG]FT!&:\V/*_[8$U6!;R%DKGB-')HZ/V&7E@B7XF[5?J!>7$U M2:FNZ#9D?EU'=*_R44JJ(UHUO TZC6YK1[7*ZS*B=1G1IQ[7%UI&5.]T&DVC M:,V_JG5$ZS)_^U7FKZ[8^&RV,K]2 %4B9&,/6,"_L:;8/19C'(GBB'&%,6I3 M]R8EA7#D>OXZM!"78NU/MG/<"O3Y&D[2+VZ%] MS\6Y)4>Y*;/LLDEV,):F#)&.JXQ5G_W]))CZ[#^;K9294$*.+SZOZ9%?>ESK M+=^#+:]/[\I;^4/5]S).8$G%+@IA1XU8?N1DMVLI7)_CYWZ.*[^53EY1[^Y, MK3[\"P$MT'OX3HUZD2WTT)R/7%3[0=<7;EE\EYR-O8;1[V\!CI26D7]E)^UT M&\U>^[0 M4NA(X8(NF<,][3V XWL-N3SLZ,4$ASU"VUR\VT _.W! /)[XQ"?FFR--].)I M"]>[:\G?$E",OF# HO,9<6EG"LS8Q<[90XX.?^U'O3%H-K7#LR]7<;_$5K?] M,PS=Z;1? 9"F$]' ;#*!+:&F/2'[+KJO40,AVP]"\B+0-#YG0V!D#0UE!;_G M ,8P\K'/F%@(/2G*M$IA\C "FT>S(G%&,[>&&KL#-"#C;V![H@?N./@OS&SB MK_ HW3XX@0?3!"%PEA#_@BT& 4V#^9]@3#KM)L#ORN@ >J2L=[K0;1&-8Y:6/6WP.O/U[O!8Q GEC M:"Y@G/!_4BC& Z0R4CXD7R9\W7+ %M<. WL\<6+8-!^[W2$2@"/?\5>$HW $ MFPK_-9ECRMP&7#<,]#M@C[NVJ5T#HNR @C:TDR@<>;X=3H$"/E[?G-S *!,G M@G$>/.W0>*6N=^+9>.5[^+^,O[W*=1CM^!1^<:U%U\^S6QZ?2VJA!Z>->LG# M"S\:G493GS\.8.UUVDWU./S8;C3;O;D'6PV0^J^(MAFZW;S %DZY'XUF8]!M MS8_<$2/3:>"NU*5^4D]I-"&EDYM1B#,31<7+.=9.%K3M:F@_MAKMOK$(1)LZ M+#ZX2#02T.1,3V1S06::J.(>IYLJ>B@22D<,^R@"R J?P ZX\.A). _(M * M=<$)>Q(9\9ZTY-TA?K9=%N8S+:.I,4!<0N+ IOKM/JU%15ZC,T :18)EA"N< MX+C[MUR/BKY2,S5]MD="_E.=F:>J>"! +"ET$9.%0O\_!7(O9V21]L#2#4HY M"*K5GC]+#?%90BI/GR*_LQGY2,? 1%U^YX6VV&T&0(>A0_0;GU*?CQFH9?"K M ,B[)4T1V/::-TXO0RH0JVDOU8^ZC<&@.\=$NPVCU8HY MSZQF%)^$>$39@Q;F-CW0E3C(WC$UJB7U2S?FYWGA]:$WV2B'7J9%%$!-1ZO769FE M)*.YC:45=D[.$D,F59]U]?3GJ J)W\#G5F3*2X%6HY/C6VDU=+T;VXB@&M@> M=6/6#<61CJSB)+J+0%V0'9>[.2W>ZZR)%R;SEARYFFG73/LE,^US82OP>_0J MA",6)LX(X,[2..32WS&?QS(!+NPCSYYAN@TPNR5OMUT\.ZJ+0[W6%$6D&3@BL%20 M'28'-9^N\A8(%>F^THTC<:,G^'6$8,CFD])#5)D'- MRFM67K/RFI7GKNPF9:"@8=N.%D3FB%X4D1)\$>..S86&-@:-'B^B@?6+]US! M\KTHU/"8C%V,G4CY=CYK!^;-M%;SR(+1A*7QX-LA7O>#*,'++QD#(JR5(KAZ M=7AX?9M1G=N,'=XN4,27-W' B+@5IEA?[20Y919% M*DCS/1E]5H]B8)9;&IKS:)/#"21[W!PQ_TY>W$; */!,Q]^AFW9H!Q@L15Y8 MNBM.[W.$C+4%.PFB\1AOG0&\Q-073WE)6$2 _&0^7(?FGD5/+_>.J+[**5,% M$ 6?$NF_OC90? WE2C",U>ISS0<_EUF+]P!M&=@Q@*OU*-(PS)'[A: M<[Q7 M9;4%SH\,Y;$-VV)MT]4W_>W.WFEUF[V^,1-" M?2(OPC"6'+7N' W]B83_O'JI5+#\:F>NPF_E6K3HG4:O5;TNS*N2V \U;>]- M:>'R:1O#T0O6^-<3;W7SH=4]83-B;L;A5(2(JTI_D.?=#'-]H?RNP^RF4.YOV]E"F,W^M"-YRF&LN,E0 M595A^JO4CS%:*STU6XOF8URMY1C8'8[B9'E1E\Q0DV7C MX"ZZA^860!]Z&IN+DA3IL&,/6*3;P&)>0*K,@=.H=1JM9E,+_A5A29FAY\&S M< S(9X8U01P6W'D/#>W:]$(GCL_4F(L3^E.*"\. ++5B6D=$<=U&MD.9MA1\ M/\+:'-GB.**VV5^V9U(U&UI! RL-18YS!)BXQ]C-2Q]>''%@9A3#=>&'(PSJ MU X/+FDO\'\7!Z^TB8]98?""C <-(LH'\,5:F4])P/!5X+FP,=A."6<5D/K< M]>[IC 1QK*@I2L!0U0&L@@8,BI!+Q9?2P+<$55C2QYMP%RNNN-DXN4Z",JK% M8F-I,?OV%AXSHS NT&1TE*@U@<-WD1\7I$JKP*7I:C'F:1_4K(VE%M-NZV>C*:I43:BQC!N-M4/^W72B +.R8'6L7 M(ALB X"RX7GX%<_D!%X2T&@';==TZ=/@%($I6,T])8Q"TI[)5!DVD@XLOTG M0'++BP)@Z&&UO?4A "ZE+@ M>,,YB*B67U) !U0$8'HRPQ0+ \8!M9X[P^KB>-5@Q#F&MB=%=V2U8]$B M=6 M9&5A&/+6UUXG0@Z?>LR7LI?AK3]4-KZUT*#6RD6QYL0BTKP?0:0C/IYH.Q88 MEK9V3-.6 QJ-D@(:%^W,?&A\03;J5H,+:U+9 :G,I4OL Z6\N$@_H]V:-787 M%*UF;E8_Z:E?>Y"DJZJM;]/++%!KKNQG:"]T,EA?= M.GPOUCE2LRHG)#?N:Z? U,>U@H%?5<1;:]#H%.X]63%, M%N9S(64#MTTL&)FM;DU4JOD_WUZD=3^TJ65F[Q8G;O[U:Z M"_1?5IQ*GN_*EE]\O%3Z_P+2@EO:GR 3+&^\)D[7M:*J2BV+O<4;"\/2'<&K M1*IM*/0J[-Q^,2MK;RL(J[B"[IU&6W_4&UM@R$FU-^SYKFR3 +AJKZR=VU>@ M4H=,;S9::S/\YW*;N46Y7;JJ G+[T8"/%V.L/M^5K2VW2_6F"$K4&]W',_)? MCN'X;%>V22A@M5>VMN N_Y2U!XU!MUD;W,_ X#;6W<;G:Y8N7]GN"]94"UN/ M* /50E=QK*_5Z#Y>8G -*?S#?E/!2_4,5(N\=X^M1Y26:J&K.&[0;W0?#S.O M'1B5=V#4QO[6M:$G17&6CJY'XV&WK05M%4T%JD'-1K?;JKT1SWYE1:M!SY0- M%*W^[ D;Z/8;@^ZCU8I?@"-H)F(^?N>7UU%P=,?8Y U5G0PNAJ(]]3L[,!TO MB'Q^ PMXZWCFM]_^XX=?[@$C;SYZS V2K[&!+R[RB@]_/3@5?W\=?#K[VM2_ M_L':3[/<'OTFTK8;"ZH1_KQ;2+WI7;AC37_$ M[\]>R+6!IC::S_GKX\7)Y^LYHGV!D?W[M;E/+:I8G=TL+_>FZEOIS-<@[G:2 MG^8+%8L:3^UFO]G29VL\7;@:\/@(RWYV1'6NAO;[J9U4TSVE^K6!]CMW'!9H MU\=O#X8]"#^;?2ZC3CEQ+[G#J!'%/;$ M:KS,-/U(($HL A"!H.$;V%$3?K(B3F/%2\HFL,#R L(O%G*58\1%0 D:O=$; MZ#*?)9F,ENW"\-H8B'@4P(9AG='YY8J"QK1_6)+8]0#-HM*HG5),@A< 12;3 M.%3MV>)#%CEA;HG76DY4FKG4F!_CSE8&9P=(&WWFX*S-W?)U-MZZ^DL?=[43&S( M'+,0K<78M 2B !*AA,H?/IW? M?#K[?+/4E)V#>J'^W5NF?\^_0S'6F5F;9(&\",#50_)YD%9)W_K%V.O+M(/0"[4\V8?#O4[VMM2RJ M9=%3'?K;GAKT_).);SN:WB5%K[VTH=/B\S)[5H \X,7;J3:2+5\FOG=O6UQ# M)56V50JP5L;IR.9#[8:;(Q=9A':![8E \<1>42HD<;.CU,1X&'F.,SWR'E U M3NP-&]N8Y$AM]$B@JHD=FK013,R2-BVQGPL-J&IZH>V_:1.2+5^6#W]<%!I12G7(IGM7)A[ MMV"L\M"LIID[W4H/S4YW:*RKL[8'N=5<*K,5BV7P'R>?WM8Z:JVC/C<==?XZ MLM5M@?"?]8B<#8?"L2I1H'MHHJ2)W?3-1_B$ =Y1^_@57KX MM ] /Q/MX\?38^TP?IK1,Z1/QFHOS(RJ"<=F? +43NPW1BW7(T75=B.AAC*- MFHA2[U#0/!Q8WZ%NO(H]MJB=Y)HV%#(F9HO >O.*1EIYLI\\=491O9$_$=:2R:AO] MW*$=.EQB6U'+DND1)_&"$FS8<0=.H74;I("FX&45T8SZ*=HTDOO=#@+TOD<3 M5#"_BD?$;=NQ M/NA3[U@:IY%2)YPQ.GGI-^)Z+=- %3T#-*F\.;/HR*5G,KE0DYR XD/$I=G< M+:#BA] R[@<8Q/:EN>E%H70[./&8<6G1I]W+U>;?/II_N7'L^3;'#U6Q_[JS MME9K_?N!W/R4/;"U/H&V=1WR(7.]0'O+PG^S;W9]05!+QA=B?'6[>>$PE+YA-SV1WW&]+R4Z\H#O570MU =3]VZ6=LEQGKA R/ M!NT=V)C":3WK0S>D"SVV54CW:BRR5@*@+<1<'&UTDD9*92R"]762"NB6(FAX MF6ZI'W>;J6H)FY(NB+"D;5NAK-7(6HUU=OABM,->?]?:X849>BC@!GFZ(9M,/ RSMG).:2/6T$ZL>SOP M_*GVUF.^-1-< )1JW]DN18#@T8.AO"221CCSVZ2G 8-(DUNR.JFKL7B*6YHB MC3NG:1*U3CCI;SD!<.>C!QN@44+,L\K-\C"(5.&9U7, >!.5FDP\?#(=*#]M M1?D1JLCL @1>B0G:08X*B\K-H'(>6S%K($DA"X>] MGX0G_4"S..X;91W@>:"_D22R+V;WOU8B:R6R!"6R\W*4R$_!L7;)?!9\X_>V M=FD[H,BX7E2 )EDGX>VW8KF^?/QG%(3V<%IO]'YM- CO1+CKQ@J>SK4:>XEQ5X<6Z9UY57;6D-2KV TM&SLUR%4#A^XJ&JZO*JP^?F\N]HUFK M 0%A&-VT7%/]0:JJ&0ZVF+'5ZF$EU,-J*U.'W8HDJ27R=JL:XBF<4.; F?$" M[?H.C##NU)[&EZ@GU KA"]GHBUD]9BL7W\?YG$4[/$C^!J5PA8#C]%5Y%1XL MNPM_&\?OOE/BB]>\$Y_1?N#)FPT6R6@ZN<\/(Y9D6 /T!,_43$0(U?:+S*FD\"'E4SI.8)/%$D: M)<^0?N1.I:&&**%^F(8T98WJG\!X-VW4'C''-AO3I)2C$65XLTJFO.%X8E*L MMB07%NM[+@DL5]9YK+T7]7>R"T[45 I/0LW2$I@"U5 W&ITUIJ?,:30"@%:. MTD1KK!%ZV'TU5R=T(:#92D-90!%3B:*[<#ORKL'>VMZ8FR,&9Y *KN)&_1X! M=6LGT1W.*_9'#A0G.L&B;!Q/2KNT!ZTF*.%3T-A]&WBBBV6;87MG M%B:Q5H1RKQ_KS565^Q[NZ7%ID4R$9]=+BC_%R[4%U4DDP'!XNC,'.[>JSWRF M1!TDM5!P_5 KE-L(S#5:>JO5UYNS.9O]9ZEX"D<$GM!K(:5F==#/]C?/85Z@ M?8 OG;JVXTM601^IV+M3Y30)2NFNHYY*U6PU[73V*&B'!_*OU6YXXM=6N=]) M8VD>OG\+0EF$1'4S)15&6WWG@=A&EH4@W [30K0 MH,IBFH ]6SR'+X"^T*#)YT:>'3!6=K'*NF^;8:H3Y6FZ)I;JJZ\BA&!NDCB8HZW;L[M*U1X97&[\?_JQZWVBBIB MM]%#[V^M7-7.NJT[ZP;/4&?*UY/2<_.!>_Z=#;SB'9B'@1Z6"A5E? M4%)$,*NA9EV"Q[.PR5MY:^Y:7O@C%^I2L]':,<#)\N1Z+:%6%>B ,U94K>3% MNG+>T[ZQRYO[J&V KK B([& >Y*>LSLS7H\\]*%R']L2Y"5V1*G =66BX_RY5]P3_B%G%J^5>U'P+%0)'[ M?H6R-_0@AM!NBO-G:$36EF)Q^J4-@M4V"SH^A^S51[T\PPO=1[?$)"=!531.U H_"67P#)7!1Q6^JB\I MH\RN14.N]^"SR:\'XM^#130P?[S*HK*::J4EB19,3;2[(%I5O5M)<$F)=R2^ M!LF;IV.7+\V66*PK':FUEU7@N<4>\!;H3N+CT:PNG?U5JC0$7_87J= $GF-; M*B\P]HH7H+>BG -3RI;7=%4=NGK$^57354U7-;^JZ:HR=+5__&IM;5+N8E_O M+)DTS^MFFIR7'F>^T8;B &J@>GO0[.NM9FNV@K12 HEZWI'_]O3L@JYP+GV. M=]:9CHWV>E[RY3NA8W^F'YZZ$T]A!NK$VLIFS;HT404*^+'(?6H;L_CRT1G';A.]8^-YZV.W\K'3G_^Q MTYN]1KMG;//<%4MU];FK(AG5YVY-A VV+N[*.G;EF=\[2?/>:)=SS6J6E$]0 M[>GB#>JGHG:WBGU1D!2A,R\CN"J0E]YJ#'I;<017;S]KBGX1%*TWNH.MN*"K MMY^;B+_=:J.%470!BE[5*;K=QM3Y:BMZ-477%+V6@[S5JKC'8+7]K&\.%^_R MI>\-^?]A[TU[VT:R!=#O!NY_((QQ; [:1G,MT=Y\5)S\/[$I2I MDL4.1:JYV/']]>^<4\55E"79%%62"YA[.Y:H8M6ILZ]1)+K^Y<9+K>FR7]M% MS:#$OC4]U1T@P$2&/;45O3:B;"<:HX\'H_N=%Q(W/@Y'^KX5/=41VNJ8P]Y. MC7%U[E-C]$O Z+$Y'N^41>N@R_XO&1=(FCLJ0E'O.K5?^T7XM8?FP.JKK1UJ MC-88O872<0#VCH[4//>6KT43_(7HUI?.;(J#Y?HM8P=E6SI2<^Q.$\NVS7Y/ MQVHT2A\-2K]Y&L<,6@=I]G_!*XV6 M-,',T"4QVBO]A'3KOME5O8QZ6[?'.MR&(W2QX/2 MBILJK<17MNGF=^1!EUUEB#4)XC:5O^:[:ZKE_&[_?"HR06M@CO9B=BE%%DIM M1M.HIM&]&Y*J4$3C6DJ;^OF!D>?6.K\F3UR@WS%[>[&,E2(+I3:C:?0%TNC) MHWKN:&C:1TRE.F2YSN1G]RR#%,\YOMI!BMY*#\0D2&X\KJP+0N'! M0OH6: &[-S3[O:X"$96]DJ]2F]&\1/.20[R%OFW:]C[*:U6AWL:U,K4#/T>) MQ'L> *5O@188]GMF;[!37K)A>$KS$LU+-"]I\!9.VM=++-OL[Z6NO!WZ+;J1 M?HP9W%/=5501@'8;A\R/ID$(>_,#G\M/71^;[/QD='"['H]C0(=HP1PX"CX7 MSIFWSA]4NLLYG[C)//U((%1IF7N.J SPP8W= _[EKZ,]W,_BZ!^GDV@Q M]=PHI@]/C26L&PSQW<]D=8;#/4_"^Q^G'?&WQ%S\>X6+LK*7T:*&%<7!0@WW MHO(Y&=LVM"I#GR5Q\"SHE\A>W&5K4-EZ[=5\1-+N"NXB/ZS!E9O0^#&#^LHK M4!:"C^!5OH JD+_R<]A?\T7,YS<\A.5-P^Y87>/W\-SXC<./8<'8C8Q[%AEL ML0A<2E/*.L"=&U>^\1_F)RQ\ $9(/^[!]F?<^#G Q*9@FB4T1?@'?G,9S!?, M?\#UPN .LY[@0_Z=.PGR9'R*&4[>+)O=AIS/L=W<#8_O.??+B_@3XSJ(W= - MHM*.STX+?YV^-D%Z\9#?/)0>BF;,\PSHT $/ M7W\Y<_G4>"<.<,>-J^D45@E!JA@AOT4HE->#!>"6V:TX%*X0++@02*(K.#X+ MG[C!1 Q)R@ LX$M98MP1-]85'P[."Z14\Z\O0!)B8= BYME59+ URP?&CVG; M"_: _RG"[,OUJP%-&\8]PO;]9(Z/D<"$(\_AR9GW@!_APO0J^$F??L'$U]DI M<3/I7N#*00]R*CA%IQN:]8C#X&/8Z9L'SD+ H)C[.& J!7<=#ITO8[8+&(#O M=OV$XT\1"SCMD!7V![\W\#5 E: + D+C33,ZW=)>\4JYCX+;@-U4KVK\M])A M) K6PMFRMP>TU=D.>%SA,)L ZE3D) MN"O1,[)+:/3*[@$S&0V,21+B0X3=1)_X;>1^%XB!()K BKEPZPKA-J+GD%*) MTUR!;*)OY9=56".KO_61V2"9!I$K^/2]B_A9$40"PP5QD;1=PLH$T0,P\W9XW&YMBR*SB8R\(2 M-H*!GR"L8^-5YWS8Z1>P$5@>N40$CXYCM,] U6;P.9N#H0D<,.6.%?E-6T%4 M>87](@;=/JSE> DQ:&9X010AGX8[ -4]DBK(*PN'%9T;B-)RY[B)&?<04D)$ MPP_%2,/E0]5H/X0@#&[-#V*@(51G0)>1ND>-CB"< LCY;_$REB <(93P)RD6 MQ )K%D$(G'U)A=[(I'G$A[%*!V_7H;%CMKM#KT<;KHM'3&_AT%CANMCSG=4 M?05\=PW$1IPP ZO.OXAN@'T7KC1BLC_?Q_(L)PNH-+6Y_TK =UT.XC'Z$9:U MC^X6'@#I47@+^L7E+'1!"XB,7]F"X7]1Q($V*^NARK\EW>T"]%;/L 9%OT.Z M=EFM*6J5N8:&"A6^.7TA*3R&T'B6K!5AJ-UP ^V0WL#L=3LYOST3_QQU![V_ M]4CG%C8*6:8%HXW_E8!6E)INKA^!9N()\^V&W[J^+XW&WUEF[M-)\[_[*VUA M8-I52S@W^)8LX1()"@43?G"1W"91;-C"J;#J35.IMM:\,4(U1BHF!4T2C6S0 M]M%**5T::%AOA1H_!:L%0(.?T6;ROP>E.W+]NP",E17*;-'82P>Q#4<52^]= M$L)"2S=&*E;F Q**+2&0P9DS2S=$YP5U<"%T<.^A1M=JU>=]P.[VJX)WQ+(? M=?7@AVX4):@!(UJ/;>%12JT'H:+'P4DM*S&-R\]B>,7;>G9B(K-!,@%=7.@& MN>(1\D64\,]7RJ52T8$V2A9)"0X*!S PR+PKV ME'S&!-T*K)MSZ6BA7PB83YD;&G,6?@/;A'Z'#(%>1R\WYX67 WG@0W#N B#2AR*XFLS4]1Y6LC*PXK=PZA$CSR%2X!;"?B-?56&-B^R' M9Z<7$]!O)\G<^!"<&]W3UW2NW.F![@3I]KOA^-*J\Z_,S:J^/_DM.<9M$(MP M;'Y/LH!X38)L1?)2>B-#U_ #"IEY$H.D\#*76]'WO6"@^B L+R*ZP_(9R%9/ MN:406H#RG+;L^RA^2F(-SO#NRZ=^YF-[U1^9-KK8R)N2RKR2NPE80.=_C9O M3S+L%-9^W?IX4$ $(!.XW:DK[!"ZVZI ?QM6MLT\D";5EZ_V=>&VM_-VH<_Q M7#+^FCM_D9Q]YSJLU&;LU.%6SP+0J0-(350JR;;HPHX<%[%BZCH&FP!U!^%# MA1^LD ,WI)3.A4-*++DGY9(76K5_)6$1.; MY&> CTI/CP\"T8ZBZ4*=?C@8U$0"EAX:;O#0T-K@(:NSX\C#FHO:F9->]$H7 M/GK9F+?>1P]&#E_GI-_&@ZD&UC5^4>\R5:,2HS!15"Y9RUF@@L)I*!S3: 6J M%2OTWJ(B>9W<1&"?DF:&'.T#<&*Z$]N2K/IM:&:ORT,;:=BC:E^OX6I/<4)K M+V9[7LRNJEZV@S=[M^_LL^0"K4UAU9?3C'JZG ^UJ4.3>_ Y<,0/[K? 8\2< MPPD+&?DRKSF:*N@P0"'XB&=3>L3(ZQ1,_ 3-*"Z9C^7^J0!E+QCZ6EP)YL(_LT.,BZDA'0P4KN& MGC3&KS'(T&G3?]7NX%'(F$0!\8[_8*N6ZJ'ZMR$7)P),GHL!Z)5:R MBI$4%O\W>L'FS/6KJ8Q(]$$"ZKW';]&#(PS>=:J;+GLXNK('G3N@M>X6_"^U MD3I*R[2Z0]L:];H5Y\C6TR\.35=N5F$MQHBW2,%?D7%/CM1K'MZZ)*CCB&'D ME-37+'0OA)3\Z@_TK.?E >7K;L_'M2+=O>Z,9OD %*FFB)V0JM[#4JKG<@' MNZN2OQ=D,ZHE^)6;Q@DK"P#_@4=N7<=8>.CK1HA&D1O%N!!(=Z$S(_- 7@." M>>KZH&^1(AV 2.-B09_S24U*Y4T2@:8=1;3X":T.;&N!G LTG)L_A7)>G\-; MHC7T%4H&5YM!CIG(A8Q;?-$R--/H4R7LM#?< )O!-KM=,!\**0"D%%883;;! MVFSS5C>=Z>BRW&.;))!'(J$E!QTS?NI \BY;C@2L-@S+[ M,)=8S\JL<[$'- ^D'8&^9I%L(Y)LLA*)4J!\A2$AH(M!:%&'P'S?Q=Q@5+CK MGL^2JRV[_A<5,V4IY6503)A^90V$>4L%1&1*$W2%;2--('F >S(,'&0]CQL: M1@6#I)6';,4KYB$M@>@>4Z+(VB$/ 7/P963Z97RQ7%(D;J)H<&&+\\92#%;& M*6!SE%"D'0'/=@0@=FR1BY,GA#W-%9!2=Q.),9NY #H;N *^3'-8:G&SD:3 MQ9HJ"UQ96EK29E85_MEIR+*!*0\BN4AXB#&WJ&=V!IW79NNY18\GB(+5 MN4G MOV.3/)(K3>Y97 4J&,\LK MO[:(=:1;W- !3S=8/&;5H=^U2]MM03AG:[L4C[@17D*W/B_Q\5A$M[_?S5\X M3KE2GAS/CA,FQ0"_Y[(;UW-1]Q?)A"$6G8-TD0;!3QL"8--JD"A^CI7T+A:G4P/G52>&G6J3ZUN=O4$ M7KHUO!NDOET, SY8BD;COAU*;N7*-5ZI@U?#@\.KIPYFLZQQ;0L>I8:P-2E+ M1/YE_3FE[Z!(,&Y@:K#C#%YP8W.A#D M :1'!X"[7EFR.$!K&=US8ZE^#S8[0=Y[%CM.+QL\S25O*A%[%>-:&IJLSKC MX)N0T*K/C^Z;W?%.N84ZUZD'HK^$@>CCOCG:[01?U>>AI_)O&P_ <=CBEY7, M*DRI^^.CL77IVE-F)#\'NFV*R^:=<;L\71O3AY][/A6Y(';-M_8@UE6ABMIY MH7O=S/&2: N3.(^11'?J&]MP N=N**)IQ67;.:&'9\T7@PA9;<*@-B*]]-12 M0\1&(])%?G_2Z,VHK?0\:?:OZK;1GN,7^A9H@:%I=570S?9%O(W,V0[V8%3\N[.Y19:&D9S4W@35YP'8UN>:9"R[/> M2-7^7"4"N. M*UL."Z>/K&)*7[DN9M+%3+*8J??8T#5ZKML9]KOCI8BE+GHZM(J"$^6BAJI# M3%<]*9Y.=7@(I*N>MM5$1D.S,U0\ZWL_R5/;IG@=7O)42Z5030)6[=RGIV1; M[J_FJOWSJ<@!]Z%SJ$(1C21['TY"T5[)4]%D;]7)L]\S[9&]!_VD';+8=\9W M^YZ6Y[J4'U4MGG-\M56+)Z7AJ6Y]O(RT:M5O004-:%^$VTA*]>&4NQTE_KZ, ME&K5;Z';L\QNOZ^ IK8;\GTI*=4Z 4\GX.F,ZO:S@XN1X;1&M5L=ZW4VT6G7 M3^AM0@=&ZGW+;V(SIW'U$JY/=,;U'D;1R%M^A/DK'\NY\HU?^$THIBCVZX9L MT1!M( 3FRL&FL\ ##30R\+_8^2*&=E^904:Z&X:.+#/B>4[:>(70]2+:=0P[C683EW8:W7:._S. MC2,C2FXB=^("SB!8Y=S'>,9B(^0+]D#CPM@MPZ' QB+D;_AW-Z*W38#\L\DQ M-P_EM<5.\H%C-)8UG?&8HP:\/5J(86>)'[N>&$Z)-V&PJ/!8<6V$DY=,<%ZS M,4U@P9IIC\&""S2-SHU?TE&7^0S+TC%Q37KM\ND 1(L@).CC$AQ6SN94.@5. M*%>A?;M^'."@YCATG<)HYC7WG\]B%&.JX>1LB_ZIP/"@-H:7QS<=AM M&=8KY]@^MH'( %:*]P ?77V^_)U^*B9*P]M'G4'Q]<4!A$P,$8)?BLF^+JWD M1XB3L-8-36+U'A"F%]>71F_8>6-WWG3[Q?FH%U$ZJBX#*<$?)Z/Z 6R1!$O( M)WR^H%7%X-TB5J2SY<4P1 $=-Z*MX>%$2\EF(4H,!7SQ7/Q<;KN:C13R9B=GD'HLB=^KB7%ZX,+SEPO@I(I,ESHL4$"2AD:;Q77Z^ M$G47+*W"D'.K2L.LS%)9QH,I9UZ6$*SRS/D6=W[H5Y,OT(378YW""_R*,V"Q M<+V_LP'$XL3GQOVH$[04J(Q#9N'^T.-T[@&=(J<-$S.2TE7. M^<9QJ8/AV.P.+?P&WK'@#HWQ3-6"Q%\P%_@_\P"9S1Q9D4UF\@D6CV8@8J9 M#5%)JTA\L85)QK)"[LYODC 2!\R1CT!CF5;7-NW18&N!(X;_5B3,"DHH$K0< MH4XP@3/1KN!$>%=R&GR$KR'&[H$2 P(@>V%Y9S4B"!\HB*&@+._P!5(,3=SI M%! $9\\#T,0+X/B)%Q/2E' )Q4-(:A7LAQ:EBXURA%J^8\OLVI8Y+M]R.HHZ MEW/J#L'5@ST/W9K2@J0D2#85%FP+<9%.K$^3^)9$Q5L0%9>S$(P#$!6_@H&% M_]U,3.!D=1!XHV%G/X)"0,.VQN9PU&M?.@2PH6,2"/:H;PY!=2G?Y7;BH/:/ MO_^81&]N&5O\]$DHI1]1)_V<+QJ]!8,&-@I,ZC.P@I\] -(__^?D[^G/KA%J MT@_Q[J_$C1\^!#&O^1'JP"+K46HO?'S_ M^>(WX_KSU>6O;:I3J_:]1UL/N=H%!AD\P;C?^W"S"WFY!DN QX:ISR/E;,"2 MB"<:?1,($/^OP/D7(0<6B8)2,%HI_, &SGU%P/+A1V"GH:CIUJU2DAB/+'%> M=[\?@D?V,V-WW+CAW!=GF)C&++CG8+F7I3UZ%&Z!IR!CMVF'Y \$V<.C.%LL M(%$?2>\4-Q9)Z, O<8?Y=N3/\RU=<_2'&A=H/411CN'%@1.?&&;SU)T/02A= X07WKQ7T0H V MAN:\W4L=-47ZOHHOP3AN<(-G2D54]<''<=%10W]E4+WPI_C"R+A0 :RS)$; M_@P#1ON%G;+)GTF4NU'KSXF>S*GP5I?@YE#D(%.4IFX8H<_](457\8%$1""W M"#7E":BT4H=,3RN/(G<P#NL?6G#A++=EM^Y%V"?E3U0FQS?IS1&GD$UA;T79NS[UD&J,^FO?#E7HN METQ;R/V"0QA1#.0=*H-WJ,XM/$!L(2Q)HI.'R&$1QID#A_-)M,*+TNZ)*8XQ MZ)ECRUKOPU8@Z+6$P,-J6E?]4W5HOOS4H/+4EIA;MD\DFM@CV^SGQ@4H0'R^ M\(('CL>](1UY3LM$:1H(ZCX,$4&6/>J8--A@A$P#ISD6E(<2=@.)7 MU9&78S0E+QPHV+FRN*DO#DP2CY.&G+OCC(H_3M(#:N!HTT2I;PY?6ZNRJ8A1 M@\XFN#*P-GJJBIU-8-12K"_'DYJ\C]Q3>A:]+EZ(-$\%9R+7IHD6?[=G(Y)B M<+0^)OIX-+28.=&:0[AQ?S![2HA010QOA(.58P<;8EL)U1!./6MH]D>4SK$F MG+("PV08Y3@P;.N(@XK8U7KP[\J) \)7Z7&JG4T)Z@9+2]\'B33FTA0PZ7/*W=CH,0%J =KOFX-N M7WK=RBRZD+LG^/&P-SR7OD*P!OT\"Q-W,^->1I: (1&/TE^N=U\BUJ#_S@]B MXX''PH^'+DT7>49Y\S_(1$C@#7 S>"M+H,Z84Y[(2:B$_C)5R3TAJ5+ ]D>\ MY;3!1%%K E,)F"\R#04[Z96EW]3UR%.-3E)WZCKRCHIGS_C*-7< UW M!$=< MR,O-_OC []B$U7*6BCPKO>^D],*("WM2OI;**>&<(H+"LV1(-$)A][>":IE! M:9?+*%X)O-3N[1J=S>+W6>[S1.X(P2-2=T]7HR*%&8D1+)W;C MA/*MA4];+)*]IQIVJMT@@BS-OG\L\XQ'_LE\2^1;S\GX&;@*IX,.)34,E.Q);@H$?JKQ^KUD3X!5N3T M5:3Q,=Z!+-^?K$;):E"S]I8VQ+_2B2L12&)!E4R4B8OE!S=)RI_A.GD>W>%W MA618S_TK<2?$7$S\711X\F[@<5_PO1#6S_X492E8 M"4*/53=$&J[85#6@"@>]%84IQ;*:0O1V$5#PMK@[?)Q-T1J)EL7FFF2;C;-F MBJDV^==74]PY]R,"H23B*&&4LB\B M!WZ/BIYDPO@F_N#N17&'GX;H247)C"50"G"/0EYYPEX\"SE_0Q76L!/0>*DL.D@K=]'? M3:(H=4)6J@26L+=?I80E3R4:[*@IN[Y(',.P9Q:UXN%<" %XG1"49L'9*DI) MEXZ&,HG+Y#/?* Y P@?&6;'XLD?6C#)54@/5Q9$7B*1U#AK##=7>EY_.&J@,"6+3%\#8;2#M,P(8<\:]@':(AI#Z?"65;TH%.\T*0%*4_& M>R@;)"*!AD@K^TU6^%Q].[MG^*SX0\:S*.X01?-"#(0\AR(&3QE-(I6)%BMY M&),H3:7ZV0/8O+EV9@'5Y E=!_D"/C /)MP3^0>%Y5##**_FIR['\FKT:K4;:$%Y0!(OM83410$,$O:P,+;F(*HB&&'P2TJU9&?Y/\V7Y=#<-^6%SA M3NB^!(M1(H>_%K% _PD<)L/U!?_,E O=YI4UZIF#7H\H^)5EVV:_URU6H0G/ MRII\4?JU\*WDN=_>0[E%7#WHZNEAS;9/C%?]?M<<=SMBWW:O;W9& [EO)6YC MTU3;5: K)!QBLQ*0 Y+WURR1-=6JR1]\2_JP2*U=EQ:YG.MF%C/M1-?%]"I2 M2STZ-]Z#.)U,7&&85QR!>6HEOJ6DG5>2+;'_7UKS:=+;BK&N,G=$)UDF;["6 MXOL"M7E\A^L;XPY6O6:Z>Z$<(=M-^EYJ#KF6<1YK:S]23@*@M7LB=\J]!*5B MSK"30%2J<\9L5Q[ZE*15NHI* ')%:BNA8L71.OQ)42%%N8JK@KH_/9[.J$2D M\3CZJC]B"2K:3C[-)I;]ZX^PUJNP!59:DZB%@RM8S^C0+/32ZL/?.0H7^MFT:UFYV4\EF M.P0:U5B[!SSY+WT":'(!YV>WW'B7^FL_HJ-5#61^I=%7HZ]FNAIKCP1K-=/= MFUXOD64D!E&J/&7[JNCGQ&K 6]?W9?]"]#)CKL<3K8#28-\#&+6]NYUL/W"Z M]:FNHNJH(6)4[P8T#AX #F+EV-%BX',DP6/O/6EZ5O@.47#KB=G'P0;5N8%= M(>'A0. <' ';+ M^+>G*+L*1>!L%\MI:F=-*&E/(8: M#2#"&^54E$;10*.?1K_] /\Y(F"_RDECZ-> ;:/33Z*<\^CU3-=XF MS>, ',GOJ.1O8F3=])O1G)N$4IOZ3/,)6FJY#]L_WP%P'D22DQHL40J)E=J, MIBA-44] $E5PN'%!WJ;2>6 $M;4BJPEJ5VHPF*$U0RA)4PR9H3_60 M327IGV;/4.>M79B:SX&&VHIQ;R593H+DQN.*^>/W<,!#R=#=4#_>*RHKM1E- M5\=&5^T57ZB"R(W+;K65Y/U250M:LHI4U68]B5*HK-1F-%T=&UVU5R/3#B(7 M+= ?J<_A9L:@.MWT]12'IL9UJ'.G>D*".L/,L*DM P2@;OFP$\P1D+UJ:1 E M-O^7?3[$3$UT[GCNE)KS=\[[PW3^SZ-#E+I=@:B(GBNG[FV.R@5(G.R@F>UE M87R);F"K&]CFU*B[+QYE2Z5]=R75#6PUJN@&MIJ%'C!=[+LKG=#9-E71=KL7 MW3]18ZKNGZC1]RC15S-:C:F'@:F:T>I&M5N-6?PZ\[[UK7YWV.WT>Q6'I6YH MV\).#J 8W#)[8N1U.TDMNB>!1L-:-#SOVT>+@;HN7->%:_33Z*<>^ITTFY*C M>]GN7#O95SVT2K7+K5=Q]155D1M%!HV$:B.A=7[$&*B[BAY 5]%=^0K4N02- MAH> ALW["G1_6]W?]D"<20?@S#O>!J,:_33Z:4^>]N2IY\G3Z*?1[Z#13_>W MU?UM%>H%IGIOE!?0ZTSQ;IR:H#1!:8+:9S?.$Y5+D'I_K:ZO^W!=39[H7TX+7/<9E*64MBLU&8T:1T=:9WK#K>Z$Z4PF:E-J-)Z^A(J[5\0)6:W.KVI[K]Z58MO93NO-H_[_1K.Z\VTE2U MD4.6\-N-866G@M]Y%PS<2K5GK-7M5'HPU#]E;?2477GJ#^8EA'O&110E!O,%\Q\,YCCP7!S!(J$1S5C(W]RP"+!TP1X092-C MD811 LS!B /CXOK2&%HCTSB]QJ8\M KW(P+Q*>#RQ*0%0Y0'WH-)SK/T32$R M@DED.(7?&/P[_ILOO9W=,WQ6_)$LX$DDE"CB482[2OMQW&*UH3%A,:S W! % M6"(7H_VEI)9$2%;XBY\]@,V;:V<&2!/)[XU%Z"+C->;!A'OG!L*GL!R\J[(: M2(ZP9C7Z.9SSK\0-\4_F UG3=@%T<_:-XPE2+(3G;AD!"EX?_,D=[&'#YPLO M>."\]$( DNQH<\.!9[A!"% !;#TW?DBA M)&_@AT@NB\=%SC,A\-.+ <%=$(<38#2(^XA1&26]9%(1:+X:94MXX4:$Y+<^ MK ]L_DXBR1U<#ETS>9'32R$,;P+:)SN77]/ \X)[HB#J0;T ="/6@.< "KSE MZ:'NTV9,J4PKDU$*J%M1)$PH2&MP0%G\NT >"5*^ZZ\DLRKXQ:+13VJA[.I> MP*$+"UT8'T,^Y2$FM5UGCI;/9@]&CQYM_U'A]GK%74D&N*J3@AJ]R]-3L^:'9,+_GD M1M^,9;=4 7=O=HZ[FQZZ.=SMG%O6_VJV>^AL]X_,:TU/.^,B\JP M98W/1UUCQTBL.?#NC_Q6>O*-!Y=[DP(B3QI&9+5\,DTR\UTK(H? R_4I$&B42:59Y5I;'Z+8:#=8AK(U"6"?*Q+ .J07)=OK2T#H@?:G5 M&!9EZ&B=JF'*..B T1IB4<%*!D.@.RH:R9WSL=W7%O(!,_@V0T9;8WC[IJZ. M&1T/4XB9B#HQEE:'.8$?P2)8-'COQC/X(>H-UB*=J<:JVR?4^9 WN.C"B!4[.H4JX&MP!; GITX@1.Q;$# MMZB#0Y]N1"575BE2D2,5;HO24A10* A0@D&;PD/=-#Q:JK7'WDY(, MI"-@K9\?Q.*Z0 #EM6J$828"LEC\.F/B>7@?O-Z-9ECMEB^\ ('E/!!8\%>$ M&.>/1[32/_[^8Q*]N65L\=-;-W*\ ,[/KZ;%PMQ/HKKN,HCBZ!IK;']&$'Z4 M];V?@3A_]N!]__R?D[^G2UWS6_SR$U\$(2)#OG3V.%T6_/&)3_]Q>BG^_77\ M^[NO'>OK?YC_U>Y8H\^=SE?QO\]77[N=K]=\4?[\])\%9J(EPY%(AK9#T!\" M($BK9[PQKM_]Z_=W'SX;G]Y]O/KT^?V'?]6))74$UP\HG[B J.!NCL>BR)VZ MQ$^01]T'1DA42%PK$G09";&P" /D'\!&IE-@03Y],DD<^!Z+8WEXYSH<) .0 M'2.F5:A(3\6<7%'4+E/A.H@&[K $>#@]<(.U\SS"JG>7'HN2&ZQ6)R&:O7C. MPF\<.859.)%)T@%P^1XX,-7Z->L*!W SK"[FY!HB[SO#V@ MT[YQPP.B-*Z=(/;@:H28_IS?3]W;71\$J'PYBBF062!C M4%> #> #L"-0M'C,0 1G=^U*+2'QA*CUJ!5$$H;XPS!X8%[\D"X-4O*>>QY) MSWPO# Q]0, I1V3^*(K/895[3B03^-Z#V"8N6-PCPN'+K[*C1(Z6!>EN_#?5 MF>! @-N TS="(W3@1X#RH,$)Q0@O3VR/7IKJ$/!C/!N^R9DQEZYB&?0:KV<\ M%(#S ^';?9,B6,1039\%]X#:H5E1E)'] 4;-$:'D!<(=9UQP$HBF(:"+1,CT M?,,!LYFN(;UMT"11P9YQAHCO> EUW "=5ZCFQ+SP!D$OFTYQ,RQHBX,-$L\B Q10;#]0K? =/:65@DZZ4J!OP(HV;MNT M"]^+,VGC:'13!US=;6[U2UIT8)YB9C56J.2'OPT[;_^XO8FR9UK![ MH*C=GI71?B$%7X3<<47N;)8A8K Y9EC^'WW?(K?VJ:JJC=@.JVHZ/V#?MKGJ: MFL9LC=G/KP@W[5'37J.V4/N(0QT?>&R<_19$T6N9(9\EQ>OHAZ+$KKZ'N&?V MNI9R"IJ.?6C,?NX1SZR>.>RKC=L[./;:_#_M?FZ'9$YVH?KMFF:Z0]OL#=9V M8]NK!UH3S>$ 5@5S:>)MFU_:07X\#O*SP7CM M,-Z]NL<5%+::7EXNO32=]J-C2=KCOO\CGO4'MG+JH^)20-/+"Z87R[3[ZAE< M>Z68(PY\7401CW602U5^H7XH8-0WQQVU(P$ZRJ51^TG)&E;?M$?JI=CI:@C5 M<5M]S[IEC4RKTW1FM*[TT;B]_R-VK3'P[?W:,&N+K7>69K=-LQ@E8CXX0L"? MN-BR&SN5>@%LWG/OL!%\8\9)DT!I4ZW;__ 7%5C.UJKB48"M)7^\4J2AU&8T MG6HZU71:JPW2->3 M ?2 H"VU:SW#XM@P]0@'!)UH;#U6;-43@C2^'A*^Z@E!ZJJ_>HZ)AHZ&CH;. M;J!SQ-5#>D*0VKFZZM=8]#NF-5*O38,N']*H_>PT].-%:UU=H4S*AYX.I+%: M8W43>HAMJ=>86T\'TM.!GG09*E"]^BVO;',X4*^^NU$,TYC](C';ZIK];M,E ML.J@MNY0]434/CF"%E56Q[2LIMFVG@]T\+A]!*AM#\Q>1^WN:RJ8(7H^T/YU M--5]#NH[B,^ V@=VTX/NE+_9MGM4:Y(Y(I*QQN:X-]8DHSW;:I",^I[MLUYG M:([LIFE&^:O5-*-IYNDTT^^!(=9T6UOEKU:5-MBMAYGTW*%#\>&H[WH_L\W^ M0+V.V#L^M9X\I"E&E90B':?2OOS]'_%LU!\JIT J+@4TO;PP>CDI37LU>PKF MX.V59(XXIJ9'#RGMI5$_&# :FMU1T\/]U"FRT*C]U< M5UC/VSW;[EM-9SWH*B*-VOL_8A=PVQH=*F[KP4-Z\%"ZDZ/H)*X'FJCLCE>* M-)3:C*933:>:3FO5(*4VH^E4#S11IV.&4J2AU&8TG6HZ?6ETNMG@H2,=%7)R MO+-"6O&,/-)1=^>5EJZ_;A3.:'D4COSW8YV BW_HJ2IZJLIZ(H!W,,-GUJ*QNO;*3S1:;Z6,V'W3[JO7)UF/:]'C6IYT M&2J0O?I]@@9F;ZQ>[]=&,4QC]HO$["Y.(NH?+6KKMCX*ZVH[/B+ZC0YVI(5& M;8W:CPR-')B=X:$.(CKB:(>>UG)PKC3UG<1G?7-LJ=UM:@>GUL-:-,4\8UB+ M98X[/4TS+]FUK1+-J._9/NN:'0LD3;]I2:/\Y6JJT53S#*JQK:XY'*C7/5A/ M;-$36X[:^[Y^HK3Z[O>SP5@]+77'9]8#6U25M^K3BQ[8HMWYQ^?./[/,X5B] MF7^*RP%-,2^88FRS-VHZ;4'YBU7%YFH]KH;O2)N=?)UYW_JV;8]L:S3*OA7] M3O1D%Z7].>I'#D9]<]SX]%UU*C(T:K]WM1M>875PY[@] M,JV.>OJ@QFV-V\^O?QX#WU8OC_7%EQRU,<5%N[G5U-6TFUO7&FFLUEC])/WL M1/NBC\D7K5ZK QV3U%C]4K'Z18^?./[I$S677\31G1=XK1\2,:P=$K';\-A& M;?Z+?^@Y%'H.14-HI=M&K[L0/3U"N1;6&E/U] B-K!I9]?0(C:_'@:]Z>D0; M>O#3M%_=XUY#1T-'0V59M3W;)]99A>G1XSV:S&=:++19'-89-,;C\QA5^V84.M4<\2A)CT^ MXE <.>J[W\^ZYJ#Q<++R%ZOG1VB*426O2,>JM$-__T<\PVF7ZLWM4UP.:(IY MP133-_NVV@/4C]CH:CVRIN="*.VH43\F,!J:W9':,]@/H8I(H[9ZJ&U;]E%7 MR&G_NL)JWN[9=M]2+]-)H[9&[6>G7@-N6PIF\;522[1-.QHEHCXK9T6<-#@L MHDFHM*G5-=^7Z1"=)EMKBDI-1F-)WN6H4_ M"K"UU#A#*=)0:C.:3C6=OC0Z?63F2GK$O_^81&]N&5O\=,UOY]R//_$%-M?P M;]^ZD>,%$5C&GV'[/WN!\^V?_W/R]^SQY";B?R7PBW=W\/^B["'# ;C"'Y_X M]!^GE^+?7\>_O_O:L;[^A_E?[8XU^MSI?!7_^WSUM=OY>LT7Y<]/_RFOMNZ: M7^B0&%I0_4DPZ2WMV;VSJA_SAR#F0);&&^/ZR\_7[_Z?+^\^?#;>_0'__WJ) M]"=KY]ILTH#\SR2*W>E#,_ZJZ90[L7O'C2LG#FBZ#0VW&9G&V_#N)I.78=O!#[E@&-\<+\%'B-<"2YK.CA= \+^4%,C\/GB1?CC^%'QL2-V&W(.=O84W@G84";!.VZ+F.B^!9A Q.ZP#L<$LX(N#>C7AY-["RYY&$8++ S&-Z&"Y@%B01!^9U MR_ 5B1]QKVULD85@")(/S$6P!:G##A3N!Q?"!GP, $5Y&>JMP_L4B M<$%^3PB$L&H4,P0_7"G/UNBVKOR,/*VQH,_BKG^(GG@UIG'Y M[LHL@+Q$L@#3RQES03WP5\-T+]C[!&FK%<)#4 A5(Z PP)GP^.0MH(H01" 1 M@'CPGY;9[W1,0"?8/EHU[![6B/!^G!E8:A'2'@@E_/F$@4H)/Z%E3**SPD+# M;*%)^O8?Y)K!@A@PR1[^G8<.R"N#Q3D%&*\ZY\.. >+.B&8LY/+UZ>]P&R2: M@^)V\<$(]R:.A;L3FUIZAC-8[($SDGPA9U.@!MI,8?O3((&_P5K%5\)'^'@] M8U""E7Z 2R5!80U37:>,"[ 8NQ5:!IQV#KH*(A4&*!C'[AE D-0OO 3&,.^+]MBW>?T"@VAY2%8T-0?5O$. >' V =(WZ M&@=1U" ,&C$-*PJS9==!Q;9JH2)L@'QD6FH$K#/ JNKTJG4$^XAR.!,-"UVU MO).;D.@7D.X:U7QD"-USBW[?/;>%5&>@MJ(^ KK97YM%]FU!:$+D&">]V#0 M%"38**@5@7&Q"%W/L 8$@IYQAAN:B\&J9!P@@&E'\%\3?N)X"6KF)N%!D,2& MY\[=F&2#:5Q,0.9.DCDPH/S?-FTT^Q,L$Y AGK!7O =!M:=U>SY]?5Y@D)\+ M2B3((\]%6*-:CQD=N 98&P#6B836&8]>H_:.W\3<-\ZLSFO@D _(8MU -[S M "_2@XJ?"Q:/&XXRMQ> C#D.3IF=I.9,9N8@(R"K0R !SPRQ)>PJGN67)$0^ M;"+OSOA(;QD+:5-3%]Y;?(G4XE)2E=LHH<"%\U?BIBB8X< -C^\YP**X&![U MWY?OC3_>7UU>?'IG?'YW^>\/5[]=_>O]NVOCM_>_O__\[FV5L][/ L2CX!ZO M .'D3ES0QDT"WJ2"4J910*G?X0)&]'G?."NB@<""XK9+:* $SRABX P.Q>^8 ME]")W #VZ 1_J 5]&,,P2&YGN49!5X=_33.' VCY,9T> MH W$:H#%E"!/AMN:<''SA(WBA_ Z@Q^4)3?RYL":ID(7R]?!FGM'P6G\2HO M<-%5C%2,_GQ"RH]HKS^TZ"U>Q@1US(7<4?F8K4#.RR,W%CZ"J>^X"^81(RMA MS'9DKB]7O#G!' [H2(T/ MI"; (1'J%*SNN:"G3%+5*T?Z]6_%H;:H/8)6YZ"^CZZ]T)$OE;J"]*(B]C.I M[L\8J)0WJ+MQU+?)0%LMPG.I_9A +@KNGUGD1E?3"W&#@,_B62W"-9>O80V$ M+4CEZ'(&D+\ X?T"&+Z6W4=SE2B[2;*XA\*6P MFP#D#-JV)&L6(5^P4$K4A:!U\ANA(, 5,")*_D"6"0YXCO1[#V[MEOL\))=3 MYC^1'IDO/NWH&A4))6LEBGZP, $RDCX:>_P&. !F_^ M'^%RPB0K6'-$"@F_33RQQ/6;__?<*(*H_DW+8,#7X]$GV#9N N(ZPN!;E*"# MN.A]J>YW&@2QC]DHDRS3*I+X +"1*A3!IE;'RMX/#R"@PPEY%!H ?*Y6Y*?" MD#I<;%S_OC#QI'X29@#-/%+7W$DP\T(^\>Z[ [1S2TK5'#0H>)3@'M5!OD:G MA ,8;(*^.KG2R8 MJ@![]#A#[^:6#B?- 97C@%J8'N19*I;^ M3'Q')"#EF46IW[J6\I%3(7..A".5!%#.D,L+I._^-4LBF@)'E[%20[BX,W]^ MUY)VY=3UA/! [W<:@CL'B801C]R=/PNYB#SXKL^-.0!]%LDUKY&'BT4[,DH@ M_+UQQNQ9\)"I%1$R5SF M39'<8R)M1\A#5"/P)?/,52W:/TB_+KMQO=R"R>TU?% D$]]2AN6*W\2E-+%5 MUH:9I)0"^+YU+TET6S"W^"_WD'EW7'/#RL M]B%K>5[#,Q!+1/HV_J. +UH:'/C-:L%^-%>9$:F#_^ YD68^.OJ"G*7^Q#0F MG!(?2=+?,/];)(3\'(\E)"1)131TI7T+)BA(=RD1T>$W ^""S!(15E@',Y]E M'A1EXJ+=F_@XOR-TR8H56='XGDG([C&5.3222"9"B]^0FS--@-Q@-QM%5C<1 M=D7I^$L0 N+XEU2O \\4PKNP#OTIW:FM2TQU**_5JHK5=:NJT^6^2FHE#AL2 MB=UZ,WQ_^=YBO@]HV=&2$V]]*@LP@S3-NEJPABRMF*1"7&C.&5H&$^ VJ6KN M2.).UP#[98YQ"+A-/YB[CL'].S<,?+)>8&.RN ">Q'H]L(E$O2.\X P__&$J MG9E89BB7_F%54O0/4<$RR#;BBG+.+^?7Y\8D\#P6%GZ>_PO7J7D9GJ-T[AL6 M%6))OQJ4ZIY@MC0P H\*!:1ELV(U^"I_:[[S/(DX_[;TKG\!EW9X>IQW21B( M7)I2EHR@$1FY^HC[DH$H>)RN+)9<-DU^+X EJHMVY5Y+C)CY$RH,N@PFE+U# MIN[9Z<7UY>EK8]3MO$'?[&F!D>-Y\Q+BZ]S\.T6A-877(B=J-;=Y!5UO6HE' MG26,I\H,1?I^T%^$_"*D.I)E?U"I'L $ M%'T46(_T=='ZF];?'D5;Z\OUVW]TSD<#J]]]]^63:<@/AH.A/?K7SQ^-L^6P MXFLRF]K7V=*]=GO#TE9[5D=L=2FJ^KIVDUJ8:6'6K# [.FD&AE$PKT07ED49 M@_VS6TP6D#ER5Q42GIYA PW?@%\TT+%S'."0< MQD J);B,>H-ZN*3B$U^4;E?+4BU+=RQ+CTZ88L1"A-W1YLN$I0BQD,K K.!UE$?!Z0&@%-&O!F,O<4UC*RU9 M7XQDW;-;_:*0B0^P("<'Y9"(^H="_(I0ONA_9XZ3S!.A6ZY&?N/,"R+1M(.: M)LT";\*QA=)*W'\\0O?D@%LQ:O=)).-\$@2\E[8&FF /E&#;]N)+7#4*R*I@ M>"[O50KDD6!TS*KIWV6P24#9@!?7E\:@,S#$CD>V!:B1'I38#](<]O"2N0:7 MP*2 F831N?'%Q](?N4!Y]4P@1UFZ7=:QA4J_0Q$=9)[($EB$P21Q,',/B!^Y M5K$EEG -.]D^X@ S\Y XC87K!6@#)!.*GCU0J=M#&BX4(2#\*XHY8NF9!>P/ M2=B=/J11RT*#,F8X\G1_,\[LRJ/RE>1<#FZ(*F10K+02_++[.N\A(TH/Q%(9_W7.>PST%/"XJ-K17 5L1MA M*Z1SK,)(+TJDG-YE%0EFMN9,]I^EZC91128+&=.>L'11-X4*(W'[2Y<^1;J[PZO)2A=#=-"DQ9T9]F">"[9K [5:=#(*'(K13@1R M4"\'RD>E3%[.): 6S)T0#N<+N5A4\[W2F @U3WG=O=?RIJC3DXB=9-%Q7)F@ MQ:( ?_1 J;MA76>#G9OKNA6I%LM-(-+GQX5,Q@XX"WVX "SN#;" "PD!^1E@ MA_#-;L,/L*K6+5;]$CT+;VWZ9MQ,*/5Q;/3YD5 >_^\J:U4"P'$CJIV;4=ES M$,%6P?#.Q!^QK*DH#J;6>U+6FCC! HP -_9XGMON1M_24F'14A7VCPU?PFCF M+G*?LRP_A[U*]E6L2\X8&.4'RA(!( MCBCV&LGM9_>$G77=228Z4UE_$/R[N(^LWZHZ3+V]'.3#Y>B?J?.AF#1@N$ $ M3IQV:EY7](MM5PMC"=#80(KX'"R SM#>2(MCMRW+A0?1O[Y)"O%:WT+1$?'> MQ[:+0:A[,NEZFCI:R/#CN(LN7L)5Z@*:H[G*E"JQL6%^K2+M&S/207M/BUR% MXCXU0G:/)2KH(?"$^KQ@85S\.6K.),NRI$,ON!<34QS0%5$#GK/P&X]Q7@C\ M#;IKH6=PGJT^=<,(4<&4_\)NWG,>SP*I;6-7X=1Q@OX#465*K_@K@3WQT'N0 M&>%"4YT]1!BEHY$X\/(//):UIQ0=QF[)609W6G(ZJ:KQLKL/CO]!WR L%8K* M_QO<.)4*88E.L6<472_^(UTJS6LI:/3_!0R0Z"4FXPTO8 MC9P%A2HX+P!0F!FAS.D,[G@XP_8CXE+A>'3.20X8."KLSHUF0M.76>2I?I'I M_G46 ME7HH71N?%?;DP"\FDY8 (^H&(C%KT-@DF4%F&=&[_+0Q3/D.T2;T^8 M<84322S"]B&@SM,EDT4(D 9CX#QM\^<5DO/O8<\^7/^\!XXV][/$? SQ_)N*[T ^:I5I:.YRER\"5C0@KY.%*\A1C8N"/OY,T#.54!G@L9 MW 2T >D-,C%*<&E>-TII6>9M*<^*HO!B0EE2J-VAUJ?[;FC15T=F!30AZT#W MVSCT&]4R\&BNLAC-R8LS"A0KS;:I9?=<;[E9D)S>1L;A&FE7 M3N&+X* .=NMXFP>WW@GPBM]IX:B%H\B@$Z@B)N@6(J%:4A[#]6I)>3Q7V6A] MU9+P=68LO*4\B@)#**9&2 LS2,6T2)G)I'*-0/WEXOIG(56I3\@J5G-Z7L'2 M8HE6>Q5EGQX_.,K_?)^O2ANU1N:XTRN?HKV-E[)NRANS.[8Y'ECM[D=J1OF> M2$4J!',VU)7,V;9NVU3,:>NGPW'B;]QV5@U-7;K 5O"68 MKIL0MD>ZJ8Y*+4Y'#;G#79Q$_JIOF\/!P#C#XLSNV.P,!J_S_/,OOQJWZ%82 M7:+8(TPH9M\-!]B-*S.NBD=>FWNR5BDN#_:C3D&XB^3,L@!&&'@B1W1K^$9 M_AW+KV!'Y4&94R\16?!W,H C?@"J]IQ]HW3F[ "4\D"M%/%S@ BEM4?8F\2@ M AE8(F+TYSWED%8;/N;+4[)-S71P?<1X^E M);%:GFMYCK=VC?78;T1&DU- 'ET?=6@WJ27YT5PE2O)H!6&6JYUEJUGZ[!8' M5Z,8=:B-;7G*6?KSO/C5^IM!Q%_^6I1)8'O;U*E%?7"-H34Z?7U>[$JMR_&P>A&+V' Y?*Q:=;2+!GR".R_4@V#/C M,_NN37 MLFLSSZFG"B"(MK\/_C*UU#Z:JRS*1CGI3!0#R"9(,1+LX_&C'L:/ MBO1]*O,Z\B%I9']CV^I2UVIJ/Q(&6%J ;RS8RWF?>U&OG.02NW/,MFI8KAH>2U!FL<]BH[I,5QZ-XD<3H O-@][8;']SQMH;'LH!"E M$+3O?( :%<739ZLGN\%Z;BE?$W>%PG^+(U8&0'"?T4 :_)7HEII-6L7J&6S\ M@O^ K^F@$JQ2^\(9K%%Q)$0088;J'"X"RV"J#>6**]\(8(M$5*JBCV,/^Z0@ MJG$Q^PX4FLD&I\)26$/VL,.-92?%WECXTPA\]QO./4.-N-3.C'M*L+= M$E9C?4U(";TR];=N_7L7OA?M8[+Q>8]6M:O#:;6UJ^7F$5YE46[.9/D^%IYQ M#(E.70<8 $50I=L7Y,NY\3-W6!)Q,=@;^8,?& X/\6?Q@^ +]US0NB3R%=Q9 M2*ZR43UQ)\5J!6'K%CC)#?=A7W&UU8#PM6.G0YXV1Y%\C-4RPF Z18:>!N'1 M)L0!W$&,_P)16'B59E 'A]6:01W-5;[/U&2IS*'::W>L'B9%!\GM#/\8E%H; MS64G)0"N]R"9 1;4YE@!W,P7668,74O$&VY$OS]X$>FX">B*8IRAT/A(:>, M&U\J^1&69&,V3]83[X'+OGA3-U,4B[Q5],Q##H7.,%3$\$DQ<=AG7JHJOK(Z M)F ?:G]T9!-YW3T';HH\SW'"1,S9XCBM43!A]$SBKHJ#UM+UL:B:]IT71\NN M?K*-D8_=GQ " )#J/! ;JY1=_%E04F'30%UA.@\7\ZE3L'1-+#VGFOELL/2, M"=XN;T9LSB6%V4\DTY5[+4YC^R\7UYL7HLFN502),NQ& G88*R6+;\$>I."A M2K*Z8.SR164BD-&6P+:;PIV)J6L(B(@:#+B(:P!P0A=I'M QR:Y$L+S_=+U9 M17:]S['HEWPG&YM]Y"%Y.'6[W':XX^%V<=I7N]R?6>0Z(OW6]1*DUM] *R-N M1IBK8._<C0B=!V'@T$[VW5WN/[ %ZCU(J-3ZFIST_+3V3NY(6HOE# M-M'P)@/;1(*M?@= Z'_*&9 YHYD VP46C&X@R?U%PQ'1F2Z1 Q\QDI60RDN] MQ9?7!]6>=I%](UN'%S80R55$<2YE6^""Y5;C[(ZY7NIV2A,Y\/>R]W@J:P7R M\,F;="R.GY#P$6T[LE\!9T]B:O%!:2?5U-GS#-'J(%;8<.0"DC"293?E<^;/ M\^\H#841([P8.&$45(2 0E-P3NQP*#PHZ;!F?"[?.0Z72"=TE@XA#*,@\28% M;:5X,E=.-\V,D/+O47K2;]+HGC])?[+RG5101@CEWO&JH)ODK\) FWP**,7) M!CD7=G<&F$?%87BO$WX35]UXP, @FC MJE+I-SWUA,.. ;E*V5P\M< MNFJL,7^3W\5%>21%DK.")0901X:H1TD>(GUH#6>#XY(WH?%CEOFU'*F MRV;$D$)L\ QX/84(2^]=!O >=M*SJUN1!-D0%C6 ,_T.N#YF1)DX!J4\ TKP3N\G3; M"ZWVS[<#'F29XS9%H2JXW%>)L+;EV =&6%L+XB,AK%Z;XKT=7&Y:YO?@PQ.E MCA'>TAG4^4KB1PZDQ*BLZ$849KKG,P34;IWPSS,/XS.C; M%0W2H W*WJ;\*,Q;BA_25#HF$[9,S'[#<;1WZ+7-$;B0NE><5P\[N*!T2%@# M\[3J3I.F+F%_IC1=3I8*%?=33 [\(=W=F2Q >BTRYV1VGACM2YGKF/%5>LVF M'9XVD<:E%D_\%A.[/Z7WJ,6W%M^KFSH)9#$R;#EN_O\2KE3+\J.YRDR6C^R. M<2II-[Z>(&RIO0&!WSF;1&C=$T:WHF)YE$Z#+-4')0W,Z9:+LS= M#L);YKO_)]8% "0.=78HE'\MO_B6![=@6L]H0BC#Y'0SF^F9[P65B#G[$_LJ MTO!++KHBU)=#724TMQ[[6$[JUJHT2L 4--$B@'H#8,?*I4V=&]?P VKDZ%&/ MRD(2-Q[?GU#7=P%%CF^/X)%85D0 U&43R4S2.HH)GFG.'H M%SCG;8#W76HC+?IBD5*%^>L;]YW<2,,HJB2_,#?\ QMN_2ZZ9>"OM5JB9=AJ MQH=MV_Y(6[05L.;1-E;JW*3V+6A]Y BO\B)O$24'EGL Q%ON@R#$JBRP_#$- M/VLG^<6G(9K7,?4/$H:^:,DHVB_*)M%@*(M:;3'^NU!Z)MH:B8$)4QIC+3M: MP;\7S"6)+E "!!\K]+@Z8YC4Y<9BR==9CZ)TS#K-1\-CHA62<9&5PJ5Z MANLO$OA%(JOVY$]*0 NY*%:'7_Y?<<8X$U5D;VA@MS%SX5) TC]@(1UH==G? M>55GVFN:7L2^NW-J?@*;2$0F7'"#S3%E13IMB[0&0(GJDXF_]*QL1$!U;;0C M*GG?['@,55AJ5_J3YO>'QB0TOS^>J_0:'9NSHB#G-^)7EB#UY;K-+SZ;_ EV M('",OY* ^NB'U+"7*MRI"%CP7-E"$5%#F'*BC5N!?]?:-YJAJ(Z%FJ$H@ 5-%,YJ+@H%9_%,HPZEK \W!_:4^)&@V5(G!AYB@J*HAR:5 ] M&9Q*=@VBX%04)*%@J1.^X$0,:6\.Z?AZE&]JVCL$VM-L]&BNLD4VVEVME]78 M?#4?KN1T6=N:?$P$L:RH8-)FO7F68PGW^/.UW!*-RM7<4FN#AX?[FHT=RU5> M^#4D^4,DW$44)TM;[^;NH=R-Y1;X!+60#.ZQQ:3X,;:VHF@=JGJB)7E4&L^& MCL/RR@7OW+EQ(1B/4*EJ76&P"D;QA,(%BS-JPB0ZC3&*[W'QTRD8J4%8:=R8 M8.??/Y.)R+YP_6QR##7%YUC=P%YRZ%6/N/Y=X(%Y? LZ*48&L_>1UBO- M[L)"]J8F\W)(<.,(7S$L^('?YQ[ECV'@PS\=$>;1T4$='7QDLBR&NHWWHK-< M(2A1QB$M'P[\GK7->>@W^-XW?N$W88)R$CM?BQ@7I37)OI 7UU_HFS<=NS(\ MOFD#)]U_#$CCI!8.#GLQSL0HNU'/?EVR=6I'E: 49\!?)B*_B#04$/]?%C2/ M+FVY*4*#8)9PWQ$J B812Y5[626_'Y$3M%-VF\2'>]I MI#15:V[XK>N3#@-ON@*]YX:'^5JBW]:X]CWO& 94V43TW4"%:H'Z$/9&/S< MC?Z3>(1"HWH4^A"C&^,S"6X[J;_'\96H2<>B$"&62 MGP@?=RGMWY==5[!Q.9(/A<9E<^!TNA434RQ3Q)/Y8$F*[##%G* ,C^1K99%=$HH4<+(P(;].,K4CJ$'V9-V;.V MJ"R=LETDDFFQ RVUXQ6;.L_:R,/#"36[%W$MP [L#%^T9 1;2$=51ID#.$MY M"!S,B"S62' Y9"2=)Y+UCTWAEEU.(#K18THH-F*@FZO+PY2N;U'TD3=X?CS< MID7X 8AP[6\YGJML5CJLZ4+RF08N44_O--NYAAT+SD%)Y0MDFD(5DI(])$,/ M(VN(+OY7"BSP,46@90TF'#.HIDQ11%S M7I;3ZUT@VWHS2C5;SHQ/$H]?32_@YVG;[>NLM_D[64KV"US-9=Y_^VI:K>S> MM:]$M\E^)AWJ-MF[.)9N?KQA3$^WR=:8LAFFZ#;9BG4RTVVR%>O1K-MD[_T* M=)MLW29[QU>@VV3K-MG'U,U7M\G6;;)UFVS=)ENWR6ZW3;;2MJ7NDGU@K7QU MEVS=)?M ;-]#(RW=)?N%=LEN/@A;#/&^E4[8RR"*HTNVH'RJ_^.3CR''3B87 M_N0*:TLO*-_O;99!HP.Z.J"K [H'':83??D:N8@L?+MI+E:#[]8!8XV).3:D MX>%](*(.2"OA-,!W,,-G0*"[.S+MGJ7CW$K'N55$;?7#Y]VQV1_9 M.GI^&-'SSR'#4GIJ*^K(,GW1:@H3UOVT_DO'R@\AI/="8^7H"NSK0+D.E.M M>8-4U3''O:Z.DA]PE+RN;GW3?U&$W5@(9W^J"^B(^Z%'S=HWK8\#;OV.:?4& M.HJOH_B'1:Y'GQQPLI)>^W;3-L'AI 8\-WA?3 3XB!._POCAH\?\&'[Y[J_$ MI7E>.M2O0_TZU*\#K)50/U9J[R'*JD/]&A/+H7ZL!-\/(AYGJ'^?O'Y5U3\J M.$]D_"U1UA(5/+KVDQ&CK=.\).B\P&28<349AEHGSH#>L,-CN5&BSGQ1S]Y7 M/_/%&@]-:ZA37_;M(#L\W%8_]<7N=,WQ^*5VCE YS>67)/1=[&Y)"2Y3]SO^ MNV4IMJ\D%I423EH/8X,-.!BWE!RRK]2+ TCY4"D]HWTEJV7V?;S?.Z'&_J4Q)72V[>T%X8%3U,JMENSW3LG6U[(&8=<\N&M#VW '9 M<]V!98ZLIOWLZER!MN@.P*+K#KL[J"#6-MVN;#H>13_A_%\Q3AV'A/-%R!U7 MC&RG&<#S!7-#;?,=E';Z,FV^,WLP,*WA^/"LOAT X_4SR?4 C,D39?:W4C(K MCB1GMC4RK<8*^5JTZ%JGF!?75DD/'SJP'B&JU%H=!]S&?7/0W5.[1=T*2;=" M>BJY'GTKI!7UEOV^V;&;5OT/IQ72^O9%V.SH#C98&*ATG-=8'Z1FNK0.*<"SWVVC31U)H"]%= M"S3=Q*@IDW/S2W^R$O,R\6K/+8GRBVJP.5%1YU&K4=%FD>@#8L;KF^=TUQ/D M3D-+3^8'>SC:"HQ5"CF5<'3A.ZH]@@:=X(G(<(6X%K>+^DN-%N'7?6*8W3VAN*H?0!)(=; MM+L-*_S;23>=$K+Q956E7!*['DZ#;%#"J1*U/>X4Y>UEWE$D@2"S&;74;4 I M1%9J,T=+52\T\1^H:M11SZ6BSI2L;7=YN,4 C3";PPD2/X48%3<95-4,=IV; M;IL=JZ74=*7H0ZG-/(]83PX/[0XAHT-!L&'GNM[C^5<;)4@\/>6A)F&"VL1? MW(:<^L._Y8L@LS8[G6[E9CQOT!5<-KNP*]F^;V*JO4!5/6;O9'N MTK9O2_3P,%O]J'#7[(]U5VCU L!??FU97.VKIE^E^OM]='(:]ENJE-?]H%4J M25<(!_OF>-12(8#R 43EZ\&;[2:F2I6I+@IOQW Z#KAU1Z;=:VFHIRH4HHO" M]XYVAQ!"5!%NW;'9;]Q[HGY-^!."EACK3$O)\U_^DN#\T-]=WYTG\T_P8^9] M9 \T&ON7(+Q:< RU^;?T AT%/>8HZ)(.NZL\=LF8]AL+K9QVJ+K+9G/5O$HX MHT>/UF[JJCKAMLVB-@VZ'!3'DN,]V>.^RI>*_U] 6O")\2O(A$DPWQ*FVRH^ MJF++:@?/LX5AZ[Z;39)+GBGT%/9'O9B3]7:5-]&(5D9OZ9L]:ZT#I<$HL=H7 M=KPG>T[.BMHGZW64)S*K8W:W9OC'$H#8H=QN754!N;TV1OMBC-7C/=G6%&&X]&>[#G9.VJ?;&O!W3Z5]<;F>-#1!O<1&-SVMM=XO&;I MXR?;?[6B6M!:HPRH!:[F6%_7'*QO,/%BS.?C/9D*'O=&H76R3Z5%+7@UQPU& MYF!]9JAV8"COP-#&_LZUH2[*F]: C90--JS\'P@8&(W,\6-NKZ@4X@M8./FHD6S5O]<-#^"^//H;!G3OA MDU_@=)\XC4;^R "P.LUUBS37@\AE'73KJ"8.%GLG&?F!! I@L^O\+6LO@=\9 M^#!FB]6FS%=>9]+?8H$S)F:=XO/I@ML(Y4XMISENF*6A?@!'6IX" MN"D./;F[6%M8IK%6+/#!]372[@=IM^X/H5Q'T6:Z/NBND(I03E8#LG."T=U& M7QA>#35>:;S2_$KCU8'@U>'QJZ=V&QL=0";9>2BURV_@S-W.R^Y[N*\)P1XU>0U M'4!/Z&<#K-LUA]WQ+IB@>BVF-=D5L>A$T]T^Z:YC@L+U,NA.MW8_#'&G?J/X M9P/,Z@S-WM#>)=VUU7A>TYVFNX,!V'CGXD[U>0_;F]_MYV0^]Y9KS6IFO'5# M[L1!6+2G]VM0;];77<^94(N)6%US/-R)(UB]^]08_2(PVC('XYVXH-6[3SV' MY0#FL#P;HWL]2%QX^/PH^];SU,+H4_J8D/F ML+=38UR="]4H?7PH71-U,Z=#-=JQO;UC>]31H1J-T4>#T4-S1T4HZEVG]FN_"+_VT!Q8 M?;6U0XW1&J.W4#H.P-[1D9KGWO)UC,WV@@4V$(J,VY#YV'0K#I;KMPQ=MJ4= MV]MS$=LV^ST=J]$H?30H_>9E(+-V:K\$IW9W (9+5_$4,XW2&J45X<\Z1K/_ M"UYILZ3Y9<9^*V).M%?Z,%T>O;[95;V,7,=9-$8K(@O5N4KMD7X1'NENWQSK M#THK;*JW$5[;IYG?D09==98@U">(VE;_VI["VJU#N?\JL"N1@#_CI\,Y.M?*3PXWO:&S6V*R# ME3JRHY%9M:O4R/P2D-D:VNIW'-]+L+*G?+#RN7-F'PU2/.?X:@BL]$),@ MN?'X0;H@]CQ82-\"+6#WAF:_UU4@HK)7\E5J,YJ7:%YRB+?0MTW;WD=YK2K4 MV[A6IG;@YRB1>,\#H/0MT +#?L_L#7;*2S:,3VE>HGF)YB6'? M]RS;[>RDK M;X=\BUZD'V,&UU1W$]7[I]W&(?.C:1#"WOS Y_)3U\<>.S\9'=RNQ^,8L"%: M, >.@L^%<^:M

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end